

# FELLOWS-IN-TRAINING ABSTRACT AUTHOR INDEX

## A

Abramson, S. B. F119  
 Aceves-Avila, F. J. F123  
 Aceves-Avila, J. F46  
 Adams, E. F69  
 Adler, C. F7  
 Adler, R. S. F32  
 Aguilar, D. F109, F113  
 Ahlskog, E. J. F67  
 Ahn, C. F60  
 Ahn, Y. S. F139, F53, F54  
 Aizer, J. F135, F82  
 Al-Mussawir, H. F119  
 Alarcon, G. S. F37  
 Albert, D. A. F6  
 Algulin, J. F33  
 Alibhai, S. M. F38  
 Aliprantis, A. O. F1  
 Alkassab, F. F60  
 Allam, F. F70  
 Alpert, D. R. F66  
 Ansari-Ali, S. Z. F69  
 Arango, A. M. F88  
 Arkachaisri, T. F18  
 Arnett, F. C. F60  
 Arozullah, A. M. F69  
 Askari, A. F129, F51  
 Askari, A. D. F131  
 Athreya, B. H. F11  
 Attinger, C. E. F124  
 Attur, M. F119  
 Ayala, R. F18

## B

Badley, E. F38  
 Baechler, E. C. F77  
 Bajwa, H. A. F77  
 Ballinger, S. F15, F34  
 Barham, B. F16  
 Barnes, J. P. F108, F114  
 Barron, K. S. F11, F16  
 Basavaraju, R. V. F20  
 Basu, D. F126  
 Battilawa, F. M. F77  
 Bauer, J. W. F77  
 Beam, T. F34  
 Becker, M. L. F13  
 Behrens, E. M. F18  
 Behrens, T. W. F77  
 Belilos, E. F100, F102  
 Belitskaya-Levy, I. F119  
 Ben-Artzi, A. F122  
 Benseler, S. M. F17  
 Berman, J. F122  
 Bernatsky, S. F79  
 Beukelman, T. F18  
 Bieber, J. F6  
 Birmingham, J. D. F96  
 Bitar, I. F142  
 Bombardier, C. F105, F38  
 Bonilla, E. F70  
 Bostrom, M. P. F143

## C

Boudreau, R. F36  
 Bowyer, S. F15, F34  
 Bracaglia, C. F10, F25  
 Bradke, A. F91  
 Brander, V. A. F133  
 Brandwein, S. R. F47, F48  
 Braun, M. C. F88  
 Bresnihan, B. F132  
 Brown, K. F44  
 Brunner, H. I. F 36  
 Brunner, H. I. F7  
 Buckwalter, K. F34  
 Bude, R. F35  
 Burnham, J. F6  
 Bykerk, V. F117, F43

## D

Crawson, C. F75  
 Cron, R. Q. F13, F18  
 Crow, M. K. F2, F3  
 Cruz, M. L. F12  
 Cupples, A. F120  
 Cupps, T. R. F124  
 Cupps, T. R. F28  
 Curtis, J. F41  
 Cush, J. J. F106

## E

Dahle, A. F61  
 Dao, K. F106  
 Davis, M. D. P. F63  
 Deane, K. F44  
 Deane, K. D. F55  
 DeGuzman, M. M. F24  
 DelBello, M. F7  
 Demissie, S. F120  
 Derk, C. T. F28  
 Desai, S. P. F33  
 Di Gangi, M. F128  
 DiFrancesco, M. F7  
 Dong, C. F140  
 Donka, T. F43  
 Druzin, M. F62  
 Dubois, R. W. F109  
 Dubois, R. W. F113  
 Dunlop, D. W. F133  
 Duran-Barragan, S. F123, F46

## F

E. Stenboeg, M. Pfeiffer-Jensen, F23  
 B. fiirgaard, M. Oest, e. F90  
 Edgerton, C. C. F90  
 Edmundowicz, D. F68  
 Einhorn, E. F127  
 Eisenberg, D. F109, F113  
 Eisenberg, M. E. F107  
 El-Gabalawy, H. F140  
 Elkorn, K. B. F140  
 Elliott, J. R. F68  
 Ellman, M. H. F56  
 Erkan, D. F66  
 Espe, K. J. F77  
 Estrada-y-Martin, R. F60

## G

Flyckt, R. L.R. F62  
 Foo, L. F32  
 Fortin, P. R. F78, F80  
 Foti, R. F128  
 Fowlkes, B. F35  
 Fraenkel, L. F104  
 Friedberg, R. F121  
 Friedman, G. D. F59  
 Fritzler, M. F60

## H

Gallo, L. F18  
 Gatti, R. A. F8  
 Gaucher, S. F104  
 Gerhard-Herman, M. D. F82  
 German, A. F7  
 Ghelman, B. P. F143  
 Gilliland, B. C. F125  
 Ginzler, E. M. F81  
 Gizenski, A. M. F44  
 Gladman, D. F94  
 Gladman, D. D. F72, F73, F76, F78, F80, F83, F93, F95  
 Glass, R. F33  
 Glimcher, L. H. F1  
 Goek\*, O. N. F110  
 Goodman, E. F106  
 Gota, C. E. F98  
 Gourh, P. F88  
 Gravallese, E. F1  
 Gravallese, E. M. F33  
 Greenberg, J. F40  
 Greenstein, N. F40  
 Gregersen, P. K. F77  
 Greidinger, E. L. F89  
 Griffith, C. E. F115  
 Groh, B. F18  
 Gross, M. F61  
 Gruber, B. L. F130, F64  
 Guevara, J. F6  
 Guttikonda, R. F4  
 Guzhva, O. F65

# FELLOWS-IN-TRAINING ABSTRACT AUTHOR INDEX

## A

- Abramson, S. B. F119  
 Aceves-Avila, F. J. F123  
 Aceves-Avila, J. F46  
 Adams, E. F69  
 Adler, C. F7  
 Adler, R. S. F32  
 Aguilar, D. F109, F113  
 Ahlskog, E. J. F67  
 Ahn, C. F60  
 Ahn, Y. S. F139, F53, F54  
 Aizer, J. F135, F82  
 Al-Mussawir, H. F119  
 Alarcon, G. S. F37  
 Albert, D. A. F6  
 Algulin, J. F33  
 Alibhai, S. M. F38  
 Aliprantis, A. O. F1  
 Alkassab, F. F60  
 Allam, F. F70  
 Alpert, D. R. F66  
 Ansari-Ali, S. Z. F69  
 Arango, A. M. F88  
 Arkachaisri, T. F18  
 Arnett, F. C. F60  
 Arozullah, A. M. F69  
 Askari, A. F129, F51  
 Askari, A. D. F131  
 Athreya, B. H. F11  
 Attinger, C. E. F124  
 Attur, M. F119  
 Ayala, R. F18

## B

- Badley, E. F38  
 Baechler, E. C. F77  
 Bajwa, H. A. F77  
 Ballinger, S. F15, F34  
 Barham, B. F16  
 Barnes, J. P. F108, F114  
 Barron, K. S. F11, F16  
 Basavaraju, R. V. F20  
 Basu, D. F126  
 Battilawa, F. M. F77  
 Bauer, J. W. F77  
 Beam, T. F34  
 Becker, M. L. F13  
 Behrens, E. M. F18  
 Behrens, T. W. F77  
 Belilos, E. F100, F102  
 Belitskaya-Levy, I. F119  
 Ben-Artzi, A. F122  
 Benseler, S. M. F17  
 Berman, J. F122  
 Bernatsky, S. F79  
 Beukelman, T. F18  
 Bieber, J. F6  
 Birmingham, J. D. F96  
 Bitar, I. F142  
 Bombardier, C. F105, F38  
 Bonilla, E. F70  
 Bostrom, M. P. F143

## C

- Boudreau, R. F36  
 Bowyer, S. F15, F34  
 Bracaglia, C. F10, F25  
 Bradke, A. F91  
 Brander, V. A. F133  
 Brandwein, S. R. F47, F48  
 Braun, M. C. F88  
 Bresnihan, B. F132  
 Brown, K. F44  
 Brunner, H. I. F 36  
 Brunner, H. I. F7  
 Buckwalter, K. F34  
 Bude, R. F35  
 Burnham, J. F6  
 Bykerk, V. F117, F43

## D

- Crawson, C. F75  
 Cron, R. Q. F13, F18  
 Crow, M. K. F2, F3  
 Cruz, M. L. F12  
 Cupples, A. F120  
 Cupps, T. R. F124  
 Cupps, T. R. F28  
 Curtis, J. F41  
 Cush, J. J. F106

## E

- Dahle, A. F61  
 Dao, K. F106  
 Davis, M. D. P. F63  
 Deane, K. F44  
 Deane, K. D. F55  
 DeGuzman, M. M. F24  
 DelBello, M. F7  
 Demissie, S. F120  
 Derk, C. T. F28  
 Desai, S. P. F33  
 Di Gangi, M. F128  
 DiFrancesco, M. F7  
 Dong, C. F140  
 Donka, T. F43  
 Druzin, M. F62  
 Dubois, R. W. F109  
 Dubois, R. W. F113  
 Dunlop, D. W. F133  
 Duran-Barragan, S. F123, F46

## F

- E. Stenboeg, M. Pfeiffer-Jensen, F23  
 B. fiirgaard, M. Oest, e. F90  
 Edgerton, C. C. F90  
 Edmundowicz, D. F68  
 Einhorn, E. F127  
 Eisenberg, D. F109, F113  
 Eisenberg, M. E. F107  
 El-Gabalawy, H. F140  
 Elkorn, K. B. F140  
 Elliott, J. R. F68  
 Ellman, M. H. F56  
 Erkan, D. F66  
 Espe, K. J. F77  
 Estrada-y-Martin, R. F60

## G

- Gallo, L. F18  
 Gatti, R. A. F8  
 Gaucher, S. F104  
 Gerhard-Herman, M. D. F82  
 German, A. F7  
 Ghelman, B. P. F143  
 Gilliland, B. C. F125  
 Ginzler, E. M. F81  
 Gizenski, A. M. F44  
 Gladman, D. F94  
 Gladman, D. D. F72, F73, F76, F78, F80, F83, F93, F95  
 Glass, R. F33  
 Glimcher, L. H. F1  
 Goek\*, O. N. F110  
 Goodman, E. F106  
 Gota, C. E. F98  
 Gourh, P. F88  
 Gravallese, E. F1  
 Gravallese, E. M. F33  
 Greenberg, J. F40  
 Greenstein, N. F40  
 Gregersen, P. K. F77  
 Greidinger, E. L. F89  
 Griffith, C. E. F115  
 Groh, B. F18  
 Gross, M. F61  
 Gruber, B. L. F130, F64  
 Guevara, J. F6  
 Guttikonda, R. F4  
 Guzhva, O. F65

## H

- Harley, J. B. F3  
 Harrison, M. J. F135  
 Hawker, G. A. F110, F111  
 Healy, P. F94  
 Hector, R. F109, F113  
 Hegde, N. F31  
 Hellwell, P. F94  
 Henderson, S. G. F4  
 Hernandez-Rios, G. F123, F46  
 Hersh, A. O. F14  
 Herzenberg, L. A. F92  
 Herzenberg, L. A. F92  
 Hines, P. L. F108, F114  
 Hiraki, L. T. F17  
 Hirsch, R. F36  
 Hoffman, G. S. F97, F98  
 Hoffman, H. F86  
 Holers, V. F44  
 Holers, V. M. F55

Holland, S.	F7	Krasnokutsky, S.	F108, F114	Mittoo, S.	F57	Poterucha, J.	F75
Holmgren, A. R.	F63	Krasnokutsky, S.	F119	Moder, K.	F75	Potter, H. G.	F32
Hooker, R. S.	F45	Kraus, V.	F119	Moder, K. G.	F67	Purdue, E.	F143
Horstman, L.	F53	Kraus, V. B.	F142	Modi, A.	F65		
Horstman, L. L.	F139, F54	Kremer, J.	F40	Molloy, E. S.	F98		
Howe, P.	F112	Krishnan, E.	F59	Mongey, A.	F136	Rahmani, D.	F39
Hua, J.	F3	Krueger, G.	F94	Monrad, S.	F91	Ramos-Remus, C.	F123, F46
Huber, D.	F36	Kubo, K.	F92	Moore, T. L.	F26	Rangan, B. V.	F45
Hughes, G. C.	F125	Kumar, M.	F29	Moratz, C.	F89, F90	Rao, V.	F74
Hughes, S. L.	F133	Kumar, N.	F67	Morgan, S.	F41	Raya E.	F103
Hummers, L.	F57	Kunz, D. P.	F130, F64	Morillas, P.	F103	Raychaudhuri, S. P.	F92
Hunnicutt, T.	F107	Kwoh, C.	F36	Moses, N.	F99	Raychaudhuri1, S. K.	F92
Hunter, D.	F120			Mozaffarian, N.	F125	Reddy, M. Muralidhar.	F121
Hymson, L.	F112, F39			Mueller, E.	F39	Reed, G.	F135, F137, F40
				Muhkerjee, P.	F140	Reiss, T. H.	F133
				Myones, B. L.	F24	Ress, R. M.	F109, F113
						Reville, J. D.	F60, F88
I						Rewers, M.	F55
Ibanez, D.	F73, F76, F78, F80, F83	Laing, T. J.	F126	Nakata, R.	F140	Rice, J.	F107
Iglesias, E.	F103	Langford, C. A.	F97, F98	Nash, P.	F94	Ringold, S.	F22
Ingraham, K. M.	F28, F58	Laughlin, J. C.	F84, F86	Natarajan, M.	F130, F64	Ris, D.	F7
Inman, R. D.	F95	Lautenbach, E.	F140	Nelson, S.	F7	Ritchlin, C.	F94
Ivashkiv, L.	F143	Laxer, R. M.	F13	Nestor, B.	F143	Rivera, M.	F102
J		Lee, S.	F21	Neupane, H.	F70	Robinson, D.	F109, F113
Jackson, K.	F41	Lee, S. J.	F119	Niewold, T. B.	F3	Robinson, J.	F69
Jackson, S. A.	F115	Lehman, T. J. A.	F96	Nikpour, M.	F73, F76, F83	Roesller, B.	F35
Jamal, S.	F38, F43	Leonardi, R.	F128	Nocton, J. J.	F19	Rogers, T.	F61
Jayamuni, S.	F11	Leonetti, C.	F128	Norris, J. M.	F55	Rohekar, G.	F117
Jiang, S.	F49	Li, X.	F105	O'Brien, M. S.	F28	Roppelt, H.	F64
Jiang, W. Y.	F92	Li, X.	F38	O'Shea, F. D.	F95	Rosé, C. D.	F13
Jimenez, J. J.	F139, F53, F54	Liang, M. H.	F82	Oberstein, E. M.	F139, F53, F54	Rosen, P.	F116
Johnson, D. S.	F121, F45	Lichtenberg, L.	F69	Offer, R.	F46	Rosenberg, A.	F133
Johnson, S. R.	F111	Lidicker, J.	F52	Ogrinc, M.	F70	Rosenkranz, M.	F18
Johnson*, S. R.	F110	Lidicker, J. R.	F138	Olguin, J.	F46	Russak, S. M.	F109, F113
Jonnala, G.	F141, F5	Lisse, J.	F112, F39	Olson, N. Y.	F20	Russell, A. S.	F46
Jung, S.	F118	Liu, N.	F4	Olvera, N. R.	F112	Ruth, N.	F7
Jy, W.	F139, F53, F54	Livote, E.	F143	Ombrello, M. J.	F26	S	
K		Loftus, E. V.	F101	Onel, K. B.	F12	Saad, K. G.	F41
Kadanoff, R.	F69	Lopez-Ben, R.	F37	Orozco, C.	F106	Safford, M.	F41
Kale, A. S.	F24	Lu, W.	F50	Ortmann, W. A.	F77	Sagar H, Rudraraju S, Leisen J.,	
Kalunian, K.	F96	Lubrano, E.	F94	Orzechowski, N. M.	F101, F67	F30	
Kamdar, A. A.	F24	Lumapas, A.	F129, F51	Osborn, T. G.	F63	Sagar H, Granda J.,	F87
Kao, A. H.	F68	Lvovich, S.	F7			Said, N.	F85
Kaplan, M. J.	F91	M				Salazar, J.	F16
Karlson, E. W.	F82	Ma, J.	F49, F50	Pala, O.	F40	Salerno, A.	F68
Karmazyn, B.	F34	Mahowald, M. L.	F77	Palonen, K.	F41	Salifu, M. O.	F81
Karp, D. R.	F121	Majka, D. S.	F55	Pan, H.	F49, F50	Salimi, B.	F15
Kastner, D. L.	F11, F16	Majmudar, S.	F31, F42	Park, G. S.	F9	Salmon, J. E.	F66
Katchamart, W.	F105, F117	Mandl, L. A.	F143	Parrish, L. A.	F55	Sanchez-Ortiz, A.	F123
Kaur, P.	F52	Mandl, L. A.	F32, F66	Patel, A.	F64	Sandroni, P.	F63
Kaur, P. P.	F138	Manek, N. J.	F63	Patel, J.	F119	Scanzello, C. R.	F2
Kavanaugh, A.	F94	Manzi, S.	F68	Patel, V.	F65	Schentag, C. T.	F93, F95
Kavanaugh, A.	F96	Margarettan, M. E.	F27	Pavlov, H.	F32	Schmidt, K.	F15, F34
Kazi, S.	F45	Marques, M. B.	F71	Pearle, A. D.	F2	Schmitz, A.	F56, F84, F86
Keith, M. P.	F89	Martinez-Vidal, M. P.	F29	Pepmueller, P. H.	F137	Schneider, R.	F143
Keller, S. J.	F133	Masunaga, T.	F92	Perez, M. D.	F24	Schoenwetter, M.	F109, F113
Kervitsky, D.	F44	Mavromatis, B.	F124	Perl, A.	F70	Schumacher, H.	F118, F127
Kessler, C.	F124	Mayer, C. T.	F118, F127	Pessler, F.	F118, F127	Sculco, T. P.	F143
Keystone, C.	F43	Mayes, M. D.	F60	Petri, M.	F77	Segal, B.	F61, F77
Keystone, E.	F43	McCurdy, D. K.	F8	Petrolla, A.	F129	Seol, J.	F106
	F100, F102	McDaniel, G.	F119	Phillips, P. E.	F70	Shadick, N. A.	F33
		McDonough, A. K.	F71	Pillinger, M.	F122	Shah, A. A.	F62
		McHugh, K. P.	F1	Pineau, C. A.	F79	Shanmugam, V. K.	F124
		McNearney, T. A.	F107	Ping, L.	F50	Sherry, D. D.	F13
		McNearney, T. A.	F60	Plass, N.	F16	Sherry, D. D.	F6
		Mease, P.	F94	Pollack, S.	F42	Sierra-Jimenez, G.	F123, F46
		Meehan, R.	F44	Posalski, J. D.	F55	Silver, A. S.	F81
		Mehta, H.	F91	Posever, J.	F112, F39	Silverman, E. D.	F17
		Mehta, K. B.	F42	Post, D.	F82	Simkin, P. A.	F125
		Messner, R.	F77			Singh, J. A.	F110
		Meyer, C.	F9				
		Mirocha, J.	F55				
		Mirza, N.	F70				

	F77	U	X
Singh, S.	F21	Urowitz, M. B.	Xie, A.
Singh-Grewal, D.	F110	F72, F73, F76, F78, F80, F83	F41
Singh-Grewal*, D.	F46		Xu, P.
Skeith, K.	F77	Utset, T. O.	F49, F50
Slattery, C. A.	F119	Utset, T. O.	
Smiles, S.		Utset, T. O.	
Solomon, D. H.	F110, F33	F84, F86	
Spalding, S. J.	F116, F36		
Spangler, J.	F18	V	
Spannow, A.	F23	Vagell, M.	Yang, M.
Specks, U.	F101	van der Heijde, D.	F120
Spencer, C. H.	F12	Vasantha, L. C.	Yazici, Y.
St-Pierre, Y.	F79	Vaz, A.	F108, F114, F99
Starosta, M. A.	F47, F48	Veale, D.	Yelin, E. H.
Steen, V. D.	F124	Veale, D. J.	F14
Steen, V. D.	F58	Velazquez, M.	Ying, J.
Stojanov, S.	F16	Vlad*, S. C.	Ytterberg, S. R.
Strand, V.	F94	Vogt, M. T.	F101
Stringer, E.	F21	Volkov, S.	Yu, X.
Su, E. P.	F143	von Scheven, E.	F49, F50
Sumbul-Yuksel, B.	F40	Vora, S. S.	
Sun, F.	F50		
Sundel, R. P.	F10, F25	W	Z
Sundy, J. S.	F115	Wagner-Weiner, L.	Zimmermann, B.
Swe, K.	F39	Wallace, C. A.	F31, F85
Swedler, W. I.	F133	Wallace, D. J.	Zurakowski, D.
Sweiss, N. J.	F56	Walsh, C. A.	F10, F25
Syed, M. S.	F30, F87	Walsh, N.	
Syverson, G.	F19	Wang, L.	
T		Wang, X.	
Tai, L.	F8	Wani, S.	
Tamura, K.	F92	Warren, R. W.	
Tan, F. K.	F88	Watts, N.	
Taylor, W.	F94	Webb-Detiege, T. A.	
Tehrani, R.	F69	Weinblatt, M. E.	
Teng, G. Gee.	F41, F71	Weinstein, A.	
Tesfasyone, H.	F77	Weisman, M. H.	
Thomas-John, M.	F136	Wilson, J.	
Tian, J.	F49, F50	Wise, B.	
Toloza, S. M.A.	F78, F80, F95	Wener, M. H.	
Toombs-Smith, S.	F107	Wigley, F.	
Toth, A. P.	F142	Williams, L.	
Tracy, N.	F107	Wilson, J.	
Tsokos, G. C.	F89, F90	Wise, R.	
Tulloch-Reid, D. M.	F72	Wolanskyj, A. P.	
Turchin, I.	F79	Wong, K.	
Tutuncu, Z.	F96		
Tyrrell, P. N.	F17		

# FELLOWS-IN-TRAINING ABSTRACT KEYWORD INDEX

## A

- access to care F38  
acute-phase reactants F102  
adverse events F15, F52  
amyloid F127  
anakinra F142  
animal models F118  
ankylosing spondylitis (AS) F112, F123, F95  
anti-CCP F44, F47  
anti-TNF drugs F104, F39, F51, F98  
anticardiolipin F71  
antinuclear antibodies (ANA) F70  
antiphospholipid syndrome F66, F67  
arthrocentesis F122  
arthropathy F127  
arthroplasty F143  
atherosclerosis F9  
autoimmune diseases F92  
autoimmunity F90  
autoinflammatory diseases F125

## B

- B cells F4  
barriers to care F38, F45  
Behcet's syndrome F103, F99  
biologic response modifiers F52  
biomarkers F119, F121  
bone density F138, F33, F84

## C

- C-reactive protein (CRP) F42  
cardiovascular disease F40, F68, F82  
CD T cells F90  
central nervous system involvement F48, F87  
childhood diseases F14  
cigarette smoking F79  
classification criteria F110, F72, F93  
coccidioidomycosis F39  
cognitive dysfunction F7  
complement F88, F89  
computed tomography (CT) F9  
computer technology F116  
connective tissue disease F124, F28  
corticosteroids F138  
cost F105  
costimulatory molecules F140, F92  
crystal-induced arthritis F118  
cutaneous lupus F79  
cyclophosphamide F10, F24, F25  
cytokines F2

## D

- damage index F79  
dermatomyositis F31  
diagnostic criteria F46  
digital ulcers F56, F58  
disability F58  
disease activity F105, F43, F45, F73, F76, F8, F83  
disease-modifying antirheumatic drugs (DMARDs) F126  
drug toxicity F85

## E

- early rheumatoid arthritis F32, F46  
education, medical F122, F134  
emergency room F115  
endothelial cells F53  
endothelium F82  
environmental factors F55  
eosinophils F129  
epidemiology F120, F135, F18, F46  
Epstein-Barr virus F125  
ethnic studies F17  
extraarticular manifestations F47, F48

## F

- fractures F131, F136

## G

- gender F100, F139  
genetic factors F120, F3  
genetic research F88  
giant cell arteritis F102  
gout F115

## H

- Health Assessment Questionnaire F109, F113  
health care F104, F107  
health disparity F133  
hemophagocytosis F125  
hip osteoarthritis F143  
homocysteine F84  
hypermobility F131

## I

- imaging techniques F35, F36  
immune complex F26  
immunodeficiency F20  
immunoglobulin therapy F20  
immunosuppression F15, F28  
infection F106, F28, F29, F30  
infectious arthritis F27, F30  
inflammation F118, F89  
inflammatory arthritis F126, F35, F36, F37  
inflammatory bowel disease (IBD) F101  
infliximab F15  
interferons F3  
interleukins (IL) F140, F5  
interstitial lung disease F44, F57  
intraarticular F142

## J

- joint destruction F34  
joint procedures F122, F22  
juvenile arthritis F19  
juvenile dermatomyositis F21  
juvenile idiopathic F22, F26, F34, arthritis F6  
juvenile rheumatoid F13, F18 arthritis

## K

- knee F142

## L

- laboratory tests F19  
leukocytes F139, F54  
literacy F69  
liver function F75  
lupus anticoagulant F71  
lupus flares F77  
lupus nephritis F141, F24, F4, F5, F77, F8, F91

## M

- magnetic resonance imaging (MRI) F32, F7  
malignancy F74  
menopause F80  
methotrexate F13, F41  
microarray F119  
mixed connective tissue disease F62  
morbidity F58, F59  
mortality F59  
MRL-lpr/lpr mice F90  
muscular dystrophy F31  
musculoskeletal examination F23

## N

- neurologic involvement F103, F63  
neutrophils F139, F53  
nonsteroidal antiinflammatory drugs (NSAIDs) F19

## O

- oligoarthritis F6  
opportunistic infections F106  
osteoarthritis F119, F120, F134, F2  
osteoclasts F1  
osteolysis F143, F64  
osteoporosis F131, F134, F135, F136, F137, F138, F78, F80  
outcome measures F108, F114, F14, F36, F94  
oxidative stress F61

## P

- pediatric rheumatology F10, F12, F17, F23, F24, F25, F8  
periodic fever F11, F16  
phagocytosis F127  
phenotype F95  
physical examination F43  
physical therapy F86  
plasma cells F4  
plasmapheresis F50  
platelets F54, F66  
polymyalgia rheumatica F100  
practice guidelines F117  
practice patterns F107  
pregnancy F62  
prevention F68  
proteomics F121, F77  
psoriatic arthritis F93, F94, F95, F96  
pulmonary function F57, F60

## Q

- quality of care F115, F116, F117  
quality of life F69, F86, F96


R	T
race/ethnicity F133, F60	T cells F2
RANTES F141	Takayasu's arteritis F98
Raynaud's phenomenon F63	temporomandibular joint F22
registry F18	tendonitis/bursitis F29
renal disease F72, F97	therapy F20, F92
rheumatoid arthritis (RA) F104, F105, F121, F123, F33, F39, F40, F41, F42, F43, F44, F45, F47, F48, F49, F55, F99	thrombocytopenia F71
rheumatoid arthritis, pathogenesis F140, F53, F54	tissue necrosis factor (TNF) F114, F130, F52, F85
rheumatoid arthritis, synovium F132	total joint replacement F133
rheumatoid arthritis, treatment F117, F135, F38, F50	transcription factor F1
rheumatoid factor F55	transplantation F81, F97
ribonucleoprotein (RNP) F89	treatment F6, F87
risk factors F136, F56	tumor necrosis factor (TNF) F106, F108
rituximab F12, F132, F31	
S	U
Sarcoidosis F130	ulcers F124
scleroderma, localized F128, F61	ultrasound F23, F32, F34, F35, F37
scleroderma, systemic F111, F61, F64, F9	
Sjögren's syndrome F65	
socioeconomic factors F107	
surveys F116	
synovial fluid F26	
synovitis F29	
systemic lupus erythematosus (SLE) F10, F109, F113, F12, F123, F14, F17, F3, F65, F66, F68, F69, F7, F70, F72, F73, F74, F75, F76, F78, F80, F81, F82, F83, F84, F85, F86, F88	
systemic sclerosis F56, F57, F59, F60, F62	
W	V
Wegener's granulomatosis F97	

# LATE-BREAKING ABSTRACT AUTHOR INDEX

<b>A</b>	<b>D</b>	<b>Hensor, E. MA.</b>	<b>L4</b>	<b>M</b>
Aalto, K.	L3	Hill, J.	L36	Mack, M.
Abram, F.	L45	Hochberg, M. C.	L33	Mackay, M.
Abud Mendoza, C.	L2	Honkanen, V.	L3	MacKenzie, N. M.
Acruri, V.	L39	Huizinga, T. W.J.	L31	Mader, R.
Adawi, M.	L41			Mahowald, M. L.
Akdogan, A.	L35			Maras, Y.
Allaart, C. F.	L31			Mariette, X.
Alten, R.	L8			Marinescu, L.
Altshuler, D.	L23			Markovits, D.
Antoni, C. E.	L25			Martel-Pelletier, J.
Apras Bilgen, S.	L35			Martinez-Pons, M.
Aranda, R.	L43			Martini, A.
Aranow, C.	L21			Martins, D. C.
Arnett, F. C.	L17			Matteson, E. L.
Arora-Singh, R. K.	L18			Mayes, M. D.
				Mayes, M. Davidica
<b>B</b>				McCune, J.
Baechler, E.	L23			Melo-Gomes, J.
Baechler, E. C.	L32			Meshkin, B.
Baeten, D.	L9			Meunier, P. J.
Baker, D. G.	L12			Miceli-Richard, C.
Bala, M.	L25			Mircetic, V.
Balow, J.	L20			Molad, Y.
Bar Yehuda, S.	L41			Moser, K.
Battiwalla, F. M.	L32			Munaflo, A.
Bauer, J. W.	L32			Murray, J.
Becker, J.	L43			
Becquemont, L.	L11			<b>N</b>
Behrens, T.	L23			Nahir, M.
Behrens, T. W.	L32			Nasanov, E.
Bejarano, V.	L10			Nash, P.
Belostatsky, O.	L34			Nayiager, S.
Berman, A.	L43			Nesterov, I.
Beutler, A.	L25			Novitzke, J.
Bias, P.	L45			
Bjarnadottir, M. V.	L29			<b>O</b>
Block, A. J.	L2			O'Connor, P. J.
Bloom, B. J.				Oldenhof, J.
Blum, K.	L39			Ortmann, W. A.
Bojhanen, P.	L23			Ortolani, S.
Bombardier, C.	L30,			
Braun, J.	L24			<b>P</b>
Braverman, E.	L39			Pagliaro, L.
Breedveld, F. C.				Paz, E.
Brown, A. K.	L4			Pelletier, J.
Burgos-Vargas, R.	L2			Pena-Rossi, C.
Burgos-Vargas, R.				Perry, M.
Buttgereit, F.	L8			Peterfy, C. G.
				Petri, M.
<b>C</b>				Prieur, A. M.
Calguneri, M.	L35			
Cannon, C. P.	L37			<b>Q</b>
Caspis, D.	L41			Quinn, M.
Chakravarty, E.	L19			L4,
Charron, D.	L11			L10
Chen, T. JH.	L39			
Chibnik, L. B.	L16			
Choquette, D.	L45			
Coddington, C.	L43			
Cohn, I.	L41			
Collins, C. E.	L21			
Comets, E.	L11			
Compston, J.	L38			
Conaghan, P. G.	L10, L4			
Coombs, J.				
Cornet, P. L. N.	L2			
Cornet, P. L. N.	L43			
Covucci, A.	L2			
Criswell, L.	L23			
Crofford, L. J.	L44			
Curtis, S. P.	L37			
<b>D</b>				<b>R</b>
Da Costa, D.	L27			Rahman, M. U.
Dall'Era, M.	L19			Ravaud, P.
Daly, M.	L23			Raynauld, J.
Dasgupta, B.	L12			Reece, R. J.
Davies, L.	L23			Reginster, J.
de Jonge, R.	L31			Reitblat, T.
de Vries-Bouwstra, J.	L31			Rischmueller, M.
Dhar, P.	L19			Rojas, J.
Dijkgraaf, M. G.	L7			Rosenbaum, M.
Dijkmans, B. A. C.	L7			Rosner, I.
Dimic, A.	L36			Rossier, C.
Dinant, H.	L7			Roux, C.
DiVoti, J.	L34			Ruaau, D.
Doering, G.	L8			Rubinow, A.
Dougados, M.	L43			
<b>E</b>				
Farbstein, M.	L41			
Feeley, D.	L6			
Fishman, P.	L41			
Fishman-Furman, S.	L41			
Fitzcharles, M.	L27			
Fleisher, T.	L20			
Fletcher, M. P.	L15			
Farre, Ø.	L15			
Foundation for Applied Rheumatology Research, Leid, e.	L31			
Freedman, J.	L41			
<b>F</b>				
Gaffney, P.	L23			
Gathany, T.	L12			
Genovese, M.	L19			
Gerlag, D. M.	L13			
Gerlag, D. M.	L9			
Gerloni, V.	L2			
Gertberg, M.	L34			
Ghimire, B.	L29			
Ghimire, S.	L29			
Giannini, E. H.	L2			
Goeckooper-Ruiterman, Y. PM.	L31			
Gough, A. K.	L10			
Gouri, P.	L17,			
	L18			
Graham, R. R.	L23			
Gran, J. T.	L15			
Green, L.	L41			
Greenwald, R.	L34			
Gregersen, P. K.	L32			
Gruben, D.	L31			
Guchelaar, H.	L31			
Gulseth, H. C.	L15			
Guzzo, C.	L25			
<b>H</b>				
Haibel, H.	L24			
Haig, G.	L44			
Hall, S.	L6			
Han, C.	L25			
Haraoui, B.	L45			
Hardin, J. A.	L21			
Heldmann, F.	L24			
<b>I</b>				
Ikeda, K.	L4			
Illei, G. G.	L20			
<b>J</b>				
Jackish, J. G.	L22			
Johnson, B.	L6			
Ju, X.	L28			
<b>K</b>				
Kagan, A.	L16			
Kahan, A.	L42			
Kalunian, K.	L19			
Kalyoncu, U.	L35			
Kamran, M.	L21			
Kane, M. A.	L29			
Kang, J.	L21			
Karadag, O.	L35			
Karim, Z.	L4			
Käss, A. S.	L15			
Kaur, A.	L37			
Kavanaugh, A.	L19			
Kavanaugh, A.	L25			
Kay, J.	L12			
Kay, J.	L16			
Keenan, A.	L10			
Keiserman, M.	L43			
Keouth, T.	L32			
Kern, M.	L32			
Kerns, W.	L41			
Kim, T.	L26			
Kim, T.	L26			
Kiraz, S.	L35			
Kisacik, B.	L35			
Klareskog, L.	L9			
Kotaniemi, K.	L3			
Kraan, M. C.	L7			
Kremer, J. M.	L40			
Krishnaswami, S.	L40			
Krueger, G. G.	L25			
Krug, H. E.	L1			
Kryder, J.	L29			
Kupper, H.	L11,			
Kushnaryov, A.	L1			
Kyogoku, C.	L23			
<b>L</b>				
Lahdenne, P.	L3			
Laine, L.	L37			
Langevitz, P.	L41			
Lapteva, L.	L20			
Latva, K.	L3			
Laufer, S.	L45			
Le Cessie, S.	L31			
Lea, T.	L15			
Lee, H.	L26			
Lems, W. F.	L7			
Li, X.	L30			
Lin, C.	L43			
Lindahl, P.	L3			
Lipsky, P.	L20			
Listing, J.	L24			
Loiseau, P.	L11			
Lopatinskaya, L.	L9			
Lovell, D. J.	L2			
<b>Q</b>				
Quinn, M.	L4,			
	L10			
<b>R</b>				
Rahman, M. U.	L12			
Ravaud, P.	L11			
Raynauld, J.	L45			
Reece, R. J.	L10			
Reginster, J.	L38,			
	L42			
Reitblat, T.	L41			
Rischmueller, M.	L36			
Rojas, J.	L12			
Rosenbaum, M.	L41			
Rosner, I.	L41			
Rossier, C.	L36			
Roux, C.	L38			
Ruaau, D.	L28			
Rubinow, A.	L41			

Rubio Pérez, N. E.	L2	Slattery, C. A.	L32	V	Wessels, J. AM.
Rudwaleit, M.	L24	Smith, M. D.	L9		Wijbrands, C. A.
Ruperto, N.	L2	Somers, E.	L22		L13,
		Songcharoen, S.	L43		L7
		Szechinski, J.	L8		
		Sztajnbok, F.	L2		
		T			
Saad-Magalhäes, C.	L2	Tackey, E.	L20		
Saldate, S.	L43	Tak, P.	L36		
Sawitzke, A.	L5	Tak, P. P.	L13		
Schaeffler, A.	L8	Tak, P. P.	L7, L9		
Scheinberg, M.	L2	Tamouza, R.	L11		
Schiff, M.	L33	Tan, F.	L18		
Schiff, M.	L43	Tan, F. K.	L17		
Schuller, R.	L33	Tanay, A.	L41		
Serono and ZymoGenetics Atacicept Study Group	L19	Tavares, R.	L30		
Sharma, U.	L44	Taylor, A.	L6		
Shirota, Y.	L20	Tesfasyone, H.	L32		
Shmidt, E.	L36	Thurlings, R.	L36		
Sieper, J.	L24	Thurlings, R. M.	L13		
Sigal, L. H.	L2	Tishler, M.	L41		
Stijkens, D.	L7	Todd, D. J.	L16		
Silva, C. A.	L2	Torjesen, P.	L15		
Silverman, M.	L41	Tynjälä, P.	L3		
Simpson, S.	L44				
Singh, J. A.	L1				
Singh, S.	L32				

## LATE-BREAKING ABSTRACT KEYWORD INDEX





# Arthritis & Rheumatism

An Official Journal of the American College of Rheumatology  
www.arthritisrheum.org and www.interscience.wiley.com

VOLUME 54

JANUARY 2006

NO. 1

## Special Articles

Editorial: New Prospects for Autoimmune Disease Therapy: B Cells on Deathwatch <i>E. William St.Clair and Thomas F. Tedder</i> .....	1
Editorial: Smoking and Rheumatoid Arthritis: Another Reason to Just Say No <i>Jennifer D. Gorman</i> .....	10
Editorial: Receptor for Advanced Glycation End Products and Its Ligands: Initiators or Amplifiers of Joint Inflammation—a Bit of Both? <i>Bernhard Moser, Kevan C. Herold, and Ann Marie Schmidt</i> .....	14
Review: T Cell Epitope-Specific Immune Therapy for Rheumatic Diseases <i>Salvatore Albani and Berent Prakken</i> .....	19

## Rheumatoid Arthritis Clinical Studies

The PREMIER Study: A Multicenter, Randomized, Double-Blind Clinical Trial of Combination Therapy With Adalimumab Plus Methotrexate Versus Methotrexate Alone or Adalimumab Alone in Patients With Early, Aggressive Rheumatoid Arthritis Who Had Not Had Previous Methotrexate Treatment <i>Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley B. Cohen, Karel Pavelka, Ronald van Vollenhoven, John Sharp, John L. Perez, and George T. Spencer-Green, for the PREMIER Investigators</i> .....	26
A New Model for an Etiology of Rheumatoid Arthritis: Smoking May Trigger HLA-DR (Shared Epitope)-Restricted Immune Reactions to Autoantigens Modified by Citrullination <i>Lars Klareskog, Patrik Stolt, Karin Lundberg, Henrik Källberg, Camilla Bengtsson, Johan Grunewald, Johan Rönnelid, Helena Erlandsson Harris, Ann-Kristin Ulfgren, Solbritt Rantapää-Dahlqvist, Anders Eklund, Leonid Padyukov, Lars Alfredsson, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group</i> .....	38
Ultrasoundographic and Radiographic Results From a Two-Year Controlled Trial of Immediate or One-Year-Delayed Addition of Infliximab to Ongoing Methotrexate Therapy in Patients With Erosive Early Rheumatoid Arthritis <i>P. C. Taylor, A. Steuer, J. Gruber, C. McClinton, D. O. Cosgrove, M. J. K. Blomley, P. A. Marsters, C. L. Wagner, and R. N. Maini</i> .....	47
The Effectiveness of Anti-Tumor Necrosis Factor Therapy in Preventing Progressive Radiographic Joint Damage in Rheumatoid Arthritis: A Population-Based Study <i>Axel Finckh, Julia F. Simard, Jeffrey Duryea, Matthew H. Liang, Jie Huang, Synove Daneel, Adrian Forster, Cem Gabay, and Pierre-André Guerne, for the Swiss Clinical Quality Management in Rheumatoid Arthritis Project</i> .....	54
Contribution of Congestive Heart Failure and Ischemic Heart Disease to Excess Mortality in Rheumatoid Arthritis <i>Paulo J. Nicola, Cynthia S. Crowson, Hilal Maradit-Kremers, Karla V. Ballman, Véronique L. Roger, Steven J. Jacobsen, and Sherine E. Gabriel</i> .....	60
Association of Early Radiographic Damage With Impaired Physical Function in Rheumatoid Arthritis: A Ten-Year, Longitudinal Observational Study in 238 Patients <i>Sigríð Ódegård, Robert Landewé, Désirée van der Heijde, Tore K. Kvien, Petter Mowinckel, and Till Uhlig</i> ..	68
<b>Rheumatoid Arthritis Basic Science Studies</b>	
Anti-Tumor Necrosis Factor Therapy Increases Synovial Osteoprotegerin Expression in Rheumatoid Arthritis <i>Anca Irinel Catrina, Erik af Klint, Sofia Ernestam, Sergiu-Bogdan Catrina, Dimitrios Makrygiannakis, Ileana Ruxandra Botusan, Lars Klareskog, and Ann-Kristin Ulfgren</i> .....	76
Association Between Protein Tyrosine Phosphatase 22 Variant R620W in Conjunction With the HLA-DRB1 Shared Epitope and Humoral Autoimmunity to an Immunodominant Epitope of Cartilage-Specific Type II Collagen in Early Rheumatoid Arthritis <i>Harald Burkhardt, Ulrike Hüffmeier, Bernd Spriewald, Beate Böhm, Rolf Rau, Stefan Kallert, Åke Engström, Rikard Holmdahl, and André Reis</i> .....	82

A Functional Haplotype of the <i>PADI4</i> Gene Associated With Increased Rheumatoid Arthritis Susceptibility in Koreans <i>Changsoo Paul Kang, Hye-Soon Lee, Hyoungseok Ju, Hyunmi Cho, Changwon Kang, and Sang-Cheol Bae</i>	90
Increased Expression of Receptor for Advanced Glycation End Products by Synovial Tissue Macrophages in Rheumatoid Arthritis <i>Katsue Sunahori, Masahiro Yamamura, Jiro Yamana, Koji Takasugi, Masanori Kawashima, and Hirofumi Makino</i>	97
Acute-Phase Serum Amyloid A Stimulation of Angiogenesis, Leukocyte Recruitment, and Matrix Degradation in Rheumatoid Arthritis Through an NF- $\kappa$ B-Dependent Signal Transduction Pathway <i>Ronan H. Mullan, Barry Bresnihan, Lucy Golden-Mason, Trevor Markham, Rosemary O'Hara, Oliver Fitzgerald, Douglas J. Veale, and Ursula Fearon</i>	105
<b>Sjögren's Syndrome</b>	
BAFF-Induced Changes in B Cell Antigen Receptor-Containing Lipid Rafts in Sjögren's Syndrome <i>Frédérique d'Arbonneau, Jacques-Olivier Pers, Valérie Devauchelle, Yvon Pennec, Alain Saraux, and Pierre Youinou</i>	115
Dissemination of a Sjögren's Syndrome-Associated Extranodal Marginal-Zone B Cell Lymphoma: Circulating Lymphoma Cells and Invariant Mutation Pattern of Nodal Ig Heavy- and Light-Chain Variable-Region Gene Rearrangements <i>A. Hansen, K. Reiter, A. Pruss, C. Loddenkemper, O. Kaufmann, A. M. Jacobi, J. Scholze, P. E. Lipsky, and T. Dörner</i>	127
<b>Spondylarthropathy</b>	
Spondylarthritis-Associated and Non-Spondylarthritis-Associated B27 Subtypes Differ in Their Dependence Upon Tapasin for Surface Expression and Their Incorporation Into the Peptide Loading Complex <i>Jane C. Goodall, Lou Ellis, and J. S. Hill Gaston</i>	138
<b>Experimental (or Inflammatory) Arthritis</b>	
Requirement of Type I Interferon Signaling for Arthritis Triggered by Double-Stranded RNA <i>Mattias Magnusson, Fariba Zare, and Andrej Tarkowski</i>	148
Interleukin-6 Modulates Production of T Lymphocyte-Derived Cytokines in Antigen-Induced Arthritis and Drives Inflammation-Induced Osteoclastogenesis <i>Peter K. K. Wong, Julian M. W. Quinn, Natalie A. Sims, Annemarie van Nieuwenhuijze, Ian K. Campbell, and Ian P. Wicks</i>	158
<b>Fibromyalgia</b>	
Fibromyalgia Diagnosis: A Comparison of Clinical, Survey, and American College of Rheumatology Criteria <i>Robert S. Katz, Frederick Wolfe, and Kaleb Michaud</i>	169
The Impact of a Diagnosis of Fibromyalgia on Health Care Resource Use by Primary Care Patients in the UK: An Observational Study Based on Clinical Practice <i>Gwenda Hughes, Carlos Martinez, Eric Mylon, Charles Taieb, and Simon Wessely</i>	177
<b>Systemic Sclerosis</b>	
Pulmonary Arterial Hypertension Is a Major Mortality Factor in Diffuse Systemic Sclerosis, Independent of Interstitial Lung Disease <i>Salim Trad, Zahir Amoura, Catherine Beigelman, Julien Haroche, Nathalie Costedoat, Le Thi Huong Du Boutin, Patrice Cacoub, Camille Frances, Bertrand Wechsler, Philippe Grenier, and Jean-Charles Piette</i>	184
Elevated Serum BAFF Levels in Patients With Systemic Sclerosis: Enhanced BAFF Signaling in Systemic Sclerosis B Lymphocytes <i>Takashi Matsushita, Minoru Hasegawa, Koichi Yanaba, Masanari Kodera, Kazuhiko Takehara, and Shinichi Sato</i>	192
Variations of Neuronal Nitric Oxide Synthase in Systemic Sclerosis Skin <i>Lidia Ibba-Manneschi, Sirkku Niissalo, Anna Franca Milia, Yannick Allanore, Angela Del Rosso, Alessandra Pacini, Mirko Manetti, Annarita Toscano, Paola Cipriani, Vasiliki Liakouli, Roberto Giacomelli, André Kahan, Yrjö T. Konttinen, and Marco Matucci-Cerinic</i>	202
Monocyte Chemoattractant Protein 1 Released From Glycosaminoglycans Mediates Its Profibrotic Effects in Systemic Sclerosis Via the Release of Interleukin-4 From T Cells <i>Jörg H. W. Distler, Astrid Jüngel, David Caretto, Ursula Schulze-Horsel, Otylia Kowal-Bielecka, Renate E. Gay, Beat A. Michel, Ulf Müller-Ladner, Joachim R. Kalden, Steffen Gay, and Oliver Distler</i>	214

**Osteoarthritis Clinical Studies**

Projections of US Prevalence of Arthritis and Associated Activity Limitations <i>Jennifer M. Hootman and Charles G. Helmick</i> .....	226
Associations Between Pain, Function, and Radiographic Features in Osteoarthritis of the Knee <i>Béla Szebenyi, Anthony P. Hollander, Paul Dieppe, Brian Quilty, John Duddy, Shane Clarke, and John R. Kirwan</i> .....	230
Association of Higher Levels of Serum Cartilage Oligomeric Matrix Protein and N-Telopeptide Crosslinks With the Development of Radiographic Hip Osteoarthritis in Elderly Women <i>A. Kelman, L. Lui, W. Yao, A. Krumme, M. Nevitt, and N. E. Lane</i> .....	236

**Clinical Image**

Comet Cells in Rheumatoid Arthritis <i>Antonio Brucato, Valeria Tombini, and Cleofe Guffanti</i> .....	243
---	-----

**Osteoarthritis Basic Science Studies**

Collagen and Proteoglycan Turnover in Focally Damaged Human Ankle Cartilage: Evidence for a Generalized Response and Active Matrix Remodeling Across the Entire Joint Surface <i>Matthias Aurich, Jackson Mwale, Agnes Reiner, Juergen A. Mollenhauer, Jens O. Anders, Reneé A. Fuhrmann, Klaus E. Kuettner, A. Robin Poole, and Ada A. Cole</i> .....	244
Activation of Receptor for Advanced Glycation End Products in Osteoarthritis Leads to Increased Stimulation of Chondrocytes and Synoviocytes <i>Marjan M. C. Steenvoorden, Tom W. J. Huizinga, Nicole Verzijl, Ruud A. Bank, H. Karel Ronday, Hilco A. F. Luning, Floris P. J. G. Lafeber, René E. M. Toes, and Jeroen DeGroot</i> .....	253
The Therapeutic Effects of Basic Fibroblast Growth Factor Contained in Gelatin Hydrogel Microspheres on Experimental Osteoarthritis in the Rabbit Knee <i>Atsuo Inoue, Kenji A. Takahashi, Yuji Arai, Hitoshi Tonomura, Kei Sakao, Masazumi Saito, Mikihiro Fujioka, Hiroyoshi Fujiwara, Yasuhiko Tabata, and Toshikazu Kubo</i> .....	264
Production of Lipid Peroxidation Products in Osteoarthritic Tissues: New Evidence Linking 4-Hydroxyonenal to Cartilage Degradation <i>Barbara Morquette, Qin Shi, Patrick Lavigne, Pierre Ranger, Julio C. Fernandes, and Mohamed Benderdour</i> .....	271

**Pharmacology**

More Pronounced Inhibition of Cyclooxygenase 2, Increase in Blood Pressure, and Reduction of Heart Rate by Treatment With Diclofenac Compared With Celecoxib and Rofecoxib <i>Burkhard Hinz, Harald Dormann, and Kay Brune</i> .....	282
---	-----

**Gout**

Association of the Human Urate Transporter 1 With Reduced Renal Uric Acid Excretion and Hyperuricemia in a German Caucasian Population <i>Juergen Graessler, Anett Graessler, Susette Unger, Steffi Kopprasch, Anne-Kathrin Tausche, Eberhard Kuhlsch, and Hans-Egbert Schroeder</i> .....	292
---	-----

**Antiphospholipid Antibody and Systemic Lupus Erythematosus**

Antiphospholipid Antibodies From Patients With the Antiphospholipid Syndrome Induce Monocyte Tissue Factor Expression Through the Simultaneous Activation of NF- $\kappa$ B/Rel Proteins Via the p38 Mitogen-Activated Protein Kinase Pathway, and of the MEK-1/ERK Pathway <i>Chary López-Pedrera, Paula Buendía, María José Cuadrado, Emilio Siendones, María Angeles Aguirre, Nuria Barberroja, Cristina Montiel-Duarte, Antonio Torres, Munther Khamashta, and Francisco Velasco</i> ...	301
Accuracy of Anti-Ribosomal P Protein Antibody Testing for the Diagnosis of Neuropsychiatric Systemic Lupus Erythematosus: An International Meta-Analysis <i>Fotini B. Karassa, Antonella Afeltra, Ales Ambrozic, Deh-Ming Chang, Filip De Keyser, Andrea Doria, Mauro Galeazzi, Shunsei Hirohata, Ilse E. A. Hoffman, Murat Inanc, Loreto Massardo, Alessandro Mathieu, Chi Chiu Mok, Gabriella Morozzi, Giovanni Sanna, Alberto J. Spindler, Athanasios G. Tzioufas, Taku Yoshio, and John P. A. Ioannidis</i> .....	312
Prevention and Reversal of Nephritis in MRL/lpr Mice With a Single Injection of C-Reactive Protein <i>Wilfredo Rodriguez, Carolyn Mold, Lorraine L. Marnell, Julie Hutt, Gregg J. Silverman, Dao Tran, and Terry W. Du Clos</i> .....	325
Toll-like Receptor 9 Signaling Protects Against Murine Lupus <i>Xiaobo Wu and Stanford L. Peng</i> .....	336
Production of a Novel Class of Polyreactive Pathogenic Autoantibodies in BXD2 Mice Causes Glomerulonephritis and Arthritis <i>Hui-Chen Hsu, Tong Zhou, Helen Kim, Stephen Barnes, PingAr Yang, Qi Wu, Juling Zhou, Bruce A. Freeman, Ming Luo, and John D. Mountz</i> .....	343

**Erratum**

- Error in one designation of HLA relationship between mother and child in Table 1, and error in terminology, in article by Stevens et al (Arthritis Rheum, September 2005) ..... 355

**Childhood Arthritis**

- Transforming Growth Factor  $\beta$ 1 in the Pathogenesis of Autoimmune Congenital Complete Heart Block: Lesson From Twins and Triplets Discordant for the Disease

*Rolando Cimaz, Maria Orietta Borghi, Maria Gerosa, Martina Biggioggero, Elena Raschi, and Pier Luigi Meroni* .....

356

- An Altered Immune Response to Epstein-Barr Nuclear Antigen 1 in Pediatric Systemic Lupus Erythematosus

*Micah T. McClain, Brian D. Pooz, Benjamin F. Bruner, Kenneth M. Kaufman, John B. Harley, and Judith A. James* .....

360

- Polymorphisms in the Mannose-Binding Lectin Gene As Determinants of Age-Defined Risk of Coronary Artery Lesions in Kawasaki Disease

*Maarten H. Biezeveld, Judy Geissler, Gerrit Jan Weverling, Irene M. Kuipers, Jan Lam, Jaap Ottenkamp, and Taco W. Kuijpers* .....

369

**Letters**

- The American College of Rheumatology N (ACR-N) Debate: Going Back Into the Middle of the Tunnel? Comment on the Articles by Siegel and Zhen and by Boers

*Daniel Aletaha and Josef S. Smolen* .....

377

**Reply**

*Jeffrey N. Siegel and Bo-Guang Zhen* .....

378

- Low Bone Density and Vertebral Fractures in Systemic Lupus Erythematosus: Comment on the Article by Bultink et al

*Florina Constantinescu and Paul J. DeMarco* .....

378

**Reply**

*Irene E. M. Bultink, Willem F. Lems, Ben A. C. Dijkmans, Piet J. Kostense, and Alexandre E. Voskuyl* .....

379

- Echocardiography Is Not Sufficient to Diagnose Pulmonary Arterial Hypertension in Systemic Sclerosis: Comment on the Article by Wigley et al

*Anton Vonk-Noordegraaf, Alexandre E. Voskuyl, and Ben A. C. Dijkmans* .....

380

**Reply**

*Fredrick M. Wigley, Joao A. C. Lima, Maureen Mayes, David McLain, J. Lincoln Chapin, and Clive Ward-Able* .....

380

- Anti-Tumor Necrosis Factor  $\alpha$  Therapy and the Risk of JC Virus Infection

*Jonathan C. P. Roos and Andrew J. K. Ostor* .....

381

**Clinical Image**

- Takayasu Arteritis Presenting With Subclavian Aneurysm

*Keith Colvine, Ivor Gerber, and Fiona McQueen* .....

382

**ACR Announcements**

A14

VOLUME 54

FEBRUARY 2006

NO. 2

**Special Articles**

- Editorial: Evil Humors Take Their Toll as Innate Immunity Makes Gouty Joints TREM-ble

*Ru Liu-Bryan and Robert Terkeltaub* .....

383

- Editorial: Are Bone Morphogenetic Proteins Effective Inducers of Cartilage Repair? Ex Vivo Transduction of Muscle-Derived Stem Cells

*Mary B. Goldring* .....

387

- Editorial: Potential Antiinflammatory and Immunomodulatory Effects of Statins in Rheumatologic Therapy

*Claire Arnaud and François Mach* .....

390

- Review: Statins as Antiinflammatory and Immunomodulatory Agents: A Future in Rheumatologic Therapy?

*Aryeh M. Abeles and Michael H. Pilling* .....

393

- Review: The Type I Interferon System in Systemic Lupus Erythematosus

*Lars Rönnblom, Maija-Leena Eloranta, and Gunnar V. Alm* .....

408

Special Article: The American College of Rheumatology Response Criteria for Proliferative and Membranous Renal Disease in Systemic Lupus Erythematosus Clinical Trials <i>Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria</i>	421
<b>Cartilage Biology</b>	
Cartilage Repair Using Bone Morphogenetic Protein 4 and Muscle-Derived Stem Cells <i>Ryosuke Kuroda, Arydas Usas, Seiji Kubo, Karin Corsi, Hairong Peng, Tim Rose, James Cummins, Freddie H. Fu, and Johnny Huard</i>	433
The Accumulation of Intracellular ITEGE and DIPEN Neoepitopes in Bovine Articular Chondrocytes Is Mediated by CD44 Internalization of Hyaluronan <i>Jennifer J. Embry Flory, Amanda J. Fosang, and Warren Knudson</i>	443
<b>Gout</b>	
Induction of Triggering Receptor Expressed on Myeloid Cells 1 in Murine Resident Peritoneal Macrophages by Monosodium Urate Monohydrate Crystals <i>Yousuke Murakami, Tohru Akahoshi, Izumi Hayashi, Hirahito Endo, Shinichi Kawai, Matsuhisa Inoue, Hirobumi Kondo, and Hideto Kitasato</i>	455
<b>Experimental/Inflammatory Arthritis</b>	
Activation of p38 MAPK Is a Key Step in Tumor Necrosis Factor-Mediated Inflammatory Bone Destruction <i>Jochen Zwerina, Silvia Hayer, Kurt Redlich, Klaus Bobacz, Giorgos Kollias, Josef S. Smolen, and Georg Schett</i>	463
CD28-Dependent Differentiation Into the Effector/Memory Phenotype Is Essential for Induction of Arthritis in Interleukin-1 Receptor Antagonist-Deficient Mice <i>Motoko Kotani, Kazuya Hirata, Shuhei Ogawa, Katsuyoshi Habiro, Yasuo Ishida, Seiichi Tanuma, Reiko Horai, Yoichiro Iwakura, Hidehiro Kishimoto, and Ryo Abe</i>	473
The Impact of Glycosylation on HLA-DR1-Restricted T Cell Recognition of Type II Collagen in a Mouse Model <i>Alexei von Delwig, Daniel M. Altmann, John D. Isaacs, Clifford V. Harding, Rikard Holmdahl, Norman McKie, and John H. Robinson</i>	482
Prevention of Spontaneous Arthritis by Inhibiting Homeostatic Expansion of Autoreactive CD4+ T Cells in the K/BxN Mouse Model <i>Eunkyeong Jang, Hong Ro Kim, Sin Hye Cho, Doo-Jin Paik, Jung Mogg Kim, Sang-Koo Lee, and Jeehee Youn</i>	492
<b>Clinical Images</b>	
Dysphagia Is Sometimes Easier to Swallow Than Spinal Surgery <i>R. Rajendram, J. Ehtisham, and R. W. Smith</i>	507
<b>Autoinflammatory Syndrome</b>	
PYPaf1 Nonsense Mutation in a Patient With an Unusual Autoinflammatory Syndrome: Role of PYPaf1 in Inflammation <i>I. Jéru, H. Hayrapetyan, P. Duquesnoy, T. Sarkisian, and S. Amselem</i>	508
<b>Heritable Disorders of Connective Tissue</b>	
Clinical Study of Hereditary Disorders of Connective Tissues in a Chilean Population: Joint Hypermobility Syndrome and Vascular Ehlers-Danlos Syndrome <i>Jaimie F. Bravo and Carlos Wolff</i>	515
<b>Osteoarthritis Basic Science Studies</b>	
Association Between a Variation in LRCH1 and Knee Osteoarthritis: A Genome-Wide Single-Nucleotide Polymorphism Association Study Using DNA Pooling <i>Tim D. Spector, Richard H. Reneland, Steven Mah, Ana M. Valdes, Deborah J. Hart, Stefan Kammerer, Maria Langdown, Carolyn R. Royal, Josephine Atienza, Michael Doherty, Proton Rahman, Matthew R. Nelson, and Andreas Braun</i>	524
Reproducible Genetic Associations Between Candidate Genes and Clinical Knee Osteoarthritis in Men and Women <i>Ana M. Valdes, Mark Van Oene, Deborah J. Hart, Gabriela L. Surdulescu, John Loughlin, Michael Doherty, and Tim D. Spector</i>	533
Interleukin-1 in Combination With Oncostatin M Up-Regulates Multiple Genes in Chondrocytes: Implications for Cartilage Destruction and Repair <i>H. E. Barksby, W. Hui, I. Wappler, H. H. Peters, J. M. Milner, C. D. Richards, T. E. Cawston, and A. D. Rowan</i>	540

<b>Osteoarthritis Clinical Studies</b>	
Validity, Factor Structure, and Clinical Relevance of the AUSCAN Osteoarthritis Hand Index <i>Kelli D. Allen, Joanne M. Jordan, Jordan B. Renner, and Virginia B. Kraus</i>	551
<b>Pharmacology</b>	
Acquired Resistance to Chloroquine in Human CEM T Cells Is Mediated by Multidrug Resistance–Associated Protein 1 and Provokes High Levels of Cross-Resistance to Glucocorticoids <i>Ruud Oerlemans, Joost van der Heijden, Josefine Vink, Ben A. C. Dijkmans, Gertjan J. L. Kaspers, Willem F. Lems, George L. Scheffer, Ilan Ifrany, Rik J. Scheper, Jacqueline Cloos, Yehuda G. Assaraf, and Gerrit Jansen</i>	557
<b>Spondylarthropathy</b>	
Inflammatory Back Pain in Ankylosing Spondylitis: A Reassessment of the Clinical History for Application as Classification and Diagnostic Criteria <i>Martin Rudwaleit, Anke Metter, Joachim Listing, Joachim Sieper, and Jürgen Braun</i>	569
<b>Rheumatoid Arthritis Basic Science Studies</b>	
Apoptosis of Rheumatoid Synovial Cells by Statins Through the Blocking of Protein Geranylgeranylation: A Potential Therapeutic Approach to Rheumatoid Arthritis <i>Takao Nagashima, Hitoaki Okazaki, Kazuo Yudoh, Hiroaki Matsuno, and Seiji Minota</i>	579
PUMA Regulation and Proapoptotic Effects in Fibroblast-like Synoviocytes <i>Hoon-Suk Cha, Sanna Rosengren, David L. Boyle, and Gary S. Firestein</i>	587
A New Classification of HLA-DRB1 Alleles Differentiates Predisposing and Protective Alleles for Rheumatoid Arthritis Structural Severity <i>Pierre-Antoine Gourraud, Jean-Frédéric Boyer, Thomas Barnetche, Michel Abbal, Anne Cambon-Thomsen, Alain Cantagrel, and Arnaud Constantin</i>	593
<b>Rheumatoid Arthritis Clinical Studies</b>	
The LUNDEX, a New Index of Drug Efficacy in Clinical Practice: Results of a Five-Year Observational Study of Treatment With Infliximab and Etanercept Among Rheumatoid Arthritis Patients in Southern Sweden <i>Lars Erik Kristensen, Tore Saxne, and Pierre Geborek</i>	600
Risk Genotypes in Folate-Dependent Enzymes and Their Association With Methotrexate-Related Side Effects in Rheumatoid Arthritis <i>Michael H. Weissman, Daniel E. Furst, Grace S. Park, Joel M. Kremer, Katie M. Smith, Daniel J. Wallace, Jacques R. Caldwell, and Thierry Dervieux</i>	607
Reconstitution of Peripheral Blood B Cells After Depletion With Rituximab in Patients With Rheumatoid Arthritis <i>Maria J. Leandro, Geraldine Cambridge, Michael R. Ehrenstein, and Jonathan C. W. Edwards</i>	613
Treatment of Early Seropositive Rheumatoid Arthritis: Doxycycline Plus Methotrexate Versus Methotrexate Alone <i>James R. O'Dell, Jennifer R. Elliott, Jack A. Mallek, Ted R. Mikuls, Cynthia A. Weaver, Scott Glickstein, Kent M. Blakely, Raymond Hausch, and Rob D. Leff</i>	621
Treatment for Rheumatoid Arthritis and the Risk of Hospitalization for Pneumonia: Associations With Prednisone, Disease-Modifying Antirheumatic Drugs, and Anti-Tumor Necrosis Factor Therapy <i>Frederick Wolfe, Liron Caplan, and Kaleb Michaud</i>	628
Morphologic and Quantitative Assessment of CD20+ B Cell Infiltrates in Rheumatoid Arthritis–Associated Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia <i>Sarah R. Atkins, Carl Turesson, Jeffery L. Myers, Henry D. Tazelaar, Jay H. Ryu, Eric L. Matteson, and Tim Bongartz</i>	635
Incidence of Noncardiac Vascular Disease in Rheumatoid Arthritis and Relationship to Extraarticular Disease Manifestations <i>Kimberly P. Liang, Kelly V. Liang, Eric L. Matteson, Robyn L. McClelland, Teresa J. H. Christianson, and Carl Turesson</i>	642
<b>Systemic Sclerosis</b>	
Signaling Pathways Regulating Intercellular Adhesion Molecule 1 Expression by Endothelin 1: Comparison With Interleukin-1 $\beta$ in Normal and Scleroderma Dermal Fibroblasts <i>Charlotte E. Waters, Xu Shi-Wen, Chris P. Denton, David J. Abraham, and Jeremy D. Pearson</i>	649
<b>Systemic Lupus Erythematosus</b>	
A Murine Model of Mixed Connective Tissue Disease Induced With U1 Small Nuclear RNP Autoantigen <i>Eric L. Greidinger, YunJuan Zang, Kimberly Jaimes, Scott Hogenmiller, Mehdi Nassiri, Pablo Bejarano, Glen N. Barber, and Robert W. Hoffman</i>	661

Platelet C4d Is Highly Specific for Systemic Lupus Erythematosus Jeanne S. Navratil, Susan Manzi, Amy H. Kao, Shanthi Krishnaswami, Chau-Ching Liu, Margie J. Ruffing, Penny S. Shaw, Abbey C. Nilson, Emily R. Dryden, Jeffrey J. Johnson, and Joseph M. Ahearn.....	670
<b>Concise Communications</b>	
Association of IgG anti-NR2 Glutamate Receptor Antibodies in Cerebrospinal Fluid With Neuropsychiatric Systemic Lupus Erythematosus Taku Yoshio, Koichi Onda, Hiroyuki Nara, and Seiji Minota .....	675
Adalimumab Reduces Spinal Symptoms in Active Ankylosing Spondylitis: Clinical and Magnetic Resonance Imaging Results of a Fifty-Two-Week Open-Label Trial Hildrun Haibel, Martin Rudwaleit, Henning C. Brandt, Zarho Grozdanovic, Joachim Listing, Hartmut Kupper, Jürgen Braun, and Joachim Sieper .....	678
<b>Letters</b>	
How Psychological Stress via Hormones and Nerve Fibers May Exacerbate Rheumatoid Arthritis: Comment on the Review by Straub et al J. P. Persijn .....	682
Reply Rainer H. Straub, Johannes W. J. Bijlsma, and Maurizio Cutolo .....	682
The Randomized Clinical Trial of Doxycycline in Knee Osteoarthritis: Comment on the Editorial by Dieppe Kenneth D. Brandt and Steven A. Mazzuca.....	684
<b>ACR Announcements</b> .....	A15

VOLUME 54

MARCH 2006

NO. 3

**Special Articles**

Editorial: Lymphoma in Rheumatoid Arthritis: An Immune System Set Up for Failure Cornelia M. Weyand, Jörg J. Goronzy, and Paul J. Kurtin.....	685
Winners of the 2005 American College of Rheumatology Annual Slide Competition American College of Rheumatology Audiovisual Aids Subcommittee .....	690

**Rheumatoid Arthritis Clinical Studies**

Association of Chronic Inflammation, Not Its Treatment, With Increased Lymphoma Risk in Rheumatoid Arthritis Eva Baecklund, Anastasia Iliadou, Johan Askling, Anders Ekbom, Carin Backlin, Fredrik Granath, Anca Irinel Catrina, Richard Rosengren, Nils Feltelius, Christer Sundström, and Lars Klareskog .....	692
Predictors of Joint Damage in Patients With Early Rheumatoid Arthritis Treated With High-Dose Methotrexate With or Without Concomitant Infliximab: Results From the ASPIRE Trial Josef S. Smolen, Désirée M. F. M. van der Heijde, E. William St.Clair, Paul Emery, Joan M. Bathon, Edward Keystone, Ravinder N. Maini, Joachim R. Kalden, Michael Schiff, Daniel Baker, Chenglong Han, John Han, and Mohan Bala, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group .....	702

Development of Antiinfliximab Antibodies and Relationship to Clinical Response in Patients With Rheumatoid Arthritis Gerrit Jan Wolbink, Marijn Vis, Willem Lems, Alexandre E. Voskuyl, Els de Groot, Michael T. Nurmohamed, Steven Stapel, Paul P. Tak, Lucien Aarden, and Ben Dijkmans .....	711
---	-----

Infliximab Treatment Maintains Employability in Patients With Early Rheumatoid Arthritis Josef S. Smolen, Chenglong Han, Désirée van der Heijde, Paul Emery, Joan M. Bathon, Edward Keystone, Joachim R. Kalden, Michael Schiff, Mohan Bala, Daniel Baker, John Han, Ravinder N. Maini, and E. William St.Clair.....	716
---	-----

Circulating Levels of B Lymphocyte Stimulator in Patients With Rheumatoid Arthritis Following Rituximab Treatment: Relationships With B Cell Depletion, Circulating Antibodies, and Clinical Relapse Geraldine Cambridge, William Stohl, Maria J. Leandro, Thi-Sau Migone, David M. Hilbert, and Jonathan C. W. Edwards .....	723
--	-----

Deiminated Epstein-Barr Virus Nuclear Antigen 1 Is a Target of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Federico Pratesi, Cristina Tommasi, Consuelo Anzilotti, Daniele Chimenti, and Paola Migliorini .....	733
---	-----

## Rheumatoid Arthritis Basic Science Studies

Sphingosine 1-Phosphate/Sphingosine 1-Phosphate Receptor 1 Signaling in Rheumatoid Synovium: Regulation of Synovial Proliferation and Inflammatory Gene Expression <i>Masayasu Kitano, Timothy Hla, Masahiro Sekiguchi, Yutaka Kawahito, Rikio Yoshimura, Keiji Miyazawa, Tsuyoshi Iwasaki, and Hajime Sano</i>	742
Sphingosine Kinase 1–Mediated Inhibition of Fas Death Signaling in Rheumatoid Arthritis B Lymphoblastoid Cells <i>Xiuju Pi, Shi-Yu Tan, Michael Hayes, Lijun Xiao, James A. Shayman, Song Ling, and Joseph Holoshitz</i>	754
CXCL16-Mediated Cell Recruitment to Rheumatoid Arthritis Synovial Tissue and Murine Lymph Nodes Is Dependent Upon the MAPK Pathway <i>Jeffrey H. Ruth, Christian S. Haas, Christy C. Park, M. Asif Amin, Rita J. Martinez, G. Kenneth Haines, III, Shiva Shahrrara, Phillip L. Campbell, and Alisa E. Koch</i>	765
Hypermethylated Promoter Region of <i>DR3</i> , the Death Receptor 3 Gene, in Rheumatoid Arthritis Synovial Cells <i>Nozomi Takami, Kayo Osawa, Yasushi Miura, Koichiro Komai, Mariko Taniguchi, Masahiko Shiraishi, Keizo Sato, Tetsuhiro Iguchi, Kazuko Shiozawa, Akira Hashiramoto, and Shunichi Shiozawa</i>	779
Expression of Platelet-Derived Growth Factors C and D in the Synovial Membrane of Patients With Rheumatoid Arthritis and Osteoarthritis <i>Dirk Pohlers, René Huber, Bärbel Ukena, and Raimund W. Kinne</i>	788
<b>Osteoarthritis Clinical Studies</b>	
The Association of Meniscal Pathologic Changes With Cartilage Loss in Symptomatic Knee Osteoarthritis <i>D. J. Hunter, Y. Q. Zhang, J. B. Niu, X. Tu, S. Amin, M. Clancy, A. Guermazi, M. Grigorian, D. Gale, and D. T. Felson</i>	795
The Impact of Body Mass Index on Later Total Hip Arthroplasty for Primary Osteoarthritis: A Cohort Study in 1.2 Million Persons <i>Gunnar B. Flugsrud, Lars Nordsletten, Birgitte Espehaug, Leif I. Havelin, Anders Engeland, and Haakon E. Meyer</i>	802
<b>Osteoarthritis Basic Science Studies</b>	
Comparative Analysis of Gene Expression Profiles in Intact and Damaged Regions of Human Osteoarthritic Cartilage <i>Tomoo Sato, Koji Konomi, Satoshi Yamasaki, Satoko Aratani, Kaneyuki Tsuchimochi, Masahiro Yokouchi, Kayo Masuko-Hongo, Naoko Yagishita, Hiroshi Nakamura, Setsuro Komiya, Moroe Beppu, Haruhito Aoki, Kusuki Nishioka, and Toshihiro Nakajima</i>	808
Catabolic Stress Induces Features of Chondrocyte Senescence Through Overexpression of Caveolin 1: Possible Involvement of Caveolin 1–Induced Down-Regulation of Articular Chondrocytes in the Pathogenesis of Osteoarthritis <i>Sheng-Ming Dai, Zheng-Zheng Shan, Hiroshi Nakamura, Kayo Masuko-Hongo, Tomohiro Kato, Kusuki Nishioka, and Kazuo Yudoh</i>	818
Expression Profiling of Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Normal and Degenerate Human Achilles Tendon <i>Gavin C. Jones, Anthony N. Corps, Caroline J. Pennington, Ian M. Clark, Dylan R. Edwards, Michelle M. Bradley, Brian L. Hazleman, and Graham P. Riley</i>	832
Higher Chondrogenic Potential of Fibrous Synovium– and Adipose Synovium–Derived Cells Compared With Subcutaneous Fat–Derived Cells: Distinguishing Properties of Mesenchymal Stem Cells in Humans <i>Tomoyuki Mochizuki, Takeshi Muneta, Yusuke Sakaguchi, Akimoto Nimura, Akiko Yokoyama, Hideyuki Koga, and Ichiro Sekiya</i>	843
<b>Experimental Arthritis</b>	
Treatment of Murine Collagen-Induced Arthritis by the Stress Protein BiP Via Interleukin-4–Producing Regulatory T Cells: A Novel Function for an Ancient Protein <i>Rebecca J. Brownlie, Linda K. Myers, Paul H. Wooley, Valerie M. Corrigall, Mark D. Bodman-Smith, Gabriel S. Panayi, and Stephen J. Thompson</i>	854
Vasoactive Intestinal Peptide Induces CD4+,CD25+ T Regulatory Cells With Therapeutic Effect in Collagen-Induced Arthritis <i>Elena Gonzalez-Rey, Amelia Fernandez-Martin, Alejo Chorny, and Mario Delgado</i>	864
Effects of a Novel Tylophorine Analog on Collagen-Induced Arthritis Through Inhibition of the Innate Immune Response <i>Xin You, Meng Pan, Wenli Gao, Her-Shyong Shiah, Jian Tao, Dongqing Zhang, Fotios Koumpouras, Shuang Wang, Hongyu Zhao, Joseph A. Madri, David Baker, Yung-Chi Cheng, and Zhinan Yin</i>	877
Antigen-Induced, Tolerogenic CD11c+,CD11b+ Dendritic Cells Are Abundant in Peyer's Patches During the Induction of Oral Tolerance to Type II Collagen and Suppress Experimental Collagen-Induced Arthritis <i>So-Youn Min, Kyung-Su Park, Mi-La Cho, Jung-Won Kang, Young-Gyu Cho, Sue-Yun Hwang, Min-Jung Park, Chong-Hyeon Yoon, Jun-Ki Min, Sang-Heon Lee, Sung-Hwan Park, and Ho-Youn Kim</i>	887

<b>Systemic Lupus Erythematosus Clinical Studies</b>	
Obstetric Hospitalizations in the United States for Women With Systemic Lupus Erythematosus and Rheumatoid Arthritis	899
<i>Eliza F. Chakravarty, Lorene Nelson, and Eswar Krishnan</i> .....	899
Acute Occlusive Large Vessel Disease Leading to Fatal Stroke in a Patient With Systemic Lupus Erythematosus: Arteritis or Atherosclerosis?	899
<i>Katrin L. Conen, Christina Jeanneret, Burkhard Hecker, Gieri Cathomas, and Barbara C. Biedermann</i> .....	908
<b>Systemic Lupus Erythematosus Basic Science Studies</b>	
Critical Comparative Analyses of Anti- $\alpha$ -Actinin and Glomerulus-Bound Antibodies in Human and Murine Lupus Nephritis	914
<i>Manar Kalaaji, Gunnar Sturfelt, Janne Erikke Mjelle, Hans Nossent, and Ole Petter Rekvig</i> .....	914
Involvement of Phosphatidylserine, $\alpha\beta3$ , CD14, CD36, and Complement C1q in the Phagocytosis of Primary Necrotic Lymphocytes by Macrophages	914
<i>Andrea Böttcher, Udo S. Gaapl, Barbara G. Fürnrohr, Martin Herrmann, Irute Girkontaite, Joachim R. Kalden, and Reinhard E. Voll</i> .....	927
Accumulation of Apoptotic Cells in the Epidermis of Patients With Cutaneous Lupus Erythematosus After Ultraviolet Irradiation	927
<i>Annegret Kuhn, Martin Herrmann, Susanne Kleber, Maria Beckmann-Welle, Karin Fehsel, Ana Martin-Villalba, Percy Lehmann, Thomas Ruzicka, Peter H. Krammer, and Victoria Kolb-Bachofen</i> ...	939
Intracellular Mammalian DNA Stimulates Myeloid Dendritic Cells to Produce Type I Interferons Predominantly Through a Toll-like Receptor 9-Independent Pathway	939
<i>David A. Martin and Keith B. Elkon</i> .....	951
<b>Systemic Sclerosis</b>	
DNA Topoisomerase I Binding to Fibroblasts Induces Monocyte Adhesion and Activation in the Presence of Anti-Topoisomerase I Autoantibodies From Systemic Sclerosis Patients	963
<i>Jill Hénault, Geneviève Robitaille, Jean-Luc Senécal, and Yves Raymond</i> .....	963
<b>Ankylosing Spondylitis</b>	
Association of the <i>IL1</i> Gene Cluster With Susceptibility to Ankylosing Spondylitis: An Analysis of Three Canadian Populations	974
<i>Walter P. Maksymowich, Proton Rahman, Jeff P. Reeve, Dafna D. Gladman, Lynette Peddle, and Robert D. Inman</i> .....	974
<b>Vasculitis</b>	
Abundance of the Long Pentraxin PTX3 at Sites of Leukocytoclastic Lesions in Patients With Small-Vessel Vasculitis	986
<i>Andre P. van Rossum, Hendri H. Pas, Fausto Fazzini, Minke G. Huitema, Pieter C. Limburg, Marcel F. Jonkman, and Cees G. M. Kallenberg</i> .....	986
Association of Killer Cell Immunoglobulin-Like Receptor Genotypes With Microscopic Polyangiitis	992
<i>Risa Miyashita, Naoyuki Tsuchiya, Toshio Yabe, Shigeto Kobayashi, Hiroshi Hashimoto, Shoichi Ozaki, and Katsushi Tokunaga</i> .....	992
<b>TRAPS</b>	
Neutrophils From Patients With <i>TNFRSF1A</i> Mutations Display Resistance to Tumor Necrosis Factor-Induced Apoptosis: Pathogenetic and Clinical Implications	998
<i>Andrea D'Osualdo, Francesca Ferlito, Ignazia Prigione, Laura Obici, Antonella Meini, Francesco Zulian, Alessandra Pontillo, Fabrizia Corona, Roberto Barcellona, Marco Di Duca, Giuseppe Santamaria, Francesco Traverso, Paolo Picco, Maurizia Baldi, Alessandro Plebani, Roberto Ravazzolo, Isabella Ceccherini, Alberto Martini, and Marco Gattorno</i> .....	998
<b>Pigmented Villonodular Synovitis</b>	
Analysis of Pigmented Villonodular Synovitis With Genome-Wide Complementary DNA Microarray and Tissue Array Technology Reveals Insight Into Potential Novel Therapeutic Approaches	1009
<i>Katharina Finis, Holger Sültmann, Markus Ruschhaupt, Andreas Buess, Birgit Helmchen, Ruprecht Kuner, Marie-Luise Gross, Bernd Fink, Peter Schirmacher, Annemarie Poustka, and Irina Berger</i> .....	1009
<b>Concise Communications</b>	
Progressive Multifocal Leukoencephalopathy in Patients With Systemic Lupus Erythematosus	1020
<i>Kenji Itoh, Toshikazu Kano, Chiaki Nagashio, Akio Mimori, Makiko Kinoshita, and Morito Sumiya</i> .....	1020
The Functional -169T→C Single-Nucleotide Polymorphism in FCRL3 Is Not Associated With Rheumatoid Arthritis in White North Americans	1022
<i>Xiaolan Hu, Monica Chang, Randall K. Saiki, Michelle A. Cargill, Ann B. Begovich, Kristin G. Ardlie, Lindsey A. Criswell, Michael F. Seldin, Christopher I. Amos, Peter K. Gregersen, Daniel L. Kastner, and Elaine F. Remmers</i> .....	1022
<b>Clinical Image</b>	
Corneal Tophus Deposition in Gout	1025
<i>Berta Bernad, Javier Narvaez, Cesar Diaz-Torné, Marc Diez-Garcia, and Jose Valverde</i> .....	1025

**Letters**

Presence of a Primary Hip Osteoarthritis Susceptibility Locus on Chromosome 6: Comment on the Article by Meenagh et al	1026
Kay Chapman, Andrew Carr, John Loughlin, and Janet S. Sinsheimer.....	1026
Does Diclofenac Induce Accelerated Progression of Hip and Knee Radiographic Osteoarthritis?	
Comment on the Article by Reijman et al	
Changhai Ding .....	1027
Reply	
M. Reijman, S. M. A. Bierma-Zeinstra, H. A. P. Pols, B. W. Koes, B. H. C. Stricker, and J. M. W. Hazes... ACR Announcements .....	1028

**Errata**

Omission of financial disclosure statements of Dr. C. L. Wagner and Dr. R. N. Maini in article by Taylor et al (Arthritis Rheum, January 2006), and error in listing of institutional affiliation of Dr. A. Fosang in article by Flory et al (Arthritis Rheum, February 2006) .....	1028
ACR Announcements .....	A13

VOLUME 54

APRIL 2006

NO. 4

**Special Articles**

ACR Presidential Address: Yesterday, Today, and Tomorrow Elizabeth A. Tindall .....	1029
Review: Extremity Magnetic Resonance Imaging in Rheumatoid Arthritis: Report of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force.....	1034
Response: Office-Based Low-Field Extremity Magnetic Resonance Imaging: Is the Glass Half Empty or Half Full? David E. Yocum, Philip G. Conaghan, Ewa Olech, and Charles G. Peterfy.....	1048
Editorial: When Is a Replication Not a Replication? Or How to Spot a Good Genetic Association Study Tim D. Spector, Kourosh R. Ahmadi, and Ana M. Valdes .....	1051
Editorial: Targeting the Inflamed Synovium: The Quest for Specificity Toby Garrood and Costantino Pitzalis.....	1055
Editorial: Stopping Traffic in Sjögren's Syndrome Philip L. Cohen .....	1061

**Rheumatoid Arthritis Clinical Studies**

Comparison of Etanercept and Methotrexate, Alone and Combined, in the Treatment of Rheumatoid Arthritis: Two-Year Clinical and Radiographic Results from the TEMPO Study, a Double-Blind, Randomized Trial Désirée van der Heijde, Lars Klareskog, Vicente Rodriguez-Valverde, Catalin Codreanu, Horatiu Bolosiu, Jose Melo-Gomes, Jesus Tornero-Molina, Joseph Wajdula, Ronald Pedersen, and Saeed Fatenejad, for the TEMPO Study Investigators .....	1063
The Safety of Infliximab, Combined With Background Treatments, Among Patients With Rheumatoid Arthritis and Various Comorbidities: A Large, Randomized, Placebo-Controlled Trial Rene Westhovens, David Yocum, John Han, Alberto Berman, Ingrid Strusberg, Piet Geusens, and Mahboob U. Rahman, for the START Study Group .....	1075
Efficacy and Toxicity of Methotrexate in Early Rheumatoid Arthritis Are Associated With Single-Nucleotide Polymorphisms in Genes Coding for Folate Pathway Enzymes Judith A. M. Wessels, Jeska K. de Vries-Bouwstra, Bas T. Heijmans, P. Eline Slagboom, Yvonne P. M. Goekoop-Ruiterman, Cornelia F. Allaart, Pit J. S. M. Kerstens, Derkjen van Zeben, Ferdinand C. Breedveld, Ben A. C. Dijkmans, Tom W. J. Huizinga, and Henk-Jan Guchelaar .....	1087
High-Resolution Multipinhole Single-Photon-Emission Computed Tomography in Experimental and Human Arthritis B. Ostendorf, A. Scherer, A. Wirwar, J. W. Hoppin, C. Lackas, N. U. Schramm, M. Cohnen, U. Mödder, W. B. van den Berg, H. W. Müller, M. Schneider, and L. A. B. Joosten.....	1096

**Rheumatoid Arthritis Basic Science Studies**

Association of Tumor Necrosis Factor $\alpha$ Polymorphism, But Not the Shared Epitope, With Increased Radiographic Progression in a Seropositive Rheumatoid Arthritis Inception Cohort Dinesh Khanna, Hui Wu, Grace Park, Vivian Gersuk, Richard H. Gold, Gerald T. Nepom, Weng Kee Wong, John T. Sharp, Elaine F. Reed, Harold E. Paulus, and Betty P. Tsao, for the Western Consortium of Practicing Rheumatologists .....	1105
--	------

The HLA-DRB1 Shared Epitope Alleles Are Primarily a Risk Factor for Anti-Cyclic Citrullinated Peptide Antibodies and Are Not an Independent Risk Factor for Development of Rheumatoid Arthritis	
<i>Annette H. M. van der Helm-van Mil, Kirsten N. Verpoort, Ferdinand C. Breedveld, Tom W. J. Huizinga, René E. M. Toes, and René R. P. de Vries</i> .....	1117
Synovial Membrane Cytokine Expression Is Predictive of Joint Damage Progression in Rheumatoid Arthritis: A Two-Year Prospective Study (the DAMAGE Study Cohort)	
<i>Bruce W. Kirkham, Marissa N. Lassere, John P. Edmonds, Katherine M. Juhasz, Paul A. Bird, C. Soon Lee, Ron Shnier, and Ian J. Portek</i> .....	1122
Regulatory Role of Heme Oxygenase 1 in Inflammation of Rheumatoid Arthritis	
<i>Hideo Kobayashi, Mitsuhiro Takeno, Tomoyuki Saito, Yukiko Takeda, Yohei Kirino, Koji Noyori, Takeshi Hayashi, Atsuhisa Ueda, and Yoshiaki Ishigatsubo</i> .....	1124
Evaluation of Classical Complement Pathway Activation in Rheumatoid Arthritis: Measurement of C1q-C4 Complexes as Novel Activation Products	
<i>Diana Wouters, Alexandre E. Voskuyl, Esmeralda T. H. Molenaar, Ben A. C. Dijkmans, and C. Erik Hack</i> .....	1143
Peripheral Blood T Lymphocytes From Patients With Early Rheumatoid Arthritis Express RANKL and Interleukin-15 on the Cell Surface and Promote Osteoclastogenesis in Autologous Monocytes	
<i>Maria-Eugenia Miranda-Carús, Marta Benito-Miguel, Alejandro Balsa, Tatiana Cobo-Ibáñez, Carlos Pérez de Ayala, Dora Pascual-Salcedo, and Emilio Martín-Mola</i> .....	1151
<b>Sjögren's Syndrome</b>	
Antimuscarinic Antibodies in Primary Sjögren's Syndrome Reversibly Inhibit the Mechanism of Fluid Secretion by Human Submandibular Salivary Acinar Cells	
<i>L. J. Dawson, J. Stanbury, N. Venn, B. Hasdimir, S. N. Rogers, and P. M. Smith</i> .....	1165
Antagonist of Interferon-Inducible Protein 10/CXCL10 Ameliorates the Progression of Autoimmune Sialadenitis in MRL/lpr Mice	
<i>Hitoshi Hasegawa, Atsushi Inoue, Masashi Kohno, Masatake Muraoka, Tatsuhiko Miyazaki, Miho Terada, Takashi Nakayama, Osamu Yoshie, Masato Nose, and Masaki Yasukawa</i> .....	1174
<b>Experimental Arthritis</b>	
Intraarticular Induction of Interleukin-1 $\beta$ Expression in the Adult Mouse, With Resultant Temporomandibular Joint Pathologic Changes, Dysfunction, and Pain	
<i>Yu-Ching Lai, Solomon S. Shaftel, Jen-nie H. Miller, Ross H. Tallents, Yoon Chang, Carl A. Pinkert, John A. Olschowka, Ian M. Dickerson, J. Edward Puzas, M. Kerry O'Banion, and Stephanos Kyrikanides</i> ... 1184	
Targeting of Angiogenic Endothelial Cells at Sites of Inflammation by Dexamethasone	
Phosphate-Containing RGD Peptide Liposomes Inhibits Experimental Arthritis	
<i>Gerben A. Koning, Raymond M. Schiffelers, Marca H. M. Wauben, Robbert J. Kok, Enrico Mastrobattista, Grietje Molema, Timo L. M. ten Hagen, and Gert Storm</i> .....	1198
<b>Osteoarthritis Basic Science Studies</b>	
Mesenchymal Multipotency of Adult Human Perosteal Cells Demonstrated by Single-Cell Lineage Analysis	
<i>Cosimo De Bari, Francesco Dell'Accio, Johan Vanlaue, Jeroen Eyckmans, Ilyas M. Khan, Charles W. Archer, Elena A. Jones, Dennis McGonagle, Thimios A. Mitsiadis, Costantino Pitzalis, and Frank P. Luyten</i> .....	1209
Potent Induction of Chondrocytic Differentiation of Human Adipose-Derived Adult Stem Cells by Bone Morphogenetic Protein 6	
<i>Bradley T. Estes, Arthur W. Wu, and Farshid Guilak</i> .....	1222
Activation of the Peroxisome Proliferator-Activated Receptor $\alpha$ Pathway Potentiates Interleukin-1 Receptor Antagonist Production in Cytokine-Treated Chondrocytes	
<i>Mathias François, Pascal Richette, Lydia Tsagris, Catherine Fitting, Cedric Lemay, Mourad Benallaoua, Khadija Tahiri, and Marie-Therese Corvol</i> .....	1233
<b>Osteoarthritis Clinical Studies</b>	
Frizzled-Related Protein Variants Are Risk Factors for Hip Osteoarthritis	
<i>N. E. Lane, K. Lian, M. C. Nevitt, J. M. Zmuda, L. Lui, J. Li, J. Wang, M. Fontech, N. Umbrias, M. Rosenbach, P. de Leon, and M. Corr</i> .....	1246
Low Vitamin K Status Is Associated With Osteoarthritis in the Hand and Knee	
<i>Tuhina Neogi, Sarah L. Booth, Yu Qing Zhang, Paul F. Jacques, Robert Terkeltaub, Piran Aliabadi, and David T. Felson</i> .....	1255
Disc Space Narrowing As a New Risk Factor for Vertebral Fracture: The OFELY Study	
<i>Elisabeth Sornay-Rendu, Chloé Allard, Françoise Munoz, François Duboeuf, and Pierre D. Delmas</i> .....	1262

**Systemic Lupus Erythematosus**

Identification and Characterization of an Xp22.33;Yp11.2 Translocation Causing a Triplication of Several Genes of the Pseudoautosomal Region 1 in an XX Male Patient With Severe Systemic Lupus Erythematosus

- Pierre Chagnon, Rayfel Schneider, Josée Hébert, Paul R. Fortin, Sylvie Provost, Claude Belisle, Marianne Gingras, Véronique Bolduc, Claude Perreault, Earl Silverman, and Lambert Busque ..... 1270  
Genetic Variation in Toll-like Receptor 9 and Susceptibility to Systemic Lupus Erythematosus Philip L. De Jager, Angela Richardson, Tim J. Vyse, and John D. Rioux ..... 1279

**Childhood Arthritis**

The Complex Nature of the Interaction Between Disease Activity and Therapy on the Lipid Profile in Patients With Pediatric Systemic Lupus Erythematosus

- Talin Sarkissian, Joseph Beyenne, Brian Feldman, Khosrow Adeli, and Earl Silverman ..... 1283  
Primary Central Nervous System Vasculitis in Children Susanne M. Benseler, Earl Silverman, Richard I. Aviv, Rayfel Schneider, Derek Armstrong, Pascal N. Tyrrell, and Gabrielle deVeber ..... 1291

**Systemic Sclerosis**

Inhibition of Systemic Sclerosis Dermal Fibroblast Type I Collagen Production and Gene Expression by Simvastatin

- Natalia Louneva, Gonzalo Huaman, Joanna Fertala, and Sergio A. Jiménez ..... 1298  
Contribution of Activin Receptor-like Kinase 5 (Transforming Growth Factor  $\beta$  Receptor Type I) Signaling to the Fibrotic Phenotype of Scleroderma Fibroblasts Yunliang Chen, Xu Shi-wen, Mark Eastwood, Carol M. Black, Christopher P. Denton, Andrew Leask, and David J. Abraham ..... 1309

**Spondylarthropathy**

Additional Human  $\beta_2$ -Microglobulin Curbs HLA-B27 Misfolding and Promotes Arthritis and Spondylitis Without Colitis in Male HLA-B27-Transgenic Rats

- Tri M. Tran, Martha L. Dorris, Nimman Satumira, James A. Richardson, Robert E. Hammer, Jie Shang, and Joel D. Taurog ..... 1317

**Psoriatic Arthritis**

A High-Resolution Magnetic Resonance Imaging Study of Distal Interphalangeal Joint Arthropathy in Psoriatic Arthritis and Osteoarthritis: Are They the Same?

- Ai Lyn Tan, Andrew J. Grainger, Steven F. Tanner, Paul Emery, and Dennis McGonagle ..... 1328

**Fibromyalgia**

Acute Heavy-Resistance Exercise-Induced Pain and Neuromuscular Fatigue in Elderly Women With Fibromyalgia and in Healthy Controls: Effects of Strength Training

- Heli Valkeinen, Arja Häkkinen, Pekka Hannonen, Keijo Häkkinen, and Markku Alén ..... 1334

**Chondrocalcinosis**

Ectopic Calcification Among Families in The Azores: Clinical and Radiologic Manifestations in Families With Diffuse Idiopathic Skeletal Hyperostosis and Chondrocalcinosis

- Jácome Bruges-Armas, Ana Rita Couto, Andrew Timms, Margarida R. Santos, Bruno Filipe Bettencourt, Maria José Peixoto, Katherine Colquhoun, Eugene G. McNally, Victor Carneiro, Gabriel Herrero-Beaufort, and Matthew A. Brown ..... 1340

**Concise Communication**

Systemic Sclerosis: Brain Abnormalities Revealed by Conventional Magnetic Resonance Imaging and Magnetization Transfer Imaging

- Maria I. Argyropoulou, Niki Tsifetaki, Anastasia K. Zikou, Vassilios Xydis, Aliki I. Venestanopoulou, Persefoni Margariti, and Alexandros A. Drosos ..... 1350

**Clinical Image**

Mutilans-Type Rheumatoid Arthritis

- Mittermayer B. Santiago ..... 1352

**Letters**

Is Atherosclerosis in Rheumatoid Arthritis Related to Disease Severity and Extraarticular Manifestations? Comment on the Article by Chung et al

- Carl Turesson and Eric L. Matteson ..... 1353

Reply Cecilia P. Chung, Annette Oeser, Tebeb Gebretsadik, Ayumi Shintani, and C. Michael Stein ..... 1353

The Pros and Cons of Muscle Co-contraction in Osteoarthritis of the Knee: Comment on the Article by Lewek et al

- Martijn Steultjens, Joost Dekker, and Martin van der Esch ..... 1354

Reply Michael D. Lewek, Daniel K. Ramsey, Lynn Snyder-Mackler, and Katherine S. Rudolph ..... 1354

Aromatase Inhibitors and Osteoporosis: Comment on the Review by Felson and Cummings Prabha Ranganathan and Reina Armamento-Villareal.....	1355
Reply David Felson and Steven R. Cummings .....	1356
<b>ACR Announcements</b> .....	<b>A14</b>

VOLUME 54

MAY 2006

NO. 5

**Special Articles**

Editorial: Molecular Mechanisms of Cartilage Destruction: Mechanics, Inflammatory Mediators, and Aging Collide <i>Richard F. Loeser</i> .....	1357
Editorial: Contribution of Angiogenic Genes to the Complex Genetic Trait Underlying Kawasaki Disease <i>Sherry Thornton</i> .....	1361
Review: Methotrexate Pharmacogenetics: The First Step Toward Individualized Therapy in Rheumatoid Arthritis <i>Prabha Ranganathan and Howard L. McLeod</i> .....	1366

**Clinical Pharmacology**

Cardiovascular Outcomes in New Users of Coxibs and Nonsteroidal Antiinflammatory Drugs: High-Risk Subgroups and Time Course of Risk <i>Daniel H. Solomon, Jerry Avorn, Til Stürmer, Robert J. Glynn, Helen Mogun, and Sebastian Schneeweiss</i> ..	1378
---	------

**Rheumatoid Arthritis Clinical Studies**

The Efficacy and Safety of Rituximab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results of a Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial <i>Paul Emery, Roy Fleischmann, Anna Filipowicz-Sosnowska, Joy Schechtman, Leszek Szczepanski, Arthur Kavanaugh, Artur J. Racewicz, Ronald F. van Vollenhoven, Nicole F. Li, Sunil Agarwal, Eva W. Hessey, and Timothy M. Shaw, for the DANCER Study Group</i> .....	1390
Combination Treatment With Methotrexate, Cyclosporine, and Intraarticular Betamethasone Compared With Methotrexate and Intraarticular Betamethasone in Early Active Rheumatoid Arthritis: An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study <i>Merede Lund Hetland, Kristian Stengaard-Pedersen, Peter Junker, Tine Lottenburger, Torkell Ellingsen, Lis Smedegård Andersen, Ib Hansen, Henrik Skjødt, Jens Kristian Pedersen, Ulrik Birk Lauridsen, Anders Svendsen, Ulrik Tarp, Jan Pødenphant, Gert Hansen, Hanne Lindegaard, Anselmo de Carvalho, Mikkel Østergaard, Kim Hørslev-Petersen, and the CIMESTRA Study Group</i> .....	1401
Preliminary Evidence for a Structural Benefit of the New Bisphosphonate Zoledronic Acid in Early Rheumatoid Arthritis <i>Stephen J. Jarrett, Philip G. Conaghan, Victor S. Sloan, Philemon Papanastasiou, Christine-Elke Ortmann, Philip J. O'Connor, Andrew J. Grainger, and Paul Emery</i> .....	1410
The Effect of Therapeutic Glucocorticoids on the Adrenal Response in a Randomized Controlled Trial in Patients With Rheumatoid Arthritis <i>John R. Kirwan, Sarah H. Hickey, Roger Häggren, Herman Mielants, Ewa Björck, Tore Persson, and Frank A. Wollheim</i> .....	1415
Followup Radiographic Data on Patients With Rheumatoid Arthritis Who Participated in a Two-Year Trial of Prednisone Therapy or Placebo <i>Johannes W. G. Jacobs, Amalia A. van Everdingen, Suzan M. M. Verstappen, and Johannes W. J. Bijlsma</i> ..	1422
Guillain-Barré and Miller Fisher Syndromes Occurring With Tumor Necrosis Factor $\alpha$ Antagonist Therapy <i>In-Sook J. Shin, Alan N. Baer, Hyon J. Kwon, Elektra J. Papadopoulos, and Jeffrey N. Siegel</i> .....	1429
Leflunomide Use and the Risk of Interstitial Lung Disease in Rheumatoid Arthritis <i>Samy Suissa, Marie Hudson, and Pierre Ernst</i> .....	1435
Radiographic Joint Space Width in the Fingers of Patients With Rheumatoid Arthritis of Less Than One Year's Duration <i>Ewan C. Goligher, Jeffrey Duryea, Matthew H. Liang, Frederick Wolfe, and Axel Finckh</i> .....	1440

Performance of an Automated Computer-Based Scoring Method to Assess Joint Space Narrowing in Rheumatoid Arthritis: A Longitudinal Study <i>Axel Finckh, Paola de Pablo, Jeffrey N. Katz, Gesa Neumann, Ying Lu, Frederick Wolfe, and Jeffrey Duryea</i>	1444
<b>Rheumatoid Arthritis Basic Science Studies</b>	
LIGHT (TNFSF14), a Novel Mediator of Bone Resorption, Is Elevated in Rheumatoid Arthritis <i>J. R. Edwards, S. G. Sun, R. Locklin, C. M. Shipman, I. E. Adamopoulos, N. A. Athanasou, and A. Sabokbar</i>	1451
Intraarticular Corticosteroids Decrease Synovial RANKL Expression in Inflammatory Arthritis <i>Dimitrios Makrygiannakis, Erik af Klint, Sergiu-Bogdan Catrina, Ileana Ruxandra Botusan, Elin Klareskog, Lars Klareskog, Ann-Kristin Ulfgren, and Anca Irinel Catrina</i>	1463
Fas Activation of a Proinflammatory Program in Rheumatoid Synoviocytes and Its Regulation by FLIP and Caspase 8 Signaling <i>Guillermo Palao, Begoña Santiago, María Galindo, Joaquín Rullas, José Alcamí, Juan C. Ramírez, and José L. Pablos</i>	1473
Linkage Analysis of Rheumatoid Arthritis in US and UK Families Reveals Interactions Between HLA-DRB1 and Loci on Chromosomes 6q and 16p <i>Sally John, Christopher Amos, Neil Shephard, Wei Chen, Adam Butterworth, Carol Etzel, Damini Jawaheer, Michael Seldin, Alan Silman, Peter Gregersen, and Jane Worthington</i>	1482
Association of the IL4R Single-Nucleotide Polymorphism I50V With Rapidly Erosive Rheumatoid Arthritis <i>Iryna Prots, Alla Skapenko, Jörg Wendler, Stefan Mattyasovszky, Clarisse L. Yoné, Bernd Spriewald, Harald Burkhardt, Rolf Rau, Joachim R. Kalden, Peter E. Lipsky, and Hendrik Schulze-Koops</i>	1491
<b>Sjögren's Syndrome</b>	
Tissue-Specific Up-Regulation of the Proteasome Subunit $\beta$ 5i (LMP7) in Sjögren's Syndrome <i>Thomas Egerer, Lorena Martinez-Gamboa, Anja Dankof, Bruno Stuklmüller, Thomas Dörner, Veit Krenn, Karl Egerer, Paul E. Rudolph, Gerd-R. Burmester, and Eugen Feist</i>	1501
<b>Osteoarthritis/Cartilage Biology Basic Science Studies</b>	
Cellular Events Leading to Chondrocyte Death After Cartilage Impact Injury <i>D. M. Green, P. C. Noble, J. S. Ahuero, and H. H. Birdsall</i>	1509
A Novel Role for Suppressor of Cytokine Signaling 3 in Cartilage Destruction Via Induction of Chondrocyte Desensitization Toward Insulin-Like Growth Factor <i>R. L. Smeets, S. Veenbergen, O. J. Arntz, M. B. Bennink, L. A. B. Joosten, W. B. van den Berg, and F. A. J. van de Loo</i>	1518
<b>Osteoarthritis Clinical Studies</b>	
Increase in Bone Marrow Lesions Associated With Cartilage Loss: A Longitudinal Magnetic Resonance Imaging Study of Knee Osteoarthritis <i>David J. Hunter, Yuqing Zhang, Jingbo Niu, Joyce Goggins, Shreyasee Amin, Michael P. LaValley, Ali Guermazi, Harry Genant, Daniel Gale, and David T. Felson</i>	1529
Development of a Preliminary Index That Predicts Adverse Events After Total Knee Replacement <i>Daniel H. Solomon, Lori B. Chibnik, Elena Losina, Jenny Huang, Anne H. Fossel, Elaine Husni, and Jeffrey N. Katz</i>	1536
<b>Systemic Lupus Erythematosus Basic Science Studies</b>	
Impaired Recognition of Apoptotic Neutrophils by the C1q/Calreticulin and CD91 Pathway in Systemic Lupus Erythematosus <i>Suzanne Donnelly, Wendy Roake, Simon Brown, Philip Young, Haley Naik, Paul Wordsworth, David A. Isenberg, Kenneth B. M. Reid, and Paul Eggleton</i>	1543
"Endogenous Adjuvant" Activity of the RNA Components of Lupus Autoantigens Sm/RNP and Ro 60 <i>Kindra M. Kelly, Haoyang Zhuang, Dina C. Nacionales, Philip O. Scumpia, Robert Lyons, Jun Akaogi, Pui Lee, Bryan Williams, Masahiro Yamamoto, Shizuo Akira, Minoru Satoh, and Westley H. Reeves</i>	1557
<b>Systemic Lupus Erythematosus Clinical Studies</b>	
Antibodies to Ribosomal P Proteins: A Potential Serologic Marker for Lupus Membranous Glomerulonephritis <i>Ana Patrícia do Nascimento, Vilma dos Santos Trindade Viana, Leonardo de Abreu Testagrossa, Elaine Pires Leon, Eduardo Ferreira Borba, Rui Toledo Barros, and Eloísa Bonfá</i>	1568
Lupus-Like Disease and High Interferon Levels Corresponding to Trisomy of the Type I Interferon Cluster on Chromosome 9p <i>Haoyang Zhuang, Mona Kosboth, Pui Lee, Amanda Rice, Daniel J. Driscoll, Roberto Zori, Sonali Narain, Robert Lyons, Minoru Satoh, Eric Sobel, and Westley H. Reeves</i>	1573

Systemic Lupus Erythematosus in a Multiethnic US Cohort: Clinical Features, Course, and Outcome in Patients With Late-Onset Disease <i>Ana M. Bertoli, Graciela S. Alarcón, Jaime Calvo-Alén, Mónica Fernández, Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group</i>	1580
<b>Childhood Arthritis</b>	
Vascular Endothelial Growth Factor Gene Haplotypes in Kawasaki Disease <i>W. B. Breunis, M. H. Biezeveld, J. Geissler, J. Ottenkamp, I. M. Kuipers, J. Lam, A. Hutchinson, R. Welch, S. J Chanock, and T. W. Kuipers</i>	1588
Predictors of Disease Course and Remission in Systemic Juvenile Idiopathic Arthritis: Significance of Early Clinical and Laboratory Features <i>D. Singh-Grewal, R. Schneider, N. Bayer, and B. M. Feldman</i>	1595
A Comparison of Response Criteria to Evaluate Therapeutic Response in Patients With Juvenile Idiopathic Arthritis Treated With Methotrexate and/or Anti-Tumor Necrosis Factor $\alpha$ Agents <i>A. Lurati, I. Pontikaki, B. Teruzzi, F. Desiati, V. Gerloni, M. Gattinara, R. Cimaz, and F. Fantini</i>	1602
<b>Vasculitis Clinical Studies</b>	
Solid Malignancies Among Patients in the Wegener's Granulomatosis Etanercept Trial <i>John H. Stone, Janet T. Holbrook, Matthew A. Marriott, Andrea K. Tibbs, Lourdes P. Sejismundo, Y.-I. Min, Ulrich Specks, Peter A. Merkel, Robert Spiera, John C. Davis, E. William St.Clair, W. Joseph McCune, Steven R. Ytterberg, Nancy B. Allen, and Gary S. Hoffman, for the Wegener's Granulomatosis Etanercept Trial Research Group</i>	1608
<b>Vasculitis Basic Science Studies</b>	
Mediation of Endothelial Cell Damage by Serine Proteases, but Not Superoxide, Released From Antineutrophil Cytoplasmic Antibody-Stimulated Neutrophils <i>X. Lu, A. Garfield, G. E. Rainger, C. O. S. Savage, and G. B. Nash</i>	1619
Mouse Monoclonal Anti-Human Thrombomodulin Antibodies Bind to and Activate Endothelial Cells Through NF- $\kappa$ B Activation In Vitro <i>Hiroyuki Nara, Hiroshi Okamoto, Seiji Minota, and Taku Yoshi</i>	1629
<b>Psoriatic Arthritis</b>	
Alefacept in Combination With Methotrexate for the Treatment of Psoriatic Arthritis: Results of a Randomized, Double-Blind, Placebo-Controlled Study <i>Philip J. Mease, Dafna D. Gladman, and Edward C. Keystone, on behalf of the Alefacept in Psoriatic Arthritis Study Group</i>	1638
<b>Ankylosing Spondylitis</b>	
Major Reduction in Spinal Inflammation in Patients With Ankylosing Spondylitis After Treatment With Infliximab: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Magnetic Resonance Imaging Study <i>Jürgen Braun, Robert Landewé, Kay-Geert A. Hermann, John Han, Songkai Yan, Paul Williamson, and Désirée van der Heijde, for the ASSERT Study Group</i>	1646
<b>Experimental Arthritis</b>	
Connective Tissue Growth Factor/CCN2 Overexpression in Mouse Synovial Lining Results in Transient Fibrosis and Cartilage Damage <i>E. N. Blaney Davidson, E. L. Vitters, F. M. Mooren, N. Oliver, W. B. van den Berg, and P. M. van der Kraan</i>	1653
Functional Characterization of a Soluble gp130 Isoform and Its Therapeutic Capacity in an Experimental Model of Inflammatory Arthritis <i>Peter J. Richards, Mari A. Nowell, Sankichi Horiuchi, Rachel M. McLoughlin, Ceri A. Fielding, Sandra Grau, Naoki Yamamoto, Michael Ehrmann, Stefan Rose-John, Anwen S. Williams, Nicholas Topley, and Simon A. Jones</i>	1662
Hyaluronan Molecular Reflection by Synovial Lining Is Concentration Dependent and Reduced in Dilute Effusions in a Rabbit Model <i>S. Sabaratnam, R. M. Mason, and J. R. Levick</i>	1673
<b>Pain</b>	
Importance of Genetic Influences on Chronic Widespread Pain <i>Kenji Kato, Patrick F. Sullivan, Birgitta Evengård, and Nancy L. Pedersen</i>	1682
<b>Clinical Images</b>	
An Uncommon Cause of Hip Pain <i>Deep H. Datal, Rodolfo Curiel, Lily Somwaru, and Kathleen A. Brindle</i>	1686
<b>Myopathy</b>	
Brachio-Cervical Inflammatory Myopathies: Clinical, Immune, and Myopathologic Features <i>Alan Pestronk, Ksenija Kos, Glenn Lopate, and Muhammad T. Al-Lozi</i>	1687

<b>Muckle-Wells Syndrome</b>	
Recovery From Deafness in a Patient With Muckle-Wells Syndrome Treated With Anakinra Tristan Mirault, David Launay, Laurence Cuisset, Eric Hachulla, Marc Lambert, Viviane Queyrel, Thomas Quemeneur, Sandrine Morell-Dubois, and Pierre-Yves Hatron .....	1697
<b>Concise Communications</b>	
Anti-Cyclic Citrullinated Peptide Antibodies in Psoriasis Patients Without Arthritis Raik Böckelmann, Harald Gollnick, and Bernd Bonnekoh .....	1701
Systemic Lupus Erythematosus in a Multiethnic US Cohort: XXXVI. Influence of Mannose-Binding Lectin Exon 1 Polymorphisms in Disease Manifestations, Course, and Outcome Ana M. Bertoli, Mónica Fernández, Gerald McGwin, Jr., Graciela S. Alarcón, Filemon K. Tan, John D. Reveille, and Luis M. Vilá.....	1703
<b>Erratum</b>	
Omission of two names in article by Kitano et al (Arthritis Rheum, March 2006) .....	1704
<b>Letters</b>	
I Am the Very Model of a Modern Rheumatologist ( <i>with apologies to Gilbert and Sullivan</i> ) Jerry A. Green .....	1705
Does Obesity Play a Role in Functional Capacity and Inflammation in Patients With Lupus? Comment on the Article by Oeser et al Sumapa Chaiamnuay and Graciela S. Alarcón .....	1705
Reply Annette Oeser, Cecilia P. Chung, Patrick G. Arbogast, and C. Michael Stein .....	1706
Chemokine Receptor Expression by Peripheral Blood B Lymphocytes in Patients With Primary Sjögren's Syndrome: Comment on the Article by Hansen et al E. Perucha, E. Reyes, A. Prieto, M. Álvarez de Mon, A. Rodríguez, and A. Zea .....	1707
Reply Arne Hansen, Thomas Dörner, and Peter E. Lipsky.....	1708
Effect of Folic Acid Supplementation on the Efficacy of Methotrexate Treatment in Rheumatoid Arthritis: Comment on the Article by Khanna et al Sarah L. Morgan, Joseph E. Baggott, and Graciela S. Alarcón .....	1708
Reply Dinesh Khanna, Harold Paulus, and Daniel E. Furst .....	1709
<b>Clinical Images</b>	
Giant Cell Arteritis Revealed by Positron Emission Tomography John M. Loeb and Barry Engelstad .....	1710
<b>ACR Announcements</b> .....	A16

VOLUME 54

JUNE 2006

NO. 6

**Special Articles**

Editorial: Journal Policies on Authorship and Disclosures Patricia P. Katz, Edward H. Yelin, and Michael D. Lockshin .....	1711
Review: Gene Therapy for Arthritis: What Next? Christopher H. Evans, Steven C. Ghivizzani, and Paul D. Robbins .....	1714
Editorial: Preventing and Repairing Vascular Damage in Scleroderma: Should We Focus Beyond Vasodilatation to Recruitment of Endothelial Precursor Cells? Robert M. Clancy .....	1730
Editorial: Biomarkers in Spondylarthritis: A Peripheral Vision Tae-Hwan Kim and Robert D. Inman .....	1733
<b>Rheumatoid Arthritis Basic Science Studies</b>	
Noggin Haploinsufficiency Differentially Affects Tissue Responses in Destructive and Remodeling Arthritis Rik J. U. Lories, Melina Daans, Inge Derese, Patrick Matthys, Ahmad Kasran, Przemko Tylzanowski, Jan L. Ceuppens, and Frank P. Luyten .....	1736

CD40 Ligation of Rheumatoid Synovial Fibroblasts Regulates RANKL-Mediated Osteoclastogenesis: Evidence of NF- $\kappa$ B-Dependent, CD40-Mediated Bone Destruction in Rheumatoid Arthritis Hak-Yong Lee, Hyun-Soon Jeon, Eun-Kyung Song, Myung-Kwan Han, Sung-II Park, Sang-II Lee, Hee-Jin Yun, Jung-Ryul Kim, Jong-Suk Kim, Yong-Chul Lee, Sung-II Kim, Hang-Rae Kim, Jin-Young Choi, Insoo Kang, Ho-Youn Kim, and Wan-Hee Yoo.....	1747
Surface-Bound Anti-Type II Collagen-Containing Immune Complexes Induce Production of Tumor Necrosis Factor $\alpha$ , Interleukin-1 $\beta$ , and Interleukin-8 From Peripheral Blood Monocytes via Fc $\gamma$ Receptor IIa: A Potential Pathophysiologic Mechanism for Humoral Anti-Type II Collagen Immunity in Arthritis Mohammed Mullazehi, Linda Mathsson, Jon Lampi, and Johan Rönnelid.....	1759
The Ratio of Circulating Osteoprotegerin to RANKL in Early Rheumatoid Arthritis Predicts Later Joint Destruction P. P. Geusens, R. B. M. Landewé, P. Garnero, D. Chen, C. R. Dunstan, W. F. Lems, P. Stinissen, D. M. F. M. van der Heijde, S. van der Linden, and M. Boers .....	1772
<b>Rheumatoid Arthritis Clinical Studies</b>	
Anti-Interleukin-6 Receptor Antibody Therapy Favors Adrenal Androgen Secretion in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Study Rainer H. Straub, Peter Härlé, Seizo Yamana, Takemasa Matsuda, Kiyoshi Takasugi, Tadamitsu Kishimoto, and Norihiro Nishimoto .....	1778
Comparison of the Response to Infliximab or Etanercept Monotherapy With the Response to Cotherapy With Methotrexate or Another Disease-Modifying Antirheumatic Drug in Patients With Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register Kimme L. Hyrich, Deborah P. M. Symmons, Kath D. Watson, and Alan J. Silman, on behalf of the British Society for Rheumatology Biologics Register.....	1786
<b>Ankylosing Spondylitis</b>	
Identification of Synovial Biomarkers of Response to Experimental Treatment in Early-Phase Clinical Trials in Spondylarthritis Elli Kruithof, Leen De Rycke, Bernard Vandooren, Filip De Keyser, Oliver FitzGerald, Iain McInnes, Paul P. Tak, Barry Bresnihan, Eric M. Veys, and Dominique Baeten, on behalf of the OMERACT Special Interest Group on Synovial Analysis in Clinical Trials .....	1795
Immunohistochemical Analysis of Hip Arthritis in Ankylosing Spondylitis: Evaluation of the Bone-Cartilage Interface and Subchondral Bone Marrow Heiner Appel, Maren Kuhne, Simone Spiekermann, Dorothee Köhler, Josef Zacher, Harald Stein, Joachim Sieper, and Christoph Loddenkemper.....	1805
<b>Osteoarthritis</b>	
Caspase Inhibitors Reduce Severity of Cartilage Lesions in Experimental Osteoarthritis Darryl D'Lima, Juan Hermida, Sanshiro Hashimoto, Clifford Colwell, and Martin Lotz.....	1814
Lack of Association Between Chondrocalcinosis and Increased Risk of Cartilage Loss in Knees With Osteoarthritis: Results of Two Prospective Longitudinal Magnetic Resonance Imaging Studies T. Neogi, M. Nevitt, J. Niu, M. P. LaValley, D. J. Hunter, R. Terkeltaub, L. Carbone, H. Chen, T. Harris, K. Kwoh, A. Guermazi, and D. T. Felson.....	1822
Transdermal Fentanyl for Improvement of Pain and Functioning in Osteoarthritis: A Randomized, Placebo-Controlled Trial Richard Langford, Frank McKenna, Stuart Ratcliffe, Jozef Vojtassák, and Ute Richarz .....	1829
<b>Osteoporosis</b>	
Intravenous Ibandronate Injections in Postmenopausal Women With Osteoporosis: One-Year Results From the Dosing Intravenous Administration Study Pierre D. Delmas, Silvano Adami, Cezary Strugala, Jacob A. Stakkestad, Jean-Yves Reginster, Dieter Felsenberg, Claus Christiansen, Roberto Civitelli, Marc K. Drezner, Robert R. Recker, Michael Bolognese, Claire Hughes, Daiva Masanauskaitė, Penelope Ward, Philip Sambrook, and David M. Reid.....	1838
<b>Experimental Arthritis</b>	
Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis: Vascular Superoxide Production by NAD(P)H Oxidase and Uncoupled Endothelial Nitric Oxide Synthase Yoshisuke Haruna, Yoshitaka Morita, Norio Komai, Toyotaka Yada, Takeo Sakuta, Naruya Tomita, David A. Fox, and Naoki Kashihara .....	1847
Formatted Anti-Tumor Necrosis Factor $\alpha$ VH Proteins Derived From Camelids Show Superior Potency and Targeting to Inflamed Joints in a Murine Model of Collagen-Induced Arthritis Ken Coppiepers, Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwerys, Peter Casteels, Els Beirnaert, Heidi Jonckheere, Christophe Van de Wiele, Ludovicus Staelens, Jeroen Hostens, Hilde Revets, Erik Remaut, Dirk Elewaut, and Pieter Rottiers .....	1856

Efficient New Cationic Liposome Formulation for Systemic Delivery of Small Interfering RNA Silencing Tumor Necrosis Factor $\alpha$ in Experimental Arthritis <i>Maroun Khouri, Pascale Louis-Prence, Virginie Escriou, Danièle Noel, Céline Largeau, Céline Cantos, Daniel Scherman, Christian Jorgensen, and Florence Apparailly.....</i>	1867
Immunoregulatory Effects of Allogeneic Mixed Chimerism Induced by Nonmyeloablative Bone Marrow Transplantation on Chronic Inflammatory Arthritis and Autoimmunity in Interleukin-1 Receptor Antagonist-Deficient Mice <i>Seok Goo Cho, So-Youn Min, Min Jung Park, Kyung Wha Lee, Young-Gyu Cho, Mi-La Cho, Hong Seok Chang, Se-Ho Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim, and Ho-Youn Kim .....</i>	1878
<b>Cartilage Biology</b>	
Dynamic Shear Stimulation of Bovine Cartilage Biosynthesis of Proteoglycan 4 <i>Gayle E. Nugent, Nicole M. Aneloski, Tannin A. Schmidt, Barbara L. Schumacher, Michael S. Voegtle, and Robert L. Sah .....</i>	1888
Effects of Vibration and Hyaluronic Acid on Activation of Three-Dimensional Cultured Chondrocytes <i>Ryohei Takeuchi, Tomoyuki Saito, Hiroyuki Ishikawa, Hidetake Takigami, Mari Dezawa, Chizuka Ide, Yutaka Itokazu, Mitsugu Ikeda, Toshihiko Shiraishi, and Shin Morishita.....</i>	1897
<b>Systemic Lupus Erythematosus</b>	
Functional Assay of Type I Interferon in Systemic Lupus Erythematosus Plasma and Association With Anti-RNA Binding Protein Autoantibodies <i>Jing Hua, Kyriakos Kirou, Christina Lee, and Mary K. Crow .....</i>	1906
Induction of Interferon- $\alpha$ by Immune Complexes or Liposomes Containing Systemic Lupus Erythematosus Autoantigen- and Sjögren's Syndrome Autoantigen-Associated RNA <i>Tanja Lövgren, Maija-Leena Eloranta, Berthold Kastner, Marie Wahren-Herlenius, Gunnar V. Alm, and Lars Rönnblom.....</i>	1917
Relationship of Serum Paraoxonase 1 Activity and Paraoxonase 1 Genotype to Risk of Systemic Lupus Erythematosus <i>Laura M. Tripi, Susan Manzi, Qi Chen, Margaret Kenney, Penny Shaw, Amy Kao, Franklin Bontempo, Candace Kammerer, and M. Ilyas Kamboh.....</i>	1928
Systemic Lupus Erythematosus in a Multiethnic US Cohort. XXXIV. Deficient Mannose-Binding Lectin Exon 1 Polymorphisms Are Associated With Cerebrovascular but Not With Other Arterial Thrombotic Events <i>Jaime Calvo-Alén, Graciela S. Alarcón, Monty B. Tew, Filemon K. Tan, Gerald McGwin, Jr., Barri J. Fessler, Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group .....</i>	1940
<b>Systemic Sclerosis</b>	
Increase in Circulating Endothelial Precursors by Atorvastatin in Patients With Systemic Sclerosis <i>Masataka Kuwana, Junichi Kaburaki, Yuka Okazaki, Hidekata Yasuoka, Yutaka Kawakami, and Yasuo Ikeda .....</i>	1946
Abnormal Microvascular Response Is Localized to the Digits in Patients With Systemic Sclerosis <i>A. K. Murray, T. L. Moore, T. A. King, and A. L. Herrick .....</i>	1952
Gene Profiling of Scleroderma Skin Reveals Robust Signatures of Disease That Are Imperfectly Reflected in the Transcript Profiles of Explanted Fibroblasts <i>Humphrey Gardner, Jeffrey R. Shearstone, Raj Bandaru, Tom Crowell, Matthew Lynes, Maria Trojanowska, Jaspreet Pannu, Edwin Smith, Stefania Jablonska, Maria Blaszczyk, Filemon K. Tan, and Maureen D. Mayes .....</i>	1961
Transition From Primary Raynaud's Phenomenon to Secondary Raynaud's Phenomenon Identified by Diagnosis of an Associated Disease: Results of Ten Years of Prospective Surveillance <i>Mirko Hirschl, Katharina Hirschl, Matthias Lenz, Reinhold Katzenbach, Hans-Peter Hutter, and Michael Kundi.....</i>	1974
Allogeneic Marrow Transplantation in Patients With Severe Systemic Sclerosis: Resolution of Dermal Fibrosis <i>Richard A. Nash, Peter A. McSweeney, J. Lee Nelson, Mark Wener, George E. Georges, Amelia A. Langston, Howard Shulman, Keith M. Sullivan, Julie Lee, Gretchen Henstorf, Rainer Storb, and Daniel E. Furst .....</i>	1982
<b>Childhood Arthritis</b>	
Long-Term Safety and Efficacy of Etanercept in Children With Polyarticular-Course Juvenile Rheumatoid Arthritis <i>Daniel J. Lovell, Andreas Reiff, Olcay Y. Jones, Rayfel Schneider, James Nocton, Leonard D. Stein, Abraham Gedalia, Norman T. Ilowite, Carol A. Wallace, James B. Whitmore, Barbara White, and Edward H. Giannini, for the Pediatric Rheumatology Collaborative Study Group .....</i>	1987

**Fibromyalgia**

- Reduced Brain Habituation to Somatosensory Stimulation in Patients With Fibromyalgia  
*Pedro Montoya, Carolina Sitges, Manuel García-Herrera, Alfonso Rodríguez-Cotes, Raúl Izquierdo,  
Magdalena Trayols, and Dolores Collado* ..... 1995

**Polymyositis/Dermatomyositis**

- Unusually High Frequency of Autoantibodies to PL-7 Associated With Milder Muscle Disease in Japanese Patients With Polymyositis/Dermatomyositis  
*Yoshioki Yamasaki, Hidehiro Yamada, Toshiko Nozaki, Jun Akaogi, Cody Nichols, Robert Lyons,  
Anthony Chin Loy, Edward K. L. Chan, Westley H. Reeves, and Minoru Satoh* ..... 2004

**Erratum**

- Omission of Disclosure of Interest Paragraph in Article by Navratil et al (Arthritis Rheum, February 2006) ..... 2009

**Amyloidosis**

- AA Amyloidosis Complicating Hyperimmunoglobulinemia D With Periodic Fever Syndrome: A Report of Two Cases  
*Helen J. Lachmann, Hugh J. B. Goodman, Peter A. Andrews, Hugh Gallagher, James Marsh,  
Stephan Breuer, Dorota M. Rowczenio, Alison Bybee, and Philip N. Hawkins* ..... 2010
- Diagnostic Accuracy of Subcutaneous Abdominal Fat Tissue Aspiration for Detecting Systemic Amyloidosis and Its Utility in Clinical Practice  
*Ingrid I. van Cameren, Bouke P. C. Hazenberg, Johan Bijzet, and Martin H. van Rijswijk* ..... 2015

**Concise Communications**

- Temporal Expression Pattern of Duffy Antigen in Rheumatoid Arthritis: Up-Regulation in Early Disease  
*Lucy Gardner, Catherine Wilson, Angela M. Patterson, Barry Bresnihan, Oliver FitzGerald,  
Michael A. Stone, Brian A. Ashton, and Jim Middleton* ..... 2022
- Failure to Confirm Coxsackievirus Infection in Primary Sjögren's Syndrome  
*Jacques-Eric Gottenberg, Coralie Pallier, Marc Ittah, Frédéric Lavie, Corinne Miceli-Richard,  
Jérémie Sellam, Patrice Nordmann, Nicholas Cagnard, Jean Sibilia, and Xavier Mariette* ..... 2026
- Variation in Radiologic Joint Destruction in Rheumatoid Arthritis Differs Between Monozygotic and Dizygotic Twins and Pairs of Unrelated Patients  
*Annette H. M. van der Helm-van Mil, M. Kern, Peter K. Gregersen, and Tom W. J. Huizinga* ..... 2028

**Clinical Images**

- Tropical Pyomyositis of the Lower Limbs  
*Rahul Grover, Varun Dhir, Kannan Guruprasad, Atin Kumar, and Rohini Handa* ..... 2030

**Letters**

- The Benefit of Low-Dose Glucocorticoid Treatment in Early Rheumatoid Arthritis May Outweigh the Risk: Comment on the Editorial by Harris  
*Johannes W. G. Jacobs, Maarten Boers, John R. Kirwan, and Johannes W. J. Bijlsma* ..... 2031
- Reply  
*Edward D. Harris, Jr.* ..... 2032
- Efficacy of Combination Therapy in Rheumatoid Arthritis: Comment on the Review by Smolen et al  
*Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Markku Korpela, Markku Hakala, and Hannu Kautiainen* ..... 2032
- Reply  
*Edward Keystone, Daniel Aletaha, and Josef S. Smolen* ..... 2034

- Implications of Radiographic Joint Damage in Rheumatoid Arthritis: Comment on the Editorial by Weisman  
*Arthur Kavanaugh* ..... 2035
- Association of Antioxidized Low-Density Lipoprotein Antibodies With Vascular Arterial Events and Renal Manifestations in Systemic Lupus Erythematosus Patients: Comment on the Article by Frostegård et al  
*Ana M. Bertoli, Mónica Fernández, Gerald McGwin, Jr., Luis M Vilá, John D. Reveille, and Graciela S. Alarcón* ..... 2035

- Lyn Deficiency in B Cells From Patients With Systemic Lupus Erythematosus: Comment on the Article by Flores-Borja et al  
*Stamatis-Nick C. Liossis, Elena E. Solomou, and Petros P. Sfikakis* ..... 2036
- Reply  
*Fabian Flores-Borja, Panagiotis S. Kabouridis, Elizabeth C. Jury, David A. Isenberg, and Rizgar A. Mageed* ..... 2037

**Clinical Images**

- Intersection Syndrome of the Forearm  
*Jeffrey Browne and Clyde A. Helms* ..... 2038

**Special Article**

- Review: Tumor Necrosis Factor-Neutralizing Therapies Improve Altered Hormone Axes: An Alternative Mode of Antiinflammatory Action  
*Rainer H. Straub, Peter Härlé, Piercarlo Sarzi-Puttini, and Maurizio Cutolo* ..... 2039

**Rheumatoid Arthritis Clinical Studies**

- Identification of Genes Modulated in Rheumatoid Arthritis Using Complementary DNA Microarray Analysis of Lymphoblastoid B Cell Lines From Disease-Discordant Monozygotic Twins  
*Christian S. Haas, Chad J. Creighton, Xiujun Pi, Ira Maine, Alisa E. Koch, G. Kenneth Haines, III, Song Ling, Arul M. Chinaiyan, and Joseph Holoshitz* ..... 2047
- Increased Case Fatality Rates Following a First Acute Cardiovascular Event in Patients With Rheumatoid Arthritis  
*S. Van Doornum, C. Brand, B. King, and V. Sundararajan* ..... 2061
- Prospective Study of Fetal DNA in Serum and Disease Activity During Pregnancy in Women With Inflammatory Arthritis  
*Zhen Yan, Nathalie C. Lambert, Monika Østensen, Kristina M. Adams, Katherine A. Guthrie, and J. Lee Nelson* ..... 2069

**Rheumatoid Arthritis Basic Science Studies**

- Direct Modulation of Rheumatoid Inflammatory Mediator Expression in Retinoblastoma Protein-Dependent and -Independent Pathways by Cyclin-Dependent Kinase 4/6  
*Yoshinori Nonomura, Kenji Nagasaki, Hiroyuki Hagiyama, Chiyoko Sekine, Toshihiro Nanki, Mimi Tamamori-Adachi, Nobuyuki Miyasaka, and Hitoshi Kohsaka* ..... 2074
- Regulation of Pre-B Cell Colony-Enhancing Factor by STAT-3-Dependent Interleukin-6 Trans-Signaling: Implications in the Pathogenesis of Rheumatoid Arthritis  
*Mari A. Nowell, Peter J. Richards, Ceri A. Fielding, Simona Ognjanovic, Nick Topley, Anwen S. Williams, Gillian Bryant-Greenwood, and Simon A. Jones* ..... 2084
- Differential Survival of Leukocyte Subsets Mediated by Synovial, Bone Marrow, and Skin Fibroblasts: Site-Specific Versus Activation-Dependent Survival of T Cells and Neutrophils  
*Andrew Filer, Greg Parsonage, Emily Smith, Chloe Osborne, Andrew M. C. Thomas, S. John Curnow, G. Ed Rainger, Karim Raza, Gerard B. Nash, Janet Lord, Mike Salmon, and Christopher D. Buckley* ..... 2096
- Overexpression of Synoviolin in Peripheral Blood and Synoviocytes From Rheumatoid Arthritis Patients and Continued Elevation in Nonresponders to Infliximab Treatment  
*Myew-Ling Toh, Hubert Marotte, Jean-Luc Blond, Umar Jhumka, Assia Eljaafari, Bruno Mougin, and Pierre Miossec* ..... 2109
- Inflammatory Cytokine Regulation of Transgene Expression in Human Fibroblast-like Synoviocytes Infected With Adeno-Associated Virus  
*Russell S. Traister, Sylvie Fabre, Zhong Wang, Xiao Xiao, and Raphael Hirsch* ..... 2119
- Regulation of JNK by MKK-7 in Fibroblast-like Synoviocytes  
*Tomoyuki Inoue, Deepa Hammaker, David L. Boyle, and Gary S. Firestein* ..... 2127

**Ankylosing Spondylitis**

- Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial  
*Désirée van der Heijde, Alan Kivitz, Michael H. Schiff, Joachim Sieper, Ben A. C. Dijkmans, Jürgen Braun, Maxime Dougados, John D. Reveille, Robert L. Wong, Hartmut Kupper, and John C. Davis, Jr., for the ATLAS Study Group* ..... 2136

**Osteoarthritis**

- The Heritable Determinants of Cartilage Oligomeric Matrix Protein  
*Frances M. K. Williams, Toby Andrew, Tore Saxne, Dick Heinegard, Tim D. Spector, and Alex J. MacGregor* ..... 2147

**Clinical Images**

- B Cell Depletion in the Appendix Following Rituximab Treatment  
*Daphna Paran, Leonor Trej'o, and Dan Caspi* ..... 2151

**Cartilage Biology**

- The Catabolic Pathway Mediated by Toll-like Receptors in Human Osteoarthritic Chondrocytes  
*Hyun Ah Kim, Mi-La Cho, Hye Young Choi, Chang Sik Yoon, Joo Yeon Jhun, Hey Jwa Oh, and Ho-Young Kim* ..... 2152
- Effects of Interleukin-1 on Calcium Signaling and the Increase of Filamentous Actin in Isolated and In Situ Articular Chondrocytes  
*Scott Pritchard and Farshid Guilak* ..... 2164

<b>Systemic Lupus Erythematosus</b>	
Anti-20S Proteasome Autoantibodies Inhibit Proteasome Stimulation by Proteasome Activator PA28 Michael Brychcy, Ulrike Kuckelkorn, Gert Hausdorf, Karl Egerer, Peter-M. Kloetzel, Gerd-R. Burmester, and Eugen Feist .....	2175
Abnormal Differentiation of Memory T Cells in Systemic Lupus Erythematosus Ruth D. Fritsch, Xinglei Shen, Gabor G. Illei, Cheryl H. Yarboro, Calman Prussin, Karen S. Hathcock, Richard J. Hodes, and Peter E. Lipsky .....	2184
Nephritogenic Anti-DNA Antibodies Regulate Gene Expression in MRL/lpr Mouse Glomerular Mesangial Cells Xiaoping Qing, Jiri Zavadil, Michelle B. Crosby, Mark P. Hogarth, Bevra H. Hahn, Chandra Mohan, Gary S. Gilkeson, Erwin P. Bottinger, and Chaim Puterman .....	2198
Association Between Serum Total Cholesterol Level and Renal Outcome in Systemic Lupus Erythematosus Analiese Tisseverasinghe, Sooyeon Lim, Celia Greenwood, Murray Urowitz, Dafna Gladman, and Paul R. Fortin .....	2211
Homocysteine Levels and Disease Duration Independently Correlate With Coronary Artery Calcification in Patients With Systemic Lupus Erythematosus Joan M. Von Feldt, Lisabeth V. Scalzi, Andrew J. Cucchiara, Suneetha Morthala, Carmel Kealey, Stephanie D. Flagg, Anna Genin, Alison L. Van Dyke, Eleni Nackos, Avantika Chander, Erika Gehrie, Randy Q. Cron, and Alexander S. Whitehead .....	2220
<b>Childhood Arthritis</b>	
Anti-La/SSB Autoantibodies in Maternal Serum: A Marker of Low Risk for Neonatal Lupus in an Offspring Eleni A. Stea, John G. Routsias, Robert M. Clancy, Jill P. Buyon, Haralampos M. Moutsopoulos, and Athanasios G. Tzioufas .....	2228
A Randomized Controlled Trial of Calcium Supplementation to Increase Bone Mineral Density in Children With Juvenile Rheumatoid Arthritis Daniel J. Lovell, David Glass, Julie Ranz, Sandy Kramer, Bin Huang, Rosa I. Sierra, Carol J. Henderson, Murray Passo, Brent Graham, Suzanne Bowyer, Gloria Higgins, Robert Rennebohm, Kenneth N. Schikler, and Edward Giannini .....	2235
<b>Clinical Image</b>	
Coexistence of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Posterior Longitudinal Ligament of the Cervical Spine in a Patient With Ankylosing Spondylitis Tae-Hwan Kim and Jae-Bum Jun .....	2242
<b>Systemic Sclerosis</b>	
Systemic Sclerosis-Associated Sjögren's Syndrome and Relationship to the Limited Cutaneous Subtype: Results of a Prospective Study of Sicca Syndrome in 133 Consecutive Patients J. Avouac, C. Sordet, C. Depinay, M. Ardizzone, M. C. Vacher-Lavenu, J. Sibilia, A. Kahan, and Y. Allanore .....	2243
Induction of Apoptosis and Fibrillin 1 Expression in Human Dermal Endothelial Cells by Scleroderma Sera Containing Anti-Endothelial Cell Antibodies S. Sohail Ahmed, Filemon K. Tan, Frank C. Arnett, Li Jin, and Yong-Jian Geng .....	2250
Hemorheologic Profile in Systemic Sclerosis: Role of NOS3 -786T>C and 894G>T Polymorphisms in Modulating Both the Hemorheologic Parameters and the Susceptibility to the Disease Cinzia Fatini, Lucia Mannini, Elena Sticchi, Veronica Rogai, Serena Guiducci, Maria Letizia Conforti, Marina Cinelli, Alberto Moggi Pignone, Paola Bolli, Rosanna Abbate, and Marco Matucci Cerinic .....	2263
Association Between Enhanced Type I Collagen Expression and Epigenetic Repression of the <i>FLII</i> Gene in Scleroderma Fibroblasts Youngqing Wang, Pan-Sheng Fan, and Bashar Kahaleh .....	2271
<b>Sjögren's Syndrome</b>	
Identification of Transitional Type II B Cells in the Salivary Glands of Patients With Sjögren's Syndrome Capucine Daridon, Jacques-Olivier Pers, Valérie Devauchelle, Christine Martins-Carvalho, Pascal Hutin, Yvon-Louis Pennec, Alain Saraux, and Pierre Youinou .....	2280
Increased Extracellular Levels of the Novel Proinflammatory Cytokine High Mobility Group Box Chromosomal Protein 1 in Minor Salivary Glands of Patients With Sjögren's Syndrome Monica Ek, Karin Popovic, Helena Erlandsson Harris, Cecilia Söderberg Nauclér, and Marie Wahren-Herlenius .....	2289
Salivary Gland Epithelial Cells: A New Source of the Immunoregulatory Hormone Adiponectin Stergios Katsiougianis, Efstatia K. Kapsogeorgou, Menelaos N. Manoussakis, and Fotini N. Skopouli ....	2295

Impaired Salivary Gland Function in NOD Mice: Association With Changes in Cytokine Profile but Not With Histopathologic Changes in the Salivary Gland Malin V. Jonsson, Nicolas Delaleu, Karl A. Brokstad, Ellen Berggreen, and Kathrine Skarstein .....	2300
<b>Autoinflammatory Disease</b>	
Manipulation of Isoprenoid Biosynthesis as a Possible Therapeutic Option in Mevalonate Kinase Deficiency Marit S. Schneiders, Sander M. Houten, Marjolein Turkenburg, Ronald J. A. Wanders, and Hans R. Waterham .....	2306
A Severe Case of Chronic Infantile Neurologic, Cutaneous, Articular Syndrome Treated With Biologic Agents Tomoyo Matsubara, Masanari Hasegawa, Masahiro Shiraishi, Hal M. Hoffman, Takashi Ichiyama, Takeo Tanaka, Haruo Ueda, Tokuhiro Ishihara, and Susumu Furukawa .....	2314
<b>Errata</b>	
Error in Listed Primer Sequences Used for Human PiT-1 in Article by Cecil et al (Arthritis Rheum, January 2005), and Omission of Roman Numeral from Subtitle of article by Bertoli et al (Arthritis Rheum, May 2006).....	2320
<b>Psoriatic Arthritis</b>	
Association Between the Interleukin-1 Family Gene Cluster and Psoriatic Arthritis Proton Rahman, Shuying Sun, Lynette Peddle, Tara Snelgrove, William Melay, Celia Greenwood, and Dafna Gladman .....	2321
<b>Vasculitis</b>	
Antigenic Targets and Pathogenicity of Anti-Aortic Endothelial Cell Antibodies in Takayasu Arteritis Sunil Kumar Chauhan, Naresh Kumar Tripathy, and Soniya Nityanand.....	2326
<b>Concise Communications</b>	
Association of Intermittent Hydrarthrosis With MEFV Gene Mutations Juan D. Cañete, Juan I. Aróstegui, Rubén Queiró, Raimon Sanmartí, Javier Ballina, Xavier Bosch, and Jordi Yagüe .....	2334
Concomitant Interferon- $\alpha$ Therapy and Tumor Necrosis Factor $\alpha$ Inhibition for Rheumatoid Arthritis and Hepatitis C Timothy B. Niewold and Allan Gibofsky .....	2335
<b>Letters</b>	
How Should Best Strategy and Tight Control Be Translated Into Clinical Practice? Comment on the Article by Goeckoop-Ruiterman et al Henning Zeidler and Jan L. Hülsemann .....	2338
Reply Yvonne P. M. Goeckoop-Ruiterman, Cornelia F. Allaart, Ferdinand C. Breedveld, Jeska K. de Vries-Bouwstra, and Ben A. C. Dijkmans .....	2339
Clinical Significance of the Long-Term Symptom-Modifying Effects of Glucosamine Sulfate: Comment on the Article by Brandt and Mazzuca Olivier Bruyere, Jean-Yves Reginster, Giampaolo Giacovelli, Beatrice Barbetta, Lucio C. Rovati, and Karel Pavelka .....	2339
Reply K. D. Brandt and S. A. Mazzuca .....	2341
Usefulness of the British Isles Lupus Assessment Group Index in Pediatric Clinical Trials: Comment on the Article by Ruperto et al David Isenberg and Caroline Gordon .....	2343
B Cell Therapy With the Anti-CD22 Monoclonal Antibody Epratuzumab: Comment on the Editorial by St.Clair and Tedder David M. Goldenberg, Rhona Stein, John P. Leonard, Serge D. Steinfeld, Thomas Dörner, and Gerd R. Burmester .....	2344
Reply Thomas F. Tedder and E. William St.Clair .....	2344
Cortisol Secretion and Symptoms in Patients With Fibromyalgia: Comment on the Article by McLean et al Patrick Luyten and Boudewijn Van Houdenhove .....	2345
Reply Samuel A. McLean, David A. Williams, Richard E. Harris, Richard H. Gracely, Michael E. Geisser, Ananda Sen, Daniel J. Clauw, Leslie J. Crofford, and William J. Kop .....	2346
Further Support for the Statins as Antiinflammatory and Immunomodulatory Agents: Comment on the Review by Abeles and Pillinger and the Editorial by Arnaud and Mach Kenneth N. Schikler .....	2347

Possible Role of Tick-Borne Infection in "Cat-Scratch Disease": Comment on the Article by Giladi et al Raphael B. Stricker, Joseph H. Brewer, Joseph J. Burrascano, Richard Horowitz, Lorraine Johnson, Steven E. Phillips, Virginia R. Savel, and Virginia T. Sherr.....	2347
<b>ACR Announcements .....</b>	<b>A17</b>

VOLUME 54

AUGUST 2006

NO. 8

**Special Articles**

Editorial: Fulfilling Koch's Postulates of Autoimmunity: Anti-NR2 Antibodies in Mice and Men David S. Pisetsky .....	2349
Editorial: Are We Coming to Terms With Tumor Necrosis Factor Inhibition in Pregnancy? Jane E. Salmon and Deborah Alpert .....	2353
Review: Therapeutic B Cell Depletion and Regeneration in Rheumatoid Arthritis: Emerging Patterns and Paradigms Gregg J. Silverman .....	2356

**Rheumatoid Arthritis Clinical Studies**

Rates of Serious Infection, Including Site-Specific and Bacterial Intracellular Infection, in Rheumatoid Arthritis Patients Receiving Anti-Tumor Necrosis Factor Therapy: Results From the British Society for Rheumatology Biologics Register W. G. Dixon, K. Watson, M. Lunt, K. L. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, A. J. Silman, and D. P. M. Symmons, on behalf of the British Society for Rheumatology Biologics Register .....	2368
Regeneration of B Cell Subsets After Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis Petra Roll, Arumugam Palanichamy, Christian Kneitz, Thomas Dorner, and Hans-Peter Tony .....	2377
A Randomized Controlled Trial With an Anti-CCL2 (Anti-Monocyte Chemotactic Protein 1) Monoclonal Antibody in Patients With Rheumatoid Arthritis Jasper J. Haringman, Danielle M. Gerlag, Tom J. M. Smeets, Dominique Baeten, Filip Van den Bosch, Barry Bresnihan, Ferdinand C. Breedveld, Huib J. Dinant, Francois Legay, Hermann Gram, Pius Loetscher, Robert Schmouder, Thasia Woodworth, and Paul P. Tak .....	2387

**Rheumatoid Arthritis Basic Science Studies**

Regulation of Interleukin-1 $\beta$ -Induced Chemokine Production and Matrix Metalloproteinase 2 Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts Salahuddin Ahmed, Angela Pakozdi, and Alisa E. Koch .....	2393
---	------

**Experimental Arthritis**

Inhibition of Angiogenesis by Interleukin-4 Gene Therapy in Rat Adjuvant-Induced Arthritis Christian S. Haas, M. Asif Amin, Brittany B. Allen, Jeffrey H. Ruth, G. Kenneth Haines, III, James M. Woods, and Alisa E. Koch .....	2402
A Peptide From Thrombospondin 1 Modulates Experimental Erosive Arthritis by Regulating Connective Tissue Growth Factor Joanne M. Manns, Audrey B. Uknis, Mario C. Rico, Alexis Agelan, Julian Castaneda, Israel Arango, Mary F. Barbe, Fayed F. Safadi, Steven N. Popoff, and Raul A. DeLa Cadena .....	2415
Increased Arthritis Susceptibility in Cartilage Proteoglycan-Specific T Cell Receptor-Transgenic Mice Suzanne E. Berlo, Teun Guichelaar, Corlinda B. ten Brink, Peter J. van Kooten, Femke Hauet-Broeren, Katalin Ludanyi, Willem van Eden, Chris P. Broeren, and Tibor T. Glant .....	2423

**Sjögren's Syndrome**

Influence of CTLA4 Haplotypes on Susceptibility and Some Extraglandular Manifestations in Primary Sjögren's Syndrome Sarah Downie-Doyle, Noushin Bayat, Maureen Rischmueller, and Susan Lester .....	2434
---	------

**Osteoarthritis Basic Science Studies**

Effects of Ovariectomy and Estrogen Therapy on Type II Collagen Degradation and Structural Integrity of Articular Cartilage in Rats: Implications of the Time of Initiation Svetlana Oestergaard, Bodil C. Sondergaard, Perille Hoegh-Andersen, Kim Henriksen, Per Qvist, Claus Christiansen, László B. Tankó, and Morten A. Karsdal .....	2441
---	------

Phosphocitrate Blocks Calcification-Induced Articular Joint Degeneration in a Guinea Pig Model <i>Herman S. Cheung, John D. Sallis, Konstantino D. Demadis, and Andrzej Wierzbicki</i>	2452
Contribution of Runt-Related Transcription Factor 2 to the Pathogenesis of Osteoarthritis in Mice After Induction of Knee Joint Instability <i>Satoru Kamekura, Yosuke Kawasaki, Kazuto Hoshi, Takashi Shimoaka, Hirotaka Chikuda, Zenjiro Maruyama, Toshihisa Komori, Shingo Sato, Shu Takeda, Gerard Karsenty, Kozo Nakamura, Ung-il Chung, and Hiroshi Kawaguchi</i>	2462
Identification in Human Osteoarthritic Chondrocytes of Proteins Binding to the Novel Regulatory Site AGRE in the Human Matrix Metalloprotease 13 Promoter <i>Zhiyong Fan, Ginette Tardif, Christelle Boileau, Joseph P. Bidwell, Changshan Geng, David Hum, Alexander Watson, Jean-Pierre Pelletier, Martin Lavigne, and Johanne Martel-Pelletier</i>	2471
<b>Osteoarthritis Clinical Studies</b>	
Estradiol and Its Metabolites and Their Association With Knee Osteoarthritis <i>MaryFran R. Sowers, Daniel McConnell, Mary Jannausch, Ayse G. Buyuktur, Marc Hochberg, and David A. Jamadar</i>	2481
Change in Joint Space Width: Hyaline Articular Cartilage Loss or Alteration in Meniscus? <i>D. J. Hunter, Y. Q. Zhang, X. Tu, M. LaValley, J. B. Niu, S. Amin, A. Guermazi, H. Genant, D. Gale, and D. T. Felson</i>	2488
Diurnal Variation of Serum and Urine Biomarkers in Patients With Radiographic Knee Osteoarthritis <i>S. Y. Kong, T. V. Stabler, L. G. Criscione, A. L. Elliott, J. M. Jordan, and V. B. Kraus</i>	2496
<b>Systemic Lupus Erythematosus</b>	
Anti- <i>N</i> -Methyl-D-Aspartate Receptor Antibodies, Cognitive Dysfunction, and Depression in Systemic Lupus Erythematosus <i>Larissa Lapteva, Miroslawa Nowak, Cheryl H. Yarboro, Kazuki Takada, Tresa Roebuck-Spencer, Thomas Weickert, Joseph Bleiberg, Donald Rosenstein, Maryland Pao, Nicholas Patronas, Sonya Steele, Melissa Manzano, Jan Willem C. van der Veen, Peter E. Lipsky, Stefano Marenco, Robert Wesley, Bruce Volpe, Betty Diamond, and Gabor G. Illei</i>	2505
Relationship Between Serum NR2a Antibodies and Cognitive Dysfunction in Systemic Lupus Erythematosus <i>Melanie J. Harrison, Lisa D. Ravdin, and Michael D. Lockshin</i>	2515
Association of $\alpha$ -Actinin-Binding Anti-Double-Stranded DNA Antibodies With Lupus Nephritis <i>Yves Renaudineau, Sabine Croquefer, Sandrine Jousse, Eric Renaudineau, Valérie Devauchelle, Paul Guéguen, Catherine Hanrotel, Boris Gilburd, Alain Saraux, Yehuda Shoenfeld, Chaim Putterman, and Pierre Youinou</i>	2523
Evaluation of the Genetic Association of the PTPN22 R620W Polymorphism in Familial and Sporadic Systemic Lupus Erythematosus <i>Kenneth M. Kaufman, Jennifer A. Kelly, Billy J. Herring, Adam J. Adler, Stuart B. Glenn, Bahram Namjou, Summer G. Frank, Sarah L. Dawson, Gail R. Bruner, Judith A. James, and John B. Harley</i>	2533
Proinflammatory High-Density Lipoprotein as a Biomarker for Atherosclerosis in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis <i>Maureen McMahon, Jennifer Grossman, John Fitzgerald, Erika Dahlin-Lee, Daniel J. Wallace, Bernard Y. Thong, Humeira Badsha, Kenneth Kalunian, Christina Charles, Mohamad Navab, Alan M. Fogelman, and Bevra H. Hahn</i>	2541
Mortality in Systemic Lupus Erythematosus <i>S. Bernatsky, J.-F. Boivin, L. Joseph, S. Manzi, E. Ginzler, D. D. Gladman, M. Urowitz, P. R. Fortin, M. Petri, S. Barr, C. Gordon, S.-C. Bae, D. Isenberg, A. Zoma, C. Aranow, M.-A. Dooley, O. Nived, G. Sturfelt, K. Steinsson, G. Alarcón, J.-L. Senécal, M. Zummer, J. Hanly, S. Ensworth, J. Pope, S. Edworthy, A. Rahman, J. Sibley, H. El-Gabalawy, T. McCarthy, Y. St. Pierre, A. Clarke, and R. Ramsey-Goldman</i>	2550
<b>Antiphospholipid Syndrome</b>	
Anti- $\beta_2$ -Glycoprotein I Antibodies in Complex With $\beta_2$ -Glycoprotein I Can Activate Platelets in a Dysregulated Manner Via Glycoprotein Ib-IX-V <i>Tong Shi, Bill Giannakopoulos, Xiaokai Yan, Pei Yu, Michael C. Berndt, Robert K. Andrews, Juan Rivera, G. Michael Iverson, Keith A. Cockerill, Matthew D. Linnik, and Steven A. Krilis</i>	2558
Mortality in the Catastrophic Antiphospholipid Syndrome: Causes of Death and Prognostic Factors in a Series of 250 Patients <i>Silvia Bucciarelli, Gerard Espinosa, Ricard Cervera, Doruk Erkan, José A. Gómez-Puerta, Manuel Ramos-Casals, Josep Font, and Ronald A. Asherson, for the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies)</i>	2568

**Childhood Arthritis**

- Urinary Neutrophil Gelatinase–Associated Lipocalin as a Biomarker of Nephritis in Childhood-Onset Systemic Lupus Erythematosus  
*Hermine I. Brunner, Michelle Mueller, Cynthia Rutherford, Murray H. Passo, David Witte, Alexei Grom, Jaya Mishra, and Prasad Devarajan* ..... 2577

- RANTES and Monocyte Chemoattractant Protein 1 as Sensitive Markers of Disease Activity in Patients With Juvenile Rheumatoid Arthritis: A Six-Year Longitudinal Study

- Tsung-Chieh Yao, Ming-Ling Kuo, Lai-Chu See, Liang-Shiou Ou, Wen-I Lee, Chin-Kan Chan, and Jing-Long Huang* ..... 2585

- Distinct Synovial Immunopathologic Characteristics of Juvenile-Onset Spondylarthritis and Other Forms of Juvenile Idiopathic Arthritis

- Elli Kruithof, Veronique Van den Bossche, Leen De Rycke, Bernard Vandooren, Rik Joos, Juan D. Cañete, Paul P. Tak, Annemieke M. H. Boots, Eric M. Veys, and Dominique Baeten* ..... 2594

**Clinical Image**

- Skin Hyperpigmentation Over Inflamed Joints  
*M. A. Ostromova, C. R. Lovell, N. J. McHugh, and R. J. Mann* ..... 2604

**Systemic Sclerosis**

- Bone Marrow Endothelial Progenitors Are Defective in Systemic Sclerosis

- Nicoletta Del Papa, Nadia Quirici, Davide Soligo, Cinzia Scavullo, Michela Cortiana, Chiara Borsotti, Wanda Maglione, Denise P. Comina, Claudio Vitali, Paolo Fraticelli, Armando Gabrielli, Agostino Cortelezzi, and Giorgio Lambertenghi-Deliliers* ..... 2605

- Expression of Allograft Inflammatory Factor 1 in Tissues From Patients With Systemic Sclerosis and In Vitro Differential Expression of Its Isoforms in Response to Transforming Growth Factor  $\beta$

- Francesco Del Galdo, Gerd G. Maul, Sergio A. Jiménez, and Carol M. Artlett* ..... 2616

- Attenuation of Collagen Production With Small Interfering RNA of SPARC in Cultured Fibroblasts From the Skin of Patients With Scleroderma

- Xiaodong Zhou, Filemon K. Tan, Xinjian Guo, and Frank C. Arnett* ..... 2626

- Adenosine A<sub>2A</sub> Receptors in Diffuse Dermal Fibrosis: Pathogenic Role in Human Dermal Fibroblasts and in a Murine Model of Scleroderma

- E. S. L. Chan, P. Fernandez, A. A. Merchant, M. C. Montesinos, S. Trzaska, A. Desai, C. F. Tung, D. N. Khoa, M. H. Pillinger, A. B. Reiss, M. Tomic-Canic, J. F. Chen, M. A. Schwarzchild, and B. N. Cronstein* ..... 2632

- Induction of Prolonged Infiltration of T Lymphocytes and Transient T Lymphocyte–Dependent Collagen Deposition in Mouse Lungs Following Adenoviral Gene Transfer of CCL18

- Irina G. Luzina, John C. Papadimitriou, Richard Anderson, Kerill Pochetuhen, and Sergei P. Atamas* ..... 2643

**Pain**

- Reduced Levels of Antiinflammatory Cytokines in Patients With Chronic Widespread Pain

- Nurcan Uçeyler, Regine Valenza, Michael Stock, Robert Schedel, Günter Sprotte, and Claudia Sommer* ..... 2656

**Psoriatic Arthritis**

- Classification Criteria for Psoriatic Arthritis: Development of New Criteria From a Large International Study

- William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants, and the CASPAR Study Group* ..... 2665

**Periodic Syndrome**

- Modeling of Tumor Necrosis Factor Receptor Superfamily 1A Mutants Associated With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Indicates Misfolding Consistent With Abnormal Function

- Susana L. Rebelo, Susan E. Bainbridge, Mohammad R. Amel-Kashipaz, Paul M. Radford, Richard J. Powell, Ian Todd, and Patrick J. Tighe* ..... 2674

**Gout**

- Gout and the Risk of Acute Myocardial Infarction

- Eswar Krishnan, Joshua F. Baker, Daniel E. Furst, and H. Ralph Schumacher* ..... 2688

**Lyme Disease**

- Lyme Myositis

- Aaron R. Holmgren and Eric L. Matteson* ..... 2697

**Concise Communication**

- Pregnancy Outcome in Women Who Were Exposed to Anti–Tumor Necrosis Factor Agents: Results From a National Population Register

- Kimme L. Hyrich, Deborah P. M. Symmons, Kath D. Watson, and Alan J. Silman* ..... 2701

**Erratum**

- Error in appearance of Figure 7 in article by Brychey et al (Arthritis Rheum, July 2006) ..... 2702

**Letters**

Mutational Analysis in Neonatal-Onset Multisystem Inflammatory Disease: Comment on the Articles by Frenkel et al and Saito et al	2703
Ivona Aksentijevich, Elaine F. Remmers, Raphaela Goldbach-Mansky, Andreas Reiff, and Daniel L. Kastner .....	2703
Reply	
Joost Frenkel and Marjan van Kempen .....	2704
Reply	
Megumu Saito, Akihiro Fujisawa, Ryuta Nishikomori, Naotomo Kambe, Yoshiki Miyachi, Toshio Heike, and Tatsutoshi Nakahata .....	2704
Rheumatoid Arthritis Etiology and HLA-Linked Odorant Receptor Gene Polymorphisms: Comment on the Article by Klareskog et al	
Andreas Ziegler and Barbara Uchanska-Ziegler .....	2705
<b>Clinical Images</b>	
A Not-So Crystal-Clear Ankle Mass	
Emily N. Vinson .....	2706
<b>ACR Announcements</b>	A11

VOLUME 54

SEPTEMBER 2006

NO. 9

**Special Articles**

Editorial: Leukocyte Migration to Rheumatoid Joints: Enzymes Take Over Gaby Palmer, Cem Gabay, and Beat A. Imhof .....	2707
<b>Rheumatoid Arthritis Basic Science Studies</b>	
Dysregulation of Interleukin-10-Dependent Gene Expression in Rheumatoid Arthritis Synovial Macrophages Taras T. Antoniv and Lionel B. Ivashkiv .....	2711
Function of Interleukin-20 as a Proinflammatory Molecule in Rheumatoid and Experimental Arthritis Yu-Hsiang Hsu, Hsing-Hui Li, Mei-Yi Hsieh, Ming-Fei Liu, Kuo-Yuan Huang, Lin-Show Chin, Pei-Chih Chen, He-Hsiung Cheng, and Ming-Shi Chang .....	2722
Up-Regulated Transforming Growth Factor $\beta$ -Inducible Gene h3 in Rheumatoid Arthritis Mediates Adhesion and Migration of Synoviocytes Through $\alpha v \beta 3$ Integrin: Regulation by Cytokines Eon Jeong Nam, Keum Hee Sa, Dong Wan You, Jang Hee Cho, Jae Seok Seo, Seung Woo Han, Jae Yong Park, Sung Il Kim, Hee Soo Kyung, In San Kim, and Young Mo Kang .....	2734
Differential Tissue Expression and Activation of p38 MAPK $\alpha$ , $\beta$ , $\gamma$ , and $\delta$ Isoforms in Rheumatoid Arthritis Adelheid Korb, Makiyah Tohidast-Akrad, Erdal Cetin, Roland Axmann, Josef Smolen, and Georg Schett ..	2745
<b>Rheumatoid Arthritis Clinical Studies</b>	
Tumor Necrosis Factor $\alpha$ Antagonist Use and Cancer in Patients With Rheumatoid Arthritis Soko Setoguchi, Daniel H. Solomon, Michael E. Weinblatt, Jeffrey N. Katz, Jerry Avorn, Robert J. Glynn, E. Francis Cook, Greg Carney, and Sebastian Schneeweiss .....	2757
Insulin Resistance and Impaired Beta Cell Function in Rheumatoid Arthritis Patrick H. Dessein and Barry I. Joffe .....	2765
Association of HLA-C3 and Smoking With Vasculitis in Patients With Rheumatoid Arthritis Carl Turesson, Daniel J. Schaid, Cornelia M. Weyand, Lennart T. Jacobsson, Jörg J. Goronyz, Ingemar F. Petersson, Sonja A. Dechant, Britt-Marie Nyähll-Wåhlin, Lennart Truedsson, Gunnar Sturfelt, and Eric L. Matteson .....	2776
Measuring Function in Rheumatoid Arthritis: Identifying Reversible and Irreversible Components Daniel Aletaha, Josef Smolen, and Michael M. Ward .....	2784
Rituximab for Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating Primary Efficacy and Safety at Twenty-Four Weeks Stanley B. Cohen, Paul Emery, Maria W. Greenwald, Maxime Dougados, Richard A. Furie, Mark C. Genovese, Edward C. Keystone, James E. Loveless, Gerd-Rüdiger Burmester, Matthew W. Cravets, Eva W. Hessey, Timothy Shaw, and Mark C. Totoritis, for the REFLEX Trial Group .....	2793

Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs: A One-Year Randomized, Placebo-Controlled Study	2807
<i>M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. C. Becker, and E. Keystone</i>	
Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate	2807
<i>R. N. Maini, P. C. Taylor, J. Szechinski, K. Pavelka, J. Bröll, G. Balint, P. Emery, F. Raemen, J. Petersen, J. Smolen, D. Thomson, and T. Kishimoto, for the CHARISMA Study Group</i>	2817
Relationship Between Genetic Variants in the Adenosine Pathway and Outcome of Methotrexate Treatment in Patients With Recent-Onset Rheumatoid Arthritis	2817
<i>Judith A. M. Wessels, Wouter M. Kooloos, Robert de Jonge, Jeska K. de Vries-Bouwstra, Cornelie F. Allaart, Annelies Linssen, Gerard Collee, Peter de Sonnaville, Jan Lindemans, Tom W. J. Huizinga, and Henk-Jan Guchelaar</i>	2830
IgG and IgM Anticardiolipin Antibodies Following Treatment With Infliximab Plus Methotrexate in Patients With Early Rheumatoid Arthritis	2830
<i>Sudha Visvanathan, Carrie Wagner, Josef Smolen, E. William St.Clair, Ron Hegedus, Daniel Baker, and Gregory Keenan</i>	2840
<b>Ankylosing Spondylitis</b>	
Immunohistologic Analysis of Zygapophyseal Joints in Patients With Ankylosing Spondylitis	
<i>Heiner Appel, Maren Kuhne, Simone Spiekermann, Harald Ebhardt, Zarko Grozdanovic, Dorothee Köhler, Marc Dreimann, Axel Hempfing, Martin Rudwaleit, Harald Stein, Peter Metz-Stavenhagen, Joachim Sieper, and Christoph Loddenkemper</i>	2845
<b>Experimental Arthritis</b>	
Vascular Amine Oxidases Are Needed for Leukocyte Extravasation Into Inflamed Joints	
In Vivo	
<i>Fumiko Martila-Ichihara, David J. Smith, Craig Stolen, Gennady G. Yegutkin, Kati Elima, Nathalie Mercier, Riku Kiviranta, Marjo Pihlavisto, Sakari Alaranta, Ulla Pentikäinen, Olli Pentikäinen, Ferenc Fülop, Sirpa Jalkanen, and Marko Salmi</i>	2852
Lymphocyte-Independent Connective Tissue Mast Cells Populate Murine Synovium	
<i>Kichul Shin, Michael F. Gurish, Daniel S. Friend, Alan D. Pemberton, Elisabeth M. Thornton, Hugh R. Miller, and David M. Lee</i>	2863
Soluble Human p55 and p75 Tumor Necrosis Factor Receptors Reverse Spontaneous Arthritis in Transgenic Mice Expressing Transmembrane Tumor Necrosis Factor $\alpha$	
<i>Carl K. Edwards, III, Alison M. Bendele, Leonid I. Reznikov, Giamila Fantuzzi, Elizabeth S. Chlipala, Li Li, Lyle L. Moldawer, John D. Mountz, Yi-Yang Yvonne Li, and Charles A. Dinarello</i>	2872
Early Elevation in Circulating Levels of C-Telopeptides of Type II Collagen Predicts Structural Damage in Articular Cartilage in the Rodent Model of Collagen-Induced Arthritis	
<i>Svetlana Oestergaard, Luc Chouinard, Nancy Doyle, Susan Y. Smith, László B. Tankó, and Per Kvist</i>	2886
<b>Osteoarthritis and Cartilage Biology</b>	
Pathogenesis of Osteoarthritis-like Changes in the Joints of Mice Deficient in Type IX Collagen	
<i>K. Hu, L. Xu, L. Cao, C. M. Flahiff, J. Brussiau, K. Ho, L. A. Setton, I. Youn, F. Guilak, B. R. Olsen, and Y. Li</i>	2891
Increase in Production of Matrix Metalloproteinase 13 by Human Articular Chondrocytes Due to Stimulation With S100A4: Role of the Receptor for Advanced Glycation End Products	
<i>Raghunatha R. Yammani, Cathy S. Carlson, Anne R. Bresnick, and Richard F. Loeser</i>	2901
Identification of Fibronectin Neoepitopes Present in Human Osteoarthritic Cartilage	
<i>Marc D. Zack, Elizabeth C. Amer, Charles P. Anglin, James T. Alston, Anne-Marie Malfait, and Micky D. Tortorella</i>	2912
Walking Barefoot Decreases Loading on the Lower Extremity Joints in Knee Osteoarthritis	
<i>Najia Shakoor and Joel A. Block</i>	2923
Increased Collagen Degradation Around Loosened Total Hip Replacement Implants	
<i>Guo-Feng Ma, Ahmed Ali, Nicole Verzijl, Roeland Hanemaaijer, Johan TeKoppele, Yrjö T. Kononen, and Jari Salo</i>	2928
<b>Retraction</b>	
Notice of Retraction: "Pathologic Indicators of Degradation and Inflammation in Human Osteoarthritic Cartilage Are Abrogated by Exposure to n-3 Fatty Acids" (Arthritis Rheum 2002;46:1544-53)	
<i>Bruce Caterson</i>	2933

## **Systemic Lupus Erythematosus**

- Cappuccino Mutation in an Autoimmune-Prone Strain of Mice Suggests a Role of Platelet Function in the Progression of Immune Complex Crescentic Glomerulonephritis  
*Minako Yoshida, Kan Saiga, Takaaki Hato, Shoko Iwaki, Toshiyuki Niiya, Norimasa Arita, Hiroaki Komori, Takahito Tsubaki, Hiroshi Furukawa, Miho Terada, Kazutaka Maeyama, Kyuichi Nemoto, Masato Nose, and Masao Ono* ..... 2934
- Chimerism Occurs Twice as Often in Lupus Nephritis as in Normal Kidneys  
*Idske C. L. Kremer Hovinga, Marije Koopmans, Hans J. Baelde, Annete M. van der Wal, Yvo W. J. Sijpkens, Emile de Heer, Jan A. Bruijn, and Ingeborg M. Bajema* ..... 2944
- Association of Increased Interferon-Inducible Gene Expression With Disease Activity and Lupus Nephritis in Patients With Systemic Lupus Erythematosus  
*Xuebing Feng, Hui Wu, Jennifer M. Grossman, Punchong Hanvivadhanakul, John D. FitzGerald, Grace S. Park, Xin Dong, Michelle H. Kim, Haoling H. Weng, Daniel E. Furst, Alan Gorn, Maureen McMahon, Mihaela Taylor, Ernest Brahn, Bevra H. Hahn, and Betty P. Tsao* ..... 2951
- The Prevalence and Incidence of Biopsy-Proven Lupus Nephritis in the UK: Evidence of an Ethnic Gradient  
*Mumtaz Patel, Alexandra M. Clarke, Ian N. Bruce, and Deborah P. M. Symmons* ..... 2963
- Long-Term Comparison of Rituximab Treatment for Refractory Systemic Lupus Erythematosus and Vasculitis: Remission, Relapse, and Re-treatment  
*K. G. C. Smith, R. B. Jones, S. M. Burns, and D. R. W. Jayne* ..... 2970
- Rapamycin Reduces Disease Activity and Normalizes T Cell Activation-Induced Calcium Fluxing in Patients With Systemic Lupus Erythematosus  
*David Fernandez, Eduardo Bonilla, Naureen Mirza, Brian Niland, and Andras Perl* ..... 2983

## **Childhood Arthritis**

- A Proposal for a Pediatric Version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index Based on the Analysis of 1,015 Patients With Juvenile-Onset Systemic Lupus Erythematosus  
*Raul Gutiérrez-Suárez, Nicolino Ruperto, Roberto Gastaldi, Angela Pistorio, Enrico Felici, Rubén Burgos-Vargas, Alberto Martini, and Angelo Ravelli, for the Pediatric Rheumatology International Trials Organization (PRINTO)* ..... 2989
- Successful Use of a Humanized Anti-Interleukin-6 Receptor Antibody, Tocilizumab, to Treat Amyloid A Amyloidosis Complicating Juvenile Idiopathic Arthritis  
*Yasuaki Okuda and Kiyoshi Takasugi* ..... 2997

## **Systemic Sclerosis**

- Insulin-Like Growth Factor Binding Protein 5 Induces Skin Fibrosis: A Novel Murine Model for Dermal Fibrosis  
*Hidekata Yasuoka, Drazen M. Jukic, Zhihong Zhou, Augustine M. K. Choi, and Carol A. Feghali-Bostwick* ..... 3001
- Increased Levels of Transforming Growth Factor  $\beta$  Receptor Type I and Up-Regulation of Matrix Gene Program: A Model of Scleroderma  
*Jaspreet Panju, Humphrey Gardner, Jeffrey R. Shearstone, Edwin Smith, and Maria Trojanowska* ..... 3011
- Differential Expression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 in the Skin and Endothelial Cells of Systemic Sclerosis Patients: Pathogenetic Implications  
*Paola Cipriani, Anna Franca Milia, Vasiliki Liakouli, Alessandra Pacini, Mirko Manetti, Alessandra Marrelli, Annarita Toscano, Elisa Pingotti, Antonietta Fulminis, Serena Guiducci, Roberto Perricone, Bashar Kahaleh, Marco Matucci-Cerinic, Lidia Ibba-Manneschi, and Roberto Giacomelli* ..... 3022
- Endothelin Axis Polymorphisms in Patients With Scleroderma  
*Carmen Fonseca, Elizabeth Renzoni, Piersante Sestini, Panagiotis Pantelidis, Anna Lagan, Christopher Bunn, Neil McHugh, Ken I. Welsh, Ron M. du Bois, Christopher P. Denton, Carol Black, and D. Abraham* ..... 3034
- Clinical Differences Between Idiopathic and Scleroderma-Related Pulmonary Hypertension  
*Micah R. Fisher, Stephen C. Mathai, Hunter C. Champion, Reda E. Girgis, Traci Houston-Harris, Laura Hummers, Jerry A. Krishnan, Fredrick Wigley, and Paul M. Hassoun* ..... 3043
- Nucleolar Staining Cannot Be Used as a Screening Test for the Scleroderma Marker Anti-RNA Polymerase I/III Antibodies  
*Yoshioki Yamasaki, Minna Honkanen-Scott, Liza Hernandez, Keigo Ikeda, Tolga Barker, Michael R. Bubb, Sonali Narain, Hanno B. Richards, Edward K. L. Chan, Westley H. Reeves, and Minoru Satoh* ..... 3051

**Concise Communication**

- Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Isotypes in African Americans With Early Rheumatoid Arthritis

*Ted R. Mikuls, V. Michael Holers, Leslie Parrish, Kristine A. Kuhn, Doyt L. Conn, Gary Gilkeson, Edwin A. Smith, Diane L. Kamen, Beth L. Jonas, Leigh F. Callahan, Graciela S. Alarcón, George Howard, Larry W. Moreland, and S. Louis Bridges, Jr.* ..... 3057

**Clinical Images**

- Hidden in the Heart

*Varun Dhir, Vivek Arya, Rahul Grover, Ritu Aneja, and Ashok Kumar* ..... 3059

**Letters**

- Effect of Tumor Necrosis Factor  $\alpha$  Inhibition on CD28 Surface Expression on CD4+ T Cells

*Roberto Gerli, Elena Bartoloni Bocci, and Yehuda Shoenfeld* ..... 3060

**Reply**

*Jörg J. Goronzy and Cornelia M. Weyand* ..... 3061

- Trial of Etanercept and Methotrexate with Radiographic and Patient Outcomes Two-Year Clinical and Radiographic Results: Comment on the Article by van der Heijde et al

*Yusuf Yazici and Hasan Yazici* ..... 3061

- Reconstitution of B Cells After B Cell-Depletion Therapy: Comment on the Article by Leandro et al

*Yoe Kie Onno Teng, Aukje van Tilborg, and Jacob M. van Laar* ..... 3062

**Reply**

*Maria J. Leandro, Geraldine Cambridge, Michael R. Ehrenstein, and Jonathan C. W. Edwards* ..... 3063

- Replication in Genetic Association Studies: Comment on the Editorial by Spector et al

*Josine Min, Ingrid Meulenbelt, and Eline Slagboom* ..... 3063

**Reply**

*Tim D. Spector, Kourosh R. Ahmadi, and Ana M. Valdes* ..... 3064

- Treatment of Localized Scleroderma in Childhood: Comment on the Article by Zulian et al

*Alexander Kreuter, Peter Altmeier, and Thilo Gambichler* ..... 3065

**Reply**

*Francesco Zulian and Balu H. Athreya* ..... 3066

**ACR Announcements**

A15

VOLUME 54

SEPTEMBER SUPPLEMENT 2006

NO. 9

**Annual Scientific Meetings of the American College of Rheumatology and the Association of Rheumatology Health Professionals**

S1

VOLUME 54

OCTOBER 2006

NO. 10

**Special Articles**

- In Memoriam: Jarvis Edwin Seegmiller, MD, 1920–2006

*Dennis A. Carson and Nathan J. Zvaifler* ..... 3067

- Editorial: Antimalarial Agents: Closing the Gate on Toll-like Receptors?

*Robert Lafyatis, Michael York, and Ann Marshak-Rothstein* ..... 3068

- Editorial: Therapy for Giant Cell Arteritis: Can We Do Better?

*Robert F. Spiera and Harry Spiera* ..... 3071

- Editorial: Stemming Cartilage Degeneration: Adult Mesenchymal Stem Cells as a Cell Source for Articular Cartilage Tissue Engineering

*Rocky S. Tuan* ..... 3075

- Review: Therapy for Lyme Arthritis: Strategies for the Treatment of Antibiotic-Refractory Arthritis

*Allen C. Steere and Sheryn M. Angelis* ..... 3079

**Rheumatoid Arthritis Clinical Studies**

- Influence of Male Sex on Disease Phenotype in Familial Rheumatoid Arthritis

*Damini Jawaheer, Raymond F. Lum, Peter K. Gregersen, and Lindsey A. Criswell* ..... 3087

Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Association With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis <i>Thierry Dervieux, Neal Greenstein, and Joel Kremer</i>	3095
Clinical Assessment of the Long-Term Risk of Fracture in Patients With Rheumatoid Arthritis <i>T. P. van Staa, P. Geusens, J. W. J. Bijlsma, H. G. M. Leufkens, and C. Cooper</i>	3104
Changes in Health Assessment Questionnaire Disability Scores Over Five Years in Patients with Rheumatoid Arthritis Compared With the General Population <i>Tuulikki Sokka, Hannu Kautiainen, Pekka Hannonen, and Theodore Pincus</i>	3113
Disconnect Between Inflammation and Joint Destruction After Treatment With Etanercept Plus Methotrexate: Results From the Trial of Etanercept and Methotrexate With Radiographic and Patient Outcomes <i>Robert Landewé, Désirée van der Heijde, Lars Klareskog, Ronald van Vollenhoven, and Saeed Fatenejad</i>	3119
In Vitro and In Vivo Efficacy of a Recombinant Immunotoxin Against Folate Receptor $\beta$ on the Activation and Proliferation of Rheumatoid Arthritis Synovial Cells <i>Taku Nagai, Masashi Tanaka, Yasuhiro Tsuneyoshi, Kakushi Matsushita, Nobuhiko Sunahara, Takemasa Matsuda, Hiroki Yoshida, Setsuro Komiya, Masanori Onda, and Takami Matsuyama</i>	3126
<b>Erratum</b>	
Error in reference citation in article by Setoguchi et al (Arthritis Rheum, September 2006)	3134
<b>Rheumatoid Arthritis Basic Science Studies</b>	
CTLA-4Ig Suppresses Reactive Oxygen Species by Preventing Synovial Adherent Cell-Induced Inactivation of Rap1, a Ras Family GTPase Mediator of Oxidative Stress in Rheumatoid Arthritis T Cells <i>P. H. J. Remans, C. A. Wijbrandts, M. E. Sanders, R. E. Toes, F. C. Breedveld, P. P. Tak, J. M. van Laar, and K. A. Reedquist</i>	3135
The $^{786}$ C/T Single-Nucleotide Polymorphism in the Promoter of the Gene for Endothelial Nitric Oxide Synthase: Insensitivity to Physiologic Stimuli as a Risk Factor for Rheumatoid Arthritis <i>Inga Melchers, Sabine Blaschke, Markus Hecker, and Marco Cattaruzza</i>	3144
Oncostatin M Induces Angiogenesis and Cartilage Degradation in Rheumatoid Arthritis Synovial Tissue and Human Cartilage Cocultures <i>Ursula Fearon, Ronan Mullan, Trevor Markham, Mary Connolly, Shane Sullivan, A. Robin Poole, Oliver FitzGerald, Barry Bresnihan, and Douglas J. Veale</i>	3152
IKK $\beta$ Inhibition Protects Against Bone and Cartilage Destruction in a Rat Model of Rheumatoid Arthritis <i>Lisa Schopf, Anneli Savinainen, Karen Anderson, Julie Kujawa, Michelle DuPont, Matthew Silva, Elizabeth Siebert, Sudeep Chandra, Jennifer Morgan, Pranoti Gangurde, Danyi Wen, Joan Lane, Yajun Xu, Michael Hepperle, Geraldine Harriman, Timothy Ocain, and Bruce Jaffee</i>	3163
Regulation of Mcl-1 Expression in Rheumatoid Arthritis Synovial Macrophages <i>Hongtao Liu, QiQuan Huang, Bo Shi, Polikseni Eksarko, Vladislav Temkin, and Richard M. Pope</i>	3174
<b>Experimental Arthritis</b>	
Bim Deficiency Leads to Exacerbation and Prolongation of Joint Inflammation in Experimental Arthritis <i>John C. Scatizzi, Emily Bickel, Jack Hutcheson, G. Kenneth Haines, III, and Harris Perlman</i>	3182
<b>Osteoarthritis Clinical Studies</b>	
Effect of Hormone Therapy on Risk of Hip and Knee Joint Replacement in the Women's Health Initiative <i>Dominic J. Cirillo, Robert B. Wallace, LieLing Wu, and Robert A. Yood</i>	3194
Oral Salmon Calcitonin Reduces Lequesne's Algofunctional Index Scores and Decreases Urinary and Serum Levels of Biomarkers of Joint Metabolism in Knee Osteoarthritis <i>Daniel-Henri Manicourt, Moïse Azria, Linda Mindeholm, Eugene J.-M. Thonar, and Jean-Pierre Devogelaer</i>	3205
A Prospective Population-Based Study of the Predictors of Undergoing Total Joint Arthroplasty <i>Gillian A. Hawker, Jun Guan, Ruth Croxford, Peter C. Coyte, Richard H. Glazier, Bart J. Harvey, James G. Wright, Jack I. Williams, and Elizabeth M. Badley</i>	3212
The Role of Fibroblasts and Fibroblast-Derived Factors in Periprosthetic Osteolysis <i>Tamas Koreny, Miklós Tunyogi-Csapó, Istvan Gál, Csaba Vermes, Joshua J. Jacobs, and Tibor T. Glant</i>	3221
<b>Osteoarthritis and Cartilage Biology Basic Science Studies</b>	
Tetraspanin CD151 Is Expressed in Osteoarthritic Cartilage and Is Involved in Pericellular Activation of Pro-Matrix Metalloproteinase 7 in Osteoarthritic Chondrocytes <i>Yoshinari Fujita, Takayuki Shiomi, Shigeru Yanagimoto, Hideo Matsumoto, Yoshiaki Toyama, and Yasunori Okada</i>	3233

Matrix Metalloproteinase 10 Promotion of Collagenolysis via Procollagenase Activation: Implications for Cartilage Degradation in Arthritis H. E. Barksby, J. M. Milner, A. M. Patterson, N. J. Peake, W. Hui, T. Robson, R. Lakey, J. Middleton, T. E. Cawston, C. D. Richards, and A. D. Rowan.....	3244
Premature Induction of Hypertrophy During In Vitro Chondrogenesis of Human Mesenchymal Stem Cells Correlates With Calcification and Vascular Invasion After Ectopic Transplantation in SCID Mice Karoliina Pelttari, Anja Winter, Eric Steck, Katrin Goetzke, Thea Hennig, Björn Gunnar Ochs, Thomas Aigner, and Wiltrud Richter.....	3254
Interleukin-1 $\alpha$ Induction of Tensile Weakening Associated With Collagen Degradation in Bovine Articular Cartilage Michele M. Temple, Yang Xue, Michael Q. Chen, and Robert L. Sah.....	3267
<b>Systemic Lupus Erythematosus</b>	
Abrogation of Skin Disease in Lupus-Prone MRL/Fas <sup>lpr</sup> Mice By Means of a Novel Tylophorine Analog Jin-Young Choi, Wenli Gao, Jared Odegard, Her-Shyong Shiah, Michael Kashgarian, Jennifer M. McNiff, David C. Baker, Yung-Chi Cheng, and Joseph Craft .....	3277
Low Blood Concentration of Hydroxychloroquine Is a Marker for and Predictor of Disease Exacerbations in Patients With Systemic Lupus Erythematosus Nathalie Costedoat-Chalumeau, Zahir Amoura, Jean-Sébastien Hulot, Hala Abou Hammoud, Guy Aymard, Patrice Cacoub, Camille Francès, Bertrand Wechsler, Du Le Thi Huong, Pascale Ghillani, Lucile Musset, Philippe Lechat, and Jean-Charles Piette.....	3284
Fluctuation in Self-Perceived Stress and Increased Risk of Flare in Patients With Lupus Nephritis Carrying the Serotonin Receptor 1A -1019 G Allele Daniel J. Birmingham, H. N. Nagaraja, Brad H. Rovin, Lacramioara Spetie, Yanxing Zhao, Xiaobai Li, Kevin V. Hackshaw, C. Yung Yu, William B. Malarkey, and Lee A. Hebert .....	3291
Revised British Isles Lupus Assessment Group 2004 Index: A Reliable Tool for Assessment of Systemic Lupus Erythematosus Activity Chee-Seng Yee, Vernon Farewell, David A. Isenberg, Athiveeraramapandian Prabu, Katharina Sokoll, Lee-Suan Teh, Anisur Rahman, Ian N. Bruce, Bridget Griffiths, Mohammed Akil, Neil McHugh, David D'Cruz, Munther A. Khamashta, Simon Bowman, Peter Maddison, Asad Zoma, Elizabeth Allen, and Caroline Gordon .....	3300
<b>Vasculitis</b>	
Antiplatelet and Anticoagulant Therapy in Patients With Giant Cell Arteritis Michael S. Lee, Scott D. Smith, Anat Galor, and Gary S. Hoffman.....	3306
Treatment of Giant Cell Arteritis Using Induction Therapy With High-Dose Glucocorticoids: A Double-Blind, Placebo-Controlled, Randomized Prospective Clinical Trial Mehrdad Mazlumzadeh, Gene G. Hunder, Kirk A. Easley, Kenneth T. Calamia, Eric L. Matteson, W. Leroy Griffing, Brian R. Younge, Cornelia M. Weyand, and Jörg J. Goronzy.....	3310
<b>Lyme Disease</b>	
Role of Aggrecanase 1 in Lyme Arthritis Aruna K. Behera, Ethan Hildebrand, Jon Szafranski, Han-Hwa Hung, Alan J. Grodzinsky, Robert Lafyatis, Alisa E. Koch, Robert Kalish, George Perides, Allen C. Steere, and Linden T. Hu .....	3319
<b>Erdheim-Chester Disease</b>	
Variability in the Efficacy of Interferon- $\alpha$ in Erdheim-Chester Disease by Patient and Site of Involvement: Results in Eight Patients Julien Haroche, Zahir Amoura, Salim G. Trad, Bertrand Wechsler, Philippe Cluzel, Philippe A. Grenier, and Jean-Charles Piette .....	3330
<b>Childhood Arthritis</b>	
Pediatric Granulomatous Arthritis: An International Registry Carlos D. Rosé, Carine H. Wouters, Silvia Meiorin, Trudy M. Doyle, Michael P. Davey, James T. Rosenbaum, and Tammy M. Martin .....	3337
Composition of Calcifications in Children With Juvenile Dermatomyositis: Association With Chronic Cutaneous Inflammation Lauren M. Pachman, Arthur Veis, Stuart Stock, Kathy Abbott, Frank Vicari, Pravin Patel, Diana Gicewski, Catherine Webb, Lyudmila Spevak, and Adele L. Boskey.....	3345
<b>Fibromyalgia</b>	
The Influence of Aerobic Fitness and Fibromyalgia on Cardiorespiratory and Perceptual Responses to Exercise in Patients With Chronic Fatigue Syndrome Dane B. Cook, Paul R. Nagelkirk, Ashok Poluri, John Mores, and Benjamin H. Natelson .....	3351

<b>Gout</b>	
Transglutaminase 2 Limits Murine Peritoneal Acute Gout-like Inflammation by Regulating Macrophage Clearance of Apoptotic Neutrophils	3363
David M. Rose, Anya D. Sydaske, Amir Agha-Babakhani, Kristen Johnson, and Robert Terkeltaub .....	3363
<b>Letters</b>	
Association of Methotrexate Effects and Single-Nucleotide Polymorphisms in the Folate Pathway in Rheumatoid Arthritis: Comment on the Article by Wessels et al	3372
Prabha Ranganathan .....	3372
Reply	
Judith A. M. Wessels, Tom W. J. Huizinga, and Henk-Jan Guchelaar.....	3372
Do Apoptotic Cells Accumulate in the Epidermis of Patients With Cutaneous Lupus Erythematosus After Ultraviolet Irradiation? Comment on the Article by Kuhn et al	3373
Esther Reefman, Pieter C. Limburg, Cees G. M. Kallenberg, and Marc Bijl .....	3373
Food and Drug Administration Centennial: Recognizing the Guardians of Our Drug Supply	3374
John F. Beary.....	3374
<b>ACR Announcements</b>	A15

VOLUME 54

NOVEMBER 2006

NO. 11

**Special Articles**

Editorial: Acupuncture for Treating Osteoarthritis of the Knee and the Hip	3375
Tao Liu and Chen Liu.....	3375
Editorial: The Large Print Giveth and the Small Print Taketh Away: Preemptive Treatment of Serologically Active, Clinically Quiet Systemic Lupus Erythematosus	3378
Matthew H. Liang and Julia F. Simard.....	3378
Review: Citrullinated Proteins in Rheumatoid Arthritis: Crucial . . . but Not Sufficient!	3381
Tinne Cantaert, Leen De Rycke, Tim Bongartz, Eric L. Matteson, Paul P. Tak, Anthony P. Nicholas, and Dominique Baeten .....	3381

**Pharmacology**

Simultaneous Assessment of Short-Term Gastrointestinal Benefits and Cardiovascular Risks of Selective Cyclooxygenase 2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs: An Instrumental Variable Analysis	3390
Sebastian Schneeweiss, Daniel H. Solomon, Philip S. Wang, Jeremy Rassen, and M. Alan Brookhart .....	3390

**Rheumatoid Arthritis Clinical Studies**

Effectiveness of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis in an Observational Cohort Study: Comparison of Patients According to Their Eligibility for Major Randomized Clinical Trials	3399
Angela Zink, Anja Strangfeld, Matthias Schneider, Peter Herzer, Franka Hierse, Maria Stoyanova-Scholz, Siegfried Wassenberg, Andreas Kapelle, and Joachim Listing.....	3399
Increased Serum Levels of Soluble Fractalkine (CX <sub>3</sub> CL1) Correlate With Disease Activity in Rheumatoid Vasculitis	3408
Mizuho Matsunawa, Takeo Isozaki, Tsuyoshi Odai, Nobuyuki Yajima, Hiroko T. Takeuchi, Masao Negishi, Hirotugu Ide, Mitsuru Adachi, and Tsuyoshi Kasama .....	3408
Investigation of the MHC2TA Gene, Associated With Rheumatoid Arthritis in a Swedish Population, in a UK Rheumatoid Arthritis Cohort	3417
Stephen Eyre, John Bowes, Kristian Spreckley, Catherine Potter, Susan Ring, David Strachan, Jane Worthington, and Anne Barton .....	3417

**Clinical Image**

Pigmented Villonodular Synovitis of the Knee	3422
Memduh Dursun, Sabri Yilmaz, Burak Erer, and Levent Eralp .....	3422

**Rheumatoid Arthritis Basic Science Studies**

Activation of Nitric Oxide Signaling by the Rheumatoid Arthritis Shared Epitope	3423
Song Ling, Angela Lai, Olga Borschukova, Paul Pumpens, and Joseph Holoshitz.....	3423

Glycan Analysis of Monoclonal Antibodies Secreted in Deposition Disorders Indicates That Subsets of Plasma Cells Differentially Process IgG Glycans	
<i>Lone A. Omtvedt, Louise Royle, Gunnar Husby, Knut Sletten, Catherine M. Radcliffe, David J. Harvey, Raymond A. Dwek, and Pauline M. Rudd</i>	3433
RhoA-Mediated, Tumor Necrosis Factor $\alpha$ -Induced Activation of NF- $\kappa$ B in Rheumatoid Synoviocytes: Inhibitory Effect of Simvastatin	
<i>Hanshi Xu, Peng Liu, Liuqin Liang, Farhad R. Danesh, Xiuyan Yang, Yijin Ye, Zhongping Zhan, Xueqing Yu, Hui Peng, and Lin Sun</i>	3441
<b>Inflammatory Arthritis</b>	
Efficacy and Mechanism of Action of Turmeric Supplements in the Treatment of Experimental Arthritis	
<i>Janet L. Funk, Jennifer B. Frye, Janice N. Oyarzo, Nesrin Kuscoglu, Jonathan Wilson, Gwen McCaffrey, Gregory Stafford, Guanjie Chen, R. Clark Lantz, Shivanand D. Jolad, Aniko M. Solyom, Pawel R. Kiela, and Barbara N. Timmermann</i>	3452
<b>Sjögren's Syndrome</b>	
Involvement of Specific Laminins and Nidogens in the Active Remodeling of the Basal Lamina of Labial Salivary Glands From Patients With Sjögren's Syndrome	
<i>Yoon-Jeoung Kwon, Paola Pérez, Sergio Aguilera, Claudio Molina, Lisette Leyton, Cecilia Allende, Cecilia Leyton, Mónica Brito, Rafael Romo, and María-Juliet González</i>	3465
Overexpression of Phosphorylated STAT-1 $\alpha$ in the Labial Salivary Glands of Patients With Sjögren's Syndrome	
<i>Ei Wakamatsu, Isao Matsumoto, Takanori Yasukochi, Yusuke Naito, Daisuke Goto, Mizuko Mamura, Satoshi Ito, Akito Tsutsumi, and Takayuki Sumida</i>	3476
<b>Osteoarthritis Clinical Studies</b>	
Acupuncture in Patients With Osteoarthritis of the Knee or Hip: A Randomized, Controlled Trial With an Additional Nonrandomized Arm	
<i>Claudia M. Witt, Susanne Jena, Benno Brinkhaus, Bodo Liecker, Karl Wegscheider, and Stefan N. Willich</i>	3485
Risedronate Decreases Biochemical Markers of Cartilage Degradation but Does Not Decrease Symptoms or Slow Radiographic Progression in Patients With Medial Compartment Osteoarthritis of the Knee: Results of the Two-Year Multinational Knee Osteoarthritis Structural Arthritis Study	
<i>Clifton O. Bingham, III, J. Chris Buckland-Wright, Patrick Garner, Stanley B. Cohen, Maxime Dougados, Silvano Adami, Daniel J. Clauw, Timothy D. Spector, Jean-Pierre Pelletier, Jean-Pierre Raynauld, Vibke Strand, Lee S. Simon, Joan M. Meyer, Gary A. Cline, and John F. Beary</i>	3494
Lower Prevalence of Chondrocalcinosis in Chinese Subjects in Beijing Than in White Subjects in the United States: The Beijing Osteoarthritis Study	
<i>Yuqing Zhang, Robert Terkeltaub, Michael Nevitt, Ling Xu, Tuhina Neogi, Piaran Aliabadi, Jingbo Niu, and David T. Felson</i>	3508
<b>Osteoarthritis and Cartilage Basic Science Studies</b>	
Functional Characterization of an Orphan Nuclear Receptor, Rev-ErbA $\alpha$ , in Chondrocytes and Its Potential Role in Osteoarthritis	
<i>P. Chaturvedi, M. Pratta, K. Steplewski, J. Connor, and S. Kumar</i>	3513
The Effect of O <sub>2</sub> Tension on pH Homeostasis in Equine Articular Chondrocytes	
<i>P. I. Milner, T. P. A. Fairfax, J. A. Browning, R. J. Wilkins, and J. S. Gibson</i>	3523
Large-Scale Gene Expression Profiling Reveals Major Pathogenetic Pathways of Cartilage Degeneration in Osteoarthritis	
<i>Thomas Aigner, Katrin Fundel, Joachim Saas, Pia M. Gebhard, Jochen Haag, Tilo Weiss, Alexander Zien, Franz Obermayr, Ralf Zimmer, and Eckart Bartnik</i>	3533
Amyloid Contained in the Knee Joint Meniscus Is Formed From Apolipoprotein A-I	
<i>Alan Solomon, Charles L. Murphy, Daniel Kestler, Daniel Coriu, Deborah T. Weiss, Josef Makovitzky, and Per Westermark</i>	3545
<b>Bone Biology</b>	
Impaired Skeletal Development in Interleukin-6-Transgenic Mice: A Model for the Impact of Chronic Inflammation on the Growing Skeletal System	
<i>Fabrizio De Benedetti, Nadia Rucci, Andrea Del Fattore, Barbara Peruzzi, Rita Paro, Maurizio Longo, Marina Vivarelli, Flaminia Muratori, Silvia Berni, Paola Ballanti, Serge Ferrari, and Anna Teti</i>	3551
<b>Childhood Arthritis</b>	
Patients With Juvenile Psoriatic Arthritis Comprise Two Distinct Populations	
<i>Matthew L. Stoll, David Zurakowski, Lise E. Nigrovic, David P. Nichols, Robert P. Sundel, and Peter A. Nigrovic</i>	3564

## **Reactive Arthritis/Spondylarthritis**

- Long-Term Outcome and Prognostic Factors in Enthesitis-Related Arthritis: A Case-Control Study  
*Berit Flato, Anna-Maria Hoffmann-Vold, Andreas Reiff, Øystein Førre, Gunnhild Lien, and Odd Vinje* ..... 3573
- Identification of Immunodominant CD4+ T Cell Epitopes in Patients With *Yersinia*-Induced Reactive Arthritis by Cytometric Cytokine Secretion Assay  
*Andreas Thiel, Peihua Wu, Małgorzata Lanowska, Jun Dong, Andreas Radbruch, and Joachim Sieper* ..... 3583

## **Systemic Lupus Erythematosus Basic Science Studies**

- IK Cytokine Ameliorates the Progression of Lupus Nephritis in MRL/lpr Mice  
*Masatake Muraoka, Hitoshi Hasegawa, Masashi Kohno, Atsushi Inoue, Tatsuhiko Miyazaki, Miho Terada, Masato Nose, and Masaki Yasukawa* ..... 3591
- Expansion of Toll-like Receptor 9-Expressing B Cells in Active Systemic Lupus Erythematosus: Implications for the Induction and Maintenance of the Autoimmune Process  
*Eva D. Papadimitraki, Christianna Choulaki, Eleni Koutala, George Bertsias, Christos Tsatsanis, Irini Gergianaki, Amalia Raptopoulou, Heraklis D. Kritikos, Clio Mamalaki, Prodromos Sidiropoulos, and Dimitrios T. Boumpas* ..... 3601

## **Systemic Lupus Erythematosus Clinical Studies**

- B Cell Depletion Therapy in Systemic Lupus Erythematosus: Effect on Autoantibody and Antimicrobial Antibody Profiles  
*G. Cambridge, M. J. Leandro, M. Teodorescu, J. Manson, A. Rahman, D. A. Isenberg, and J. C. Edwards* ..... 3612
- The Effect of Moderate-Dose Corticosteroids in Preventing Severe Flares in Patients With Serologically Active, but Clinically Stable, Systemic Lupus Erythematosus: Findings of a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial  
*Chung-E Tseng, Jill P. Buyon, Mimi Kim, H. Michael Belmont, Meggan Mackay, Betty Diamond, Galina Marler, Pamela Rosenthal, Kathleen Haines, Virginia Ilie, and Steven B. Abramson* ..... 3623
- Hepatocyte Growth Factor and Transforming Growth Factor  $\beta 1$  Ratio at Baseline Can Predict Early Response to Cyclophosphamide in Systemic Lupus Erythematosus Nephritis  
*Anna Capuano, Stefano Costanzi, Giusy Peluso, Gianfranco Zannoni, Valerio Gaetano Vellone, Elisa Gremese, Angelo Zoli, Cathryn Scott, Carlo Alberto Beltrami, Giulio Romano, and Gianfranco Ferraccioli* ..... 3633
- Hydroxychloroquine in Lupus Pregnancy  
*Megan E. B. Clowse, Laurence Magder, Frank Witter, and Michelle Petri* ..... 3640
- Occupational Silica and Solvent Exposures and Risk of Systemic Lupus Erythematosus in Urban Women  
*Axel Finckh, Glinda S. Cooper, Lori B. Chibnik, Karen H. Costenbader, Julie Watts, Helen Pankey, Patricia A. Fraser, and Elizabeth W. Karlson* ..... 3648

## **Systemic Sclerosis**

- Myofibroblasts and Hyalinized Collagen as Markers of Skin Disease in Systemic Sclerosis  
*Eugene Y. Kissin, Peter A. Merkel, and Robert Lafyatis* ..... 3655
- Macrophage Migration Inhibitory Factor Promoter Polymorphisms and the Clinical Expression of Scleroderma  
*Sou-Pan Wu, Lin Leng, Zeny Feng, Nianjun Liu, Hongyu Zhao, Courtney McDonald, Annette Lee, Frank C. Arnett, Peter K. Gregersen, Maureen D. Mayes, and Richard Bucala* ..... 3661

## **Myositis**

- HLA Polymorphisms in African Americans With Idiopathic Inflammatory Myopathy: Allelic Profiles Distinguish Patients With Different Clinical Phenotypes and Myositis Autoantibodies  
*Terrance P. O'Hanlon, Lisa G. Rider, Gulnara Mamyrova, Ira N. Targoff, Frank C. Arnett, John D. Reveille, Mary Carrington, Xiaojiang Gao, Chester V. Oddis, Penelope A. Morel, James D. Malley, Karen Malley, Ejaz A. Shamim, Stephen J. Chanock, Charles B. Foster, Thomas Bunch, Ann M. Reed, Lori A. Love, and Frederick W. Miller* ..... 3670
- A Novel Autoantibody to a 155-kd Protein Is Associated With Dermatomyositis  
*Ira N. Targoff, Gulnara Mamyrova, Edward P. Trieu, Osvaldo Perurena, Bhanu Koneru, Terrance P. O'Hanlon, Frederick W. Miller, and Lisa G. Rider, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups* ..... 3682

## **Autoinflammatory Disease**

- A Role for Geranylgeranylation in Interleukin-1 $\beta$  Secretion  
*Saskia H. L. Mandey, Loes M. Kuijk, Joost Frenkel, and Hans R. Waterham* ..... 3690

## **Vasculitis**

- Antiviral Therapy for Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis: A Long-Term Followup Study  
*David Saadoun, Mathieu Resche-Rigon, Vincent Thibault, Jean-Charles Piette, and Patrice Cacoub* ..... 3696

NK026680, a Novel Suppressant of Dendritic Cell Function, Prevents the Development of Rapidly Progressive Glomerulonephritis and Perinuclear Antineutrophil Cytoplasmic Antibody in SCG/Kj Mice Kan Saiga, Kazuhiro Tokunaka, Eiji Ichimura, Eriko Toyoda, Fuminori Abe, Minako Yoshida, Hiroshi Furukawa, Masato Nose, and Masao Ono .....	3707
<b>Concise Communication</b>	
Reduction of Proinflammatory Cytokine Expression in the Synovium by Targeting IKK $\beta$ In Vivo in a Rat Model Sander W. Tas, Najat Hajji, Dirk J. Stenvors, Gary S. Firestein, Margriet J. Vervoordeldonk, and Paul P. Tak .....	3716
<b>Letters</b>	
Vitamin D Deficiency Does Not Increase the Risk of Rheumatoid Arthritis: Comment on the Article by Merlino et al Markus M. J. Nielen, Dirkjan van Schaardenburg, Willem F. Lems, Rob J. van de Stadt, Margret H. M. T. de Koning, Henk W. Reesink, Moud R. Habibuw, Irene E. van der Horst-Bruinsma, Jos W. R. Twisk, and Ben A. C. Dijkmans .....	3719
Intravenous Bisphosphonates in Osteoporosis and Jaw Osteonecrosis: Comment on the Article by Delmas et al Basile N. Landis and Max Hugentobler .....	3720
<b>Reply</b>	
Pierre D. Delmas, for the DIVA study investigators .....	3721
Association of the Interleukin-1 Gene Cluster With Osteoarthritis of the Hip: Comment on the Article by Meulenbelt et al and the Letter by Smith et al Kay Chapman and John Loughlin .....	3722
Reply to Letter by Isenberg and Gordon Commenting on the Pediatric Rheumatology International Trials Organization Criteria for the Evaluation of Response to Therapy in Juvenile Systemic Lupus Erythematosus Nicolino Ruperto, Angelo Ravelli, and Alberto Martini, for the Pediatric Rheumatology International Trials Organization (PRINTO) .....	3723
<b>Clinical Image</b>	
Bilateral Black Eyes (Raccoon's Eyes) in AL Amyloidosis Rogerio Da Hora Passos, Adriano Pereira, Antonio Capone Neto, Andreza Feitosa Ribeiro, Jose Kutner, Nelson Hamerschlak, and Morton Scheinberg .....	3724
<b>ACR Announcements</b>	A14

VOLUME 54

DECEMBER 2006

NO. 12

**Special Articles**

Editorial: A Different Type of Procedure for a Different Type of Pain Michael C. Hsu and Daniel J. Clauw .....	3725
Editorial: The Notochord in the Mammalian Adult: A Paradox Juergen A. Mollenhauer .....	3728
Editorial: Hematopoietic Stem Cell Transplantation in Autoimmune Diseases: Is the Glass Half Full or Half Empty? Gabor G. Illei .....	3730
Special Article: New Regulatory Rules for Clinical Trials in the United States and the European Union: Key Points and Comparisons Marie Miossec and Pierre Miossec .....	3735
Special Article: Statistical Methods in <i>Arthritis &amp; Rheumatism</i> : Current Trends Mimi Kim .....	3741
Review: Randomized Controlled Trials of Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: The Evolution From Myeloablative to Lymphoablative Transplant Regimens Richard K. Burt, Alberto Marmont, Yu Oyama, Shimon Slavin, Renate Arnold, Falk Hiepe, Athanasios Fassas, John Snowden, Friedrich Schuening, Han Myint, Dhavalkumar D. Patel, David Collier, Helen Heslop, Robert Krance, Laisyde Statkute, Larissa Verda, Ann Traynor, Tomas Kozak, Rogier Q. Hintzen, John W. Rose, Julio Voltarelli, Yvonne Loh, Mary Territo, Bruce A. Cohen, Robert M. Craig, John Varga, and Walter G. Barr .....	3750

## Rheumatoid Arthritis

- Presence of Significant Synovitis in Rheumatoid Arthritis Patients With Disease-Modifying Antirheumatic Drug-Induced Clinical Remission: Evidence From an Imaging Study May Explain Structural Progression  
*A. K. Brown, M. A. Quinn, Z. Karim, P. G. Conaghan, C. G. Peterfy, E. Hensor, R. J. Wakefield, P. J. O'Connor, and P. Emery* ..... 3761
- Characteristics of Diffuse Large B Cell Lymphomas in Rheumatoid Arthritis  
*Eva Baecklund, Carin Backlin, Anastasia Iliadou, Fredrik Granath, Anders Ekbom, Rose-Marie Amini, Nils Feltelius, Gunilla Enblad, Christer Sundström, Lars Klareskog, Johan Askling, and Richard Rosengren* ..... 3774
- Individualized Monitoring of Drug Bioavailability and Immunogenicity in Rheumatoid Arthritis Patients Treated With the Tumor Necrosis Factor  $\alpha$  Inhibitor Infliximab  
*Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C. Kapetanovic, and Tore Saxne* ..... 3782
- Immunosuppressive Medications and Hospitalization for Cardiovascular Events in Patients With Rheumatoid Arthritis  
*Daniel H. Solomon, Jerry Avorn, Jeffrey N. Katz, Michael E. Weinblatt, Soko Setoguchi, Raisa Levin, and Sebastian Schneeweiss* ..... 3790
- Isotype Distribution of Anti-Cyclic Citrullinated Peptide Antibodies in Undifferentiated Arthritis and Rheumatoid Arthritis Reflects an Ongoing Immune Response  
*K. N. Verpoort, C. M. Jol-van der Zijde, E. A. M. Papendrecht-van der Voort, A. Ioan-Facsinay, J. W. Drijfhout, M. J. D. van Tol, F. C. Breedveld, T. W. J. Huizinga, and R. E. M. Toes* ..... 3799
- Association of Citrullinated Proteins With Synovial Exosomes  
*K. Skriner, K. Adolph, P. R. Jungblut, and G. R. Burmester* ..... 3809
- Analysis of IRF5 Gene Functional Polymorphisms in Rheumatoid Arthritis  
*Blanca Rueda, M. V. Prasad Linga Reddy, Miguel A. González-Gay, Alejandro Balsa, Dora Pascual-Salcedo, Ingemar F. Petersson, Alicia Eimon, Sergio Paire, Hugo R. Scherbarth, Bernardo A. Pons-Estel, María F. González-Escribano, Marta E. Alarcón-Riquelme, and Javier Martín* ..... 3815
- Rheumatoid Arthritis Association With the FCRL3 -169C Polymorphism Is Restricted to PTPN22 1858T-Homozygous Individuals in a Canadian Population  
*William G. Newman, Qing Zhang, Xiangdong Liu, Erin Walker, Heather Ternan, Julie Owen, Ben Johnson, Wenda Greer, Dianne P. Mosher, Walter P. Maksymowich, Vivian P. Bykerk, Edward C. Keystone, Christopher I. Amos, and Katherine A. Siminovitch* ..... 3820
- The Functional Variant of the Inhibitory Fc $\gamma$  Receptor IIb (CD32B) Is Associated With the Rate of Radiologic Joint Damage and Dendritic Cell Function in Rheumatoid Arthritis  
*Timothy R. D. J. Radstake, Barbara Franke, Mark H. Wenink, Karin C. A. M. Nabbe, Marieke J. H. Coenen, Paco Welsing, Ezio Bonvini, Scott Koenig, Wim B. van den Berg, Pilar Barrera, and Piet L. C. M. van Riel* ..... 3828
- The -169C/T Polymorphism in FCRL3 Is Not Associated With Susceptibility to Rheumatoid Arthritis or Systemic Lupus Erythematosus in a Case-Control Study of Koreans  
*Chan-Bum Choi, Changsoo Paul Kang, Sang-Seokg Seong, Sang-Cheol Bae, and Changwon Kang* ..... 3838
- Osteoarthritis**
- Knee Joint Loading Differs in Individuals With Mild Compared With Moderate Medial Knee Osteoarthritis  
*Laura E. Thorp, D. Richman Sumner, Joel A. Block, Kirsten C. Moisio, Susan Shott, and Markus A. Wimmer* ..... 3842
- Effects of Chronic Growth Hormone and Insulin-Like Growth Factor 1 Deficiency on Osteoarthritis Severity in Rat Knee Joints  
*Kari J. Ekenstedt, William E. Sonntag, Richard F. Loeser, Bruce R. Lindgren, and Cathy S. Carlson* ..... 3850
- Cartilage Biology**
- Nucleus Pulposus Notochord Cells Secrete Connective Tissue Growth Factor and Up-Regulate Proteoglycan Expression by Intervertebral Disc Chondrocytes  
*W. Mark Erwin, Keith Ashman, Paul O'Donnell, and Robert D. Inman* ..... 3859
- Fc $\gamma$  Receptors Directly Mediate Cartilage, but Not Bone, Destruction in Murine Antigen-Induced Arthritis: Uncoupling of Cartilage Damage From Bone Erosion and Joint Inflammation  
*Peter L. van Lent, Lilyanne Grevers, Erik Lubberts, Teun J. de Vries, Karin C. Nabbe, Sjef Verbeek, Birgit Oppers, Annet Sloetjes, Arjen B. Blom, and Wim B. van den Berg* ..... 3868
- Jun Activation Domain-Binding Protein 1 Binds Smad5 and Inhibits Bone Morphogenetic Protein Signaling  
*Jochen Haag and Thomas Aigner* ..... 3878
- SPARC, an Upstream Regulator of Connective Tissue Growth Factor in Response to Transforming Growth Factor  $\beta$  Stimulation  
*X. D. Zhou, M. M. Xiong, F. K. Tan, X. J. Guo, and F. C. Arnett* ..... 3885

Steroid Hormones Strongly Support Bovine Articular Cartilage Integration in the Absence of Interleukin-1 $\beta$	3890
<i>Carsten Englert, Torsten Blunk, Johann Fierlbeck, Julia Kaiser, Wolfgang Stosiek, Peter Angele, Joachim Hammer, and Rainer H. Straub</i>	
<b>Inflammation</b>	
Soluble Receptor for Advanced Glycation End Products Triggers a Proinflammatory Cytokine Cascade via $\beta$ 2 Integrin Mac-1	3898
<i>Rille Pullerits, Mikael Brisslert, Ing-Marie Jonsson, and Andrej Tarkowski</i>	
<b>Systemic Lupus Erythematosus</b>	
Association of a Transmembrane Polymorphism of Fc $\gamma$ Receptor IIb (FCGR2B) With Systemic Lupus Erythematosus in Taiwanese Patients	3908
<i>Ji-Yih Chen, Chin Man Wang, Chung-Chun Ma, Shue-Fen Luo, Jeffrey C. Edberg, Robert P. Kimberly, and Jianming Wu</i>	
<b>Antiphospholipid Syndrome</b>	
Relationship of Antiphospholipid Antibodies to Cardiovascular Manifestations of Systemic Lupus Erythematosus	3918
<i>Afshin Farzaneh-Far, Mary J. Roman, Michael D. Lockshin, Richard B. Devereux, Stephen A. Paget, Mary K. Crow, Adrienne Davis, Lisa Sammaritano, Daniel M. Levine, and Jane E. Salmon</i>	
<b>Systemic Sclerosis</b>	
Domain 1 of the Urokinase-Type Plasminogen Activator Receptor Is Required for Its Morphologic and Functional, $\beta$ 2 Integrin-Mediated Connection With Actin Cytoskeleton in Human Microvascular Endothelial Cells: Failure of Association in Systemic Sclerosis Endothelial Cells	3926
<i>Francesca Margheri, Mirko Manetti, Simona Serrati, Daniele Nosi, Marco Pucci, Marco Matucci-Cerinic, Bashar Kahaleh, Laura Bazzichi, Gabriella Fibbi, Lidia Ibba-Manneschi, and Mario Del Rosso</i>	
A Novel Autoantigen to Differentiate Limited Cutaneous Systemic Sclerosis From Diffuse Cutaneous Systemic Sclerosis: The Interferon-Inducible Gene IFI16	3939
<i>Michele Mondini, Matteo Vidali, Marco De Andrea, Barbara Azzimonti, Paolo Airò, Roberta D'Ambrosio, Piersandro Riboldi, Pier Luigi Meroni, Emanuele Albano, Yehuda Shoenfeld, Marisa Gariglio, and Santo Landolfo</i>	
Association of the PTPN22 R620W Polymorphism With Anti-Topoisomerase I- and Anticentromere Antibody-Positive Systemic Sclerosis	3945
<i>Pravitt Gourh, Filemon K. Tan, Shervin Assassi, Chul W. Ahn, Terry A. McNearney, Michael Fischbach, Frank C. Arnett, and Maureen D. Mayes</i>	
Lung Transplantation in Scleroderma Compared With Idiopathic Pulmonary Fibrosis and Idiopathic Pulmonary Arterial Hypertension	3954
<i>Lionel Schachna, Thomas A. Medsger, Jr., James H. Dauber, Fredrick M. Wigley, Neil A. Braunstein, Barbara White, Virginia D. Steen, John V. Conte, Stephen C. Yang, Kenneth R. McCurry, Marvin C. Borja, David E. Plaskon, Jonathan B. Orens, and Allan C. Gelber</i>	
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Corticosteroids and Intravenous Cyclophosphamide Followed by Oral Azathioprine for the Treatment of Pulmonary Fibrosis in Scleroderma	3962
<i>Rachel K. Hoyles, Ross W. Ellis, Jessica Wellsbury, Belinda Lees, Pauline Newlands, Nicole S. L. Goh, Christopher Roberts, Sujal Desai, Ariane L. Herrick, Neil J. McHugh, Noeleen M. Foley, Stanley B. Pearson, Paul Emery, Douglas J. Veale, Christopher P. Denton, Athol U. Wells, Carol M. Black, and Roland M. du Bois</i>	
<b>Childhood Arthritis</b>	
Systemic Sclerosis in Childhood: Clinical and Immunologic Features of 153 Patients in an International Database	3971
<i>Giorgia Martini, Ivan Foeldvari, Ricardo Russo, Ruben Cuttica, Anne Eberhard, Angelo Ravelli, Thomas J. A. Lehman, Sheila Knupp Feitosa de Oliveira, Gordana Susic, Galina Lyskina, Dana Nemcova, Robert Sundel, Fernanda Falcini, Herman Girschick, Ana Paula Lotito, Antonella Buoncompagni, Flavio Sztajnbok, Sulaiman M. Al-Mayouf, Ilonka Orbán, Clodoveo Ferri, Balu H. Athreya, Patricia Woo, and Francesco Zulian, for the Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society</i>	
Immunogenetic Risk and Protective Factors for Juvenile Dermatomyositis in Caucasians	3979
<i>Gulnara Mamyrava, Terrance P. O'Hanlon, Jason B. Monroe, Danielle Mercatante Carrick, James D. Malley, Sharon Adams, Ann M. Reed, Ejaz A. Shamim, Laura James-Newton, Frederick W. Miller, and Lisa G. Rider, for the Childhood Myositis Heterogeneity Collaborative Study Group</i>	

<b>Fibromyalgia and Pain Syndromes</b>	
A Randomized, Sham-Controlled, Proof of Principle Study of Transcranial Direct Current Stimulation for the Treatment of Pain in Fibromyalgia	
<i>Felipe Fregni, Rafaela Gimenes, Angela C. Valle, Merari J. L. Ferreira, Renata R. Rocha, Luane Natale, Riviane Bravo, Sergio P. Rigonatti, Steven D. Freedman, Michael A. Nitsche, Alvaro Pascual-Leone, and Paulo S. Boggio</i>	3988
<b>Fear Avoidance and Prognosis in Back Pain: A Systematic Review and Synthesis of Current Evidence</b>	
<i>Tamar Pincus, Steven Vogel, A. Kim Burton, Rita Santos, and Andy P. Field</i>	3999
<b>Vasculitis</b>	
Interleukin-10 Promoter Polymorphisms in Giant Cell Arteritis	
<i>Luigi Boiardi, Bruno Casali, Enrico Farnetti, Nicolò Pipitone, Davide Nicoli, PierLuigi Macchioni, Luca Cimino, GianLuigi Bajocchi, Maria Grazia Catanoso, Laura Pattacini, and Carlo Salvarani</i>	4011
<b>Erdheim-Chester Disease</b>	
Immunohistochemical Evidence of a Cytokine and Chemokine Network in Three Patients With Erdheim-Chester Disease: Implications for Pathogenesis	
<i>Antonella Stoppacciaro, Marina Ferrarini, Chiara Salmaggi, Cristina Colarossi, Luisa Praderio, Moreno Tresoldi, Angelo A. Beretta, and Maria Grazia Sabbadini</i>	4018
<b>Concise Communication</b>	
Lack of Genetic Association of the Interleukin-4 Receptor Single-Nucleotide Polymorphisms I50V and Q551R With Erosive Disease in Psoriatic Arthritis	
<i>Jesús Lascorz, Ulrike Hüffmeier, Hendrik Schulze-Koops, Alla Skapenko, André Reis, Jörg Lohmann, Jörg Wendler, Heiko Traupe, Wolfgang Küster, and Harald Burkhardt</i>	4023
<b>Letters</b>	
Lack of Association of Antibodies to Ribosomal P Proteins With Lupus Membranous Glomerulonephritis: Comment on the Article by do Nascimento et al	
<i>Maria Laura Bertolaccini, Veronica Murru, Paula Alba, and Munther A. Khamashtha</i>	4025
Reply	
<i>Ana Patrícia do Nascimento, Vilma dos Santos Trindade Viana, Leonardo de Abreu Testagrossa, Elaine Pires Leon, Eduardo Ferreira Borba, Rui Toledo Barros, and Eloísa Bonfá</i>	4026
<b>Clinical Images</b>	
Scapular Winging	
<i>Emily N. Vinson</i>	4027
<b>Fellow Abstracts and Late-Breaking Abstracts, American College of Rheumatology, 2006 Annual Scientific Meeting</b>	
Reviewers	4028
Contents, Volume 54, 2006	4127
Indexes	4133
ACR Announcements	4171
	A15

## AUTHOR INDEX

*Arthritis and Rheumatism*, Volume 54, Numbers 1-12, 2006

### A

- Aarden L, 711  
 Abbal M, 593  
 Abbate R, 2263  
 Abbott K, 3345  
 Abe F, 3707  
 Abe R, 473  
 Abeles AM, 393  
 Abraham DJ, 649, 1309, 3034  
 Abramson SB, 3623  
 Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group, 702  
 Adachi M, 3408  
 Adami S, 1838, 3494  
 Adamopoulos IE, 1451  
 Adams KM, 2069  
 Adams S, 3979  
 Adeli K, 1283  
 Adler AJ, 2533  
 Adolph K, 3809  
 af Klint E, 76, 1463  
 Afeltra A, 312  
 Agarwal S, 1390  
 Agelan A, 2415  
 Agha-Babakhani A, 3363  
 Aguilera S, 3465  
 Aguirre MA, 301  
 Ahearn JM, 670  
 Ahmadi KR, 1051, 3064  
 Ahmed S, 2393  
 Ahmed SS, 2250  
 Ahn CW, 3945  
 Ahuero JS, 1509  
 Aigner T, 3254, 3533, 3878  
 Airò P, 3939  
 Akahoshi T, 455  
 Akaogi J, 1557, 2004  
 Akil M, 3300  
 Akira S, 1557  
 Aksentijevich I, 2703  
 Al-Lozi MT, 1687  
 Al-Mayouf SM, 3971  
 Alaranta S, 2852  
 Alarcón GS, 1580, 1703, 1705, 1708, 1940, 2035, 2550, 3057  
 Alarcón-Riquelme ME, 3815  
 Alba P, 4025  
 Albani S, 19  
 Albano E, 3939  
 Alcamí J, 1473  
 Alefacept in Psoriatic Arthritis Study Group, 1638  
 Alén M, 1334  
 Aletaha D, 377, 2034, 2784  
 Alfredsson L, 38  
 Ali A, 2928  
 Aliabadi P, 1255, 3508  
 Allaart CF, 1087, 2339, 2830

- Allanore Y, 202, 2243  
 Allard C, 1262  
 Allen BB, 2402  
 Allen E, 3300  
 Allen KD, 551  
 Allen NB, 1608  
 Allende C, 3465  
 Alm GV, 408, 1917  
 Alpert D, 2353  
 Alston JT, 2912  
 Altmann DM, 482  
 Altmeyer P, 3065  
 Alvarez de Mon M, 1707  
 Ambrozic A, 312  
 Amel-Kashipaz MR, 2674  
 American College of Rheumatology Audiovisual Aids Subcommittee, 690  
 American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force, 1034  
 Amin MA, 765, 2402  
 Amin S, 795, 1529, 2488  
 Amini R-M, 3774  
 Amos CI, 1022, 1482, 3820  
 Amoura Z, 184, 3284, 3330  
 Amselem S, 508  
 Anders JO, 244  
 Andersen LS, 1401  
 Anderson K, 3163  
 Anderson R, 2643  
 Andrew T, 2147  
 Andrews PA, 2010  
 Andrews RK, 2558  
 Anjea R, 3059  
 Aneloski NM, 1888  
 Angel P, 3890  
 Angelis SM, 3079  
 Anglin CP, 2912  
 Antoniv TT, 2711  
 Anzilotti C, 733  
 Aoki H, 808  
 Apparailly F, 1867  
 Appel H, 1805, 2845  
 Arai Y, 264  
 Aranda R, 2807  
 Arango I, 2415  
 Aranow C, 2550  
 Aratani S, 808  
 Arbogast PG, 1706  
 Archer CW, 1209  
 Ardizzone M, 2243  
 Ardlie KG, 1022  
 Argyropoulou MI, 1350  
 Arita N, 2934  
 Armamento-Villareal R, 1355  
 Armstrong D, 1291  
 Arnaud C, 390  
 Arner EC, 2912  
 Arnett FC, 2250, 2626, 3661, 3670, 3885, 3945

- Arnold R, 3750  
 Arntz OJ, 1518  
 Aróstegui JI, 2334  
 Artlett CM, 2616  
 Arya V, 3059  
 Asherson RA, 2568  
 Ashman K, 3859  
 Ashton BA, 2022  
 Askling J, 692, 3774  
 Assaraf YG, 557  
 Assassi S, 3945  
 ASSERT Study Group, 1646  
 Atamas SP, 2643  
 Athanasou NA, 1451  
 Athreya BH, 3066, 3971  
 Atienza J, 524  
 Atkins SR, 635  
 ATLAS Study Group, 2136  
 Aurich M, 244  
 Aviv RI, 1291  
 Avorn J, 1378, 2757, 3790  
 Avouac J, 2243  
 Axmann R, 2745  
 Aymard G, 3284  
 Azria M, 3205  
 Azzimonti B, 3939

### B

- Backlin C, 692, 3774  
 Badley EM, 3212  
 Badsha H, 2541  
 Bae S-C, 90, 2550, 3838  
 Baecklund E, 692, 3774  
 Baelde HJ, 2944  
 Baer AN, 1429  
 Baeten D, 1795, 2387, 2594, 3381  
 Baggott JE, 1708  
 Bainbridge SE, 2674  
 Bajema IM, 2944  
 Bajocchi G, 4011  
 Baker D, 702, 716, 877, 2840  
 Baker DC, 3277  
 Baker JF, 2688  
 Bala M, 702, 716  
 Baldi M, 998  
 Balint G, 2817  
 Ballanti P, 3551  
 Ballina J, 2334  
 Ballman KV, 60  
 Balsa A, 1151, 3815  
 Bandaru R, 1961  
 Bank RA, 253  
 Barborroja N, 301  
 Barbe MF, 2415  
 Barber GN, 661  
 Barbetta B, 2339  
 Barcellona R, 998  
 Barker T, 3051  
 Barksby HE, 540, 3244  
 Barnes S, 343  
 Barnetche T, 593

- Barr S, 2550  
 Barr WG, 3750  
 Barrera P, 3828  
 Bartnik E, 3533  
 Barton A, 3417  
 Bathon JM, 702, 716  
 Bayat N, 2434  
 Bayer N, 1595  
 Bazzichi L, 3926  
 Beary JF, 3374, 3494  
 Becker JC, 2807  
 Beckmann-Welle M, 939  
 Begovich AB, 1022  
 Behera AK, 3319  
 Beigelman C, 184  
 Beirnaert E, 1856  
 Bejarano P, 661  
 Belisle C, 1270  
 Belmont HM, 3623  
 Beltrami CA, 3633  
 Benallaoua M, 1233  
 Bendle AM, 2872  
 Benderdour M, 271  
 Bendtsen K, 3782  
 Bengtsson C, 38  
 Benito-Miguel M, 1151  
 Bennink MB, 1518  
 Benseler SM, 1291  
 Beppu M, 808  
 Beretta AA, 4018  
 Berger I, 1009  
 Berggreen E, 2300  
 Berlo SE, 2423  
 Berman A, 1075  
 Bernad B, 1025  
 Bernatsky S, 2550  
 Berndt MC, 2558  
 Berni S, 3551  
 Bertolaccini ML, 4025  
 Bertoli AM, 1580, 1703, 2035  
 Bertsias G, 3601  
 Bettencourt BF, 1340  
 Beyenne J, 1283  
 Bickel E, 3182  
 Bidwell JP, 2471  
 Biedermann BC, 908  
 Bierma-Zeinstra SMA, 1028  
 Bizeveld MH, 369, 1588  
 Biggiogero M, 356  
 Bijl M, 3373  
 Bijlsma JWJ, 682, 1422, 2031, 3104  
 Bijzet J, 2015  
 Bingham CO III, 3494  
 Bird PA, 1122  
 Birdsall HH, 1509  
 Birmingham DJ, 3291  
 Björck E, 1415  
 Black CM, 1309, 3034, 3962  
 Blakely KM, 621  
 Blaney Davidson EN, 1653  
 Blaschke S, 3144

- Blaszczyk M, 1961  
 Bleiberg J, 2505  
 Block JA, 2923, 3842  
 Blom AB, 3868  
 Blomley MJK, 47  
 Blond J-L, 2109  
 Blunk T, 3890  
 Bobacz K, 463  
 Bocci EB, 3060  
 Böckelman R, 1701  
 Bodman-Smith MD, 854  
 Boers M, 1772, 2031  
 Boggio PS, 3988  
 Böhm B, 82  
 Boiardi L, 4011  
 Boileau C, 2471  
 Boivin J-F, 2550  
 Bolduc V, 1270  
 Bolli P, 2263  
 Bolognese M, 1838  
 Bolosiu H, 1063  
 Bonfá E, 1568, 4026  
 Bongartz T, 635, 3381  
 Bonilla E, 2983  
 Bonnekok B, 1701  
 Bontempo F, 1928  
 Bonvini E, 3828  
 Booth SL, 1255  
 Boots AMH, 2594  
 Borghi MO, 356  
 Borja MC, 3954  
 Borschukova O, 3423  
 Borsotti C, 2605  
 Bosch X, 2334  
 Boskey S, 3345  
 Böttcher A, 927  
 Bottigner EP, 2198  
 Botusan IR, 76, 1463  
 Boumpas DT, 3601  
 Bowes J, 3417  
 Bowman S, 3300  
 Bowyer S, 2235  
 Boyer J-F, 593  
 Boyle DL, 587, 2127  
 Bradley MM, 832  
 Brahn E, 2951  
 Brand C, 2061  
 Brandt HC, 678  
 Brandt KD, 684, 2341  
 Braun A, 524  
 Braun J, 569, 678, 1646, 2136  
 Braunstein NA, 3954  
 Bravo JF, 515  
 Bravo R, 3988  
 Breedveld FC, 26, 1087, 1117,  
     2339, 2387, 3135, 3799  
 Bresnick AR, 2901  
 Bresnihan B, 105, 1795, 2022,  
     2387, 3152  
 Breuer S, 2010  
 Breunis WB, 1588  
 Brewer JH, 2347  
 Bridges SL Jr., 3057  
 Brindle KA, 1686  
 Brinkhaus B, 3485  
 Brisslert M, 3898
- British Society for  
 Rheumatology Biologics  
 Register Control Centre  
 Consortium, 2368  
 British Society for  
 Rheumatology Biologics  
 Register, 1786, 2368  
 Brito M, 3465  
 Broerop CP, 2423  
 Brokstad KA, 2300  
 Bröll J, 2817  
 Brookhart MA, 3390  
 Brown AK, 3761  
 Brown MA, 1340  
 Brown S, 1543  
 Browne J, 2038  
 Browning JA, 3523  
 Brownlie RJ, 854  
 Brucato A, 243  
 Bruce IN, 2963, 3300  
 Bruges-Armas J, 1340  
 Brujin JA, 2944  
 Brunke K, 282  
 Bruner BF, 360  
 Bruner GR, 2533  
 Brunner HI, 2577  
 Brusseau J, 2891  
 Bruyere O, 2339  
 Bryant-Greenwood G, 2084  
 Brychey M, 2175  
 Bubb MR, 3051  
 Bucala R, 3661  
 Bucciarelli S, 2568  
 Buckland-Wright JC, 3494  
 Buckley CD, 2096  
 Buendia P, 301  
 Bultink IEM, 379  
 Bunch T, 3670  
 Buness A, 1009  
 Bunn C, 3034  
 Buoncompagni A, 3971  
 Burgos-Vargas R, 2989  
 Burkhardt H, 82, 1491, 4023  
 Burmester G-R, 1501, 2175,  
     2344, 2793, 3809  
 Burns SM, 2970  
 Burrascano JJ, 2347  
 Burn RK, 3750  
 Burton AK, 3999  
 Busque L, 1270  
 Butterworth A, 1482  
 Buyon JP, 2228, 3623  
 Buyuktur AG, 2481  
 Bybee A, 2010  
 Bykerk VP, 3820
- C  
 Cacoub P, 184, 3284, 3696  
 Cagnard N, 2026  
 Calamia KT, 3310  
 Caldwell JR, 607  
 Callahan LF, 3057  
 Calvo-Alén J, 1580, 1940  
 Cambon-Thomsen A, 593  
 Cambridge G, 613, 723, 3063,  
     3612  
 Campbell IK, 158
- Campbell PL, 765  
 Cafete JD, 2334, 2594  
 Cantaert T, 3381  
 Cantagrel A, 593  
 Cantos C, 1867  
 Cao L, 2891  
 Caplan L, 628  
 CAPS Registry Project Group  
 (European Forum on  
 Antiphospholipid Antibodies),  
     2568  
 Capuano A, 3633  
 Carbone L, 1822  
 Caretto D, 214  
 Cargill MA, 1022  
 Carlson CS, 2901, 3850  
 Carneiro V, 1340  
 Carney G, 2757  
 Carr A, 1026  
 Carrick DM, 3979  
 Carrington M, 3670  
 Carson DA, 3067  
 Casali B, 4011  
 CASPAR Study Group, 2665  
 Caspi D, 2151  
 Castaneda J, 2415  
 Casteels P, 1856  
 Catanoso MG, 4011  
 Caterson B, 2933  
 Cathomas G, 908  
 Catrina AI, 76, 692, 1463  
 Catrina S-B, 76, 1463  
 Cattaruzza M, 3144  
 Cawston TE, 540, 3244  
 Ceccherini I, 998  
 Cerinic MM, 2263  
 Cervera R, 2568  
 Cetin E, 2745  
 Ceuppens JL, 1736  
 Cha H-S, 587  
 Chagnon P, 1270  
 Chaiamnuay S, 1705  
 Chakravarty EF, 899  
 Champion HC, 3043  
 Chan C-K, 2585  
 Chan EKL, 2004, 3051  
 Chan ESL, 2632  
 Chander A, 2220  
 Chandra S, 3163  
 Chang D-M, 312  
 Chang HS, 1878  
 Chang M, 1022  
 Chang M-S, 2722  
 Chang Y, 1184  
 Chanock SJ, 1588, 3670  
 Chapin JL, 380  
 Chapman K, 1026, 3722  
 CHARISMA Study Group, 2817  
 Charles C, 2541  
 Chaturvedi P, 3513  
 Chauhan SK, 2326  
 Chen D, 1772  
 Chen G, 3452  
 Chen H, 1822  
 Chen J-Y, 3908  
 Chen JF, 2632  
 Chen MQ, 3267
- Chen P-C, 2722  
 Chen Q, 1928  
 Chen W, 1482, 2951  
 Chen Y, 1309  
 Cheng H-H, 2722  
 Cheng Y-C, 877, 3277  
 Cheung HS, 2452  
 Chibnik LB, 1536, 3648  
 Chikuda H, 2462  
 Childhood Myositis  
     Heterogeneity Collaborative  
     Study Group, 3682, 3979  
 Chimenti D, 733  
 Chin L-S, 2722  
 Chinnaiyan AM, 2047  
 Chiu B, 499  
 Chlipala ES, 2872  
 Cho H, 90  
 Cho JH, 2734  
 Cho M-L, 887, 1878, 2152  
 Cho SG, 1878  
 Cho SH, 492  
 Cho Y-G, 887, 1878  
 Choi AMK, 3001  
 Choi C-B, 3838  
 Choi HY, 2152  
 Choi J-Y, 1747, 3277  
 Chorny A, 864  
 Chouinard L, 2886  
 Choulaki C, 3601  
 Christiansen C, 1838, 2441  
 Christianson TJH, 642  
 Chung CP, 1353, 1706  
 Chung U-i, 2462  
 Cimaz R, 356, 1602  
 CIMESTRA Study Group, 1401  
 Cimino L, 4011  
 Cinelli M, 2263  
 Cipriani P, 202, 3022  
 Cirillo DJ, 3194  
 Civitelli R, 1838  
 Clancy M, 795  
 Clancy RM, 1730, 2228  
 Clark IM, 832  
 Clarke A, 2550  
 Clarke AM, 2963  
 Clarke S, 230  
 Clauw DJ, 2346, 3494, 3725  
 Cline GA, 3494  
 Cloos J, 557  
 Clowse MEB, 3640  
 Cluzel P, 3330  
 Cobo-Ibáñez T, 1151  
 Cockerill KA, 2558  
 Codreanu C, 1063  
 Coenen MJH, 3828  
 Cohen BA, 3750  
 Cohen PL, 1061  
 Cohen SB, 26, 2793, 3494  
 Cohen M, 1096  
 Colarossi C, 4018  
 Cole AA, 244  
 Collado D, 1995  
 Collee G, 2830  
 Collier D, 3750  
 Colquhoun K, 1340  
 Colvine K, 382

- Colwell C, 1814  
 Combe B, 2807  
 Comina DP, 2605  
 Conaghan PG, 1048, 1410, 3761  
 Conen KL, 908  
 Conforti ML, 2263  
 Conn DL, 3057  
 Connolly M, 3152  
 Connor J, 3513  
 Constantin A, 593  
 Constantinescu F, 378  
 Conte JV, 3954  
 Cook DB, 3351  
 Cook EF, 2757  
 Cooper C, 3104  
 Cooper GS, 3648  
 Coppieters K, 1856  
 Corin D, 3545  
 Corona F, 998  
 Corps AN, 832  
 Corr M, 1246  
 Corrigall VM, 854  
 Corsi K, 433  
 Cortelezzi A, 2605  
 Cortiana M, 2605  
 Corvol M-T, 1233  
 Cosgrove DO, 47  
 Costanzi S, 3633  
 Costedoat-Chalumeau N, 184, 3284  
 Costenbader KH, 3648  
 Couto AR, 1340  
 Covucci A, 2807  
 Coyte PC, 3212  
 Craft J, 3277  
 Craig RM, 3750  
 Cravets MW, 2793  
 Creighton CJ, 2047  
 Criscione LG, 2496  
 Criswell LA, 1022, 3087  
 Crofford LJ, 2346  
 Cron RQ, 2220  
 Cronstein BN, 2632  
 Croquefer S, 2523  
 Crosby MB, 2198  
 Crow MK, 1906, 3918  
 Crowell T, 1961  
 Crowson CS, 60  
 Croxford R, 3212  
 Cuadrado MJ, 301  
 Cucchiara AJ, 2220  
 Cuisset L, 1697  
 Cummings SR, 1356  
 Cummins J, 433  
 Curiel R, 1686  
 Curnow SJ, 2096  
 Cutolo M, 682, 2039  
 Cuttica R, 3971
- D**
- Da Hora Passos R, 3724  
 Daans M, 1736  
 Dahl-Lee E, 2541  
 Dai S-M, 818  
 Dalal DH, 1686  
 D'Ambrosio R, 3939  
 DANCER Study Group, 1390
- Daneel S, 54  
 Danesh FR, 3441  
 Dankof A, 1501  
 d'Arbonneau F, 115  
 Daridon C, 2280  
 Dauber JH, 3954  
 Davey MP, 3337  
 Davis A, 3918  
 Davis JC Jr., 1608, 2136  
 Dawson LJ, 1165  
 Dawson SL, 2533  
 D'Cruz D, 3300  
 de Abreu Testagrossa L, 1568, 4026  
 De Andrea M, 3939  
 De Bari C, 1209  
 De Benedetti F, 3551  
 De Carvalho A, 1401  
 de Haard H, 1856  
 de Heer E, 2944  
 De Jager PL, 1279  
 de Jonge R, 2830  
 De Keyser F, 312, 1795  
 de Koning MHMT, 3719  
 de Leon P, 1246  
 de Pablo P, 1444  
 De Rycke L, 1795, 2594, 3381  
 de Sonnaville P, 2830  
 de Vries RRP, 1117  
 de Vries TJ, 3868  
 de Vries-Bouwstra JK, 1087, 2339, 2830  
 Dechant SA, 2776  
 DeGroot J, 253  
 Dekker J, 1354  
 Del Fattore A, 3551  
 Del Galdo F, 2616  
 Del Papa N, 2605  
 Del Rosso A, 202  
 Del Rosso M, 3926  
 DeLa Cadena RA, 2415  
 Delaleu N, 2300  
 Delgado M, 864  
 Dell'Accio F, 1209  
 Delmas PD, 1262, 1838, 3721  
 Demadis KD, 2452  
 DeMarco PJ, 378  
 Denton CP, 649, 1309, 3034, 3962  
 Depinay C, 2243  
 Derese I, 1736  
 Dervieux T, 607, 3095  
 Desai A, 2632  
 Desai S, 3962  
 Desiati F, 1602  
 Dessein PH, 2765  
 Devarajan P, 2577  
 Devauchelle V, 115, 2280, 2523  
 deVeber G, 1291  
 Devereux RB, 3918  
 Devogelaer J-P, 3205  
 Dezawa M, 1897  
 Dhir V, 2030, 3059  
 Di Duca M, 998  
 Diamond B, 2505, 3623  
 Diaz-Torné C, 1025  
 Dickerson IM, 1184
- Dieppe P, 230  
 Diez-Garcia M, 1025  
 Dijkmans BAC, 379, 380, 557, 711, 1087, 1143, 2136, 2339, 3719  
 Dinant HJ, 2387  
 Dinarello CA, 2872  
 Ding C, 1027  
 Distler JHW, 214  
 Distler O, 214  
 DIVA Study Investigators, 3721  
 Dixon WG, 2368  
 D'Lima D, 1814  
 do Nascimento AP, 1568, 4026  
 Doherty M, 524, 533  
 Dong J, 3583  
 Dong X, 2951  
 Donnelly S, 1543  
 Dooley M-A, 2550  
 Doornum SV, 2061  
 Doria A, 312  
 Dormann H, 282  
 Dörner T, 127, 1501, 1708, 2344, 2377  
 Dorris ML, 1317  
 dos Santos Trindade Viana V, 1568, 4026  
 D'Osualdo A, 998  
 Dougados M, 2136, 2793, 3494  
 Downie-Doyle S, 2434  
 Doyle N, 2886  
 Doyle TM, 3337  
 Dreier T, 1856  
 Dreimann M, 2845  
 Drezner MK, 1838  
 Drijfhout JW, 3799  
 Driscoll DJ, 1573  
 Drosos AA, 1350  
 Dryden ER, 670  
 du Bois RM, 3034, 3962  
 Du Boutin LTH, 184  
 Du Clos TW, 325  
 Duboeuf F, 1262  
 Duddy J, 230  
 Dunstan CR, 1772  
 DuPont M, 3163  
 Duquesnoy P, 508  
 Dursun M, 3422  
 Duryea J, 54, 1440, 1444  
 Dwek RA, 3433
- E**
- Easley KA, 3310  
 Eastwood M, 1309  
 Eberhard A, 3971  
 Ebhardt H, 2845  
 Edberg JC, 3908  
 Edmonds JP, 1122  
 Edwards CK III, 2872  
 Edwards DR, 832  
 Edwards JCW, 613, 723, 3063, 3612  
 Edwards JR, 1451  
 Edworthy S, 2550  
 Egerer K, 1501, 2175  
 Egerer T, 1501
- Eggleton P, 1543  
 Ehrenstein MR, 613, 3063  
 Ehrmann M, 1662  
 Ehtisham J, 507  
 Eimon A, 3815  
 Ek M, 2289  
 Ekbom A, 692, 3774  
 Ekenstedt KJ, 3850  
 Eklund A, 38  
 Eksarko P, 3174  
 El-Gabalawy H, 2550  
 Elewaut D, 1856  
 Elim A, 2852  
 Eljaafari A, 2109  
 Elkorn KB, 951  
 Ellingsen T, 1401  
 Elliott AL, 2496  
 Elliott JR, 621  
 Ellis L, 138  
 Ellis RW, 3962  
 Eloranta M-L, 408, 1917  
 Emery P, 702, 716, 1328, 1390, 1410, 2793, 2817, 3761, 3962  
 Enblad G, 3774  
 Endo H, 455  
 Engeland A, 802  
 Engelstad B, 1710  
 Englert C, 3890  
 Engström Å, 82  
 Ensworth S, 2550  
 Epidemiological Investigation of Rheumatoid Arthritis Study Group, 38  
 Eralp L, 3422  
 Erer B, 3422  
 Erkan D, 2568  
 Ernestam S, 76  
 Ernst P, 1435  
 Erwin WM, 3859  
 Escriou V, 1867  
 Espenhaug B, 802  
 Espinosa G, 2568  
 Estes BT, 1222  
 Etzel C, 1482  
 Evans CH, 1714  
 Evengård B, 1682  
 Eyckmans J, 1209  
 Eyre S, 3417
- F**
- Fabre S, 2119  
 Fairfax TPA, 3523  
 Falcini F, 3971  
 Fan P-S, 2271  
 Fan Z, 2471  
 Fantini F, 1602  
 Fantuzzi G, 2872  
 Farewell V, 3300  
 Farnetti E, 4011  
 Farzaneh-Far A, 3918  
 Fassas A, 3750  
 Fatenejad S, 1063, 3119  
 Fatini C, 2263  
 Fazzini F, 986  
 Fearon U, 105, 3152  
 Feghali-Bostwick CA, 3001  
 Fehsel K, 939

- Feist E, 1501, 2175  
 Feitosa de Oliveira SK, 3971  
 Feldman BM, 1283, 1595  
 Felici E, 2989  
 Felsenberg D, 1838  
 Felson DT, 795, 1255, 1356,  
     1529, 1822, 2488, 3508  
 Feltelius N, 692, 3774  
 Feng X, 2951  
 Feng Z, 3661  
 Ferlito F, 998  
 Fernandes JC, 271  
 Fernandez D, 2983  
 Fernández M, 1580, 1703, 2035  
 Fernandez P, 2632  
 Fernandez-Martin A, 864  
 Ferraccioli G, 3633  
 Ferrari S, 3551  
 Ferrarini M, 4018  
 Ferreira MJL, 3988  
 Ferreira Borba E, 1568, 4026  
 Ferri C, 3971  
 Fertala J, 1298  
 Fessler BJ, 1940  
 Fibbi G, 3926  
 Field AP, 3999  
 Fielding CA, 1662, 2084  
 Fierbeck J, 3890  
 Filer A, 2096  
 Filipowicz-Sosnowska A, 1390  
 Finckh A, 54, 1440, 1444, 3648  
 Finis K, 1009  
 Fink B, 1009  
 Firestein GS, 587, 2127, 3716  
 Fischbach M, 3945  
 Fisher MR, 3043  
 Fitting C, 1233  
 FitzGerald JD, 2541, 2951  
 FitzGerald O, 105, 1795, 2022,  
     3152  
 Flagg SD, 2220  
 Flahiff CM, 2891  
 Flatø B, 3573  
 Fleischmann R, 1390  
 Flores-Borja F, 2037  
 Flory JJE, 443  
 Flugsrud GB, 802  
 Foeldvari I, 3971  
 Fogelman AM, 2541  
 Foley NM, 3962  
 Fonseca C, 3034  
 Font J, 2568  
 Fonteche M, 1246  
 Forre Ø, 3573  
 Forster A, 54  
 Fortin PR, 1270, 2211, 2550  
 Fosang AJ, 443  
 Fossel AH, 1536  
 Foster CB, 3670  
 Fox DA, 1847  
 Francès C, 184, 3284  
 François M, 1233  
 Frank SG, 2533  
 Franke B, 3828  
 Fraser PA, 3648  
 Fraticelli P, 2605  
 Freedman SD, 3988  
 Freeman BA, 343  
 Fregnani F, 3988  
 Frenkel J, 2704, 3690  
 Friend DS, 2863  
 Fritsch RD, 2184  
 Frye JB, 3452  
 Fu FH, 433  
 Fuhrmann RA, 244  
 Fujioka M, 264  
 Fujisawa A, 2704  
 Fujita Y, 3233  
 Fujiwara H, 264  
 Fulminis A, 3022  
 Fülop F, 2852  
 Fundel K, 3533  
 Funk JL, 3452  
 Furie RA, 2793  
 Fürnrohr BG, 927  
 Furst DE, 607, 1709, 1982, 2688,  
     2951  
 Furukawa H, 2934, 3707  
 Furukawa S, 2314  
**G**  
 Gabay C, 54, 2707  
 Gabriel SE, 60  
 Gabrielli A, 2605  
 Gaapl US, 927  
 Gál I, 3221  
 Gale D, 795, 1529, 2488  
 Galeazzi M, 312  
 Galindo M, 1473  
 Gallagher H, 2010  
 Galor A, 3306  
 Gambichler T, 3065  
 Gangurde P, 3163  
 Gao W, 877, 3277  
 Gao X, 3670  
 García-Herrera M, 1995  
 Gardner H, 1961, 3011  
 Gardner L, 2022  
 Garfield A, 1619  
 Gariglio M, 3939  
 Garnero P, 1772, 3494  
 Garrood T, 1055  
 Gastaldi R, 2989  
 Gaston JSH, 138  
 Gattinara M, 1602  
 Gattorno M, 998  
 Gay RE, 214  
 Gay S, 214  
 Gebhard PM, 3533  
 Geborek P, 600, 3782  
 Gebretsadik T, 1353  
 Gedalia A, 1987  
 Gehrie E, 2220  
 Geisser ME, 2346  
 Geissler J, 369, 1588  
 Gelber AC, 3954  
 Genant H, 1529, 2488  
 Geng C, 2471  
 Geng Y-J, 2250  
 Genin A, 2220  
 Genovese MC, 2793  
 Georges GE, 1982  
 Gerber I, 382  
 Gergianaki I, 3601  
 Gerlag DM, 2387  
 Gerli R, 3060  
 Gerloni V, 1602  
 Gerosa M, 356  
 Gersuk V, 1105  
 Geusens PP, 1075, 1772, 3104  
 Ghillani P, 3284  
 Ghivizzani SC, 1714  
 Giacomelli R, 202, 3022  
 Giacovelli G, 2339  
 Giannakopoulos B, 2558  
 Giannini EH, 1987, 2235  
 Gibofsky A, 2335  
 Gibson JS, 3523  
 Giczewski D, 3345  
 Gilburd B, 2523  
 Gilkeson GS, 2198, 3057  
 Gimenes R, 3988  
 Gingras M, 1270  
 Ginzler E, 2550  
 Girgis RE, 3043  
 Girkontaite I, 927  
 Girschick H, 3971  
 Gladman DD, 974, 1638, 2211,  
     2321, 2550, 2665  
 Glant TT, 2423, 3221  
 Glass D, 2235  
 Glazier RH, 3212  
 Glenn SB, 2533  
 Glickstein S, 621  
 Glynn RJ, 1378, 2757  
 Gockoop-Ruiterman YPM,  
     1087, 2339  
 Goetzke K, 3254  
 Goggins J, 1529  
 Goh NSL, 3962  
 Gold RH, 1105  
 Goldbach-Mansky R, 2703  
 Golden-Mason L, 105  
 Goldenberg DM, 2344  
 Goldring MB, 387  
 Goligher EC, 1440  
 Gollnick H, 1701  
 Gómez-Puerta JA, 2568  
 González M-J, 3465  
 González-Escribano MF, 3815  
 González-Gay MA, 3815  
 Gonzalez-Rey E, 864  
 Goodall JC, 138  
 Goodman HJB, 2010  
 Gordon C, 2343, 2550, 3300  
 Gorman JD, 10  
 Gorn A, 2951  
 Goronzy JJ, 685, 2776, 3061,  
     3310  
 Goto D, 3476  
 Gottenberg J-E, 2026  
 Gourh P, 3945  
 Gourraud P-A, 593  
 Gracey RH, 2346  
 Graessler A, 292  
 Graessler J, 292  
 Graham B, 2235  
 Grainger AJ, 1328, 1410  
 Gram H, 2387  
 Granath F, 692, 3774  
 Grau S, 1662  
 Green DM, 1509  
 Green JA, 1705  
 Greenstein N, 3095  
 Greenwald MW, 2793  
 Greenwood C, 2211, 2321  
 Greer W, 3820  
 Gregersen PK, 1022, 1482, 2028,  
     3087, 3661  
 Greidinger EL, 661  
 Gremese E, 3633  
 Grenier PA, 184, 3330  
 Grevers L, 3868  
 Griffing WL, 3310  
 Griffiths B, 3300  
 Grigorian M, 795  
 Grodzinsky AJ, 3319  
 Grom A, 2577  
 Groot Ed, 711  
 Gross M-L, 1009  
 Grossman JM, 2541, 2951  
 Grover R, 2030, 3059  
 Grozdanović Z, 678, 2845  
 Gruber J, 47  
 Grunewald J, 38  
 Guan J, 3212  
 Guchelaar H-J, 1087, 2830, 3372  
 Guéguen P, 2523  
 Guermazi A, 795, 1529, 1822,  
     2488  
 Guérin P-A, 54  
 Guffanti C, 243  
 Guichelaar T, 2423  
 Guiducci S, 2263, 3022  
 Guilak F, 1222, 2164, 2891  
 Guo XJ, 2626, 3885  
 Gurish MF, 2863  
 Guruprasad K, 2030  
 Guthrie KA, 2069  
 Gutiérrez-Suárez R, 2989  
**H**  
 Haag J, 3533, 3878  
 Haas CS, 765, 2047, 2402  
 Habibuw MR, 3719  
 Habiro K, 473  
 Hachulla E, 1697  
 Hack CE, 1143  
 Hackshaw KV, 3291  
 Hagiyama H, 2074  
 Hahn BH, 2198, 2541, 2951  
 Haibel H, 678  
 Haines GK III, 765, 2047, 2402,  
     3182  
 Haines K, 3623  
 Hajji N, 3716  
 Hakala M, 2032  
 Häkkinen A, 1334  
 Häkkinen K, 1334  
 Hällgren R, 1415  
 Hamerschlak N, 3724  
 Hammaker D, 2127  
 Hammer J, 3890  
 Hammer RE, 1317  
 Hammoud HA, 3284  
 Han C, 702, 716  
 Han J, 702, 716, 1075, 1646  
 Han M-K, 1747

- Han SW, 2734  
 Handa R, 2030  
 Hanemaaijer R, 2928  
 Hanly J, 2550  
 Hannonen P, 1334, 2032, 3113  
 Hanrotel C, 2523  
 Hansen A, 127, 1708  
 Hansen G, 1401  
 Hansen I, 1401  
 Hanvivadhanakul P, 2951  
 Harding CV, 482  
 Haringman JJ, 2387  
 Härlé P, 1778, 2039  
 Harley JB, 360, 2533  
 Haroche J, 184, 3330  
 Harriman G, 3163  
 Harris ED Jr., 2032  
 Harris HE, 38, 2289  
 Harris RE, 2346  
 Harris T, 1822  
 Harrison MJ, 2515  
 Hart DJ, 524, 533  
 Haruna Y, 1847  
 Harvey BJ, 3212  
 Harvey DJ, 3433  
 Hasdimir B, 1165  
 Hasegawa H, 1174, 3591  
 Hasegawa M, 192, 2314  
 Hashimoto H, 992  
 Hashimoto S, 1814  
 Hashimamoto A, 779  
 Hassoun PM, 3043  
 Hathcock KS, 2184  
 Hato T, 2934  
 Hatron P-Y, 1697  
 Haute-Broeren F, 2423  
 Hausch R, 621  
 Hausdorf G, 2175  
 Havelin LI, 802  
 Hawker GA, 3212  
 Hawkins PN, 2010  
 Hayashi I, 455  
 Hayashi T, 1132  
 Hayer S, 463  
 Hayes M, 754  
 Hayrapetyan H, 508  
 Hazenberg BPC, 2015  
 Hazes JMW, 1028  
 Hazleman BL, 832  
 Hébert J, 1270  
 Hebert LA, 3291  
 Hecker B, 908  
 Hecker M, 3144  
 Hegedus R, 2840  
 Heijmans BT, 1087  
 Heike T, 2704  
 Heinegard D, 2147  
 Hellwell P, 2665  
 Helmchen B, 1009  
 Helwick CG, 226  
 Helms CA, 2038  
 Hempfing A, 2845  
 Hénault J, 963  
 Henderson CJ, 2235  
 Hennig T, 3254  
 Henriksen K, 2441  
 Hensor E, 3761
- Henstorf G, 1982  
 Hepperle M, 3163  
 Hermann K-GA, 1646  
 Hermida J, 1814  
 Hernandez L, 3051  
 Herold KC, 14  
 Herrero-Beaumont G, 1340  
 Herrick AL, 1952, 3962  
 Herring BJ, 2533  
 Herrmann M, 927, 939  
 Herzer P, 3399  
 Heslop H, 3750  
 Hessey EW, 1390, 2793  
 Hetland ML, 1401  
 Hickey SH, 1415  
 Hiepe F, 3750  
 Hierse F, 3399  
 Higgins G, 2235  
 Hilbert DM, 723  
 Hildebrand E, 3319  
 Hintzen RQ, 3750  
 Hinz B, 282  
 Hirata K, 473  
 Hirohata S, 312  
 Hirsch R, 2119  
 Hirschl K, 1974  
 Hirschl M, 1974  
 Hla T, 742  
 Ho K, 2891  
 Hochberg M, 2481  
 Hodes RJ, 2184  
 Hoegh-Andersen P, 2441  
 Hoffman GS, 1608, 3306  
 Hoffman HM, 2314  
 Hoffman IEA, 312  
 Hoffman RW, 661  
 Hoffmann-Vold A-M, 3573  
 Hogarth MP, 2198  
 Hogenmiller S, 661  
 Holbrook JT, 1608  
 Holers VM, 3057  
 Hollander AP, 230  
 Holmdahl R, 82, 482  
 Holmgren AR, 2697  
 Holoshitz J, 754, 2047, 3423  
 Honkanen-Scott M, 3051  
 Hootman JM, 226  
 Hoppin JW, 1096  
 Horai R, 473  
 Horiuchi S, 1662  
 Horowitz R, 2347  
 Horslev-Petersen K, 1401  
 Hoshi K, 2462  
 Hostens J, 1856  
 Houston-Harris T, 3043  
 Houten SM, 2306  
 Howard G, 3057  
 Royal CR, 524  
 Hoyles RK, 3962  
 Hsieh M-Y, 2722  
 Hsu H-C, 343  
 Hsu MC, 3725  
 Hsu Y-H, 2722  
 Hu K, 2891  
 Hu LT, 3319  
 Hu X, 1022  
 Hua J, 1906
- Huaman G, 1298  
 Huang B, 2235  
 Huang J, 54, 1536  
 Huang J-L, 2585  
 Huang K-Y, 2722  
 Huang Q, 3174  
 Huard J, 433  
 Huber R, 788  
 Hudson M, 1435  
 Hüffmeier U, 82, 4023  
 Hugentobler M, 3720  
 Hughes C, 1838  
 Hughes G, 177  
 Hui W, 540, 3244  
 Huitema MG, 986  
 Huizinga TWJ, 253, 1087, 1117,  
     2028, 2830, 3372, 3799  
 Hulot J-S, 3284  
 Hülsemann JL, 2338  
 Hum D, 2471  
 Hummers L, 3043  
 Hunder GG, 3310  
 Hung H-H, 3319  
 Hunter DJ, 795, 1529, 1822,  
     2488  
 Huong DLT, 3284  
 Husky G, 3433  
 Husni E, 1536  
 Hutchesson J, 3182  
 Hutchinson A, 1588  
 Hutin P, 2280  
 Hutt J, 325  
 Hutter H-P, 1974  
 Hwang S-Y, 887  
 Hyrich KL, 1786, 2368, 2701
- I**
- Ibba-Manneschi L, 202, 3022,  
     3926  
 Ichimura E, 3707  
 Ichiyama T, 2314  
 Ide C, 1897  
 Ide H, 3408  
 Ifergan I, 557  
 Iguchi T, 779  
 Ikeda K, 3051  
 Ikeda M, 1897  
 Ikeda Y, 1946  
 Iliadou A, 692, 3774  
 Ilie V, 3623  
 Illei GG, 2184, 2505, 3730  
 Ilowite NT, 1987  
 Imhof BA, 2707  
 Inanc M, 312  
 Inman RD, 499, 974, 1733, 3859  
 Inoue A, 264, 1174, 3591  
 Inoue M, 455  
 Inoue T, 2127  
 International Myositis  
     Collaborative Study Group,  
     3682  
 Ioan-Facsinay A, 3799  
 Ioannidis JPA, 312  
 Isaacs JD, 482  
 Isenberg DA, 1543, 2037, 2343,  
     2550, 3300, 3612  
 Ishida Y, 473
- Ishigatsubo Y, 1132  
 Ishihara T, 2314  
 Ishikawa H, 1897  
 Isozaki T, 3408  
 Ito S, 3476  
 Itoh K, 1020  
 Itokazu Y, 1897  
 Ittah M, 2026  
 Ivashkiv LB, 2711  
 Iverson GM, 2558  
 Iwaki S, 2934  
 Iwakura Y, 473  
 Iwasaki T, 742  
 Izquierdo R, 1995
- J**
- Jablonska S, 1961  
 Jacobi AM, 127  
 Jacobs JJ, 3221  
 Jacobs JWG, 1422, 2031  
 Jacobsen SJ, 60  
 Jacobsson LT, 2776  
 Jacques PF, 1255  
 Jaffee B, 3163  
 Jaimes K, 661  
 Jalkanen S, 2852  
 Jamadar DA, 2481  
 James JA, 360, 2533  
 James-Newton L, 3979  
 Jang E, 492  
 Jannausch M, 2481  
 Jansen G, 557  
 Jarrett SJ, 1410  
 Jawaher D, 1482, 3087  
 Jayne DRW, 2970  
 Jeanneret C, 908  
 Jena S, 3485  
 Jeon H-S, 1747  
 Jérôme I, 508  
 Jhumka U, 2109  
 Jhun JY, 2152  
 Jiménez SA, 1298, 2616  
 Jin L, 2250  
 Joffe BI, 2765  
 John S, 1482  
 Johnson B, 3820  
 Johnson JJ, 670  
 Johnson K, 3363  
 Johnson L, 2347  
 Jol-van der Zijde CM, 3799  
 Jolad SD, 3452  
 Jonas BL, 3057  
 Jonckheere H, 1856  
 Jones EA, 1209  
 Jones GC, 832  
 Jones OY, 1987  
 Jones RB, 2970  
 Jones SA, 1662, 2084  
 Jonkman MF, 986  
 Jonsson I-M, 3898  
 Jonsson MV, 2300  
 Joos R, 2594  
 Joosten LAB, 1096, 1518  
 Jordan JM, 551, 2496  
 Jorgensen C, 1867  
 Joseph L, 2550  
 Jousse S, 2523

Ju H, 90  
Juhasz KM, 1122  
Jukic DM, 3001  
Jun J-B, 2242  
Jungblut PR, 3809  
Jüngel A, 214  
Junker P, 1401  
Jury EC, 2037  
Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES), 3971

## K

Kabouridis PS, 2037  
Kaburaki J, 1946  
Kahaleh B, 2271, 3022, 3926  
Kahan A, 202, 2243  
Kaiser J, 3890  
Kalaaji M, 914  
Kalden JR, 214, 702, 716, 927, 1491  
Kalish R, 3319  
Källberg H, 38  
Kallenberg CGM, 986, 3373  
Kallert S, 82  
Kulanian K, 2541  
Kambe N, 2704  
Kamboh MI, 1928  
Kamekura S, 2462  
Kamen DL, 3057  
Kammerer C, 1928  
Kammerer S, 524  
Kang C, 90, 3838  
Kang CP, 90, 3838  
Kang I, 1747  
Kang J-W, 887  
Kang YM, 2734  
Kano T, 1020  
Kao AH, 670, 1928  
Kapelle A, 3399  
Kapetanovic MC, 3782  
Kapsogeorgou EK, 2295  
Karassa FB, 312  
Karim Z, 3761  
Karlson EW, 3648  
Karsdal MA, 2441  
Karsenty G, 2462  
Kasama T, 3408  
Kashgarian M, 3277  
Kashihara N, 1847  
Kaspers GJL, 557  
Kasran A, 1736  
Kastner B, 1917  
Kastner DL, 1022, 2703  
Kato K, 1682  
Kato T, 818  
Katsiougiannis S, 2295  
Katz JN, 1444, 1536, 2757, 3790  
Katz PP, 1711  
Katz RS, 169  
Katzschlager R, 1974  
Kaufman KM, 360, 2533  
Kaufmann O, 127  
Kautiainen H, 2032, 3113  
Kavanaugh AF, 26, 1390, 2035  
Kawaguchi H, 2462

Kawahito Y, 742  
Kawai S, 455  
Kawakami Y, 1946  
Kawasaki Y, 2462  
Kawashima M, 97  
Kealey C, 2220  
Keenan G, 2840  
Kelly JA, 2533  
Kelly KM, 1557  
Kelman A, 236  
Kenney M, 1928  
Kern M, 2028  
Kerstens PJSM, 1087  
Kestler D, 3545  
Keystone EC, 702, 716, 1638, 2034, 2793, 2807, 3820  
Khamasha MA, 301, 3300, 4025  
Khan IM, 1209  
Khanna D, 1105, 1709  
Khoa DN, 2632  
Khoury M, 1867  
Kiela PR, 3452  
Kim CC, 1878  
Kim H, 343  
Kim H-R, 1747  
Kim H-Y, 887, 1747, 1878, 2152  
Kim HA, 2152  
Kim HR, 492  
Kim IS, 2734  
Kim J-R, 1747  
Kim J-S, 1747  
Kim JM, 492  
Kim M, 3623, 3741  
Kim MH, 2951  
Kim S-I, 1747, 2734  
Kim T-H, 1733, 2242  
Kimberly RP, 3908  
King B, 2061  
King TA, 1952  
Kinne RW, 788  
Kinoshita M, 1020  
Kirino Y, 1132  
Kirkham BW, 1122  
Kirou K, 1906  
Kirwan JR, 230, 1415, 2031  
Kishimoto H, 473  
Kishimoto T, 1778, 2817  
Kissin EY, 3655  
Kitano M, 742  
Kitasato H, 455  
Kiviranta R, 2852  
Kivitz A, 2136  
Klareskog E, 1463  
Klareskog L, 38, 76, 692, 1063, 1463, 3119, 3774  
Kleber S, 939  
Kloetzel P-M, 2175  
Kneitz C, 2377  
Knudson W, 443  
Kobayashi H, 1132  
Kobayashi S, 992  
Koch AE, 765, 2047, 2393, 2402, 3319  
Kodera M, 192  
Koenig S, 3828  
Koes BW, 1028  
Koga H, 843

Köhler D, 1805, 2845  
Kohno M, 1174, 3591  
Kohsaka H, 2074  
Kok RJ, 1198  
Kolb-Bachofen V, 939  
Kollrias G, 463  
Konnai K, 779  
Komai N, 1847  
Komiyama S, 808, 3126  
Komori H, 2934  
Komori T, 2462  
Kondo H, 455  
Konceru B, 3682  
Kong SY, 2496  
Koning GA, 1198  
Konomi K, 808  
Konttila YT, 202, 2928  
Kooloos WM, 2830  
Koopmans M, 2944  
Kop WJ, 2346  
Kopprasch S, 292  
Korb A, 2745  
Korenny T, 3221  
Korpela M, 2032  
Kos K, 1687  
Kosborth M, 1573  
Kostencs PJ, 379  
Kotani M, 473  
Koumpouras F, 877  
Koutala E, 3601  
Kowal-Bielecka O, 214  
Kozak T, 3750  
Kramer S, 2235  
Krammer PH, 939  
Krance R, 3750  
Kraus VB, 551, 2496  
Kremer JM, 607, 3095  
Kremer Hovinga ICL, 2944  
Krenn V, 1501  
Kreuter A, 3065  
Krilis SA, 2558  
Krishnan E, 899, 2688  
Krishnan JA, 3043  
Krishnaswami S, 670  
Kristensen LE, 600  
Kritikos HD, 3601  
Kruithof E, 1795, 2594  
Krumme A, 236  
Kubo S, 433  
Kubo T, 264  
Kuckelkorn U, 2175  
Kuettnar KE, 244  
Kuhlich E, 292  
Kuhn A, 939  
Kuhn KA, 3057  
Kuhne M, 1805, 2845  
Kuijik LM, 3690  
Kuijpers TW, 369, 1588  
Kuijpers IM, 369, 1588  
Kujawa J, 3163  
Kumar A, 2030, 3059  
Kumar S, 3513  
Kundi M, 1974  
Kuner R, 1009  
Kuo M-L, 2585  
Kupper H, 678, 2136  
Kuroda R, 433

Kurtin PJ, 685  
Kuscuglu N, 3452  
Küster W, 4023  
Kutner J, 3724  
Kuwana M, 1946  
Kvien TK, 68  
Kwoh K, 1822  
Kwon HJ, 1429  
Kwon Y-J, 3465  
Kyrgianides S, 1184  
Kyung HS, 2734

## L

Lachmann HJ, 2010  
Lackas C, 1096  
Lafeber FPJG, 253  
Lafyatis R, 3068, 3319, 3655  
Lagan A, 3034  
Lai A, 3423  
Lai Y-C, 1184  
Lakey R, 3244  
Lam J, 369, 1588  
Lambert M, 1697  
Lambert NC, 2069  
Lambertenghi-Deliliers G, 2605  
Lampa J, 1759  
Landewé RBM, 68, 1646, 1772, 3119  
Landis BN, 3720  
Landolfo S, 3939  
Lane J, 3163  
Lane NE, 236, 1246  
Langdown M, 524  
Langford R, 1829  
Langston AA, 1982  
Lanowska M, 3583  
Lantz RC, 3452  
Lapteva L, 2505  
Largeau C, 1867  
Larsson L, 3782  
Lascorz J, 4023  
Lassere MN, 1122  
Launay D, 1697  
Lauridsen UB, 1401  
Lauwereys M, 1856  
LaValley MP, 1529, 1822, 2488  
Lavie F, 2026  
Lavigne M, 2471  
Lavigne P, 271  
Leandro MJ, 613, 723, 3063, 3612  
Leask A, 1309  
Lechat P, 3284  
Lee A, 3661  
Lee C, 1906  
Lee CS, 1122  
Lee DM, 2863  
Lee H-S, 90  
Lee H-Y, 1747  
Lee J, 1982  
Lee JW, 1878  
Lee KW, 1878  
Lee MS, 3306  
Lee P, 1557, 1573  
Lee S-H, 887  
Lee S-I, 1747  
Lee S-K, 492

- Lee W-I, 2585  
 Lee Y-C, 1747  
 Lees B, 3962  
 Leff RD, 621  
 Legay F, 2387  
 Lehman TJA, 3971  
 Lehmann P, 939  
 Leirisalo-Repo M, 2032  
 Lemay C, 1233  
 Lems WF, 379, 557, 711, 1772, 3719  
 Leng L, 3661  
 Lenz M, 1974  
 Leonard JP, 2344  
 Lester S, 2434  
 Leufkens HGM, 3104  
 Levick JR, 1673  
 Levin R, 3790  
 Levine DM, 3918  
 Lewek MD, 1354  
 Leyton C, 3465  
 Leyton L, 3465  
 Li H-H, 2722  
 Li J, 1246  
 Li L, 2872  
 Li NF, 1390  
 Li X, 3291  
 Li Y, 2891  
 Li Y-YY, 2872  
 Liakouli V, 202, 3022  
 Lian K, 1246  
 Liang KP, 642  
 Liang KV, 642  
 Liang L, 3441  
 Liang MH, 54, 1440, 3378  
 Liecker B, 3485  
 Lien G, 3573  
 Lim S, 2211  
 Lima JAC, 380  
 Limburg PC, 986, 3373  
 Lindegaard H, 1401  
 Lindemans J, 2830  
 Lindgren BR, 3850  
 Ling S, 754, 2047, 3423  
 Linga Reddy MVP, 3815  
 Linnit MD, 2558  
 Linssen A, 2830  
 Liossion S-NC, 2036  
 Lipsky PE, 127, 1491, 1708, 2184, 2505  
 Listing J, 569, 678, 3399  
 Liu C, 3375  
 Liu C-C, 670  
 Liu H, 3174  
 Liu M-F, 2722  
 Liu N, 3661  
 Liu P, 3441  
 Liu T, 3375  
 Liu X, 3820  
 Liu-Bryan R, 383  
 Locklin R, 1451  
 Lockshin MD, 1711, 2515, 3918  
 Loddenkemper C, 127, 1805, 2845  
 Loeb JM, 1710  
 Loeser RF, 1357, 2901, 3850  
 Loetscher P, 2387  
 Loh Y, 3750  
 Lohmann J, 4023  
 Longo M, 3551  
 Lopate G, 1687  
 López-Pedrera C, 301  
 Lord J, 2096  
 Lories RJU, 1736  
 Losina E, 1536  
 Lotito AP, 3971  
 Lottenburger T, 1401  
 Lotz M, 1814  
 Loughlin J, 533, 1026, 3722  
 Louis-Plence P, 1867  
 Louneva N, 1298  
 Love LA, 3670  
 Loveless JE, 2793  
 Lovell CR, 2604  
 Lovell DJ, 1987, 2235  
 Lövgren T, 1917  
 Loy AC, 2004  
 Lu X, 1619  
 Lu Y, 1444  
 Lubberts E, 3868  
 Ludanyi K, 2423  
 Lui L, 236, 1246  
 Lum RF, 3087  
 LUMINA Study Group, 1580, 1940  
 Lundberg K, 38  
 Luning HAF, 253  
 Luni M, 2368  
 Luo M, 343  
 Luo S-F, 3908  
 Lurati A, 1602  
 Luyten FP, 1209, 1736  
 Luyten P, 2345  
 Luzina IG, 2643  
 Lynes M, 1961  
 Lyons R, 1557, 1573, 2004  
 Lyskina G, 3971
- M**
- Ma C-C, 3908  
 Ma G-F, 2928  
 Macchioni P, 4011  
 MacGregor AJ, 2147  
 Mach F, 390  
 Mackay M, 3623  
 Maddison P, 3300  
 Madri JA, 877  
 Maeyama K, 2934  
 Magder L, 3640  
 Mageed RA, 2037  
 Maglione W, 2605  
 Magnusson M, 148  
 Mah S, 524  
 Maine I, 2047  
 Maini RN, 47, 702, 716, 2817  
 Makino H, 97  
 Makovitzky J, 3545  
 Makrygiannakis D, 76, 1463  
 Maksymowych WP, 974, 3820  
 Malarkey WB, 3291  
 Malfait A-M, 2912  
 Mallek JA, 621  
 Malley JD, 3670, 3979  
 Malley K, 3670  
 Mamalaki C, 3601  
 Mamura M, 3476  
 Mamyrova G, 3670, 3682, 3979  
 Mandey SHL, 3690  
 Manetti M, 202, 3022, 3926  
 Manicourt D-H, 3205  
 Mann RJ, 2604  
 Mannini L, 2263  
 Manns JM, 2415  
 Manoussakis MN, 2295  
 Manson J, 3612  
 Manzano M, 2505  
 Manzi S, 670, 1928, 2550  
 Maradit-Kremers H, 60  
 Marchesoni A, 2665  
 Marder G, 3623  
 Mareno S, 2505  
 Margariti P, 1350  
 Margheri F, 3926  
 Mariette X, 2026  
 Markham T, 105, 3152  
 Marmont A, 3750  
 Marnell LL, 325  
 Marotte H, 2109  
 Marrelli A, 3022  
 Marriott MA, 1608  
 Marsh J, 2010  
 Marshak-Rothstein A, 3068  
 Marsters PA, 47  
 Martel-Pelletier J, 2471  
 Martin DA, 951  
 Martin J, 3815  
 Martin TM, 3337  
 Martin-Mola E, 1151  
 Martin-Villalba A, 939  
 Martinez C, 177  
 Martinez RJ, 765  
 Martinez-Gamboa L, 1501  
 Martini A, 998, 2989, 3723  
 Martini G, 3971  
 Martins-Carvalho C, 2280  
 Marttila-Ichihara F, 2852  
 Maruyama Z, 2462  
 Masanauksaitė D, 1838  
 Mason RM, 1673  
 Massardo L, 312  
 Mastrobattista E, 1198  
 Masuko-Hongo K, 808, 818  
 Mathai SC, 3043  
 Mathieu A, 312  
 Mathsson L, 1759  
 Matsubara T, 2314  
 Matsuda T, 1778, 3126  
 Matsumoto H, 3233  
 Matsumoto I, 3476  
 Matsunawa M, 3408  
 Matsuno H, 579  
 Matsushita K, 3126  
 Matsushita T, 192  
 Matsuyama T, 3126  
 Matteson EL, 635, 642, 1353, 2697, 2776, 3310, 3381  
 Matthys P, 1736  
 Mattyasovszky S, 1491  
 Matucci-Cerinic M, 202, 3022, 3926  
 Maul GG, 2616
- Mayes MD, 380, 1961, 3661, 3945  
 Mazlumzadeh M, 3310  
 Mazzuca SA, 684, 2341  
 McCaffrey G, 3452  
 McCarthy T, 2550  
 McClain MT, 360  
 McClelland RL, 642  
 McClinton C, 47  
 McConnell D, 2481  
 McCune WJ, 1608  
 McCurry KR, 3954  
 McDonald C, 3661  
 McGonagle D, 1209, 1328  
 McGwin G Jr., 1703, 1940, 2035  
 McHugh NJ, 2604, 3034, 3300, 3962  
 McInnes I, 1795  
 McKenna F, 1829  
 McKie N, 482  
 McLain D, 380  
 McLean SA, 2346  
 McLeod HL, 1366  
 McLoughlin RM, 1662  
 McMahon M, 2541, 2951  
 McNally EG, 1340  
 McNearney TA, 3945  
 McNiff JM, 3277  
 McQueen F, 382  
 McSweeney PA, 1982  
 Mease PJ, 1638, 2665  
 Medsger TA Jr., 3954  
 Meini A, 998  
 Meiorin S, 3337  
 Melay W, 2321  
 Melchers I, 3144  
 Melo-Gomes J, 1063  
 Merchant AA, 2632  
 Mercier N, 2852  
 Merkel PA, 1608, 3655  
 Meroni PL, 356, 3939  
 Metter A, 569  
 Metz-Stavenhagen P, 2845  
 Meulenbelt I, 3063  
 Meyer HE, 802  
 Meyer JM, 3494  
 Miceli-Richard C, 2026  
 Michaud K, 169, 628  
 Michel BA, 214  
 Middleton J, 2022, 3244  
 Mielants H, 1415, 2665  
 Migliorini P, 733  
 Migone T-S, 723  
 Mikuls TR, 621, 3057  
 Milia AF, 202, 3022  
 Miller FW, 3670, 3682, 3979  
 Miller HR, 2863  
 Miller J-nH, 1184  
 Milner JM, 540, 3244  
 Milner PI, 3523  
 Mimori A, 1020  
 Min J, 3063  
 Min J-K, 887  
 Min S-Y, 887, 1878  
 Min WS, 1878  
 Min Y-I, 1668  
 Mindeholm L, 3205

- Minota S, 579, 675, 1629  
 Miossec M, 3735  
 Miossec P, 2109, 3735  
 Miranda-Carús M-E, 1151  
 Mirault T, 1697  
 Mirza N, 2983  
 Mishra J, 2577  
 Mitsiadis TA, 1209  
 Miura Y, 779  
 Miyachi Y, 2704  
 Miyasaka N, 2074  
 Miyashita R, 992  
 Miyazaki T, 1174, 3591  
 Miyazawa K, 742  
 Mjelle JE, 914  
 Mochizuki T, 843  
 Mödder U, 1096  
 Mogun H, 1378  
 Mohan C, 2198  
 Moisio KC, 3842  
 Mok CC, 312  
 Mold C, 325  
 Moldawer LL, 2872  
 Molema G, 1198  
 Molenaar ETH, 1143  
 Molina C, 3465  
 Mollenhauer JA, 244, 3728  
 Mondini M, 3939  
 Monroe JB, 3979  
 Montesinos MC, 2632  
 Montiel-Duarte C, 301  
 Montoya P, 1995  
 Moore TL, 1952  
 Mooren FM, 1653  
 Morel PA, 3670  
 Moreland LW, 3057  
 Morell-Dubois S, 1697  
 Mores J, 3351  
 Morgan J, 3163  
 Morgan SL, 1708  
 Morishita S, 1897  
 Morita Y, 1847  
 Morozzi G, 312  
 Morquette B, 271  
 Morthala S, 2220  
 Moser B, 14  
 Mosher DP, 3820  
 Möttönen T, 2032  
 Mougin B, 2109  
 Mountz JD, 343, 2872  
 Moutsopoulos HM, 2228  
 Mowinkel P, 68  
 Mueller M, 2577  
 Mullan RH, 105, 3152  
 Mullazchi M, 1759  
 Müller HW, 1096  
 Müller-Ladner U, 214  
 Muneta T, 843  
 Munoz F, 1262  
 Murakami Y, 455  
 Muraoka M, 1174, 3591  
 Muratori F, 3551  
 Murphy CL, 3545  
 Murray AK, 1952  
 Murru V, 4025  
 Musset L, 3284  
 Mwale F, 244  
 Myers JL, 635  
 Myers LK, 854  
 Myint H, 3750  
 Myon E, 177  
 Nabbe KCAM, 3828, 3868  
 Nacionales DC, 1557  
 Nackos E, 2220  
 Nagai T, 3126  
 Nagaraja HN, 3291  
 Nagasaki K, 2074  
 Nagashima T, 579  
 Nagashio C, 1020  
 Nagelkirk PR, 3351  
 Naik H, 1543  
 Naito Y, 3476  
 Nakahata T, 2704  
 Nakajima T, 808  
 Nakamura H, 808, 818  
 Nakamura K, 2462  
 Nakayama T, 1174  
 Nam EJ, 2734  
 Namjou B, 2533  
 Nanki T, 2074  
 Nara H, 675, 1629  
 Narain S, 1573, 3051  
 Narvaez J, 1025  
 Nash GB, 1619, 2096  
 Nash RA, 1982  
 Nassiri M, 661  
 Natale L, 3988  
 Natelson BH, 3351  
 Nauclér CS, 2289  
 Navab M, 2541  
 Navrati JS, 670  
 Negishi M, 3408  
 Nelson JL, 1982, 2069  
 Nelson L, 899  
 Nelson MR, 524  
 Nemcova D, 3971  
 Nemoto K, 2934  
 Neogi T, 1255, 1822, 3508  
 Nepom GT, 1105  
 Neto AC, 3724  
 Neumann G, 1444  
 Nevitt MC, 236, 1246, 1822,  
     3508  
 Newlands P, 3962  
 Newman WG, 3820  
 Nicholas AP, 3381  
 Nichols C, 2004  
 Nichols DP, 3564  
 Nicola PJ, 60  
 Nicoli D, 4011  
 Nielsen MMJ, 3719  
 Niewold TB, 2335  
 Nigrovic LE, 3564  
 Nigrovic PA, 3564  
 Niissalo S, 202  
 Niiya T, 2934  
 Niland B, 2983  
 Nilson AC, 670  
 Nimura A, 843  
 Nishikomori R, 2704  
 Nishimoto N, 1778  
 Nishioka K, 808, 818  
 Nitsche MA, 3988  
 Nityanand S, 2326  
 Niu JB, 795, 1529, 1822, 2488,  
     3508  
 Nived O, 2550  
 Noble PC, 1509  
 Nocton J, 1987  
 Noel D, 1867  
 Nonomura Y, 2074  
 Nordmann P, 2026  
 Nordsletten L, 802  
 Nose M, 1174, 2934, 3591, 3707  
 Nosé D, 3926  
 Nossent H, 914  
 Nowak M, 2505  
 Nowell MA, 1662, 2084  
 Noyori K, 1132  
 Nozaki T, 2004  
 Nugent GE, 1888  
 Nurmohamed MT, 711  
 Nyähll-Wählin B-M, 2776  
 O'Banion MK, 1184  
 Obermayr F, 3533  
 Obici L, 998  
 Ocain T, 3163  
 Ochs BG, 3254  
 O'Connor PJ, 1410, 3761  
 Odai T, 3408  
 Oddis CV, 3670  
 Odegard J, 3277  
 Ødegård S, 68  
 O'Dell JR, 621  
 O'Donnell P, 3859  
 Oerlemans R, 557  
 Oeser A, 1353, 1706  
 Oestergaard S, 2441, 2886  
 Ogawa S, 473  
 Ognjanovic S, 2084  
 Oh H, 2152  
 O'Hanlon TP, 3670, 3682, 3979  
 O'Hara R, 105  
 Okada Y, 3233  
 Okamoto H, 1629  
 Okazaki H, 579  
 Okazaki Y, 1946  
 Okuda Y, 2997  
 Olech E, 1048  
 Oliver N, 1653  
 Olschowka JA, 1184  
 Olsen BR, 2891  
 OMERACT Special Interest  
     Group on Synovial Analysis in  
     Clinical Trials, 1795  
 Omtvedt LA, 3433  
 Onda K, 675  
 Onda M, 3126  
 Ono M, 2934, 3707  
 Oppers B, 3868  
 Orbán I, 3971  
 Orens JB, 3954  
 Ortmann C-E, 1410  
 Osawa K, 779  
 Osborne C, 2096  
 Ostendorf B, 1096  
 Østensen M, 2069

- Pediatric Rheumatology Collaborative Study Group, 1987
- Pediatric Rheumatology International Trials Organization (PRINTO), 2989, 3723
- Peixoto MJ, 1340
- Pelletier J-P, 2471, 3494
- Pelttari K, 3254
- Peluso G, 3633
- Pemberton AD, 2863
- Peng H, 433, 3441
- Peng SL, 336
- Penncic Y-L, 115, 2280
- Pennington CJ, 832
- Pentikäinen O, 2852
- Pentikäinen U, 2852
- Pereira A, 3724
- Pérez de Ayala C, 1151
- Perez JL, 26
- Pérez P, 3465
- Perides G, 3319
- Perl A, 2983
- Perlman H, 3182
- Perreault C, 1270
- Perricone R, 3022
- Persijn JP, 115, 2280
- Persson T, 1415
- Perucha E, 1707
- Peruren O, 3682
- Peruzzi B, 3551
- Pestronk A, 1687
- Peterfy CG, 1048, 3761
- Peters HH, 540
- Petersen J, 2817
- Pettersson IF, 2776, 3815
- Petri M, 2550, 3640
- Phillips SE, 2347
- Pi X, 754, 2047
- Picco P, 998
- Piette J-C, 184, 3284, 3330, 3696
- Pignone AM, 2263
- Pihlavisto M, 2852
- Pilling MH, 393, 2632
- Pincus T, 3113, 3999
- Pingiotti E, 3022
- Pinkert CA, 1184
- Pipitone N, 4011
- Pires Leon E, 1568, 4026
- Pisetsky DS, 2349
- Pistorio A, 2989
- Pitzalis C, 1055, 1209
- Plaskon DE, 3954
- Plebani A, 998
- Pochetuhu K, 2643
- Podenphant J, 1401
- Pohlers D, 788
- Pols HAP, 1028
- Poluri A, 3351
- Pons-Estel BA, 3815
- Pontikaki I, 1602
- Pontillo A, 998
- Poole AR, 244, 3152
- Poole BD, 360
- Pope J, 2550
- Pope RM, 3174
- Popoff SN, 2415
- Popovic K, 2289
- Portek IJ, 1122
- Potter C, 3417
- Poustka A, 1009
- Powell RJ, 2674
- Prabu A, 3300
- Praderio L, 4018
- Prakken B, 19
- Pratesi F, 733
- Pratta M, 3513
- PREMIER Investigators, 26
- Prieto A, 1707
- Prigione I, 998
- Pritchard S, 2164
- Prots I, 1491
- Provost S, 1270
- Prusa A, 127
- Prussin C, 2184
- Pucci M, 3926
- Pullerits R, 3898
- Pumpens P, 3423
- Puttermann C, 2198, 2523
- Puzas JE, 1184
- Q**
- Qing X, 2198
- Queiró R, 2334
- Quemeneur T, 1697
- Queyrel V, 1697
- Quilty B, 230
- Quinn JMW, 158
- Quinn MA, 3761
- Quirici N, 2605
- Qvist P, 2441, 2886
- R**
- Racewicz AJ, 1390
- Radbruch A, 3583
- Radcliffe CM, 3433
- Radford PM, 2674
- Radstake TRDJ, 3828
- Raemen F, 2817
- Rahman A, 2550, 3300, 3612
- Rahman MU, 1075
- Rahman P, 524, 974, 2321
- Raiinger GE, 1619, 2096
- Rajendram R, 507
- Ramirez JC, 1473
- Ramos-Casals M, 2568
- Ramsey DK, 1354
- Ramsey-Goldman R, 2550
- Ranganathan P, 1355, 1366, 3372
- Ranger P, 271
- Rantapää-Dahlqvist S, 38
- Ranz J, 2235
- Raptopoulou A, 3601
- Raschi E, 356
- Rassen J, 3390
- Ratcliffe S, 1829
- Rau R, 82, 1491
- Ravazzolo R, 998
- Ravdin LD, 2515
- Ravelli A, 2989, 3723, 3971
- Raymond Y, 963
- Raynauld J-P, 3494
- Raza K, 2096
- Rebelo SL, 2674
- Recker RR, 1838
- Redlich K, 463
- Reed AM, 3670, 3979
- Reed EF, 1105
- Reedquist KA, 3135
- Reefman E, 3373
- Reesink HW, 3719
- Reeve JP, 974
- Reeves WH, 1557, 1573, 2004, 3051
- REFLEX Trial Group, 2793
- Reginster J-Y, 1838, 2339
- Reid DM, 1838
- Reid KM, 1543
- Reiff A, 1987, 2703, 3573
- Reijman M, 1028
- Reiner A, 244
- Reis A, 82, 4023
- Reiss AB, 2632
- Reiter K, 127
- Rekvig OP, 914
- Remans PHJ, 3135
- Remaut E, 1856
- Remmers EF, 1022, 2703
- Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria, 421
- Renaudineau E, 2523
- Renaudineau Y, 2523
- Reneland RH, 524
- Rennebohm R, 2235
- Renner JB, 551
- Renzoni E, 3034
- Resche-Rigon M, 3696
- Reveille JD, 1580, 1703, 1940, 2035, 2136, 3670
- Revets H, 1856
- Reyes E, 1707
- Reznikov LI, 2872
- Ribeiro AF, 3724
- Riboldi P, 3939
- Rice A, 1573
- Richards CD, 540, 3244
- Richards HB, 3051
- Richards PJ, 1662, 2084
- Richardson A, 1279
- Richardson JA, 1317
- Richarz U, 1829
- Richette P, 1233
- Richter W, 3254
- Rico MC, 2415
- Rider LG, 3670, 3682, 3979
- Rigonatti SP, 3988
- Riley GP, 832
- Ring S, 3417
- RiouxD, 1279
- Rischmueller M, 2434
- Rivera J, 2558
- Roake W, 1543
- Robbins PD, 1714
- Roberts C, 3962
- Robinson JH, 482
- Robitaille G, 963
- Robson T, 3244
- Rocha RR, 3988
- Rodríguez A, 1707
- Rodríguez W, 325
- Rodríguez-Cotes A, 1995
- Rodríguez-Valverde V, 1063
- Roebuck-Spencer T, 2505
- Rogai V, 2263
- Roger VL, 60
- Rogers SN, 1165
- Roll P, 2377
- Roman MJ, 3918
- Romano G, 3633
- Romo R, 3465
- Ronday HK, 253
- Rönnblom L, 408, 1917
- Rönnelid J, 38, 1759
- Roos JCP, 381
- Rosé CD, 3337
- Rose DM, 3363
- Rose JW, 3750
- Rose T, 433
- Rose-John S, 1662
- Rosenbach M, 1246
- Rosenbaum JT, 3337
- Rosengren S, 587
- Rosenquist R, 692, 3774
- Rosenstein D, 2505
- Rosenthal P, 3623
- Rottiers P, 1856
- Routsias JG, 2228
- Rovati LC, 2339
- Rovin BH, 3291
- Rowan AD, 540, 3244
- Rowczieno DM, 2010
- Royle L, 3433
- Rucci N, 3551
- Rudd PM, 3433
- Rudolph KS, 1354
- Rudolph PE, 1501
- Rudwaleit M, 569, 678, 2845
- Rueda B, 3815
- Ruffing MJ, 670
- Rullas J, 1473
- Rupert N, 2989, 3723
- Ruschaupt M, 1009
- Russo R, 3971
- Ruth JH, 765, 2402
- Rutherford C, 2577
- Ruzicka T, 939
- Ryu JH, 635
- S**
- Sa KH, 2734
- Saadoun D, 3696
- Saas J, 3533
- Sabarathnam S, 1673
- Sabbadini MG, 4018
- Sabokbar A, 1451
- Safadi FF, 2415
- Sah RL, 1888, 3267
- Saiga K, 2934, 3707
- Saiiki RK, 1022
- Saito M, 264, 2704

- Saito T, 1132, 1897  
 Sakaguchi Y, 843  
 Sakao K, 264  
 Sakuta T, 1847  
 Sallis JD, 2452  
 Salmaggi C, 4018  
 Salmi M, 2852  
 Salmon JE, 2353, 3918  
 Salmon M, 2096  
 Salo J, 2928  
 Salvarani C, 4011  
 Sambrook P, 1838  
 Sammaritano L, 3918  
 Sanders ME, 3135  
 Sanmartí R, 2334  
 Sanna G, 312  
 Sano H, 742  
 Santamaría G, 998  
 Santiago B, 1473  
 Santiago MB, 1352  
 Santos MR, 1340  
 Santos R, 3999  
 Saraux A, 115, 2280, 2523  
 Sarkisian T, 508  
 Sarkissian T, 1283  
 Sarzi-Puttini P, 2039  
 Sato K, 779  
 Sato S, 192, 2462  
 Sato T, 808  
 Satoh M, 1557, 1573, 2004, 3051  
 Satumitra N, 1317  
 Savage COS, 1619  
 Savely VR, 2347  
 Savinainen A, 3163  
 Saxne T, 600, 2147, 3782  
 Scalzi LV, 2220  
 Scatizzi JC, 3182  
 Scavullo C, 2605  
 Schachna L, 3954  
 Schaid DJ, 2776  
 Schechtman J, 1390  
 Schedel R, 2656  
 Scheffer GL, 557  
 Scheinberg M, 3724  
 Scheper RJ, 557  
 Scherbarth HR, 3815  
 Scherer A, 1096  
 Scherman D, 1867  
 Schett G, 463, 2745  
 Schiff MH, 702, 716, 2136  
 Schiffers RM, 1198  
 Schikler KN, 2235, 2347  
 Schirmacher P, 1009  
 Schmidt AM, 14  
 Schmidt TA, 1888  
 Schmouder R, 2387  
 Schneeweiss S, 1378, 2757, 3390,  
     3790  
 Schneider M, 1096, 3399  
 Schneider R, 1270, 1291, 1595,  
     1987  
 Schneiders MS, 2306  
 Scholze J, 127  
 Schopf L, 3163  
 Schramm NU, 1096  
 Schroeder H-E, 292  
 Schuening F, 3750
- Schulze-Horsel U, 214  
 Schulze-Koops H, 1491, 4023  
 Schumacher BL, 1888  
 Schumacher HR, 2688  
 Schwarzschild MA, 2632  
 Scott C, 3633  
 Scumpia PO, 1557  
 See L-C, 2585  
 Sejimano LP, 1608  
 Sekiguchi M, 742  
 Sekine C, 2074  
 Sekiya I, 843  
 Seldin MF, 1022, 1482  
 Sellam J, 2026  
 Sen A, 2346  
 Senécal J-L, 963, 2550  
 Seo JS, 2734  
 Seong S-S, 3838  
 Serratí S, 3926  
 Sestini P, 3034  
 Setoguchi S, 2757, 3790  
 Setton LA, 2891  
 Sfikakis PP, 2036  
 Shaftel SS, 1184  
 Shahrara S, 765  
 Shakoor N, 2923  
 Shamim EA, 3670, 3979  
 Shan Z-Z, 818  
 Shang J, 1317  
 Sharp JT, 26, 1105  
 Shaw PS, 670, 1928  
 Shaw TM, 1390, 2793  
 Shayman JA, 754  
 Shearstone JR, 1961, 3011  
 Shen X, 2184  
 Shephard N, 1482  
 Sherr VT, 2347  
 Shi B, 3174  
 Shi Q, 271  
 Shi T, 2558  
 Shi-wen X, 649, 1309  
 Shiah H-S, 877, 3277  
 Shimoaka T, 2462  
 Shin I-SJ, 1429  
 Shin K, 2863  
 Shintani A, 1353  
 Shiomi T, 3233  
 Shiozawa K, 779  
 Shiozawa S, 779  
 Shipman CM, 1451  
 Shiraishi M, 779, 2314  
 Shiraishi T, 1897  
 Shnier R, 1122  
 Shoefield Y, 2523, 3060, 3939  
 Shott S, 3842  
 Shulman H, 1982  
 Sibilia J, 2026, 2243  
 Sibley J, 2550  
 Sidiropoulos P, 3601  
 Siebert E, 3163  
 Siegel JN, 378, 1429  
 Siendones E, 301  
 Sieper J, 569, 678, 1805, 2136,  
     2845, 3583  
 Sierra RI, 2235  
 Sijpkens YWJ, 2944  
 Silence K, 1856
- Silman AJ, 1482, 1786, 2368,  
     2701  
 Silva M, 3163  
 Silverman E, 1270, 1283, 1291  
 Silverman GJ, 325, 2356  
 Simard JF, 54, 3378  
 Siminovitch KA, 3820  
 Simon LS, 3494  
 Sims NA, 158  
 Singh-Grewal D, 1595  
 Sinsheimer JS, 1026  
 Sitges C, 1995  
 Skapenko A, 1491, 4023  
 Skarstein K, 2300  
 Skjodt H, 1401  
 Skopouli FN, 2295  
 Skriner K, 3809  
 Slagboom PE, 1087, 3063  
 Slavin S, 3750  
 Sletten K, 3433  
 Sloan VS, 1410  
 Sloetjes A, 3868  
 Smets RL, 1518  
 Smets TJM, 2387  
 Smith DJ, 2852  
 Smith EA, 1961, 2096, 3011,  
     3057  
 Smith KGC, 2970  
 Smith KM, 607  
 Smith PM, 1165  
 Smith RW, 507  
 Smith SD, 3306  
 Smith SY, 2886  
 Smolen JS, 377, 463, 702, 716,  
     2034, 2745, 2784, 2817, 2840  
 Snellgrove T, 2321  
 Snowden J, 3750  
 Snyder-Mackler L, 1354  
 Sobel E, 1573  
 Sokka T, 3113  
 Sokoll K, 3300  
 Soligo D, 2605  
 Solomon A, 3545  
 Solomon DH, 1378, 1536, 2757,  
     3390, 3790  
 Solomonou EE, 2036  
 Sólyom AM, 3452  
 Sommer C, 2656  
 Somwaru L, 1686  
 Sondergaard BC, 2441  
 Song E-K, 1747  
 Sonntag WE, 3850  
 Sordet C, 2243  
 Sornay-Rendu E, 1262  
 Sowers MR, 2481  
 Specks U, 1608  
 Spector TD, 524, 533, 1051,  
     2147, 3064, 3494  
 Spencer-Green GT, 26  
 Spetie L, 3291  
 Spevak L, 3345  
 Spiekermann S, 1805, 2845  
 Spiera H, 3071  
 Spiera R, 1608  
 Spiera RF, 3071  
 Spindler AJ, 312  
 Spreckley K, 3417
- Spriewald B, 82, 1491  
 Sprotte G, 2656  
 St. Pierre Y, 2550  
 Stabler TV, 2496  
 Staelens L, 1856  
 Stafford G, 3452  
 Stakkestad JA, 1838  
 Stanbury J, 1165  
 Stapel S, 711  
 START Study Group, 1075  
 Statkute L, 3750  
 St.Clair EW, 1, 702, 716, 1608,  
     2344, 2840  
 Stea EA, 2228  
 Steck E, 3254  
 Steele S, 2505  
 Steen VD, 3954  
 Steenvoorden MMC, 253  
 Steere AC, 3079, 3319  
 Stein CM, 1353, 1706  
 Stein H, 1805, 2845  
 Stein LD, 1987  
 Stein R, 2344  
 Steinfeld SD, 2344  
 Steinsson K, 2550  
 Stengaard-Pedersen K, 1401  
 Stenvers DJ, 3716  
 Steplewski K, 3513  
 Steuer A, 47  
 Steultjens M, 1354  
 Sticchi E, 2263  
 Stinissen P, 1772  
 Stock M, 2656  
 Stock S, 3345  
 Stohl W, 723  
 Stolen C, 2852  
 Stoll ML, 3564  
 Stolt P, 38  
 Stone JH, 1608  
 Stone MA, 2022  
 Stoppacciaro A, 4018  
 Storb R, 1982  
 Storm G, 1198  
 Stosick W, 3890  
 Stoyanova-Scholz M, 3399  
 Strachan D, 3417  
 Strand V, 3494  
 Strangfeld A, 3399  
 Straub RH, 682, 1778, 2039,  
     3890  
 Stricker BHC, 1028  
 Stricker RB, 2347  
 Strugala C, 1838  
 Strusberg I, 1075  
 Stuhlmüller B, 1501  
 Sturfelt G, 914, 2550, 2776  
 Stürmer T, 1378  
 Suissa S, 1435  
 Sullivan KM, 1982  
 Sullivan PF, 1682  
 Sullivan S, 3152  
 Sültmann H, 1009  
 Sumida T, 3476  
 Sumiya M, 1020  
 Sumner DR, 3842  
 Sun L, 3441  
 Sun S, 2321

- Sun SG, 1451  
 Sunahara N, 3126  
 Sunahori K, 97  
 Sundararajan V, 2061  
 Sundel RP, 3564, 3971  
 Sundström C, 692, 3774  
 Surdulescu GL, 533  
 Susic G, 3971  
 Svendsen A, 1401  
 Svenson M, 3782  
 Swiss Clinical Quality Management in Rheumatoid Arthritis Project, 54  
 Sydlaske AD, 3363  
 Symmons DPM, 1786, 2368, 2701, 2963  
 Szafranski J, 3319  
 Szczepanski L, 1390  
 Szebenyi B, 230  
 Szechinski J, 2817  
 Sztajnbok F, 3971
- T**
- Tabata Y, 264  
 Tahiri K, 1233  
 Taieb C, 177  
 Tak PP, 711, 1795, 2387, 2594, 3135, 3381, 3716  
 Takada K, 2505  
 Takahashi KA, 264  
 Takami N, 779  
 Takasugi K, 97, 1778, 2997  
 Takeda S, 2462  
 Takeda Y, 1132  
 Takehara K, 192  
 Takeno M, 1132  
 Takeuchi HT, 3408  
 Takeuchi R, 1897  
 Takigami H, 1897  
 Tallents RH, 1184  
 Tamamori-Adachi M, 2074  
 Tan AL, 1328  
 Tan FK, 1703, 1940, 1961, 2250, 2626, 3885, 3945  
 Tan S-Y, 754  
 Tanaka M, 3126  
 Tanaka T, 2314  
 Taniguchi M, 779  
 Tankó LB, 2441, 2886  
 Tanner SF, 1328  
 Tanuma S, 473  
 Tao J, 877  
 Tardif G, 2471  
 Targoff IN, 3670, 3682  
 Tarkowski A, 148, 3898  
 Tarp U, 1401  
 Tas SW, 3716  
 Taurog JD, 1317  
 Tausche A-K, 292  
 Taylor M, 2951  
 Taylor PC, 47, 2817  
 Taylor W, 2665  
 Tazelaar HD, 635  
 Tedder TF, 1, 2344  
 Teh L-S, 3300  
 TeKoppele J, 2928  
 Temkin V, 3174
- Temple MM, 3267  
 TEMPO Study Investigators, 1063  
 ten Brink CB, 2423  
 ten Hagen TLM, 1198  
 Teng YKO, 3062  
 Teodorescu M, 3612  
 Terada M, 1174, 2934, 3591  
 Terkeltaub R, 383, 1255, 1822, 3363, 3508  
 Ternan H, 3820  
 Territo M, 3750  
 Teruzzi B, 1602  
 Teti A, 3551  
 Tew MB, 1940  
 Thibault V, 3696  
 Thiel A, 3583  
 Thomas AMC, 2096  
 Thompson SJ, 854  
 Thomson D, 2817  
 Thoran EJ-M, 3205  
 Thong BY, 2541  
 Thornton EM, 2863  
 Thornton S, 1361  
 Thorp LE, 3842  
 Tibbs AK, 1608  
 Tighe PJ, 2674  
 Timmermann BN, 3452  
 Timms A, 1340  
 Tindall EA, 1029  
 Tisseverasinghe A, 2211  
 Todd I, 2674  
 Toes REM, 253, 1117, 3135, 3799  
 Toh M-L, 2109  
 Tohidast-Akrad M, 2745  
 Tokunaga K, 992  
 Tokunaka K, 3707  
 Toledo Barros R, 1568, 4026  
 Tombini V, 243  
 Tomic-Canic M, 2632  
 Tomita N, 1847  
 Tommasi C, 733  
 Tonomura H, 264  
 Tony H-P, 2377  
 Topley N, 1662, 2084  
 Tornero-Molina J, 1063  
 Torres A, 301  
 Tortorella MD, 2912  
 Toscano A, 202, 3022  
 Totoritis MC, 2793  
 Toyama Y, 3233  
 Toyoda E, 3707  
 Trad SG, 184, 3330  
 Traister RS, 2119  
 Tran D, 325  
 Tran TM, 1317  
 Traupe H, 4023  
 Traverso F, 998  
 Traynor A, 3750  
 Trej'o L, 2151  
 Tresoldi M, 4018  
 Trieu EP, 3682  
 Tripathy NK, 2326  
 Tripi LM, 1928  
 Trojanowska M, 1961, 3011  
 Truedsson L, 2776
- Truyols M, 1995  
 Trzaska S, 2632  
 Tsagris L, 1233  
 Tsao BP, 1105, 2951  
 Tsatsanis C, 3601  
 Tseng C-E, 3623  
 Tsifetaki N, 1350  
 Tsubaki T, 2934  
 Tsuchimochi K, 808  
 Tsuchiya N, 992  
 Tsuneyoshi Y, 3126  
 Tsutsumi A, 3476  
 Tu X, 795, 2488  
 Tuan RS, 3075  
 Tung CF, 2632  
 Tunyogi-Csapó M, 3221  
 Turesson C, 635, 642, 1353, 2776  
 Turkenburg M, 2306  
 Twisk JWR, 3719  
 Tylianowski P, 1736  
 Tyrrell PN, 1291  
 Tzioufas AG, 312, 2228
- U**
- Üçeyler N, 2656  
 Uchánska-Ziegler B, 2705  
 Ueda A, 1132  
 Ueda H, 2314  
 Uhlig T, 68  
 Ukena B, 788  
 Uknis AB, 2415  
 Ulfgren A-K, 38, 76, 1463  
 Umblas N, 1246  
 Unger S, 292  
 Urowitz M, 2211, 2550  
 Usas A, 433
- V**
- Vacher-Lavenu MC, 2243  
 Valdes AM, 524, 533, 1051, 3064  
 Valenza R, 2656  
 Valkenier H, 1334  
 Valle AC, 3988  
 Valverde J, 1025  
 van de Loo FAJ, 1518  
 van de Stadt RJ, 3719  
 Van de Wiele C, 1856  
 van den Berg WB, 1096, 1518, 1653, 3828, 3868  
 Van den Bosch F, 2387  
 Van den Bosche V, 2594  
 van der Esch M, 1354  
 van der Heijde DMFM, 68, 702, 716, 1063, 1646, 1772, 2136, 3119  
 van der Heijden J, 557  
 van der Helm-van Mil AHM, 1117, 2028  
 van der Horst-Bruinsma IE, 3719  
 van der Kraan PM, 1653  
 van der Linden S, 1772  
 van der Veen JWC, 2505  
 van der Wal AM, 2944
- W**
- Wagner CL, 47, 2840  
 Wahren-Herlenius M, 1917, 2289  
 Wajdula J, 1063

- Wakamatsu E, 3476  
 Wakefield RJ, 3761  
 Walker E, 3820  
 Wallace CA, 1987  
 Wallace DJ, 607, 2541  
 Wallace RB, 3194  
 Wanders RJA, 2306  
 Wang CM, 3908  
 Wang J, 1246  
 Wang PS, 3390  
 Wang S, 877  
 Wang Y, 2271  
 Wang Z, 2119  
 Wappler I, 540  
 Ward MM, 2784  
 Ward P, 1838  
 Ward-Able C, 380  
 Wassenberg S, 3399  
 Waterham HR, 2306, 3690  
 Waters CE, 649  
 Watson A, 2471  
 Watson KD, 1786, 2368, 2701  
 Watts J, 3648  
 Wauben MHM, 1198  
 Weaver CA, 621  
 Webb C, 3345  
 Wechsler B, 184, 3284, 3330  
 Wegener's Granulomatosis  
     Etanercept Trial Research  
     Group, 1608  
 Wegscheider K, 3485  
 Weickert T, 2505  
 Weinblatt ME, 2757, 2807, 3790  
 Weisman MH, 26, 607  
 Weiss DT, 3545  
 Weiss T, 3533  
 Welch R, 1588  
 Wells AU, 3962  
 Wellsbury J, 3962  
 Welsh KI, 3034  
 Welsing P, 3828  
 Wen D, 3163  
 Wendler J, 1491, 4023  
 Wener M, 1982  
 Weng HH, 2951  
 Wenink MH, 3828  
 Wesley R, 2505  
 Wessels JAM, 1087, 2830, 3372  
 Wessely S, 177  
 Westermark P, 3545  
 Western Consortium of  
     Practicing Rheumatologists,  
     1105  
 Westhovens R, 1075  
 Weverling GJ, 369
- Weyand CM, 685, 2776, 3061,  
     3310  
 White B, 1987, 3954  
 Whitehead AS, 2220  
 Whitmore JB, 1987  
 Wicks IP, 158  
 Wierzbicki A, 2452  
 Wigley FM, 380, 3043, 3954  
 Wijbrandts CA, 3135  
 Wilkins RJ, 3523  
 Williams AS, 1662, 2084  
 Williams B, 1557  
 Williams DA, 2346  
 Williams FMK, 2147  
 Williams JI, 3212  
 Williamson P, 1646  
 Willrich SN, 3485  
 Wilson C, 2022  
 Wilson J, 3452  
 Wimmer MA, 3842  
 Winter A, 3254  
 Wirrwar A, 1096  
 Witt CM, 3485  
 Witte D, 2577  
 Witter F, 3640  
 Wolbink GJ, 711  
 Wolfe F, 169, 628, 1440, 1444  
 Wolff C, 515  
 Wollheim FA, 1415  
 Wong PKK, 158  
 Wong RL, 2136  
 Wong WK, 1105  
 Woo P, 3971  
 Woods JM, 2402  
 Woodworth T, 2387  
 Wooley PH, 854  
 Wordsworth P, 1543  
 Worthington J, 1482, 3417  
 Wouters CH, 3337  
 Wouters D, 1143  
 Wright JG, 3212  
 Wu AW, 1222  
 Wu H, 1105, 2951  
 Wu J, 3908  
 Wu L, 3194  
 Wu P, 3583  
 Wu Q, 343  
 Wu S-P, 3661  
 Wu X, 336
- X
- Xiao L, 754  
 Xiao X, 2119  
 Xiong MM, 3885  
 Xu H, 3441
- Xu L, 2891, 3508  
 Xu Y, 3163  
 Xue Y, 3267  
 Ydys V, 1350
- Y
- Yabe T, 992  
 Yada T, 1847  
 Yagishita N, 808  
 Yague J, 2334  
 Yajima N, 3408  
 Yamada H, 2004  
 Yamamoto M, 1557  
 Yamamoto N, 1662  
 Yamamura M, 97  
 Yamana J, 97  
 Yamana S, 1778  
 Yamasaki S, 808  
 Yamasaki Y, 2004, 3051  
 Yammani RR, 2901  
 Yan S, 1646  
 Yan X, 2558  
 Yan Z, 2069  
 Yanaba K, 192  
 Yanagimoto S, 3233  
 Yang P, 343  
 Yang SC, 3954  
 Yang X, 3441  
 Yao T-C, 2585  
 Yao W, 236  
 Yarboro CH, 2184, 2505  
 Yasukawa M, 1174, 3591  
 Yasukochi T, 3476  
 Yasuoka H, 1946, 3001  
 Yazici H, 3061  
 Yazici Y, 3061  
 Ye Y, 3441  
 Yee C-S, 3300  
 Yegutkin GG, 2852  
 Yelin EH, 1711  
 Yilmaz S, 3422  
 Yin Z, 877  
 Yocum D, 1075  
 Yocum DE, 1048  
 Yokouchi M, 808  
 Yokoyama A, 843  
 Yoné CL, 1491  
 Yoo W-H, 1747  
 Yood RA, 3194  
 Yoon C-H, 887  
 Yoon CS, 2152  
 York M, 3068  
 Yoshida H, 3126  
 Yoshida M, 2934, 3707  
 Yoshiie O, 1174
- Z
- Zacher J, 1805  
 Zack MD, 2912  
 Zang Y, 661  
 Zannoni G, 3633  
 Zare F, 148  
 Zavadil J, 2198  
 Zea A, 1707  
 Zeidler H, 2338  
 Zhan Z, 3441  
 Zhang D, 877  
 Zhang Q, 3820  
 Zhang YQ, 795, 1255, 1529,  
     2488, 3508  
 Zhao H, 877, 3661  
 Zhao Y, 3291  
 Chen B-G, 378  
 Zhou J, 343  
 Zhou T, 343  
 Zhou XD, 2626, 3885  
 Zhou Z, 3001  
 Zhuang H, 1557, 1573  
 Ziegler A, 2705  
 Zien A, 3533  
 Zikou AK, 1350  
 Zimmer R, 3533  
 Zink A, 3399  
 Zmuda JM, 1246  
 Zoli A, 3633  
 Zoma A, 2550, 3300  
 Zori R, 1573  
 Zulian F, 998, 3066, 3971  
 Zummer M, 2550  
 Zurakowski D, 3564  
 Zvaifler NJ, 3067  
 Zwerina J, 463

## SUBJECT INDEX

*Arthritis & Rheumatism*, Volume 54, Numbers 1–12, 2006

### A

- Abatacept Study of Safety in Use with Other RA Therapies (ASSURE trial), 2807  
ABN912, RA treatment with anti-CCL2 monoclonal antibody, 2387  
Achilles tendon, gene expression profiling in, 832  
ACTH test, glucocorticoids and adrenal response in RA, 1415  
Actin cytoskeleton, 3926  
Activin receptor-like kinase 5 signaling and scleroderma phenotype, 1309  
Acupuncture, for treating knee and hip OA, 3375, 3485  
Acute gouty arthritis  
  monosodium urate crystals and, 383  
  rapid induction of TREM-1 in murine macrophages by monosodium urate monohydrate crystals, 455  
  transglutaminase 2 to limit murine peritoneal acute gout-like inflammation, 3363  
Acute myocardial infarction  
  cardiovascular risks of COX-2 inhibitors and NSAIDs, 3390  
  gout and risk of, 2688  
Acute-phase serum AA, activity of via NF- $\kappa$ B-dependent signal transduction in RA, 105  
Adalimumab  
  AS, efficacy and safety of in, 2136  
  AS, spinal symptoms reduced by, 678  
  RA, combination therapy of adalimumab plus MTX (PREMIER study), 26  
  RA, effectiveness of, 3399  
ADAMTS-4, aggrecanase 1 in Lyme arthritis, 3319  
Adeno-associated virus, inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with, 2119  
Adenosine A<sub>2A</sub> receptors, in diffuse dermal fibrosis, 2632  
Adenosine release-related genes, MTX treatment outcome and genetic variants in adenosine pathway in recent-onset RA, 2830  
Adhesion molecules, in RA, 2707  
Adiponectin, SS, salivary gland epithelial cells as source of, 2295  
Adipose synovium, properties of human synovial mesenchymal stem cells, 843  
Adjvant-induced arthritis  
  angiostatic effects of IL-4 gene therapy in rats, 2402  
  endothelial dysfunction in, rat study, 1847  
  SSAO inhibitors and, 2707  
Adolescents  
  juvenile SLE, SDI for, 2989  
  SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270  
Adrenocorticotrophic hormone, effect of therapeutic glucocorticoids on adrenal response in RA, 1415  
Adverse events, predictors of, following total knee replacement, 1536  
Aerobic fitness, in chronic fatigue syndrome, 3351  
African Americans  
  Anti-CCP antibodies and RF isotopes in African Americans with early RA, 3057  
  HLA associations with idiopathic inflammatory myopathy, 3670  
Aggrecan, internalization of aggrecan G1 by CD44, 443, 1028  
Aggrecanase 1, in Lyme arthritis, 3319  
Aging. See also Older adults  
  projections of US arthritis prevalence and associated activity limitations, 226  
AG-rich element, human OA chondrocytes and, 2471  
AIF-1, in SSc, 2616  
Alefacept, plus MTX to treat PsA, 1638  
Allograft inflammatory factor 1 (AIF-1), expression of in SSc, 2616

- $\alpha$ v $\beta$  receptors and ligands involved in uptake of necrotic cells, 927  
Alternative medicine. See Complementary and alternative medicine  
American College of Rheumatology (ACR)  
  ACR-N index, going back into the middle of the tunnel, 377, 378  
  fibromyalgia diagnosis criteria, 169  
  JIA, ACR and DAS criteria comparison, 1602  
  journal policies on authorship and disclosures, 1711  
  juvenile SLE, SDI for, 2989  
  presidential address, 1029  
  renal disease criteria for SLE clinical trials, 421  
  task force report, extremity MRI in RA, 1034, 1048  
  winners of 2005 ACR annual slide competition, 690  
Amine oxidase, prevention of leukocyte infiltration by amine oxidase inhibition in inflamed joints, mouse study, 2852  
Amyloid, apolipoprotein A-I in meniscal tissue, 3545  
Amyloidosis  
  AA as complication of hyperimmunoglobulinemia D with periodic fever syndrome, 2010  
  Amyloid A (AA), as JIA complication, tocilizumab to treat, 2997  
  Amyloid L, bilateral black eyes in, 3724  
  systemic, diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detection, 2015  
Anakinra  
  chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents, 2314  
  Muckle-Wells syndrome, improvement from deafness after treatment, 1697  
ANCA-associated vasculitis, rituximab treatment for, 2970  
Androgens  
  anti-TNF therapy and neuroendocrine axes, 2039  
  RA, anti-IL-6R antibodies and, 1778  
  steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890  
Aneurysm, Takayasu arteritis presenting with subclavian aneurysm, 382  
Angiogenesis  
  angiostatic effects of IL-4 gene therapy in rats, 2402  
  RA, activity of serum AA via NF- $\kappa$ B-dependent signal transduction, 105  
  RA, oncostatin M induces angiogenesis and cartilage degradation in RA synovial tissue and human cartilage cocultures, 3152  
Animal models. See names of specific animals  
Ankle  
  gouty tophus of, 2706  
  matrix metabolism in early cartilage lesions in, 244  
Ankylosing hyperostosis. See Diffuse idiopathic skeletal hyperostosis (DISH)  
Ankylosing spondylitis (AS)  
  adalimumab efficacy and safety, 2136  
  adalimumab for spinal symptoms, 678  
  B27 subtypes and tapasin dependence, 138  
   $\beta_2$ -microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in rats, 1317  
  DISH coexisting with ossification of posterior longitudinal ligament of cervical spine, 2242  
  hip arthritis in, 1805  
  inflammatory back pain in, 569  
  infliximab and spinal inflammation reduction, 1646  
  susceptibility and *IL1* gene cluster, 974  
  zygapophyseal joints in, immunohistologic analysis of, 2845  
Anti-20S proteasome autoantibody, inhibition of proteasome stimulation by proteasome activator PA28, 2175  
Anti- $\alpha$ -actinin, in human and murine lupus nephritis, 914

- Anti-aortic endothelial cell antibodies, and Takayasu arteritis, 2326  
 Anti- $\beta$ -glycoprotein I antibody, platelet activation by via glycoprotein I $\beta$ -IX-V, 2558  
 Anticardiolipin antibody (aCL), in patients with early RA treated with infliximab plus MTX, 2840  
 Anti-CCL2 monoclonal antibody, ABN912 treatment for RA, 2387  
 Anti-CD20 antibody. *See* Rituximab  
 Anticentromere antibody (ACA)-positive SSc, PTPN22 R620W polymorphism and, 3945  
 Anti-citrullinated protein antibody (anti-ACPA)  
     Epstein-Barr infection and, 733  
     in RA, 3381  
 Anticoagulant therapy, in GCA, 3306  
 Anti-cyclic citrullinated peptide (anti-CCP) antibodies  
     HLA-DRB1 shared epitope as risk factor for anti-CCP antibodies but not RA, 1117  
     in psoriasis patients without arthritis, 1701  
     RA, isotype distribution of anti-CCP antibodies, 3799  
     RA, RF isotopes in African Americans with early disease, 3057  
 Anti-DNA antibody  
     lupus nephritis,  $\alpha$ -actinin-binding anti-dsDNA antibodies and, 2523  
     lupus nephritis, glomerular structures recognized by nephritogenic antibodies, 914  
     neuropsychiatric SLE, association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid, 675  
     regulation of gene expression in mouse glomerular mesangial cells by, 2198  
 Anti-double-stranded DNA (anti-dsDNA) antibody  
     SLE,  $\alpha$ -actinin-binding anti-dsDNA antibodies and lupus nephritis, 2523  
     SLE, moderate-dose steroids and disease flare, 3623  
 Anti-endothelial cell antibody (AECA)  
     mouse monoclonal anti-human thrombomodulin antibodies activate endothelial cells, 1629  
     SSc, serum induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells, 2250  
 Anti-Epstein-Barr nuclear antigen 1 antibodies, in pediatric SLE, 360  
 Anti-folate receptor  $\beta$ , efficacy of immunotoxin on RA synovial cells, 3126  
 Antigen-induced arthritis  
     Fc $\gamma$  receptor II regulates severe cartilage destruction but not bone destruction, 3868  
     IL-6, role in, 158  
 Antigen-presenting cells, collagen-induced arthritis, suppression of by CD11c+, CD11b+ dendritic cells, 887  
 Antigen processing, of human type II collagen in mouse model, 482  
 Antiinflammatory effects, statins, in RA, 390, 393, 2347  
 Antitumifibram antibodies, and clinical response to RA, 711  
 Anti-IL-6R antibodies  
     for RA, 1778, 2817  
     tocilizumab in RA patients with incomplete MTX response, CHARISMA study, 2817  
     tocilizumab to treat AA amyloidosis complicating JIA, 2997  
 Anti-La/SSB antidiotypic antibodies, in maternal serum, neonatal lupus risk, 2228  
 Antimuscarinic antibodies, in primary SS, 1165  
 Antineutrophil cytoplasmic antibody (ANCA), serine-mediated endothelial cell damage, 1619  
 Anti-NR2 antibodies  
     association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid in neuropsychiatric SLE, 675  
     in mice and men (editorial), 2349  
     SLE, mood and cognition in, 2349, 2505, 2515  
 Antioxidized low-density lipoprotein antibodies, vascular arterial events and renal manifestations in SLE, 2035  
 Anti-p155 autoantibody, DM and, 3682  
 Anti-ribosomal P (anti-P) antibody  
     SLE, anti-P antibody testing for diagnosis of neuropsychiatric SLE, 312  
     SLE, in lupus glomerulonephritis, 1568, 4025, 4026  
 Antiphospholipid antibody (aPL)  
     molecular mechanisms of aPL-induced tissue factor expression, 301  
     SLE, cardiovascular manifestations of, 3918  
     SLE, platelet C4d specificity for SLE, 670  
 Antiphospholipid syndrome (APS), catastrophic, mortality in, 2568  
 Anti-PL-7, in milder muscle disease in Japanese patients with PM/DM, 2004  
 Antiplatelet therapy, in GCA, 3306  
 Anti-RNA binding protein autoantibodies, and association of IFN $\alpha$  in SLE, 1906  
 Anti-RNA polymerase I/III antibodies, SSc, nucleolar staining by, 3051  
 Anti-Ro/La autoantibodies, TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block, 356  
 Anti-topoisomerase I antibody-positive SSc, PTPN22 R620W polymorphism and, 3945  
 Anti-topoisomerase I autoantibodies, SSc, DNA topoisomerase I binding to fibroblasts, 963  
 Anti-TNF  
     AS, spinal inflammation reduction in patients receiving infliximab, 1646  
     CD28 surface expression on CD4+ T cells, 3060, 3061  
     collagen-induced arthritis treated with camelid anti-TNF VH proteins, mouse study, 1856  
     JIA, ACR and DAS criteria comparison, 1602  
     JRA, etanercept safety and efficacy in children with polyarticular-course JRA, 1987  
     LUNDEX, index of drug efficacy in clinical practice, 600  
     neuroendocrine axes and, 2039  
     in pregnancy, 2353, 2701  
     RA, aCL in patients with early RA treated with infliximab plus MTX, 2840  
     RA, antiinfliximab antibodies and clinical response in RA, 711  
     RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54  
     RA, cancer and anti-TNF $\alpha$  use, 2757  
     RA, comparison of etanercept and MTX alone and combined, two-year results of TEMPO study, 1063, 3061  
     RA, comparison of infliximab or etanercept monotherapy vs. cotherapy with another DMARD, 1786  
     RA, delaying addition of infliximab to ongoing MTX therapy in early disease, 47, 1028  
     RA, disease activity and radiographic progression after treatment with etanercept, alone or combined with MTX, 3119  
     RA, effectiveness of, 3399  
     RA, Guillain-Barré and Miller Fisher syndromes with infliximab therapy, 1429  
     RA, infliximab improves employability of patients with early RA, 716  
     RA, infliximab, safety in RA with comorbidities, 1075  
     RA, monitoring of anti-TNF $\alpha$  bioavailability and immunogenicity in, 3782  
     RA, predictors of joint damage in early RA treated with high-dose MTX with or without concomitant infliximab, 702  
     RA, rates of infection in anti-TNF-treated RA patients, 2368  
     RA, risk of pneumonia with anti-TNF treatment, 628  
     RA, rituximab plus MTX for anti-TNF-refractory RA, 2793  
     RA, synovial osteoprotegerin expression increased by, 76  
     RA with hepatitis C virus infection, concomitant IFN $\alpha$  treatment and TNF $\alpha$  inhibition for, 2335  
     risk of JC virus infection resulting in progressive multifocal leukoencephalopathy, 381  
     WG, solid malignancies among etanercept-treated patients, 1608

- Anti-type II collagen, anti-type II collagen-containing immune complexes in arthritis**, 1757  
**Antiviral therapy, for hepatitis C virus-associated mixed cryoglobulinemia vasculitis**, 3696  
**AOC3 enzyme inhibitor**  
 prevention of leukocyte infiltration by amine oxidase inhibition in inflamed joints, mouse study, 2852  
**RA and**, 2707  
**Apolipoprotein A-I, amyloid in meniscal tissue formed from**, 3545  
**Apoptosis**  
 cutaneous lupus erythematosus, UV-induced apoptotic cell accumulation in, 939, 3375  
 neutrophils from *TNFRSF1A* mutations display resistance to TNF-induced apoptosis, 998  
 PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes, 587  
**RA, Bim deficiency and exacerbation and prolongation of joint inflammation in**, 3182  
**RA, regulation of Mcl-1 expression in synovial macrophages**, 3174  
**RA, sphingosine kinase 1-mediated inhibition of Fas death signaling in B lymphoblastoid cells**, 754  
**RA, statin-induced apoptosis in synovial cells**, 579  
 receptors and ligands involved in uptake of necrotic cells, 927  
**SLE, impaired CD91 apoptotic pathways in**, 1543  
**SSc, serum induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells**, 2250  
 transglutaminase 2 to limit murine peritoneal acute gout-like inflammation, 3363
- Arm**  
 brachio-cervical inflammatory myopathies, clinical, immune, and myopathologic features of, 1687  
 intersection syndrome of the forearm, 2038
- Aromatase inhibitors, osteoporosis and**, 1355, 1356
- Arterial thrombotic events, SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in**, 1940
- Arthritis. See also specific types of arthritis**  
 anti-type II collagen-containing immune complexes in arthritis, 1759  
**AS, immunohistochemical analysis of hip arthritis in**, 1805  
**CD28 costimulation in arthritis induction in IL-1Ra-deficient mice**, 473  
*Chlamydia*-induced arthritis in rats, host-microbe interactions in, 499  
 enthesitis-related arthritis, outcome and prognostic factors, 3573  
 gene therapy for, 1714  
 high-resolution multipinhole SPECT in experimental and human arthritis, 1096  
 homeostatic proliferation-provoked arthritis, 492  
 mediation of double-stranded RNA-mediated arthritis by type I IFN, 148  
 $\beta_2$ -microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in rats, 1317  
 noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736  
**p38 MAPK inhibition and TNF-mediated arthritis**, 463  
 pediatric granulomatous arthritis, international registry, 3337  
 polyreactive pathogenic autoantibodies in BXD2 mice cause glomerulonephritis and erosive arthritis, 343  
 projections of US arthritis prevalence and associated activity limitations, 226  
 soluble p55 and p75 TNF receptors reverse spontaneous arthritis in mice expressing transmembrane TNF $\alpha$ , 2872  
 susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice, 2423
- Arthritis & Rheumatism**  
 journal policies on authorship and disclosures, 1711  
 statistical methods in, 3741
- Arthroplasty. See Total hip arthroplasty; Total knee replacement**
- Assessment instruments**  
**AUSCAN Osteoarthritis Hand Index, validity, factor structure, and clinical relevance of**, 551  
**JIA, comparison of ACR and DAS criteria**, 1602  
**juvenile SLE, SDI for**, 2989  
**LUNDEX, index of drug efficacy in clinical practice**, 600  
**SLE, pediatric, BILAG index**, 2343, 3723  
**SLE, revised BILAG-2004 index**, 3300  
 total knee replacement, preliminary index that predicts adverse events after, 1536  
**ASSURE trial, abatacept safety in RA patients receiving DMARDs**, 2807
- Atherosclerosis**  
**RA, relationship to disease severity and extraarticular manifestations**, 1353  
**SLE, proinflammatory high-density lipoprotein as biomarker for atherosclerosis in SLE and RA**, 2541
- Atorvastatin, increase in circulating endothelial precursors in SSc patients**, 1946
- Australian/Canadian (AUSCAN) Osteoarthritis Hand Index, validity, factor structure, and clinical relevance of**, 551
- Autoantigens, SLE, RNA components of autoantigens as endogenous adjuvants**, 1557
- Autoimmune diseases. See also names of specific diseases**  
 B cells and, 1  
 hematopoietic stem cell transplantation in, 3730, 3750
- Autoimmunity, Koch's postulates of**, 2349
- Autoinflammatory disease, PYPAF1 nonsense mutation in**, 508
- Autologous hematopoietic stem cell transplantation, in autoimmune diseases**, 3730, 3750
- Avoidance behavior, back pain, prognosis in**, 3999
- Azathioprine**  
**RA, immunosuppressive medications and hospitalization for cardiovascular events**, 3790  
**SSc, corticosteroids and cyclophosphamide followed by azathioprine treatment for pulmonary fibrosis in SSc**, 3962
- Azores, DISH and chondrocalcinosis, clinical and radiographic manifestations**, 1340

## B

- B27 subtypes, SpA-associated and non-SpA-associated B27 subtypes differ in tapasin dependence**, 138  
**Back pain, inflammatory, in AS**, 569  
**BAFF**  
 BAFF-induced changes in B cell antigen receptor-containing lipid rafts in, 115  
 serum BAFF levels in SSc, 192
- Basic growth fibroblast growth factor, therapeutic effects on experimental OA in rabbit knee**, 264
- B cell depletion therapy**  
**RA, B lymphocyte stimulator levels following rituximab treatment**, 723  
**RA, therapeutic B cell depletion and regeneration**, 2356, 2377  
**SLE, autoantibody and antimicrobial antibody profiles**, 3612  
**SLE, depletion in appendix following rituximab treatment**, 2151  
**SLE and ANCA-associated vasculitis, long-term comparison of rituximab treatment for**, 2970
- B cell lymphomas**  
**RA, diffuse large B cell lymphomas in**, 3774  
**SS, dissemination of an SS-associated extranodal marginal zone B cell lymphoma**, 127
- B cell regeneration**  
**RA, reconstitution of B cells after depletion by rituximab in RA patients**, 613, 3062, 3063  
**RA, therapeutic B cell depletion and regeneration**, 2356, 2377
- B cells**  
 autoimmune disease therapy and, 1

- B cells (cont'd)**
- RA-associated and idiopathic interstitial pneumonia, 635
  - RA, reconstitution of B cells after depletion by rituximab in RA patients, 613, 3062, 3063
  - RA, sphingosine kinase 1-mediated inhibition of Fas death signaling in B lymphoblastoid cells, 754
  - SLE, Lyn deficiency in B cells, 2036, 2037
  - SLE, Toll-like receptor 9-expressing B cells in active SLE, 3601
  - SS, BAFF-induced changes in B cell antigen receptor-containing lipid rafts in, 115
  - SSc, elevated serum BAFF levels in, 192
  - SS, transitional type II B cells in salivary glands of SS patients, 2280
  - Bel-2 proteins, Bim deficiency and exacerbation and prolongation of joint inflammation in, 3182
  - $\beta_2$ -microglobulin, curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in rats, 1317
  - Beta cells, insulin resistance and impaired beta cell function in RA, 2765
  - Betamethasone, MTX plus cyclosporine plus intraarticular betamethasone compared with MTX and intraarticular betamethasone in early RA, 1401
  - BILAG, SLE, revised BILAG-2004 index, 3300
  - Biologic therapy
    - chronic infantile neurologic, cutaneous, articular syndrome treated with, 2314
    - PsA, alefacept in combination with MTX to treat, 1638
    - RA, anti-IL-6R antibodies, 1778
    - RA, anti-TNF use and cancer, 2757
    - RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790
  - Biomarkers
    - collagen-induced arthritis, CTX-II as an early marker of, rodent study, 2886
    - JRA, RANTES and monocyte chemoattractant protein 1 as markers of disease activity in, 2585
    - nephritis, neutrophil gelatinase-associated lipocalin as biomarker of nephritis in childhood-onset SLE, 2577
    - OA, diurnal variation of biomarkers in knee OA, 2496
    - OA, fibronectin neopeptides in OA cartilage, 2912
    - OA, oral salmon calcitonin and knee OA, 3205
    - RA, MTX drug monitoring, 3095
    - SLE, blood concentrations of hydroxychloroquine and SLE disease activity, 3284
    - SLE, homocysteine levels and SLE duration and coronary artery calcification, 2220
    - SLE, platelet C4d specificity for, 670
    - SLE, proinflammatory high-density lipoprotein as biomarker for atherosclerosis in SLE and RA, 2541
    - SpA, 1733, 1795
    - SSc, myofibroblasts and hyalinized collagen as markers of skin disease in, 3655
    - SSc, nucleolar staining by anti-RNA polymerase I/III antibodies, 3051
    - BiP, murine collagen-induced arthritis, BiP treatment via IL-4+ regulatory T cells, 854
    - Bisphosphonates
      - OA, risedronate in medial compartment knee OA, 3494
      - osteoporosis, intravenous bisphosphonates in osteoporosis and jaw osteonecrosis, 3720, 3721
      - osteoporosis, intravenous ibandronate injections in postmenopausal women with, 1838
      - RA, early, zoledronic acid in, 1410
      - Blau syndrome, pediatric granulomatous arthritis, international registry, 3337
      - Blood pressure, COX-2 inhibition and cardiovascular side effects of diclofenac vs. celecoxib and rofecoxib, 282
    - B lymphocytes, SS, chemokine receptor expression in B lymphocytes, 1707, 1708
    - Body mass index (BMI), effects on later total hip arthroplasty for primary OA, 802
    - Body weight. See Obesity
    - Bone-cartilage interface, AS, immunohistochemical analysis of hip arthritis in, 1805
    - Bone damage, antigen-induced arthritis, IL-6 in, 158
    - Bone density, SLE, low bone density and vertebral fractures in, 378, 379
    - Bone destruction
      - Fc $\gamma$  receptor II regulates severe cartilage destruction but not bone destruction in mouse model, 3868
      - intrarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463
      - RA, CD40 ligation of synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747
      - RA, IKK $\beta$  inhibition protects against bone and cartilage destruction in RA rat model, 3163
      - TNF-mediated arthritis and p38 MAPK inhibition, 463
    - Bone erosion, RA T cells induce osteoclastogenesis in monocytes, 1151
    - Bone marrow
      - differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts, 2096
      - OA, bone marrow lesions and cartilage loss in knee OA, 1529
      - SSc, defective bone marrow endothelial progenitors in, 2605
    - Bone marrow transplantation
      - SSc, severe, allogeneic hematopoietic cell transplantation, 1982
      - T cell-depleted, nonmyeloablative bone marrow transplantation in IL-1Ra-deficient mice, 1878
    - Bone mineral density (BMD)
      - calcium supplementation to increase BMD in children with JRA, 2235
      - disc space narrowing as risk factor for vertebral fracture, 1262
    - Bone morphogenetic protein (BMP)
      - as inducers of cartilage repair, ex vivo transduction of muscle-derived stem cells, 387
      - induction of chondrocytic differentiation of stem cells by BMP-6, 1222
      - Jab1 binds Smad5 and inhibits BMP signaling, 3878
      - noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736
    - Bone resorption
      - collagen-induced arthritis, CTX-II as an early marker of, rodent study, 2886
      - fibroblasts and fibroblast-derived factors in periprosthetic osteolysis, 3221
      - RA, TNFSF14 as mediator of, 1451
    - Borrelia burgdorferi*
      - antibiotic-refractory arthritis, 3079
      - Lyme arthritis, aggrecanase 1 in, 3319
    - Botanical remedies. See Complementary and alternative medicine
    - Bovine articular cartilage
      - IL-1 $\alpha$ -induced tensile weakening of, 3267
      - shear stimulation of proteoglycan 4 metabolism in bovine cartilage, 1888
      - steroid hormones support posttraumatic integration in absence of IL-1 $\beta$ , 3890
    - Brachio-cervical inflammatory myopathies, clinical, immune, and myopathologic features of, 1687
    - Brain abnormalities, SSc, revealed by MRI and magnetization transfer imaging, 1350
    - Brain activity, FM, reduced brain habituation to somatosensory stimulation in, 1995
    - British Isles Lupus Assessment Group (BILAG)
      - SLE, revised BILAG-2004 index, 3300
      - usefulness of index in pediatric clinical trials, 2343, 3723
    - Bursitis, hip iliopsoas bursitis with SLE, 1686

## C

- C1,2C, OA, diurnal variation of biomarkers in knee OA, 2496  
C1q, receptors and ligands involved in uptake of necrotic cells, 927  
C1q-C4 complexes, evaluation of classical complement pathway activation in RA, 1143  
C1q/calreticulin pathway, SLE, impaired CD91 apoptotic pathways in, 1543  
C2C, OA, diurnal variation of biomarkers in knee OA, 2496  
C4d, platelet C4d specificity for SLE, 670  
Calcification  
DISH and chondrocalcinosis in Azores families, clinical and radiographic manifestations, 1340  
following ectopic transplantation of mesenchymal stem cells, mouse study, 3254  
juvenile DM, composition of calcifications in children, 3345  
phosphocitrate treatment of calcification-induced joint degeneration in guinea pig model, 2452  
Calcitonin, oral salmon calcitonin and knee OA, 3205  
Calcium fluxing, SLE treatment with rapamycin and, 2983  
Calcium pyrophosphate dihydrate (CPPD) crystal deposition, chondrocalcinosis in Chinese vs. white subjects, 3508  
Calcium signaling, IL-1-induced, in OA chondrocytes, 2164  
Calcium supplementation, to increase BMD in children with JRA, 2235  
Canadian populations  
AS, *IL1* gene cluster and susceptibility, 974  
RA, and *FCRL3* polymorphism in Canadian population, 3820  
Cancer, anti-TNF use in RA and, 2757  
Capuccino gene, platelet function in development of crescentic glomerulonephritis, mouse study, 2934  
Cardiovascular disease  
cardiovascular outcomes in new users of coxibs and NSAIDs, 1378  
catastrophic APS, mortality in, 2568  
GCA, antiplatelet and anticoagulant therapy in, 3306  
Kawasaki disease, polymorphism in mannose-binding lectin gene and risk of coronary artery lesions, 369  
RA, atherosclerosis in and relationship to disease severity and extraarticular manifestations, 1353  
RA, contribution of congestive heart failure and ischemic heart disease to excess mortality, 60  
RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790  
RA, increased case fatality rates following first acute cardiovascular event in, 2061  
SLE, aPL and cardiovascular manifestations of, 3918  
SLE, homocysteine levels and SLE duration and coronary artery calcification in SLE patients, 2220  
SLE, exclusive large vessel disease leading to fatal stroke, 908  
SLE, proinflammatory high-density lipoprotein as biomarker for atherosclerosis in SLE and RA, 2541  
Cardiovascular safety, of COX-2 inhibitors and NSAIDs, 3390  
Cardiovascular side effects, COX-2 inhibition by diclofenac vs. celecoxib and rofecoxib, 282  
Cartilage  
activation of cultured chondrocytes by vibration and hyaluronic acid, 1897  
AS, immunohistochemical analysis of cartilage-bone interface in hip arthritis, 1805  
BMP-4 and muscle-derived stem cells for cartilage repair in rats, 433  
BMPs as inducers of cartilage repair, ex vivo transduction of muscle-derived stem cells, 387  
cellular events leading to chondrocyte death after cartilage impact injury, 1509  
collagen and proteoglycan turnover in focally damaged ankle cartilage, 244  
estrogen therapy and structural integrity of articular cartilage in rats, 2441  
hypoxia and pH regulation in articular chondrocytes, 3523  
IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267  
induction of chondrocytic differentiation of stem cells by BMP-6, 1222  
Jab1 binds Smad5 and inhibits BMP signaling, 3878  
mesenchymal stem cells as cell source for cartilage tissue engineering, 3075  
OA, 4-hydroxyonenal and cartilage degradation, 271  
OA, catabolic pathway mediated by Toll-like receptors, 2152  
OA, caveolin 1-induced down-regulation of articular chondrocytes in pathogenesis of, 818  
OA, disease-modifying role of caspase inhibitors in, 1814  
OA, fibronectin neopeptides in cartilage, 2912  
OA, gene expression profiles in intact and damaged cartilage, 808  
OA, IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267  
OA, meniscus changes and cartilage loss in symptomatic knee OA, 795  
OA, orphan nuclear receptor Rev-ErbA $\alpha$  in chondrocytes, 3513  
RA, oncostatin M induces angiogenesis and cartilage degradation in synovial tissue and human cartilage cocultures, 3152  
shear stimulation of proteoglycan 4 metabolism in bovine cartilage, 1888  
steroid hormones and cartilage integration, 3890  
tetraspanin CD151 in human OA cartilage, 3233  
Cartilage damage  
OA, effects of connective tissue growth factor and CCN2 overexpression on fibrosis and cartilage damage, 1653  
OA, growth hormone and insulin-like growth factor 1 deficiencies and knee OA severity, rat study, 3850  
Cartilage degeneration, OA, gene expression profiling for pathogenic pathways of, 3533  
Cartilage degradation  
MMP-10 promotion of collagenolysis via procollagenase activation, 3244  
OA, risendronate in medial compartment knee OA, 3494  
OA, S100A4 stimulates MMP-13 via RAGE, 2901  
RA, oncostatin M induces angiogenesis and cartilage degradation in RA synovial tissue and human cartilage cocultures, 3152  
Cartilage destruction  
Fcγ receptor II regulates severe cartilage destruction but not bone destruction in mouse model, 3868  
molecular mechanisms of cartilage destruction, 1357  
multiple gene up-regulation by IL-1 plus oncostatin M in chondrocytes, 540  
noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736  
OA, fibronectin neopeptides in OA cartilage, 2912  
peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates IL-1Ra production in cytokine-treated chondrocytes, 1233  
RA, IKK $\beta$  inhibition protects against bone and cartilage destruction in RA rat model, 3163  
suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518  
tetraspanin CD151 in human OA cartilage, 3233  
Cartilage integration, supported by steroid hormones in absence of IL-1, 3890  
Cartilage loss  
in knee OA, 1529  
OA, chondrocalcinosis and increased risk of cartilage loss in, 1822  
Cartilage oligomeric matrix protein  
heritable determinants of, 2147  
hip, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236  
OA, diurnal variation of biomarkers in knee OA, 2496

- Cartilage repair**
- BMPs as inducers of cartilage repair, ex vivo transduction of muscle-derived stem cells, 387
  - induction of chondrocytic differentiation of stem cells by BMP-6, 1222
  - mesenchymal stem cells as cell source for cartilage tissue engineering, 3075
  - multiple gene up-regulation by IL-1 plus oncostatin M in chondrocytes, 540
  - peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates IL-1 receptor antagonist production in cytokine-treated chondrocytes, 1233
  - Caspase 8, Fas signaling in RA fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473
  - Caspase inhibitors, disease-modifying role of caspase inhibitors in OA, 1814
  - Catabolic stress, chondrocyte senescence induced through overexpression of caveolin 1, 818
  - Catastrophic APS, causes of death and prognostic factors in, 2568
  - Cathepsin K, collagen degradation around loosened total hip replacement implants, 2928
  - "Cat-scratch disease," role of tick-borne infection in, 2347
  - Caucasians, immunogenetic risk and protective factors for juvenile DM in, 3979
  - Caveolin 1, catabolic stress-induced chondrocyte senescence through overexpression of, 818
  - CCL18, CCL18/PARC-mediated lung injury, mouse study, 2643
  - CCN2, secretion by notochord cells, 3859
  - CD4 T cells
    - abnormal differentiation of memory T cells in SLE, 2184
    - anti-TNF and CD28 surface expression on CD4+ T cells, 3060, 3061
    - differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts, 2096
    - prevention of spontaneous arthritis by inhibiting homeostatic expansion of autoreactive CD4+ T cells in mice, 492
    - Treg cells with therapeutic effect in collagen-induced arthritis induced by vasoactive intestinal peptide, 864
    - Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583  - CD14, receptors and ligands involved in uptake of necrotic cells, 927
  - CD19, BAFF-induced changes in B cell antigen receptor-containing lipid rafts in, 115
  - CD25+, Treg cells with therapeutic effect in collagen-induced arthritis induced by vasoactive intestinal peptide, 864
  - CD28
    - anti-TNF and CD28 surface expression on CD4+ T cells, 3060, 3061
    - costimulation in arthritis induction in IL-1Ra-deficient mice, 473
    - CD32B, radiologic joint damage and dendritic cell function in RA associated with CD32B variant, 3828
    - CD36, receptors and ligands involved in uptake of necrotic cells, 927
    - CD40, CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747
    - CD44, internalization of aggrecan G1 by, 443, 1028
    - CD91 pathways, SLE, impaired CD91 apoptotic pathways in, 1543
    - CD151, tetraspanin CD151 in human OA cartilage, 3233
    - CDK1 gene, modulation of mediators of inflammation in RA, 2074
    - Celecoxib
      - cardiovascular outcomes in new users of, 1378
      - COX-2 inhibition by diclofenac vs. celecoxib and rofecoxib, 282
      - gastrointestinal and cardiovascular safety of, 3390    - Central nervous system, primary angiitis of the central nervous system in children, 1291
    - Cerebrovascular disease, in RA, 642
    - Cerebrovascular events
      - catastrophic APS, mortality in, 2568
      - GCA, antiplatelet and anticoagulant therapy in, 3306
      - SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940    - Cervical spine, AS, diffuse idiopathic skeletal hyperostosis coexisting with ossification of posterior longitudinal ligament of, 2242
    - Chemokine blockade, and SS, 1061
    - Chemokines
      - in Erdheim-Chester disease, 4018
      - inducible protein 10/CXCL10 antagonist and autoimmune sialadenitis in mice, 1174
      - RA, epigallocatechin-3-gallate role in chemokine production and MMP-2 activation in synovial fibroblasts, 2393
      - SS, chemokine receptor expression in B lymphocytes, 1707, 1708    - Children. See also Juvenile
      - chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents, 2314
      - enthesis-related arthritis, outcome and prognostic factors in, 3573
      - IL-6 and impaired skeletal development, mouse study, 3551
      - JRA, calcium supplementation to increase BMD in children with JRA, 2235
      - JRA, etanercept safety and efficacy in children with polyarticular-course JRA, 1987
      - JRA, RANTES and monocyte chemoattractant protein 1 as markers of disease activity in, 2585
      - juvenile DM, composition of calcifications in, 3345
      - juvenile-onset SpA, synovial immunopathologic characteristics of, 2594
      - juvenile SLE, SDI/ACR Damage Index for, 2989
      - Kawasaki disease, angiogenic genes and, 1361
      - Kawasaki disease, polymorphism in mannose-binding lectin gene and risk of coronary artery lesions of, 369
      - Kawasaki disease, VEGF gene haplotypes in, 1588
      - neonatal lupus risk, anti-La/SSB antiidiotypic antibodies in maternal serum, 2228
      - neonatal-onset multisystem inflammatory disease, mutational analysis in, 2703, 2704
      - pediatric granulomatous arthritis, international registry, 3337
      - pediatric SLE, anti-Epstein-Barr nuclear antigen 1 antibodies in, 360
      - pediatric SLE, British Isles Lupus Assessment Group index in, 2343, 3723
      - pediatric SLE, effects of disease activity and therapy on lipid profile in, 1283
      - primary angiitis of the central nervous system in, 1291
      - SLE, neutrophil gelatinase-associated lipocalin as biomarker of nephritis in childhood-onset, 2577
      - SSc in childhood, 3971
      - SSc, treatment of localized, 3065, 3066
      - TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block, 356
      - Chinese population, hereditary disorders of connective tissues in, 515
      - Chimerism, in lupus nephritis, 2944
      - Chinese population, chondrocalcinosis in Chinese vs. white subjects, 3508
      - Chlamydia*-induced arthritis, host-microbe interactions in, rat study, 499
      - Chloroquine, mechanism of acquired resistance to, 557
      - Cholesterol
        - pediatric SLE, effects of disease activity and therapy on lipid profile in, 1283
        - SLE renal outcome, association between serum cholesterol level and, 2211      - Chondrocalcinosis
        - in Chinese vs. white subjects, 3508
        - clinical and radiologic manifestations, in the Azores, 1340
        - OA, chondrocalcinosis and increased risk of cartilage loss in, 1822      - Chondrocytes
        - accumulation of intracellular ITEGE and DIPEN neoepitopes in chondrocytes mediated by CD44 internalization of hyaluronan, 443, 1028

- Chondrocytes (*cont'd*)**
- activation of cultured chondrocytes by vibration and hyaluronic acid, 1897
  - catabolic stress-induced senescence through overexpression of caveolin 1, 818
  - cellular events leading to chondrocyte death after cartilage impact injury, 1509
  - chondrogenesis of mesenchymal stem cells in vitro and in vivo, mouse study, 3254
  - hypoxia and pH regulation in articular, 3523
  - induction of chondrocytic differentiation of stem cells by bone morphogenetic protein 6, 1222
  - mesenchymal stem cells as cell source for cartilage tissue engineering, 3075
  - MMP-10 promotion of collagenolysis via procollagenase activation, 3244
  - multiple gene up-regulation by IL-1 plus oncostatin M in, 540
  - notochord cells, connective tissue growth factor secretion and up-regulation of proteoglycan expression in, 3859
  - OA, AG-rich element binding protein identification in, 2471
  - OA, catabolic pathway mediated by Toll-like receptors, 2152
  - OA, IL-1-induced calcium signaling in, 2164
  - OA, orphan nuclear receptor Rev-ErbA $\alpha$  in OA chondrocytes, 3513
  - OA, RAGE activation leads to increased stimulation of, 253
  - OA, S100A4 stimulates MMP-13 via RAGE, 2901
  - OA, tetraspanin CD151 in human cartilage, 3233
  - peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates IL-1Ra production in cytokine-treated, 1233
  - suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in, 1518
  - Chondrogenesis, of mesenchymal stem cells in vitro and in vivo, mouse study, 3254
  - Chromosome 9p, lupus-like disease and high IFN levels corresponding to trisomy of type I IFN cluster on, 1573
  - Chromosomes 6q and 16p, RA, classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 1483
  - Chronic fatigue syndrome, exercise responses in, 3351
  - Chronic infantile neurologic, cutaneous, articular syndrome (CINCA) biologic agents to treat, 2314  
mutational analysis in, 2703, 2704
  - Chronic widespread pain, cytokines in, 2656
  - Chugai Humanized Anti-Human Recombinant Interleukin-6 Monoclonal Antibody study, clinical trial of tocilizumab in RA patients with incomplete MTX response, 2817
  - Circulating endothelial precursors  
increase in by atorvastatin in SSc, 1946  
prevention and repair of vascular damage in SSc, 1730
  - Citrullinated proteins, associated with synovial exosomes in RA, 3809
  - Classification  
AS, inflammatory back pain, 569  
of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 593  
PsA, classification criteria for, 2665
  - Clinical images**
    - amyloidosis, bilateral black eyes in, 3724
    - AS, DISH coexisting with ossification of posterior longitudinal ligament of cervical spine, 2242
    - dysphagia due to osteophytes, 507
    - GCA, PET imaging, 1710
    - gout, corneal tophus deposition in, 1025
    - gouty tophus of the ankle, 2706
    - inflammatory arthritis, skin hyperpigmentation over inflamed joints, 2604
    - intersection syndrome of the forearm, 2038
    - Parsonage-Turner syndrome, scapular winging, 4027
    - pigmented villonodular synovitis of the knee, 3422  - Clinical images (*cont'd*)**
    - pyomyositis of lower limbs, 2030
    - RA, comet cells in, 243
    - RA, mutilans-type, 1352
    - SLE, B cell depletion in the appendix following rituximab treatment, 2151
    - SLE, iliopsoas bursitis of the hip with, 1686
    - Takayasu arteritis presenting with subclavian aneurysm, 382
    - WG, hidden chest lesions in, 3059
    - Clinical trials, new regulatory rules for clinical trials in US and European Union, 3735**
    - Cognitive dysfunction, anti-NR2 antibodies, and depression in SLE patients, 2505, 2515**
    - Collagen**
      - antigen processing of human type II collagen in mouse model, 482
      - anti-type II collagen-containing immune complexes in arthritis, 1759
      - collagen and proteoglycan turnover in focally damaged ankle cartilage, 244
      - OA-like changes in type IX collagen-deficient mice, 2891
      - simvastatin, inhibition of type I collagen production and gene expression in SSc by, 1298
      - SSc, CCL18/PARC-mediated lung injury, mouse study, 2643
      - SSc, enhanced type I collagen expression and epigenetic repression of *FLII* gene in, 2271
      - SSc, myofibroblasts and hyalinized collagen as markers of skin disease in, 3655
      - SSc, SPARC silencing in, 2626    - Collagen degradation**
      - around loosened total hip replacement implants, 2928
      - estrogen therapy and type II collagen degradation in rats, 2441
      - IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267    - Collagen-induced arthritis**
      - BiP treatment via IL-4+ regulatory T cells, 854
      - CTX-II as an early marker of, rodent study, 2886
      - effects of novel tylophorine analog on, 877
      - suppression of by CD11c+, CD11b+ dendritic cells, 887
      - treatment with camelid anti-TNF VH<sub>3</sub> proteins, mouse study, 1856
      - vasoactive intestinal peptide induces T regulatory cells with therapeutic effect in, 864    - Collagenolysis, MMP-10 promotion of via procollagenase activation, 3244**
    - Combination therapy**
      - chloroquine, mechanism of acquired resistance to, 557
      - JIA, ACR and EULAR criteria comparison of treatment with MTX and/or anti-TNF $\alpha$  agents, 1602
      - PsA, alefacept in combination with MTX to treat, 1638
      - RA, abatacept safety in RA patients receiving DMARDs, 2807
      - RA, adalimumab plus MTX treatment of, PREMIER study, 26
      - RA, anticardiolipin antibodies in patients with early RA treated with infliximab plus MTX, 2840
      - RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54
      - RA, combination rituximab plus MTX for anti-TNF refractory disease, 2793
      - RA, comparison of etanercept and MTX alone and combined, results of TEMPO study, 1063, 3061
      - RA, comparison of infliximab or etanercept monotherapy vs. co-therapy with another DMARD, 1786
      - RA, delaying addition of infliximab to ongoing MTX therapy in patients with early disease, 47, 1028
      - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
      - RA, doxycycline plus MTX vs. MTX alone for early seropositive RA, 621
      - RA, efficacy of, 2032, 2034
      - RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790

- Combination therapy (cont'd)**
- RA, infliximab safety in RA with comorbidities alone and with MTX, 1075
  - RA, MTX plus cyclosporine plus intraarticular betamethasone compared with MTX and intraarticular betamethasone in early disease, 1401
  - RA, predictors of joint damage with early RA treated with high-dose MTX with or without concomitant infliximab, 702
  - RA, rituximab efficacy and safety despite MTX treatment, 1390
  - RA, tocilizumab in RA patients with incomplete MTX response, CHARISMA study, 2817
- Comorbidity**
- RA, excess mortality in RA and, 60
  - RA, infliximab safety in RA with comorbidities, 1075
  - Raynaud's phenomenon, transition from primary to secondary disease, 1974
- Complement system, RA, classical complement pathway activation in,** 1143
- Complementary and alternative medicine**
- OA, acupuncture treatment for hip and knee OA, 3375, 3485
  - OA, glucosamine sulfate, long-term symptom-modifying effect of, 2338, 2340
  - turmeric supplements in treatment of experimental arthritis, 3452
- Complementary DNA microarray**
- anti-DNA antibodies, regulation of gene expression in mouse glomerular mesangial cells by, 2198
  - Jab1 binds Smad5 and inhibits bone morphogenetic protein signaling, 3878
  - pigmented villonodular synovitis, gene expression profile analysis by, 1009
- RA, gene identification in disease-discordant monozygotic twins,** 2047
- STAT-3-dependent IL-6 trans-signaling, regulation of pre-B cell colony-enhancing factor by,** 2084
- Computed tomography (CT), WG, hidden chest lesions in,** 3059
- Computers, automated computer-based scoring method for joint space narrowing in RA,** 1444
- Congenital heart block, TGF $\beta$ 1 in pathogenesis of autoimmune congenital heart block,** 356
- Congestive heart failure, excess mortality in RA and,** 60
- Connective tissue disorders**
- IFI16* in, 3939
  - joint hypermobility syndrome and vascular Ehlers-Danlos syndrome in Chilean population, 515
- Connective tissue growth factor**
- OA, effects of connective tissue growth factor and CCN2 overexpression on fibrosis and cartilage damage, 1653
  - RA, thrombospondin 1 modulates erosive arthritis by regulating, 2415
  - regulatory effects of in response to TGF $\beta$  stimulation, 3885
  - secretion by notochord cells, 3859
- Connective tissue mast cells, synovial mast cell phenotype, mouse study,** 2863
- Coronary artery disease. See Cardiovascular disease**
- Corticosteroids**
- endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198
  - for GCA, 3071
  - intrarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463
  - RA treatment and risk of pneumonia, 628
  - SLE, moderate-dose steroids and disease flare, 3623
  - SSc, corticosteroids and cyclophosphamide followed by azathioprine treatment for pulmonary fibrosis, 3962
- Cortisol**
- FM, cortisol secretion and symptoms in, 2345, 2346
- Cortisol (cont'd)**
- RA, psychological stress exacerbates RA via hormones and nerve fibers, 682
  - Cost assessment, FM, impact of diagnosis on health care resource use by UK patients, 177
  - Coxsackievirus, SS, failure to confirm infection in primary SS, 2026
  - C-propeptide of type II collagen (CTX-II) collagen-induced arthritis, CTX-II as an early marker of, rodent study, 2886
  - OA, diurnal variation of biomarkers in knee OA, 2496
  - C-reactive protein, single injection treatment of murine lupus nephritis, 325
  - Crescentic glomerulonephritis, prevented by dendritic cell inhibitor NK026680, mouse study, 3707
  - Criteria**
    - AS, inflammatory back pain, 569
    - fibromyalgia, ACR diagnosis, 169
    - JIA, ACR and DAS criteria comparison, 1602
    - PsA, classification criteria for, 2665
    - renal disease criteria for SLE clinical trials, 421  - CS846, OA, diurnal variation of biomarkers in knee OA, 2496
  - C-telopeptides, collagen-induced arthritis, CTX-II as an early marker of, rodent study, 2886
  - CTLA4 gene, haplotypes and susceptibility and extraglandular manifestations in primary SS,** 2434
  - CTLA-4 Ig, RA, CTLA-4 Ig suppression of RA synovial T cell oxidative stress, 3135
  - Cutaneous lupus erythematosus, UV-induced apoptotic cell accumulation in, 939, 3375
  - Cutaneous SSc, differentiated from limited cutaneous SSc, 3939
  - CX<sub>3</sub>CL1, fractalkine serum level correlates with disease activity in rheumatoid vasculitis,** 3408
  - CXCL10, inducible protein 10/CXCL10 antagonist and autoimmune sialadenitis in mice,** 1174
  - CXCL16, RA, expression and function of CXCL16 in human RA synovial tissue-SCID mouse chimera,** 765
  - CXCR4, differential expression in skin and endothelial cells in SSc,** 3022
  - Cyclic-dependent kinase 4/6, modulation of mediators of inflammation in RA, 2074
  - Cyclooxygenase-2 (COX-2) inhibitors**
    - cardiovascular outcomes in new users of, 1378
    - COX-2 inhibition by diclofenac vs. celecoxib and rofecoxib, 282
    - gastrointestinal and cardiovascular safety of, 3390  - Cyclophosphamide**
    - lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633
    - SSc, corticosteroids and cyclophosphamide followed by azathioprine treatment for pulmonary fibrosis in, 3962
    - SSc, pulmonary arterial hypertension is major mortality factor in diffuse, 184  - Cyclosporine**
    - RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790
    - RA, MTX plus cyclosporine plus intraarticular betamethasone compared with MTX and intraarticular betamethasone in early disease, 1401  - Cytokines**
    - Chlamydia*-induced arthritis in rats, host-microbe interactions in, 499
    - in chronic widespread pain, 2656
    - in Erdheim-Chester disease, 4018
    - IK cytokine in treatment of lupus nephritis in mice, 3591
    - inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with adeno-associated virus, 2119
    - peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates IL-1R $\alpha$  production in cytokine-treated chondrocytes, 1233

### Cytokines (cont'd)

- RA, IL-20 as proinflammatory molecule in, 2722
- RA, synovial cytokine expression and joint damage progression, 1122
- reduction of proinflammatory cytokine expression by targeting IKK $\beta$  in synovium in rat model, 3716
- soluble RAGE triggers proinflammatory cytokine cascade via  $\beta$ 2 integrin Mac-1, 3898
- SS, high mobility group box chromosomal protein 1 in salivary glands, 2289
- suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518

### D

#### DCB-3503

- effect of on collagen-induced arthritis, 877
- effect of on skin disease in murine SLE, 3277
- Deafness, Muckle-Wells syndrome, improvement after anakinra treatment, 1697
- Death receptor 3 gene, RA, hypermethylated *DR3* promoter in, 779
- Dehydroepiandrosterone (DHEA), steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890
- Dendritic cell inhibitors, NK026680 prevents crescentic glomerulonephritis, mouse study, 3707
- Dendritic cells
  - collagen-induced arthritis, suppression of by CD11c+,CD11b+ dendritic cells, 887
  - function in RA associated with CD32B (Fc $\gamma$  receptor IIb variant), 3828
  - mammalian DNA induction of type I IFN-associated dendritic cell maturation, 951
- Deposition disorders, glycan analysis of monoclonal antibodies in, IgG glycans processed differentially, 3433
- Depression, anti-NR2 antibodies and in SLE patients, 2505
- Dermal fibrosis
  - adenosine A<sub>2A</sub> receptors in diffuse dermal fibrosis, 2632
  - SSc, insulin-like growth factor binding protein 5 induced skin fibrosis, mouse study, 3001
- Dermatomyositis (DM)
  - anti-p155 autoantibody associated with, 3682
  - anti-PL-7 in milder muscle disease in Japanese patients with PM/DM, 2004
  - juvenile, composition of calcifications in, 3345
  - juvenile, immunogenetic risk and protective factors for in Caucasians, 3979
- Desensitization, suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518
- Dexamethasone
  - endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198
  - intrarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463
- Diclofenac
  - accelerated progression of hip and knee radiographic OA and, 1027
  - cardiovascular outcomes in new users of, 1378
  - COX-2 inhibition by diclofenac vs. celecoxib and rofecoxib, 282
  - gastrointestinal and cardiovascular safety of, 3390
- Dietary supplements
  - glucosamine sulfate, long-term symptom-modifying effect of in OA, 2338, 2340
  - turmeric supplements in treatment of experimental arthritis, 3452
- Diffuse idiopathic skeletal hyperostosis (DISH), clinical and radiologic manifestations, in the Azores, 1340
- Diffuse large B cell lymphomas, in RA, 3774
- Diffuse systemic sclerosis (SSc), pulmonary arterial hypertension independent of interstitial lung disease in survival, 184

### Disability

- projections of US arthritis prevalence and associated activity limitations, 226
- RA, changes in HAQ scores over 5 years, 3113
- RA, measuring function in, identifying reversible and irreversible, 2784
- RA, radiographic damage associated with impaired physical function, 68
- Disc space narrowing, as risk factor for vertebral fracture, 1262
- Disease activity
  - FM, cortisol secretion and symptoms in, 2345, 2346
  - JIA, predictors of disease course and remission in systemic, 1595
  - JRA, RANTES and monocyte chemoattractant protein 1 as markers of disease activity in, 2585
  - lupus nephritis, IFN-inducible gene expression in, 2951
  - pediatric SLE, effects of disease activity and therapy on lipid profile in, 1283
  - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
  - RA, radiographic damage associated with impaired physical function, 68
  - RA, serum fetal DNA and disease activity during pregnancy, 2069
  - rheumatoid vasculitis, fractalkine serum level correlates with disease activity, 3408
  - SLE, blood concentrations of hydroxychloroquine and SLE disease activity, 3284
  - SLE, features, course, and outcome of late-onset, 1580
  - SLE, homocysteine levels and SLE duration and coronary artery calcification, 2220
  - SLE, rapamycin treatment, 2983
  - SLE, revised BILAG-2004 index, 3300
- Disease flare
  - lupus nephritis, self-perceived stress and increased risk of flare in patients carrying the serotonin receptor 1A-1019 G allele, 3291
  - SLE, blood concentrations of hydroxychloroquine and SLE disease activity, 3284
  - SLE, moderate-dose steroids and disease flare, 3623
- Disease-modifying antirheumatic drugs (DMARDs). See also Antitumor necrosis factor (anti-TNF); Methotrexate
  - antibiotic-refractory Lyme arthritis, strategies for treatment of, 3079
  - chloroquine, mechanism of acquired resistance to, 557
  - LUNDEX, index of drug efficacy in clinical practice, 600
  - RA, anti-TNF use and cancer, 2757
  - RA, comparison of infliximab or etanercept monotherapy vs. cotherapy with another DMARD, 1786
  - RA, efficacy of combination therapy, 2032, 2034
  - RA, leflunomide use and risk of interstitial lung disease, 1435
  - RA, safety of abatacept in RA patients receiving DMARDs, 2807
  - RA, synovitis in RA patients with DMARD-induced remission, 3761
  - RA treatment and risk of pneumonia, 628
- Disease progression
  - OA, risedronate in medial compartment knee OA, 3494
  - platelet function in development of crescentic glomerulonephritis, mouse study, 2934
  - RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54
  - RA, changes in HAQ scores over 5 years, 3113
  - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
  - RA, ratio of osteoprotegerin to RANKL in early RA predicts later joint destruction, 1772
  - RA, synovial cytokine expression and joint damage progression, 1122
  - RA, TNFA polymorphism association with increased progression in seropositive RA, 1105
  - SLE, blood concentrations of hydroxychloroquine and SLE disease activity, 3284

- Disease severity**
- Chlamydia*-induced arthritis in rats, host-microbe interactions in, 499
  - RA, atherosclerosis in and relation to disease severity and extraarticular manifestations, 1353
  - RA, disease phenotype in familial RA and gender, 3087
  - Distal interphalangeal joint (DIP), MRI of joint arthropathy in PsA and OA, 1328
  - DNA**
    - autoinflammatory disease, *PYPAFI* nonsense mutation in, 508
    - mammalian DNA induction of type I IFN-associated dendritic cell maturation, 951
    - RA, serum fetal DNA and disease activity during pregnancy, 2069
    - DNA pooling, OA, association between a variation in *LRCH1* and knee OA, 524
  - Double-stranded DNA (dsDNA), mediation of double-stranded RNA-mediated arthritis by type I IFN, 148
  - Doxycycline**
    - OA, clinical trial of use in knee OA, 684
    - RA, doxycycline plus MTX vs. MTX alone for early seropositive RA, 621
  - DR3* gene, RA, hypermethylated *DR3* promoter in, 779
  - Drug efficacy**, LUNDEX, index of drug efficacy in clinical practice, 600
  - Drug resistance, chloroquine, mechanism of acquired resistance to, 557
  - Drugs. See names of individual drugs**
  - Drug safety**
    - gastrointestinal and cardiovascular safety of COX-2 inhibitors and NSAIDs, 3390
    - JRA, etanercept safety and efficacy in children with polyarticular-course, 1987
    - RA, infliximab safety in RA with comorbidities alone and with MTX, 1075
    - RA, rituximab safety and efficacy despite MTX treatment, 1390
  - Drug therapy. See also individual drugs and classes of drugs**
    - MTX pharmacogenetics, 1366
    - targeting the inflamed synovium, 1055
  - Duffy antigen, temporal expression pattern of in RA, 2022
- E**
- Echocardiography, for diagnosis of pulmonary arterial hypertension in SSc, 380
  - Ectopic calcification, DISH and chondrocalcinosis in Azores families, clinical and radiographic manifestations, 1340
  - Ehlers-Danlos syndrome, clinical study of vascular, 515
  - Elderly. *See* Older adults
  - Employment. *See* Work
  - Endogenous adjuvants, SLE, RNA components of autoantigens as, 1557
  - Endothelial cells**
    - activated by mouse monoclonal anti-human thrombomodulin antibodies, 1629
    - adjuvant-induced arthritis, endothelial dysfunction in, rat study, 1847
    - endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198
    - serine protease-mediated endothelial cell damage, 1619
    - SSc, differential expression in skin and endothelial cells of stromal cell-derived factor 1 and its receptor CXCR4, 3022
    - SSc, failed urokinase-type plasminogen activator receptor-integrin association in with SSc human microvascular endothelial cells, 3926
    - SSc, serum induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells, 2250
  - Endothelial progenitor cells, SSc, defective bone marrow endothelial progenitors in, 2605
  - Endothelin 1**, signaling pathways regulating ICAM-1 expression by, 649
  - Endothelin genes, SSc, endothelin axis polymorphisms in, 3034
  - Endothelium, RA, SNP in promoter of gene for endothelial nitric oxide synthase, 3144
  - Enthesitis-related arthritis, outcome and prognostic factors, 3573
  - Environmental issues, RA, new model for etiology involving smoking, 38
  - Environmental toxins, SLE, occupational exposure to silica and solvent and risk of SLE in urban women, 3648
  - Epidemiology, projections of US arthritis prevalence and associated activity limitations, 226
  - Epigallocatechin-3-gallate, role in chemokine production and MMP-2 activation in RA synovial fibroblasts, 2393
  - Epigenetic mediators, SSc, enhanced type I collagen expression and epigenetic repression of *FLII* gene in, 2271
  - Epitopes**
    - accumulation of intracellular ITEGE and DIPEN neopeptides in chondrocytes mediated by CD44 internalization of hyaluronan, 443, 1028
    - T cell epitope-specific immune therapy for rheumatic diseases, 19
    - Epstein-Barr nuclear antigen 1 pediatric SLE, anti-Epstein-Barr nuclear antigen 1 antibodies in, 360
    - RA, as target of ACPAs in, 733
  - Erdheim-Chester disease
    - cytokine and chemokine network in, 4018
    - variability in IFN $\alpha$  in, 3330
  - Erosive arthritis**
    - IL4R* single-nucleotide polymorphism 150V associated with rapidly erosive RA, 1491
    - polyreactive pathogenic autoantibodies in BXD2 mice cause glomerulonephritis and, 343
    - thrombospondin 1 modulates erosive arthritis by, 2415
  - Errata, 354, 1028, 2009, 2320, 2702
  - Estradiol**
    - knee OA and, 2481
    - steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890
  - Estrogen**
    - estradiol and metabolites associated with knee OA, 2481
    - Type II collagen degradation in rats and, 2441
  - Estrogen replacement therapy, effect of on risk of hip and knee joint replacement, 3194
  - Etanercept**
    - JRA, etanercept safety and efficacy in children with polyarticular-course, 1987
    - LUNDEX, index of drug efficacy in clinical practice, 600
    - pregnancy outcome following anti-TNF therapy, 2701
    - RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54
    - RA, comparison of etanercept and MTX alone and combined, two-year results of TEMPO study, 1063, 3061
    - RA, comparison of infliximab or etanercept monotherapy vs. cotherapy with another DMARD, 1786
    - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
    - RA, effectiveness of, 3399
    - WG, solid malignancies among etanercept-treated WG patients, 1608
  - Ethnicity, lupus nephritis, prevalence and incidence of biopsy-proven lupus nephritis in the UK, 2963
  - European Union, new regulatory rules for clinical trials in, 3735
  - Exercise**
    - in chronic fatigue syndrome, 3351
    - heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women with FM, 1334

Exosomes, citrullinated proteins associated with synovial exosomes, 3809  
Experimental arthritis  
Bim deficiency and exacerbation and prolongation of joint inflammation in, 3182  
cationic liposome formulation for delivery of small interfering RNA silencing TNF $\alpha$  in, 1867  
disease-modifying role of caspase inhibitors in experimental OA, 1814  
endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198  
high-resolution multipinhole SPECT in experimental arthritis and humans, 1096  
IL-20 as proinflammatory molecule in, 2722  
turmeric supplements as treatment of, 3452  
Eyes  
bilateral black eyes in AL amyloidosis, 3724  
corneal tophus deposition in gout, 1025

## F

Family studies  
DISH and chondrocalcinosis in Azores families, 1340  
OA, Frizzled-related protein variants as risk factors for hip OA, 1246  
*PTPN22* R620W polymorphism in familial and sporadic SLE, 2533  
Fas  
signaling by in RA fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473  
sphingosine kinase 1-mediated inhibition of Fas death signaling in RA B lymphoblastoid cells, 754  
Fat tissue aspiration, diagnostic accuracy of for detection of systemic amyloidosis, 2015  
Fatigue, FM, heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women with FM, 1334  
*FCGR2B* gene  
Fc $\gamma$  receptor II transmembrane polymorphism associated with SLE in Taiwanese patients, 3908

Fibroblasts (*cont'd*)  
differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts, 2096  
*MMP-10* promotion of collagenolysis via procollagenase activation, 3244  
in periprosthetic osteolysis, 3221  
RA, epigallocatechin-3-gallate role in chemokine production and MMP-2 activation in synovial fibroblasts, 2393  
regulatory effects of SPARC and connective tissue growth factor, 3885  
signaling pathways regulating ICAM-1 expression by endothelin 1, 649  
SSc, DNA topoisomerase I binding to fibroblasts, 963  
SSc, gene profiling shows robust signatures of disease imperfectly reflected in transcript profiles of explanted fibroblasts, 1961  
SSc, profibrotic effects of monocyte chemoattractant protein 1 in, 214  
SSc, SPARC silencing in, 2626  
Fibromyalgia (FM)  
cortisol secretion and symptoms in, 2345, 2346  
cytokines in patients with chronic widespread pain, 2656  
diagnostic criteria for, 169  
exercise responses in, 3351  
genetic influences on chronic widespread pain, 1682  
heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women, 1334  
impact of diagnosis on health care resource use by UK patients, 177  
reduced brain habituation to somatosensory stimulation in, 1995  
transcranial direct current stimulation for, 3725, 3988  
Fibronectin, neocitopops in OA cartilage, 2912  
Fibrosis  
diffuse dermal fibrosis, adenosine A<sub>2A</sub> receptors, 2632  
OA, effects of connective tissue growth factor and CCN2 overexpression on fibrosis and cartilage damage, 1653  
SSc, activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309  
SSc, insulin-like growth factor binding protein 5 induced skin fibrosis, mouse model, 3001  
Fibrous synovium, properties of human synovial mesenchymal stem cells, 843  
Fingers. *See also* Hand  
RA, automated computer-based scoring method for joint space narrowing, 1444  
RA, joint space width in, 1440  
SSc, abnormal microvascular response localized to digits in, 1952  
Finnish Rheumatoid Arthritis Combination (FIN-RACo), efficacy of RA combination therapy, 2032, 2034  
Fitness, in chronic fatigue syndrome, 3351  
*FLII* gene, SSc, enhanced type I collagen expression and epigenetic repression of *FLII* gene in, 2271  
FLIP, Fas signaling in RA fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473  
Fluvastatin, statin-induced apoptosis in RA synovial cells, 579  
Folic acid, RA, folic acid supplementation and MTX efficacy, 1708, 1709  
Follicular colonization, dissemination of an SS-associated extranodal marginal-zone B cell lymphoma, 127  
Food and Drug Administration, centennial of, 3374  
Forestier-Rotes Querol's disease. *See* Diffuse idiopathic skeletal hyperostosis (DISH)  
Fractalkine, serum level correlates with disease activity in rheumatoid vasculitis, 3408  
Fractures  
disc space narrowing and risk of vertebral fracture, 1262  
RA, long-term fracture risk in, 3104  
SSc, low bone density and vertebral fractures in, 378, 379

- Fractures (cont'd)**
- steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890
- Frizzled-related protein, variants as risk factors for hip OA**, 1246
- FRZB gene, variants in FRZB in hip OA**, 1246
- Functional capacity, SLE, obesity and functional capacity and inflammation**, 1705, 1706
- Functional disability**
- Australian/Canadian Osteoarthritis Hand Index, validity, factor structure, and clinical relevance of, 551
  - RA, changes in HAQ scores over 5 years, 3113
  - RA, measuring function in, identifying reversible and irreversible, 2784
- G**
- Gait analysis**
- OA, differs in mild compared with moderate medial knee, 3842
  - OA, walking barefoot decreases loading on lower extremity joints in knee, 2923
- Gastrointestinal safety, of COX-2 inhibitors and NSAIDs**, 3390
- Gender, disease phenotype in familial RA and**, 3087
- Gene array analysis, SSC, TGF $\beta$  receptor and up-regulation of matrix gene program**, 3011
- Gene expression profiles**
- anti-DNA antibodies, regulation of gene expression in mouse glomerular mesangial cells by, 2198
  - in human Achilles tendon, 832
  - lupus nephritis, IFN-inducible gene expression in, 2951
  - OA, gene expression in intact and damaged OA cartilage, 808
  - OA, pathogenetic pathways of cartilage degeneration in, 3533
  - in pigmented villonodular synovitis, 1009
  - RA, gene identification in disease-discordant monozygotic twins, 2047
  - RA, IL-10-dependent gene expression in RA synovial macrophages, 2711
  - SLE, association of IFN $\alpha$  with anti-RNA binding protein autoantibodies in, 1906
  - SSc, inhibition of type I collagen production and gene expression in human Achilles tendon, 832
  - lupus nephritis, IFN-inducible gene expression in, 2951
  - OA, gene expression in intact and damaged cartilage, 808
  - OA, pathogenetic pathways of cartilage degeneration in, 3533
  - in pigmented villonodular synovitis, 1009
  - RA, gene identification in disease-discordant monozygotic twins, 2047
  - RA, IL-10-dependent gene expression in synovial macrophages, 2711
  - SLE, association of IFN $\alpha$  with anti-RNA binding protein autoantibodies in, 1906
  - SSc, inhibition of type I collagen production and gene expression by simvastatin, 1298
- Gene therapy**
- adjuvant-induced arthritis, angiostatic effects of IL-4 gene therapy in rats, 2402
  - for arthritis, 1714
- Gene transfer**
- CCL18/PARC-mediated lung injury, mouse study, 2643
  - inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with, 2119
- Genetics. See also Family studies; Gene therapy; Mutations; Polymorphism**
- accumulation of intracellular ITEGE and DIPEN neoepitopes in chondrocytes mediated by CD44 internalization of hyaluronan, 443, 1028
  - anti-DNA antibodies, regulation of gene expression in mouse glomerular mesangial cells by, 2198
  - AS, association of IL1 gene cluster with susceptibility, 974
  - Genetics. See also Family studies; Gene therapy; Mutations; Polymorphism (cont'd)
  - AS, B27 subtypes and tapasin dependence, 138
  - association studies, features of high-quality studies, 1051, 3063, 3064
  - autoinflammatory disease, PYPAF1 nonsense mutation in, 508
  - $\beta_2$ -microglobulin in HLA-B27-transgenic rats, 1317
  - cartilage oligomeric matrix protein, heritable determinants of, 2147
  - chondrogenesis of mesenchymal stem cells, mouse study, 3254
  - crescentic glomerulonephritis, platelet function in development of, mouse study, 2934
  - cytokines in chronic widespread pain, 2656
  - DISH and chondrocalcinosis in Azores families, clinical and radiographic manifestations, 1340
  - enthesitis-related arthritis, outcome and prognostic factors, 3573
  - FM, genetic influences on chronic widespread pain, 1682
  - GCA, IL-10 promoter gene polymorphisms in, 4011
  - heart block, TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block, 356
  - HLA-DRB1 shared epitope as risk factor for predisposition to anti-CCP and not RA, 1117
  - human Achilles tendon, gene expression profiling, 832
  - hURAT1 gene, reduced renal uric acid excretion and hyperuricemia, 292
  - IFI16 in connective tissue disorders, 3939
  - intermittent hydrarthrosis, MEFV gene mutations and, 2334
  - juvenile DM, immunogenetic risk and protective factors for in Caucasians, 3979
  - Kawasaki disease, angiogenic genes and, 1361
  - Kawasaki disease, polymorphism in mannose-binding lectin gene and risk of coronary artery lesions of, 369
  - Kawasaki disease, VEGF gene haplotypes in, 1588
  - lupus-like disease and high IFN levels corresponding to trisomy of type I IFN cluster on chromosome 9p, 1573
  - lupus nephritis, IFN-inducible gene expression in, 2951
  - lupus nephritis, self-perceived stress and increased risk of flare in patients carrying serotonin receptor 1A-1019 G allele, 3291
  - microscopic polyangiitis and killer cell immunoglobulin-like receptors, 992
  - MTX pharmacogenetics, 1366
  - multiple gene up-regulation by IL-1 plus oncostatin M, 540
  - neonatal-onset multisystem inflammatory disease, mutational analysis in, 2703, 2704
  - neutrophile from TNFRSF1A mutations display resistance to TNF-induced apoptosis, 998
  - OA, association between a variation in LRCH1 and knee OA, 524
  - OA, cartilage oligomeric matrix protein, 2147
  - OA, effects of CCN2 overexpression on fibrosis and cartilage damage, 1653
  - OA, fibronectin neoepitopes in cartilage, 2912
  - OA, Frizzled-related protein variants as risk factors for hip OA, 1246
  - OA, gene expression profiles in intact and damaged cartilage, 808
  - OA, gene expression profiling for pathogenetic pathways of cartilage degeneration in, 3533
  - OA, genetic associations with clinical knee OA in women and men, 533
  - OA, IL1B associated with hip OA, 3722
  - OA, susceptibility locus for hip OA on chromosome 6, 1026
  - pediatric granulomatous arthritis, international registry, 3337
  - pigmented villonodular synovitis, gene expression profile in, 1009
  - PsA, interleukin-1 family gene cluster and, 2321
  - PsA, lack of association of IL-4 receptor SNPs with erosive disease in, 4023
  - RA, association of the IL4R SNP 150V with rapidly erosive disease, 1491
  - RA, classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 593

**Genetics.** See also Family studies; Gene therapy; Mutations; Polymorphism (*cont'd*)  
 RA, cyclin-dependent kinase 4/6 modulation of mediators of inflammation in, 2074  
 RA, disease phenotype in familial RA and sex, 3087  
 RA, *FCRL3* polymorphism and in Canadian population, 3820  
 RA, *FCRL3* SNP not associated with in white North Americans, 1022  
 RA, folate-dependent risk genotypes and MTX effects in, 607  
 RA, gene identification in disease-discordant monozygotic twins, 2047  
 RA, HLA-C3 and smoking associated with vasculitis in, 2776  
 RA, HLA-linked odorant receptor gene polymorphisms and, 2705  
 RA, hypermethylated *DR3* promoter in, 779  
 RA, IL-10-dependent gene expression in synovial macrophages, 2711  
 RA, *IRF5* gene functional polymorphisms in, 3815  
 RA, joint damage and dendritic cell function in RA associated with *FCGR2B* variant, 3828  
 RA, linkage analysis of families in US and UK, 1483  
 RA, *MHC2TA* gene association with in Swedish and UK cohort, 3417  
 RA, MTX efficacy and toxicity in early disease associated with SNPs in genes coding for folate pathway enzymes, 1087, 3372  
 RA, MTX treatment outcome and genetic variants in adenosine pathway in recent-onset disease, 2830  
 RA, *PADI4* gene associated with susceptibility in Korean population, 90  
 RA, pharmacogenomic and metabolic biomarkers to monitor MTX effects, 3095  
 RA, PTPN22\*620W and humoral immunity to type II collagen in early disease, 82  
 RA, SNP in promoter of gene for endothelial NOS, 3144  
 RA, TGF $\beta$ -inducible gene h3 in, 2734  
 RA, *TNFA* polymorphism association with increased progression in seropositive RA, 1105  
 RA, triggering of HLA-DR shared epitope genes by smoking and RA etiology, 38  
 RA and SLE, *FCRL3* polymorphism and in Korean population, 3838  
 simvastatin, inhibition of type I collagen production and gene expression in SSc by, 1298  
 SLE, association of IFN $\alpha$  with anti-RNA binding protein autoantibodies in, 1906  
 SLE, Fc $\gamma$  receptor II transmembrane polymorphism associated with in Taiwanese patients, 3908  
 SLE, mannose-binding lectin exon 1 polymorphisms and disease course and outcome, 1703  
 SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940  
 SLE, paraoxinase 1 activity, PON1 genotype, and disease risk, 1928  
 SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270  
 SLE, PTPN22 R620W polymorphism in familial and sporadic SLE, 2533  
 SLE, Toll-like receptor 9 genetic variation and susceptibility to, 1279  
 SLE, type I IFN system in, 408  
 SS, *CTLA4* haplotypes and susceptibility and extraglandular manifestations in primary SS, 2434  
 SS, dissemination of SS-associated extranodal marginal-zone B cell lymphoma, 127  
 SS, STAT-1 $\alpha$  in labial salivary glands, 3476  
 SSc, activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309  
 SSc, endothelin axis polymorphisms in, 3034  
 SSc, epigenetic repression of *FLII* gene in, 2271  
 SSc, hemorheologic profile and *NOS3* polymorphisms in, 2263

**Genetics.** See also Family studies; Gene therapy; Mutations; Polymorphism (*cont'd*)

SSc, macrophage migration inhibitory factor promoter polymorphisms and clinical expression of, 3661  
 SSc, *PTPN22* polymorphism association with anti-topoisomerase I- and anticitromere antibody-positive SSc, 3945  
 SSc, TGF $\beta$  receptor and up-regulation of matrix gene program, 3011  
 SSc, transcript profiles of explanted fibroblasts, 1961  
 TRAPS, *TNFRSF1A* mutations in, 998, 2674  
**Geranylgeranylation**  
 apoptosis of rheumatoid synoviocytes by statins through blocking of, 579  
 in IL-1 $\beta$  secretion in mevalonate kinase deficiency, 3690  
**German population, human urate transporter 1 associated with hyperuricemia in,** 292  
**Giant cell arteritis (GCA)**  
 antiplatelet and anticoagulant therapy in, 3306  
 IL-10 promoter gene polymorphisms in, 4011  
 induction therapy with high-dose glucocorticoids, 3310  
 PET imaging, 1710  
 therapy for, 3071  
**Glomerulonephritis**  
 $\alpha$ -actinin-binding anti-dsDNA antibodies and lupus nephritis, 2523  
 anti-P antibodies in lupus glomerulonephritis, 1568, 4025, 4026  
 dendritic cell inhibitor NK026680 prevents crescentic glomerulonephritis, mouse study, 3707  
 platelet function in development of crescentic glomerulonephritis, mouse study, 2934  
 polyreactive pathogenic autoantibodies in BXD2 mice cause glomerulonephritis and erosive arthritis, 343  
**Glucocorticoids**  
 GCA, induction therapy with high-dose glucocorticoids, 3310  
 RA, benefit of low-dose treatment in early disease may outweigh risk, 2031, 2032  
 RA, effect of on adrenal response in, 1415  
 RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790  
 Glucosamine sulfate, long-term symptom-modifying effect of, 2338, 2340  
 Glucose metabolism, insulin resistance and impaired beta cell function in RA, 2765  
 Glycans, differential processing of IgG glycans in deposition diseases, 3433  
 Glycoprotein I, anti- $\beta_2$ -glycoprotein I antibodies, platelet activation by via glycoprotein Ib-IX-V, 2558  
 Glycosylated CII epitope, antigen processing of human type II collagen in mouse model, 482  
**Gout**  
 acute myocardial infarction risk and, 2688  
 monosodium urate crystals and acute gouty arthritis, 383  
 rapid induction of TREM-1 in murine macrophages by monosodium urate monohydrate crystals, 455  
 Gouty tophus, of ankle, 2706  
 gp130 isoform, functional properties of soluble isoform in inflammatory arthritis, 1662  
 Graft-versus-host disease, allogeneic hematopoietic cell transplantation in severe SSc, 1982  
 Growth hormone, deficiency of and OA severity in rat knee joints, 3850  
 Guillain-Barré syndrome, with TNF $\alpha$  antagonist therapy, 1429

## H

**Hand.** See also Fingers  
 OA, validity, factor structure, and clinical relevance of AUSCAN Hand Index, 551  
 OA, vitamin K status and, 1255  
 PsA and OA, MRI study of DIP joint arthropathy in, 1328

- Hand.** *See also* Fingers (*cont'd*)  
 RA, automated computer-based scoring method for joint space narrowing, 1444  
 RA, joint space width in fingers, 1440  
 SSc, abnormal microvascular response localized to digits in, 1952  
**Health Assessment Questionnaire (HAQ), RA,** changes in HAQ scores over 5 years, 3113  
**Health care resource use, impact of FM diagnosis on resource use by UK patients,** 177  
**Heart block.** *See* Congenital heart block  
**Heart disease.** *See* Cardiovascular disease  
**Hematopoietic stem cell transplantation**  
 allogeneic hematopoietic cell transplantation with severe SSc, 1982  
 in autoimmune diseases, 3730, 3750  
**Heme oxygenase 1, regulatory role in RA inflammation,** 1132  
**Hemorheologic profile, SSc, NOS3 polymorphism and,** 2263  
**Hepatitis C, with RA, concomitant IFN $\alpha$  treatment and TNF $\alpha$  inhibition for,** 2335  
**Hepatitis C virus-associated mixed cryoglobulinemia vasculitis, antiviral therapy for,** 3696  
**Herbal remedies.** *See* Complementary and alternative medicine  
**Hereditary disorders.** *See also* Family studies; Genetics  
 joint hypermobility syndrome and vascular Ehlers-Danlos syndrome in Chilean population, 515  
**High-density lipoprotein, proinflammatory, as biomarker for atherosclerosis in SLE and RA,** 2541  
**High mobility group box chromosomal protein 1 and RAGE expression in RA macrophages,** 97  
 in salivary glands of SS patients, 2289  
**High-sensitivity C-reactive protein, diurnal variation of in knee OA,** 2496  
**Hip**  
 AS, immunohistochemical analysis of arthritis in, 1805  
 OA, acupuncture for, 3375, 3485  
 OA, diclofenac and accelerated progression of radiographic disease, 1027  
 OA, Frizzled-related protein variants as risk factors for, 1246  
 OA, IL1B associated with, 3722  
 OA, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236  
 OA, susceptibility locus on chromosome 6, 1026  
 OA, transdermal fentanyl for pain and improvement in functioning, 1829  
 SLE, iliopsoas bursitis with, 1686  
**Hip replacement**  
 BMI, effects of on later total hip arthroplasty for primary OA, 802  
 collagen degradation around loosened total hip replacement implants, 2928  
 hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194  
 predictors of, 3212  
**Histiocytosis**  
 Erdheim-Chester disease, cytokine and chemokine network in, 4018  
 Erdheim-Chester disease, variability in IFN $\alpha$  efficacy, 3330  
**HLA polymorphism, in African Americans with idiopathic inflammatory myopathy,** 3670  
**HLA-B27,  $\beta_2$ -microglobulin curbs misfolding and promotes arthritis and spondylitis in rats,** 1317  
**HLA-C3, and smoking associated with vasculitis in RA,** 2776  
**HLA-DR locus, RA, HLA-linked odorant receptor gene polymorphisms and,** 2705  
**HLA-DR shared epitope genes**  
 RA, PTPN22\*620W and humoral immunity to type II collagen in early disease, 82  
 RA, smoking and, 38  
**HLA-DRB1 alleles**  
 RA, activation of NO signaling by shared epitope, 3423  
**HLA-DRB1 alleles (*cont'd*)**  
 RA, classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 593  
 RA, linkage analysis of families in US and UK, 1483  
**HLA-DRB1 shared epitope**  
 anti-CCP, HLA-DRB1 shared epitope as risk factor for predisposition to anti-CCP and not RA, 1117  
 as risk factor for predisposition to anti-CCP and not RA, 1117  
**Homocysteine levels, disease duration and coronary artery calcification in SLE,** 2220  
**Hormone replacement therapy, effect of on risk of hip and knee joint replacement,** 3194  
**Hormones**  
 estrogen replacement therapy and risk of hip and knee joint replacement in women, 3194  
 OA, estradiol and metabolite association with knee OA, 2481  
 RA, anti-IL-6 receptor antibodies and androgen secretion, 1778  
 RA, effect of therapeutic glucocorticoids on adrenal response in, 1415  
 RA, psychological stress exacerbates RA via hormones and nerve fibers, 682  
 steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890  
**Hospitalization**  
 obstetric hospitalization in US for women with SLE and RA, 899  
 RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790  
 RA treatment and risk of pneumonia, 628  
**Host defense, Chlamydia-induced arthritis in rats, host-microbe interactions in,** 499  
 Hsp60, *Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583  
**Human dermal endothelial cells, SSc, serum induction of apoptosis and fibrillin 1 expression in,** 2250  
**Human growth factor, ratio to TGF $\beta$ 1 as predictor of cyclophosphamide response in lupus nephritis,** 3633  
**Human synovial fibroblasts. See** Fibroblasts  
**Human urate transporter 1, associated with hyperuricemia in German population,** 292  
**Humoral immunity, PTPN22\*620W and immunity to type II collagen in early RA,** 82  
**hURAT1 gene, reduced renal uric acid excretion and hyperuricemia and,** 292  
**Hyaluronan**  
 accumulation of intracellular ITEGE and DIPEN neoepitopes in chondrocytes mediated by CD44 internalization of, 443, 1028  
 OA, diurnal variation of biomarkers in knee OA, 2496  
 synovial molecular sieving of hyaluronan in rabbits, 1673  
**Hyaluronic acid, activation of cultured chondrocytes by vibration and,** 1897  
**Hydroxychloroquine**  
 chloroquine, mechanism of acquired resistance to, 557  
 RA, efficacy of combination therapy, 2032, 2034  
 SLE, blood concentrations of hydroxychloroquine and SLE disease activity, 3284  
 SLE, in lupus pregnancy, 3640  
**4-hydroxyphenol, and cartilage degradation in OA,** 271  
**Hyperimmunoglobulin D with periodic fever syndrome, AA amyloidosis as complication of,** 2010  
**Hyperostosis, AS, DISH coexisting with ossification of posterior longitudinal ligament of cervical spine,** 2242  
**Hyperpigmentation, over inflamed joints in inflammatory arthritis,** 2604  
**Hyperuricemia**  
 acute myocardial infarction, risk of and, 2688  
 human urate transporter 1 associated with in German population, 292  
**Hypoxia, and pH regulation in articular chondrocytes,** 3523

- Ibandronate**  
intravenous bisphosphonates in osteoporosis and jaw osteonecrosis, 3720, 3721  
intravenous injections in postmenopausal women with osteoporosis, 1838
- Ibuprofen**, cardiovascular outcomes in new users of, 1378
- Idiopathic inflammatory myopathy**  
brachio-cervical inflammatory myopathies, 1687  
HLA polymorphism in African Americans with, 3670
- Idiopathic pulmonary hypertension**, clinical differences from SSc-related hypertension, 3043
- IFI16**, in connective tissue disorders, 3939
- IgG**  
antimuscarinic antibodies and salivary fluid secretion in primary SS, 1165  
differential processing of glycans in deposition diseases, 3433
- IK cytokine**, in treatment of lupus nephritis in mice, 3591
- IKK $\beta$**   
Protection against bone and cartilage destruction in RA rat model, 3163  
reduction of proinflammatory cytokine expression by targeting IKK $\beta$  in synovium in rat model, 3716
- IL1 gene cluster**  
AS, association with susceptibility, 974  
OA of hip, association with, 3722  
PsA and, 2321
- IL4R gene**, RA, association of the IL4R SNP 150V with rapidly erosive RA, 1491
- IL-10 promoter gene**, polymorphisms in GCA, 4011
- Iliopsoas bursitis**, with SLE, 1686
- Imaging**  
AA amyloidosis as complication of hyperimmunoglobulinemia D with periodic fever syndrome, 2010  
AA amyloidosis as JIA complication, tocilizumab to treat, 2997  
activation of cultured chondrocytes by vibration and hyaluronic acid, 1897  
adjuvant-induced arthritis, angiostatic effects of IL-4 gene therapy in, 2402  
anti-DNA antibodies, regulation of gene expression in mouse glomerular mesangial cells by, 2198  
antigen-induced arthritis, Fc $\gamma$  receptor II regulates cartilage destruction but not bone destruction in, 3868  
antigen-induced arthritis, IL-6 in, 158  
apolipoprotein A-I in meniscal tissue, 3545  
arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice, 2423  
AS, immunohistochemical analysis of hip arthritis in, 1805  
AS, spinal symptoms reduced by adalimumab, 678  
AS, zygapophyseal joint immunohistologic analysis, 2845  
autoimmune sialadenitis and inducible protein 10/CXCL10 antagonist in mice, 1174  
 $\beta_2$ -microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis in rats, 1317  
bone morphogenetic protein 4 and muscle-derived stem cells for cartilage repair in rats, 433  
brachio-cervical inflammatory myopathies, 1687  
calcification-induced joint degeneration in guinea pig model, phosphate treatment of, 2452  
cartilage integration supported by steroid hormones in absence of IL-1 $\beta$ , 3890  
CD28 costimulation in arthritis induction in IL-1Ra-deficient mice, 473  
CD44, internalization of aggrecan G1 by, 443, 1028  
cellular events leading to chondrocyte death after cartilage impact injury, 1509

**Imaging (cont'd)**

- Chlamydia**-induced arthritis in rats, host-microbe interactions in, 499
- chondrogenesis of mesenchymal stem cells in vitro and in vivo, mouse study, 3254
- chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents, 2314
- collagen-induced arthritis, CTX-II as an early marker of, rodent study, 2886
- collagen-induced arthritis, effects of novel tylophorine analog DCB 3503 on, 877
- collagen-induced arthritis treated with camelid anti-TNF VH proteins, mouse study, 1856
- collagenolysis, MMP-10 promotion of via procollagenase activation, 3244
- crescentic glomerulonephritis, platelet function in development of, mouse study, 2934
- crescentic glomerulonephritis, prevented by dendritic cell inhibitor NK026680, mouse study, 3707
- cutaneous lupus erythematosus, UV-induced apoptotic cell accumulation in, 939, 3375
- DCB-3503 effects of, 877, 3277
- differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts, 2096
- DISH and chondrocalcinosis, clinical and radiographic manifestations, 1340
- endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198
- Erdheim-Chester disease, cytokine and chemokine network in, 4018
- Erdheim-Chester disease, variability in IFN $\alpha$  efficacy, 3330
- estrogen therapy and structural integrity of articular cartilage in rats, 2441
- fibroblasts and fibroblast-derived factors in periprosthetic osteolysis, 3221
- FM, reduced brain habituation to somatosensory stimulation in, 1995
- high-resolution multipinhole SPECT in experimental and human arthritis, 1096
- homeostatic proliferation-provoked arthritis, 492
- human synovial mesenchymal stem cell properties, 843
- idiopathic inflammatory myopathy, HLA associations in African Americans with, 3670
- IFI16** in connective tissue disorders, 3939
- IL-6** and impaired skeletal development, mouse study, 3551
- induction of chondrocytic differentiation of stem cells by bone morphogenetic protein 6, 1222
- induction of IL-1 $\beta$  expression and TMJ changes of adult mice, 1184
- inflammatory arthritis, functional properties of soluble gp130 isoform in, 1662
- inflammatory arthritis, intraarticular corticosteroids decrease synovial RANKL expression in, 1463
- Jab1 binds Smad5 and inhibits bone morphogenetic protein signaling, 3878
- JRA bone marrow core biopsy, 690
- juvenile DM, composition of calcifications in children, 3345
- juvenile-onset SpA, synovial immunopathologic characteristics of, 2594
- lupus nephritis,  $\alpha$ -actinin-binding anti-dsDNA antibodies and, 2523
- lupus nephritis, chimerism in, 2944
- lupus nephritis, glomerular structures recognized by nephritogenic antibodies, 914
- lupus nephritis, IK cytokine in treatment of in mice, 3591
- lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633
- Lyme arthritis, aggrecanase 1 in, 3319
- Lyme myositis, 691

### Imaging (*cont'd*)

- mammalian DNA induction of type I IFN-associated dendritic cell maturation, 951  
matrix metabolism in early lesions in ankle cartilage, 244  
mediation of double-stranded RNA-mediated arthritis by type I IFN, 148  
mixed connective tissue disease induced with U1 small nuclear RNP autoantigen, murine model, 661  
multiple gene up-regulation by IL-1 plus oncostatin M in chondrocytes, 540  
multipotent mesenchymal cells from human periosteum, 1209  
murine lupus, Toll-like receptor 9 signaling protects against, 336  
noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736  
notochord cells, connective tissue growth factor secretion and up-regulation of proteoglycan expression by, 3859  
OA, association between pain, function, and radiographic features of knee OA, 230  
OA, bone marrow lesions and cartilage loss in knee OA, 1529  
OA, catabolic pathway mediated by Toll-like receptors, 2152  
OA, catabolic stress-induced chondrocyte senescence through over-expression of caveolin 1, 818  
OA, chondrocalcinosis and increased risk of cartilage loss in, 1822  
OA, disease-modifying role of caspase inhibitors in, 1814  
OA, diurnal variation of biomarkers in knee OA, 2496  
OA, effects of CCN2 overexpression on fibrosis and cartilage damage, 1653  
OA, expression of platelet-derived growth factor C and platelet-derived growth factor D in synovial membrane, 788  
OA, fibronectin neopeptides in cartilage, 2912  
OA, gene expression profiling for pathogenetic pathways of cartilage degeneration, 3533  
OA, IL-1-induced calcium signaling in chondrocytes, 2164  
OA, joint space width change, hyaline articular cartilage loss or alteration in meniscus, 2488  
OA, meniscus changes and cartilage loss in symptomatic knee OA, 795  
OA, MRI study of DIP joint arthropathy in, 1328  
OA, orphan nuclear receptor Rev-ErbAα in chondrocytes, 3513  
OA, runt-related transcription factor 2 in mechanical instability-induced OA in mice, 2462  
OA, S100A4 stimulates MMP-13 via RAGE, 2901  
OA, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236  
OA, tetraspanin CD151 in human cartilage, 3233  
OA, therapeutic effects of basic growth fibroblast growth factor on experimental knee OA in rabbits, 264  
OA-like changes in type IX collagen-deficient mice, 2891  
pigmented villonodular synovitis, gene expression pattern, 1009  
polyreactive pathogenic autoantibodies in BXD2 mice cause glomerulonephritis and arthritis, 343  
prevention of leukocyte infiltration by amine oxidase inhibition in inflamed joints, mouse study, 2852  
primary angiitis of the central nervous system in children, 1291  
progressive multifocal leukoencephalopathy, 1020  
proinflammatory cytokine expression reduction by targeting IKK $\beta$  in synovium in rat model, 3716  
PsA, MRI study of DIP joint arthropathy in, 1328  
PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes, 587  
RA, ACPAs and, 3381  
RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54  
RA, automated computer-based scoring method for joint space narrowing, 1444  
RA, B cells in RA-associated and idiopathic interstitial pneumonia, 635

### Imaging (*cont'd*)

- RA, Bim deficiency and exacerbation and prolongation of joint inflammation in, 3182  
RA, CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747  
RA, citrullinated proteins associated with synovial exosomes, 3809  
RA, diclofenac and accelerated progression of hip and knee radiographic OA, 1027  
RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119  
RA, Duffy antigen expression of in, 2022  
RA, efficacy of anti-folate receptor  $\beta$  immunotoxin on synovial cell activation, 3126  
RA, expression and function of CXCL16 in human RA synovial tissue-SCID mouse chimera, 765  
RA, expression of platelet-derived growth factor C and platelet-derived growth factor D in synovial membrane, 788  
RA, extremity MRI in, 1034, 1048  
RA, Fas signaling in fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473  
RA, gene identification in disease-discordant monozygotic twins, 2047  
RA, with hepatitis C, concomitant IFN $\alpha$  treatment and TNF $\alpha$  inhibition for, 2335  
RA, IKK $\beta$  inhibition protects against bone and cartilage destruction in rat model, 3163  
RA, IL-20 as proinflammatory molecule in, 2722  
RA, implications of radiographic joint damage, 2035  
RA, joint damage and dendritic cell function associated with CD32B (Fc $\gamma$  receptor IIb variant), 3828  
RA, joint space width of fingers, 1440  
RA, office-based low-field extremity MRI, 1048  
RA, oncostatin M induces angiogenesis and cartilage degradation in synovial tissue and human cartilage cocultures, 3152  
RA, p38 MAPK isoform tissue expression and activation in, 2745  
RA, radiographic damage associated with impaired physical function, 68  
RA, radiographic followup after prednisone therapy, 1422  
RA, RAGE expression in macrophages, 97  
RA, regulation of Mcl-1 expression in synovial macrophages, 3174  
RA, regulatory role of heme oxygenase 1 in RA inflammation, 1132  
RA, sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in synovium, 742  
RA, statin effects on TNF $\alpha$ -induced, RhoA-mediated activation of in synoviocytes, 3441  
RA, synovial cytokine expression and joint damage progression, 1122  
RA, synovitis in RA patients with DMARD-induced remission, 3761  
RA T cells induce osteoclastogenesis in monocytes, 1151  
RA, TGF $\beta$ -inducible gene h3 in, 2734  
RA, thrombospondin 1 modulates erosive arthritis by regulating connective tissue growth factor, 2415  
RA, TNF $\alpha$  polymorphism association with increased progression in seropositive disease, 1105  
RA, TNFSF14 (LIGHT) as mediator of bone resorption, 1451  
radiologic joint destruction in twins and pairs of unrelated patients, 2028  
receptors and ligands involved in uptake of necrotic cells, 927  
rheumatoid vasculitis, fractalkine serum level correlation with disease activity, 3408  
shear stimulation of proteoglycan 4 metabolism in bovine cartilage, 1888  
SLE,  $\alpha$ -actinin-binding anti-dsDNA antibodies and lupus nephritis, 2523  
SLE, aPL and cardiovascular manifestations of, 3918  
SLE, impaired CD91 apoptotic pathways in, 1543  
SLE, occlusive large vessel disease in, 908

## Imaging (*cont'd*)

- SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270  
SLE, platelet C4d specificity for SLE, 670  
SLE, Toll-like receptor 9-expressing B cells in active SLE, 3601  
small-vessel vasculitis, long pentraxin PTX3 in leukocytoclastic lesions of, 986  
soluble RAGE triggers proinflammatory cytokine cascade via  $\beta$  integrin Mac-1, 3898  
SpA, synovial biomarkers in, 1795  
spinal inflammation reduction in AS patients taking infliximab, 1646  
spontaneous arthritis, reversal of by soluble p55 and p75 TNF receptors in mice expressing transmembrane TNF $\alpha$ , 2872  
SS, BAFF-induced changes in B cell antigen receptor-containing lipid rafts in, 115  
SS, cytokine profile in mice and SS-like disease progression, 2300  
SS, dissemination of an SS-associated extranodal marginal-zone B cell lymphoma, 127  
SS, high mobility group box chromosomal protein 1 in salivary glands, 2289  
SS, remodeling of basal lamina of labial salivary glands in, 3465  
SS, role of STAT-1 $\alpha$  in labial salivary glands, 3476  
SS, salivary gland epithelial cells as source of adiponectin, 2295  
SS, tissue-specific up-regulation of the proteasome subunit b5i (LMP7) in, 1501  
SS, transitional type II B cells in salivary glands, 2280  
SSc, activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309  
SSc, allogeneic hematopoietic cell transplantation in, 1982  
SSc, allograft inflammatory factor 1 expression in, 2616  
SSc, brain abnormalities revealed by MRI and magnetization transfer imaging, 1350  
SSc, CCL18/PARC-mediated lung injury, mouse study, 2643  
SSc, defective bone marrow endothelial progenitors in, 2605  
SSc, DNA topoisomerase I binding to fibroblasts, 963  
SSc, insulin-like growth factor binding protein 5 induced skin fibrosis, mouse study, 3001  
SSc, myofibroblasts and hyalinized collagen as markers of skin disease in, 3655  
SSc, neuronal NO synthase in skin, 202  
SSc, nucleolar staining by anti-RNA polymerase I/III antibodies, 3051  
SSc, serum induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells, 2250  
SSc, signatures of disease imperfectly reflected in transcript profiles of explanted fibroblasts, 1961  
SSc, SPARC silencing in, 2626  
SSc, stromal cell-derived factor 1 and its receptor CXCR4, 3022  
SSc-associated SS and relationship to limited cutaneous subtype, 2243  
STAT-3-dependent IL-6 *trans*-signaling, regulation of pre-B cell colony-enhancing factor by, 2084  
"strawberry gums" in WG, 690  
suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518  
synovial mast cell phenotype, mouse study, 2863  
TNF-mediated arthritis and p38 MAPK inhibition, 463  
TRAPS, *TNFRSF1A* mutations in, 2674  
turmeric supplements in treatment of experimental arthritis, 3452  
*Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583
- Immune complexes  
anti-type II collagen-containing, in arthritis, 1759  
IFNa induction by immune complexes or liposomes containing SS or SLE autoantigen-associated RNA, 1917  
Immunosuppressive medications, RA, and hospitalization for cardiovascular events, 3790
- Immunotoxins, RA, efficacy of anti-folate receptor  $\beta$  immunotoxin on synovial cells, 3126  
Impact injury, cellular events leading to chondrocyte death after cartilage impact injury, 1509  
In memoriam, Jarvis Edwin Seegmiller, MD, 3067  
In vitro studies  
activation of cultured chondrocytes by vibration and hyaluronic acid, 1897  
cationic liposome formulation for delivery of small interfering RNA silencing TNF $\alpha$  in experimental arthritis, 1867  
cellular events leading to chondrocyte death after cartilage impact injury, 1509  
chondrogenesis of mesenchymal stem cells, mouse study, 3254  
collagen-induced arthritis, suppression of by CD11c+,CD11b+ dendritic cells, 887  
IFNa induction by immune complexes or liposomes containing SS or SLE-autoantigen-associated RNA, 1917  
IL-6 and impaired skeletal development, mouse study, 3551  
mouse monoclonal anti-human thrombomodulin antibodies activate endothelial cells, 1629  
OA, effects of connective tissue growth factor and CCN2 overexpression on fibrosis and cartilage damage, 1653  
peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates IL-1Ra production in cytokine-treated chondrocytes, 1233  
proteoglycan 4 metabolism in bovine cartilage, 1888  
RA, classical complement pathway activation in, 1143  
RA, efficacy of anti-folate receptor  $\beta$  immunotoxin on RA synovial cells, 3126  
RA, oncostatin M induces angiogenesis and cartilage degradation in, 3152  
RA, T cells and induction of osteoclastogenesis in monocytes, 1151  
SSc, allograft inflammatory factor 1 expression in response to TGF $\beta$ , 2616  
STAT-3-dependent IL-6 *trans*-signaling, regulation of pre-B cell colony-enhancing factor by, 2084  
synoviolin, overexpression of in RA and continued elevation in nonresponders to infliximab, 2109  
TRAPS, *TNFRSF1A* mutations in, 998, 2674  
Inducible protein 10/CXCL10 antagonist and autoimmune sialadenitis in mice, 1174  
Infants. *See also* Children  
chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents, 2314  
neonatal lupus risk, anti-La/SSB antiidiotypic antibodies in maternal serum, 2228  
neonatal-onset multisystem inflammatory disease, mutational analysis in, 2703, 2704
- Infection  
antibiotic-refractory Lyme arthritis, strategies for treatment of, 3079  
anti-TNF therapy and risk of JC virus infection resulting in progressive multifocal leukoencephalopathy, 381  
catastrophic APS, mortality in, 2568  
"cat-scratch disease," role of tick-borne infection in, 2347  
*Chlamydia*-induced arthritis, host-microbe interactions in, rat study, 499  
Epstein-Barr infection and ACPAs, 733  
hepatitis C virus-associated mixed cryoglobulinemia vasculitis, anti-viral therapy for, 3696  
inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with adeno-associated virus, 2119  
microscopic polyangiitis and killer cell immunoglobulin-like receptors, 992  
pyomyositis of lower limbs, 2030  
RA, rates of infection in anti-TNF-treated patients, 2368  
SS, failure to confirm coxsackievirus infection in primary SS, 2026  
SSc, allogeneic hematopoietic cell transplantation in severe disease, 1982

- Infection (cont'd)**
- type I IFN requirement for double-stranded RNA-mediated arthritis, 148
  - Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583
- Inflammation**
- anti-type II collagen-containing immune complexes in arthritis, 1759
  - AS, immunohistochemical analysis of hip arthritis in, 1805
  - AS, spinal inflammation reduction in patients taking infliximab, 1646
  - drug therapy targeting on inflamed synovium, 1055
  - IL-6 and impaired skeletal development, mouse study, 3551
  - juvenile DM, chronic cutaneous inflammation and calcifications, 3345
  - prevention of leukocyte infiltration by amine oxidase inhibition, mouse study, 2852
  - PYPAFI* nonsense mutation and, 508
  - RA, ACPAs and, 3381
  - RA, Bim deficiency and exacerbation and prolongation of joint inflammation in, 3182
  - RA, chronic inflammation and lymphoma risk, 692
  - RA, cyclin-dependent kinase 4/6 modulation of mediators of inflammation in, 2074
  - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
  - RA, regulatory role of heme oxygenase 1 in inflammation, 1132
  - SLE, obesity and functional capacity and inflammation, 1705, 1706
  - soluble RAGE triggers proinflammatory cytokine cascade via  $\beta 2$  integrin Mac-1, 3898
  - transglutaminase 2 to limit murine peritoneal acute gout-like inflammation, 3363
  - turmeric supplements in treatment of experimental arthritis, 3452
  - vascular amine oxidases and leukocyte extravasation into inflamed joints, mouse study, 2852
- Inflammatory arthritis**
- functional properties of a soluble gp130 isoform, 1662
  - intraarticular corticosteroids decrease synovial RANKL expression in, 1463
  - RA, serum fetal DNA and disease activity during pregnancy, 2069
  - skin hyperpigmentation over inflamed joints, 2604
- Inflammatory back pain, in AS, 569**
- Infliximab**
- AS, spinal inflammation reduction in AS patients taking infliximab, 1646
  - LUNDEX, index of drug efficacy in clinical practice, 600
  - pregnancy outcome following anti-TNF therapy, 2701
  - RA, ACL in patients with early RA treated with infliximab plus MTX, 2840
  - RA, antiinfliximab antibodies and clinical response to RA, 711
  - RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54
  - RA, comparison of infliximab or etanercept monotherapy vs. cotherapy with another DMARD, 1786
  - RA, delaying addition of anti-TNF treatment to ongoing MTX therapy in patients with early disease, 47, 1028
  - RA, effectiveness of, 3399
  - RA, Guillain-Barré and Miller Fisher syndrome development, 1429
  - RA, improved employability in early disease, 716
  - RA, monitoring of anti-TNF $\alpha$  bioavailability and immunogenicity in, 3782
  - RA, predictors of joint damage in early disease treated with high-dose MTX with or without concomitant infliximab, 702
  - RA, safety in RA with comorbidities alone and with MTX, 1075
  - RA, synoviolin overexpression in and continued elevation in nonresponders to infliximab, 2109
- Injury. See Traumatic injury**
- Insulin-like growth factor**
- binding protein 5, in skin fibrosis, mouse study, 3001
- Insulin-like growth factor (cont'd)**
- induction by suppressor of cytokine signaling 3, 1518
  - type I deficiency, in rat knee OA, 3850
- Insulin resistance, and impaired beta cell function in RA, 2765**
- Integrins**
- Mac-1,  $\beta 2$ , and triggering of proinflammatory cytokine cascade by soluble RAGE, 3898
  - SSc, failed urokinase-type plasminogen activator receptor association with in human microvascular endothelial cells, 3926
- Interferon (IFN)**
- double-stranded RNA-mediated arthritis, 148
  - Erdheim-Chester disease, variability in efficacy of, 3330
  - inducible genes, *IFI16* in connective tissue disorders, 3939
  - induction of by immune complexes or liposomes containing SS- or SLE-autoantigen-associated RNA, 1917
  - IRF5* gene polymorphisms in RA, 3815
  - lupus-like disease and high levels of, corresponding to trisomy on chromosome 9p, 1573
  - lupus nephritis and gene expression induced by, 2951
  - RA with hepatitis C, concomitant treatment with IFN $\alpha$  and TNF $\alpha$  inhibition for, 2335
  - SLE, association of with anti-RNA binding protein autoantibodies in, 1906
  - SLE, type I in, 408
- Interleukin-1 (IL-1)**
- anti-type II collagen-containing immune complex-induced production of, via Fc $\gamma$  receptor IIa, 1759
  - CD28 costimulation in arthritis induction in IL-1Ra-deficient mice, 473
  - geranylgeranylation in secretion of with mevalonate kinase deficiency, 3690
  - 2L1B* associated with hip OA, 3722
  - IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267
  - multiple gene up-regulation by, with oncostatin M, 540
  - OA, IL-1-induced calcium signaling in chondrocytes, 2164
  - signaling pathways regulating ICAM-1 expression, 649
  - steroid hormones support bovine articular cartilage integration in absence of, 3890
  - TMJ changes and expression of, in adult mice, 1184
- Interleukin-1 receptor antagonist (IL-1Ra)**
- nonmyeloablative bone marrow transplantation in T cell-depleted mice deficient in, 1878
  - peroxisome proliferator-activated receptor  $\alpha$  pathway potentiates production of, in cytokine-treated chondrocytes, 1233
- Interleukin-4 (IL-4)**
- adjuvant-induced arthritis, angiostatic effects of gene therapy in rats with, 2402
  - murine collagen-induced arthritis, BiP treatment via regulatory T cells, 854
  - PsA, lack of association of IL-4 receptor in SNPs in, 4023
  - SSc, release of from T cells and profibrotic effects mediated by monocyte chemoattractant protein 1 in, 214
- Interleukin-6 (IL-6)**
- antigen-induced arthritis, 158
  - functional properties of soluble gp130 isoform and, in inflammatory arthritis, 1662
  - impaired skeletal development and, mouse study, 3551
  - RA, receptor antibodies in, 1778
  - STAT-3-dependent trans-signaling of and regulation of pre-B cell colony-enhancing factor, 2084
- Interleukin-8 (IL-8), production of, induced by surface-bound anti-type II collagen-containing immune complexes via Fc $\gamma$  receptor IIa, 1759**
- Interleukin-10 (IL-10), gene expression in RA synovial macrophages, 2711**
- Interleukin-15 (IL-15), T lymphocytes from early RA patients express RANKL and, in monocytes, 1151**

Interleukin-20 (IL-20), proinflammatory molecule in RA and experimental arthritis, 2722  
Intermittent hydrarthrosis, *MEFV* gene mutations and, 2334  
Interstitial lung disease  
  leflunomide use and risk of RA in, 1435  
  RA-associated, 635  
Intracellular adhesion molecule 1 (ICAM-1), signaling pathways regulating expression by endothelin 1, 649  
*IRF5* gene, functional polymorphisms in RA, 3815  
Ischemia  
  excess mortality in RA and, 60  
  GCA, antiplatelet and anticoagulant therapy in, 3306  
Isoprenoid biosynthesis pathway, mevalonate kinase deficiency in, 2306

## J

Jab1, Smad5 binding and inhibition of bone morphogenetic protein signaling by, 3878  
Japanese populations, PM/DM, anti-PL-7 in milder muscle disease in, 2004  
Jaw, intravenous bisphosphonates in osteoporosis and osteonecrosis of, 3720, 3721  
JC virus, anti-TNF therapy and risk of in progressive multifocal leukoencephalopathy, 381  
JNK, regulation of by MKK-7, in fibroblast-like synoviocytes, 2127  
Joint damage  
  antigen-induced arthritis, IL-6 in, 158  
  anti-type II collagen-containing immune complexes and arthritis with, 1759  
  Pain, function, and radiographic features in knee OA, 230  
  prevention of leukocyte infiltration by amine oxidase inhibition, mouse study, 2852  
RA, anti-TNF therapy and combination therapy for, 54  
RA, CD32B (Fcγ IIb variant) associated with, 3828  
RA, radiographic, implications of, 2035  
RA, predictors of in early disease treated with high-dose MTX with or without concomitant infliximab, 702  
RA, synovial cytokine expression and progression of, 1122  
RAGE and inflammation in, 14  
Joint destruction  
  calcification-induced, with phosphocitrate treatment of, guinea pig model, 2452  
RA, association of the *IL4R* SNP 150V with, 1491  
RA, disease activity and radiographic progression of, after treatment with etanercept alone or combined with MTX, 3119  
RA, epigallocatechin-3-gallate role in chemokine production and MMP-2 activation in synovial fibroblasts, 2393  
RA, ratio of osteoprotegerin to RANKL in early disease and prediction of, 1772  
RA, variation in, in twins and pairs of unrelated patients, 2028  
Remodeling, in arthritis, noggin haploinsufficiency differentially affects tissue responses, 1736  
Joint hypermobility syndrome, clinical study of, 515  
Joint loading  
  Instability, runt-related transcription factor 2 in mechanical instability-induced OA in mice, 2462  
  OA, mild compared with moderate, in the medial knee, 3842  
  OA, walking barefoot decreases loading on lower extremity joints, 2923  
Joint replacement. *See* Hip replacement; Knee replacement  
Joint space narrowing  
  automated computer-based scoring method, for RA, 1444  
  disc space narrowing as risk factor for vertebral fracture, 1262  
Joint space width  
  MCP and PIP joints in early RA, 1440  
  OA, change of during hyaline articular cartilage loss or alteration in meniscus, 2488

Joint stiffness, AUSCAN study of validity, factor structure, and clinical relevance of, 551  
Jun activation domain-binding protein 1 (Jab1), 3878  
Juvenile dermatomyositis (juvenile DM)  
  composition of calcifications in, 3345  
  immunogenetic risk and protective factors for in Caucasians, 3979  
Juvenile idiopathic arthritis (JIA)  
  AA amyloidosis as complication and treatment with tocilizumab, 2997  
  ACR and DAS criteria comparison, 1602  
  predictors of disease course and remission in, 1595  
  synovial immunopathologic characteristics of, 2594  
Juvenile-onset spondyloarthritis, synovial immunopathologic characteristics of, 2594  
Juvenile psoriatic arthritis (juvenile PsA), two populations of children with, 3564  
Juvenile rheumatoid arthritis (JRA)  
  bone marrow core biopsy, winner of annual slide competition, 690  
  calcium supplementation to increase BMD in children with, 2235  
  etanercept safety and efficacy in children with polyarticular disease, 1987  
  RANTES and monocyte chemoattractant protein 1 as markers of disease activity in, 2585  
Juvenile systemic sclerosis (juvenile SSc), 3971

## K

Kawasaki disease  
  angiogenic genes and, 1361  
  *MBL2* and coronary artery lesions of, 369  
  *VEGF* gene haplotypes in, 1588  
Kidneys  
  anti-DNA antibodies, regulation of gene expression in mouse glomerular mesangial cells by, 2198  
  glomerulonephritis, α-actinin-binding anti-dsDNA antibodies and, 2523  
  glomerulonephritis, anti-P antibodies in and lupus nephritis, 1568, 4025, 4026  
  glomerulonephritis, platelet function in development of, mouse study, 2934  
  glomerulonephritis, polyreactive pathogenic autoantibodies and erosive arthritis with in BXD2 mice, 343  
  lupus nephritis, B cell depletion in appendix following rituximab treatment, 2151  
  lupus nephritis, chimerism in, 2944  
  lupus nephritis, C-reactive protein single injection treatment of in mice, 325  
  lupus nephritis, glomerular structures recognized by nephritogenic antibodies, 914  
  lupus nephritis, IFN-inducible gene expression in, 2951  
  lupus nephritis, IK cytokine in treatment of in mice, 3591  
  lupus nephritis, neutrophil gelatinase-associated lipocalin as biomarker of, in childhood-onset SLE, 2577  
  lupus nephritis, prevalence and incidence of, in the UK, 2963  
  lupus nephritis, ratio of human growth factor to TGFβ1 as predictor of cyclophosphamide response in, 3633  
  lupus nephritis, self-perceived stress and increased risk of flare with the serotonin receptor 1A-1019 G allele in, 3291  
NK026680 dendritic cell inhibitor for prevention of, mouse study, 3707  
SLE, ACR renal disease criteria for clinical trials of, 421  
SLE, antioxidant low-density lipoprotein antibodies and vascular arterial events and renal manifestations in, 2035  
SLE renal outcome, association between serum cholesterol level and, 2211  
Killer cell immunoglobulin-like receptors, and microscopic polyangiitis, 992

- Knee**
- apolipoprotein A-I in meniscal tissue, 3545
  - chondrocalcinosis in Chinese vs. white subjects, 3508
  - joint space width change in, with hyaline articular cartilage loss or alteration in meniscus, 2488
  - OA, acupuncture for treating, 3375, 3485
  - OA, association between pain, function, and radiographic features of, 230
  - OA, association between a variation in *LRCH1* and, 524
  - OA, bone marrow lesions and cartilage loss in, 1529
  - OA, chondrocalcinosis and increased risk of cartilage loss in, 1822
  - OA, diclofenac and accelerated progression of radiographic disease, 1027
  - OA, disease-modifying role of caspase inhibitors in, 1814
  - OA, diurnal variation of biomarkers in, 2496
  - OA, doxycycline use in, 684
  - OA, estradiol and metabolites in, 2481
  - OA, genetic associations with clinical disease in women and men, 533
  - OA, glucosamine sulfate long-term symptom-modifying effect, 2338, 2340
  - OA, growth hormone and insulin-like growth factor 1 deficiencies and severity of, rat study, 3850
  - OA, joint loading, mild compared with moderate, in the medial knee, 3842
  - OA, joint space width change, with hyaline articular cartilage loss or alteration in meniscus, 2488
  - OA, meniscus changes and cartilage loss in symptomatic disease, 795
  - OA, oral salmon calcitonin and, 3205
  - OA, muscle co-contraction in, 1354
  - OA, risedronate for, 3494
  - OA, therapeutic effects of basic growth fibroblast growth factor, rabbit study, 264
  - OA, transdermal fentanyl for pain and improvement in functioning, 1829
  - OA, vitamin K status and, 1255
  - OA, walking barefoot decreases loading in, 2923
  - OA-like changes in type IX collagen-deficient mice, 2891
  - synovial molecular sieving of hyaluronan in rabbits, 1673
- Knee Osteoarthritis Structural Arthritis Trial, risedronate for knee OA**, 3494
- Knee replacement**
- hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194
  - predictors of, 3212
  - preliminary index that predicts adverse events after, 1536
- Koch's postulates, in autoimmunity**, 2349
- Korean populations**
- FCRL3* polymorphism and RA and SLE susceptibility in, 3838
  - PADI4* gene associated with RA susceptibility in, 90
- L**
- Labial salivary glands**
- SS, remodeling of basal lamina in, 3465
  - SS, role of STAT-1 $\alpha$  in, 3476
- Leflunomide**
- RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790
  - RA, use of in and risk of interstitial lung disease, 1435
- Leukocytes**
- cellular events leading to chondrocyte death after cartilage impact injury, 1509
  - differential survival of subsets of, mediated by synovial, bone marrow, and skin fibroblasts, 2096
  - migration to rheumatoid joints, 2707
  - prevention of infiltration by amine oxidase inhibition in inflamed joints, mouse study, 2852
- Leukocytes (cont'd)**
- RA, activity of serum amyloid A via NF- $\kappa$ B-dependent signal transduction, 105
  - Leukocytoclasia, long pentraxin PTX3 in small-vessel vasculitis and, 986
  - LIGHT, in RA, TNFSF14 as mediator of bone resorption, 1451
  - Linkage analysis, RA families in US and UK, 1483
  - Lipid peroxidation products, in OA, 4-hydroxynonenal and cartilage degradation, 271
  - Lipid rafts, BAFF-induced changes in, 115
  - Lipocalin, SLE, neutrophil gelatinase-associated, biomarker of nephritis in childhood-onset SLE, 2577
  - Liposome carrier system, for delivery of small interfering RNA silencing TNF $\alpha$  in experimental arthritis, 1867
  - Liposomes
    - endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide, 1198
    - IFN $\alpha$  induction by immune complexes or liposomes containing SS- or SLE-autoantigen-associated RNA, 1917  - Low back pain, in AS, 569
  - LRCH1*, association with knee OA, 524
  - Lungs**
    - Mixed connective tissue disease induced with U1 small nuclear RNP autoantigen, murine model, 661
    - RA, comet cells in, 243
    - SSc, CCL18/PARC-mediated lung injury, mouse study, 2643
    - SSc, corticosteroids and cyclophosphamide followed by azathioprine treatment for pulmonary fibrosis in, 3962
    - SSc, echocardiography to diagnose pulmonary arterial hypertension in, 380
    - SSc, lung transplantation in, 3954
    - SSc-related pulmonary hypertension, 3043
    - SSc, transplantation in, 3954
    - Lupus. *See Cutaneous lupus erythematosus; Systemic lupus erythematosus*
    - Lupus nephritis. *See also Kidneys*
      - $\alpha$ -actinin-binding anti-dsDNA antibodies and, 2523
      - B cell depletion in appendix following rituximab treatment, 2151
      - chimerism in, 2944
      - C-reactive protein single injection treatment of in mice, 325
      - glomerular structures recognized by nephritogenic antibodies, 914
      - IFN-inducible gene expression in, 2951
      - IK cytokine in treatment of in mice, 3591
      - neutrophil gelatinase-associated lipocalin as biomarker of in childhood-onset SLE, 2577
      - prevalence and incidence of in the UK, 2963
      - ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633
      - self-perceived stress and increased risk of flare and serotonin receptor 1A-1019 G allele in, 3291    - Lyme arthritis
      - aggregcanase 1 in, 3319
      - antibiotic-refractory, therapy for, 3079    - Lyme myositis
      - case report, 2697
      - winner of annual slide competition, 690    - Lymphoablative regimen, autologous hematopoietic stem cell transplantation in autoimmune diseases, 3730, 3750
    - Lymphoma**
      - chronic inflammation and risk of in RA, 692
      - diffuse large B cell, in RA, 3774
      - extranodal marginal-zone B cell, dissemination of, in SS, 127 in RA, 685    - Lymphopenia, in mice, prevention of spontaneous arthritis by inhibiting homeostatic expansion of autoreactive CD4+ T cells, 492
    - Lyn deficiency in B cells in SLE, 2036, 2037

**M**

- Mac-1,  $\beta 2$  integrin, and triggering of soluble RAGE proinflammatory cytokine cascade, 3898
- Macrophages  
RA, IL-10-dependent gene expression in synovial macrophages, 2711
- RA, RAGE expression in, 97
- RA, regulation of Mcl-1 expression in synovial macrophages, 3174
- receptors and ligands involved in uptake of necrotic cells, 927
- SSc, migration inhibitory factor promoter polymorphisms and clinical expression of, 3661
- transglutaminase 2 expression in monosodium urate crystals, 3363
- Magnetic resonance imaging (MRI)  
AS, spinal inflammation reduction in by infliximab, 1646
- AS, spinal symptoms reduced in by adalimumab, 678
- OA, chondrocalcinosis and increased risk of cartilage loss in, 1822
- OA and PsA, DIP joint arthropathy in, 1328
- pyomyositis of lower limbs, 2030
- RA, ACR task force report, 1034, 1048
- RA, office-based low-field extremity in, 1048
- RA, synovial cytokine expression and joint damage progression, 1122
- in SSc, brain abnormalities revealed by magnetization transfer imaging and, 1350
- Magnetization transfer imaging, brain abnormalities in SSc revealed by MRI and, 1350
- Major histocompatibility complex (MHC), in juvenile DM, immunogenetic risk and protective factors for in Caucasians, 3979
- Malignancy, solid, among etanercept-treated WG patients, 1608
- Mannose-binding lectin gene  
Kawasaki disease, polymorphisms and risk of coronary artery lesions of, 369
- SLE, exon 1 polymorphisms of and course and outcome in, 1703
- SLE, exon 1 polymorphisms of and vascular events in, 1940
- MAPK  
molecular mechanisms of aPL-induced tissue factor expression through, 301
- p38, inhibition and TNF-mediated arthritis, 463
- p38, isoform tissue expression and activation in RA, 2745
- Marginal-zone B cell lymphomas, dissemination of in SS, 127
- Mast cells, synovial cell phenotype, mouse study, 2863
- Matrix degeneration, in RA, activity of serum amyloid A via NF- $\kappa$ B-dependent signal transduction, 105
- Matrix metalloproteinases (MMPs)  
gene expression profiling of in human Achilles tendon, 832
- RA, cyclic-dependent kinase 4/6 modulation of mediators of inflammation in, 2074
- Matrix metalloproteinase 1 (MMP-1), collagen degradation around loosened total hip replacement implants, 2928
- Matrix metalloproteinase 2 (MMP-2), epigallocatechin-3-gallate role in chemokine production and activation of in RA synovial fibroblasts, 2393
- Matrix metalloproteinase 3 (MMP-3), diurnal variation of biomarkers in knee OA, 2496
- Matrix metalloproteinase 7 (MMP-7), tetraspanin CD151 in human OA cartilage, 3233
- Matrix metalloproteinase (MMP-10), promotion of collagenolysis via procollagenase activation of, 3244
- Matrix metalloproteinase 13 (MMP-13)  
collagen degradation around loosened total hip replacement implants, 2928
- OA, AG-rich element binding protein identification in chondrocytes, 2471
- OA, S100A4 stimulates production of via RAGE, 2901
- MBL2 gene, coronary artery lesions of Kawasaki disease and, 369
- Mcl-1, regulation of expression of in RA synovial macrophages, 3174
- MEFV gene, intermittent hydrarthrosis and, 2334
- MEK-1/ERK pathway, molecular mechanisms of aPL-induced tissue factor expression through, 301
- Memory B cells, transitional type II, in SS salivary glands, 2280
- Memory T cells, SLE, abnormal differentiation of, 2184
- Men  
FM, genetic influences on chronic widespread pain, 1682
- OA, genetic associations with clinical knee OA in women and, 533
- RA, familial disease phenotype in, 3087
- SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270
- Meniscus  
apolipoprotein A-I in, 3545
- OA, joint space width change and hyaline articular cartilage loss or alteration in meniscus, 2488
- Mesenchymal stem cells  
cartilage tissue engineering, 3075
- chondrogenesis of in vitro and in vivo, mouse study, 3254
- human periosteal cells and, 1209
- properties of, in humans, 843
- Metacarpophalangeal (MCP) joint, joint space width in fingers of RA patients, 1440
- Methotrexate (MTX)  
JIA, ACR and DAS criteria comparison in treated patients with, 1602
- PsA, treatment combination with alefacept, 1638
- RA, comparison of monotherapy and combination therapy with etanercept and, TEMPO Study, 1063, 3061
- RA, comparison of monotherapy and combination therapy with infliximab or etanercept and another DMARD and, 1786
- RA, disease activity and radiographic progression after etanercept alone or with, 3119
- RA, doxycycline alone or with, in early seropositive disease, 621
- RA, efficacy and toxicity of in early disease associated with SNPs in genes coding for folate pathway enzymes, 1087, 3372
- RA, efficacy of combination therapy, 2032, 2034
- RA, folate-dependent risk genotypes and effects of in, 607
- RA, folic acid supplementation and efficacy of in, 1708, 1709
- RA, hospitalization for cardiovascular events, 3790
- RA, pharmacogenetics of in, 1366
- RA, pharmacogenomic and metabolic biomarkers to monitor effects of during dose escalation in, 3095
- RA, predictors of joint damage, with or without concomitant infliximab, 702
- RA, relationship between genetic variants in adenosine pathway and outcome of treatment with, in recent-onset disease, 2830
- RA, rituximab efficacy and safety despite treatment with in, 1390
- RA, treatment combination with adalimumab, 26
- RA, treatment combination with anti-TNF, associated with cancer in, 2757
- RA, treatment combination with cyclosporine and intraarticular betamethasone, in early disease, 1401
- RA, treatment combination with infliximab, with aCL in early disease, 2840
- RA, treatment combination with rituximab, for anti-TNF refractory disease, 2793
- RA, tocilizumab after incomplete response to, CHARISMA study in, 2817
- Mevalonate kinase  
geranylgeranylation in IL-1 $\beta$  secretion in deficiency of, 3690
- up-regulation of by manipulation of isoprenoid biosynthesis, 2306
- MHC2TA gene, RA association in Swedish and UK cohort, 3417
- Microarray analysis. See Complementary DNA microarray
- Microcirculation  
catastrophic APS, mortality in, 2568
- SSc, abnormal response localized to digits in, 1952
- Microscopic polyangiitis, killer cell immunoglobulin-like receptor genotypes and, 992

- Microvascular endothelial cells, in SSc, failed urokinase-type plasminogen activator receptor-integrin association in, 3926
- MIF* gene, SSc, macrophage migration inhibitory factor promoter polymorphisms and clinical expression of, 3661
- Miller Fisher syndrome, with TNF $\alpha$  antagonist therapy, 1429
- Mixed connective tissue disease, induced with U1 small nuclear RNP autoantigen, murine model, 661
- Mixed cryoglobulinemia vasculitis, hepatitis C virus-associated, antiviral therapy for, 3696
- MKK-7, fibroblast-like synoviocytes, regulation of JNK by in, 2127
- Monoclonal antibodies
- anti-human mouse thrombomodulin antibodies and activation of endothelial cells, 1629
  - AS, adalimumab efficacy and safety, 2136
  - AS, adalimumab and reduction of spinal symptoms in, 678
  - IgG glycans in deposition disorders, 3433
  - RA, anti-CCL2 ABN912 treatment for, 2387
  - RA, anti-IL-6 receptor antibodies, 1778
  - RA, B cell reconstitution after rituximab depletion, 613, 3062, 3063
  - RA, B lymphocyte stimulator levels following rituximab for, 723
  - RA, rituximab for anti-TNF refractory disease, 2793
  - RA, therapeutic B cell depletion and regeneration for, 2356, 2377
  - RA, tocilizumab for after incomplete MTX response, CHARISMA study, 2817
  - SLE, epratuzumab for, 2344
  - SLE, with ANCA-associated vasculitis, rituximab treatment for, 2970
- Monoclonal immunoglobulin deposition disease, glycan analysis of monoclonal antibodies in, 3433
- Monocyte chemoattractant protein 1
- markers of disease activity in JRA, 2585
  - profibrotic effects of in SSc, 214
- Monocyte chemotactic protein 1, in RA, anti-CCL2 monoclonal antibody ABN912, 2387
- Monosodium urate monohydrate crystals
- acute gouty arthritis and, 383
  - macrophage transglutaminase 2 expression, 3363
  - rapid induction of TREM-1 in murine macrophages by, mouse studies, 455
- Mortality. *See also* Outcomes
- from autologous hematopoietic stem cell transplantation in autoimmune diseases, 3730, 3750
  - RA, contribution of congestive heart failure and ischemic heart disease, 60
  - RA, increased case fatality rates following first acute cardiovascular event in, 2061
  - in SLE, 2550
  - in SLE, association between serum cholesterol level and renal outcome, 2211
  - SSc, pulmonary arterial hypertension in diffuse disease, 184
  - SSc-related hypertension, 3043
- Mosaic analysis method, induction of IL-1 $\alpha$  expression and TMJ changes in adult mice, 1184
- Mouse studies
- anti-DNA antibodies, regulation of gene expression in glomerular mesangial cells by, 2198
  - antigen-induced arthritis, IL-6 in, 158
  - antigen processing of human type II collagen in, 482
  - arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice, 2423
  - autoimmune sialadenitis, inducible protein 10/CXCL10 antagonist and, 1174
  - CD28 costimulation in arthritis induction in IL-1R $\alpha$ -deficient mice, 473
  - chondrogenesis of mesenchymal stem cells, 3254
  - collagen-induced arthritis, BiP treatment via IL-4+ regulatory T cells, 854
- Mouse studies (*cont'd*)
- collagen-induced arthritis, CTX-II as an early marker of, 2886
  - collagen-induced arthritis, effects of novel tylophorine analog on, 877
  - collagen-induced arthritis, treatment with camelid anti-TNF VH<sub>HH</sub> proteins, 1856
  - crescentic glomerulonephritis, dendritic cell inhibitor NK026680 to prevent, 3707
  - crescentic glomerulonephritis, platelet function in development of, 2934
  - Fc $\gamma$  receptor II regulates severe cartilage destruction but not bone destruction, 3868
  - glomerulonephritis, induction by polyreactive pathogenic autoantibodies, erosive arthritis and, 343
  - high-resolution multipinhole SPECT in experimental and human arthritis, 1096
  - homeostatic proliferation-provoked arthritis, 492
  - IK cytokine in treatment of lupus nephritis, 3591
  - IL-6 and impaired skeletal development, 3551
  - induction of IL-1 $\beta$  expression and TMJ changes, 1184
  - lupus, protection with Toll-like receptor 9 signaling, 336
  - lupus nephritis, C-reactive protein single injection treatment of, 325
  - lupus nephritis, glomerular structures recognized by nephritogenic antibodies, 914
  - Mixed connective tissue disease induced with U1 small nuclear RNP autoantigen, 661
  - noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736
  - OA-like changes in type IX collagen-deficient mice, 2891
  - prevention of leukocyte infiltration by amine oxidase inhibition in inflamed joints, 2852
  - rapid induction of TREM-1 in murine macrophages by monosodium urate monohydrate crystals, 455
  - runt-related transcription factor 2 in mechanical instability-induced OA, 2462
  - SLE, DCB-3503 effect on skin disease in, 3277
  - soluble p55 and p75 TNFRs and reversal of spontaneous arthritis, 2872
  - SLE-like disease progression, cytokine profile and, 2300
  - SSc, CCL18/PARC-mediated lung injury, 2643
  - SSc, insulin-like growth factor binding protein 5-induced skin fibrosis in, 3001
  - suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518
  - synovial mast cell phenotype, 2863
  - T cell-depleted, nonmyeloablative bone marrow transplantation in IL-1Ra-deficient mice, 1878
  - TNF-mediated arthritis, p38 MAPK inhibition and, 463
  - transglutaminase 2 to limit murine peritoneal acute gout-like inflammation, 3363
  - Muckle-Wells syndrome, improvement from deafness after treatment with anakinra, 1697
  - Multidrug resistance-associated protein 1, mechanism of acquired resistance to chloroquine, 557
  - Muscle-derived stem cells
    - bone morphogenetic protein 4 and, for cartilage repair in rats, 433
    - bone morphogenetic proteins as inducers of cartilage repair, 387  - Mutations. *See also* Genetics; Polymorphism
    - autoinflammatory disease, *PYPAF1* nonsense mutation in, 508
    - crescentic glomerulonephritis, platelet function in development of, mouse study, 2934
    - MEFV* gene, with intermittent hydrarthrosis, 2334
    - neonatal-onset multisystem inflammatory disease, 2703, 2704
    - SS, dissemination of an SS-associated extranodal marginal-zone B cell lymphoma, 127
    - TNFRSF1A* and resistance to TNF-induced apoptosis, 998

Myeloablative regimen, autologous hematopoietic stem cell transplantation in autoimmune diseases, 3730, 3750  
Myocardial infarction  
gout and risk of, 2688  
RA, increased case fatality rates following first acute cardiovascular event in, 2061  
Myofibroblasts, in SSc, hyalinized collagen as markers of skin disease in, 3655  
Myopathy  
brachio-cervical inflammatory, 1687  
idiopathic inflammatory, HLA polymorphisms in African Americans with myositis autoantibodies, 3670  
Myositis, Lyme, case report, 2697

## N

Naproxen  
cardiovascular outcomes in new users of, 1378  
gastrointestinal and cardiovascular safety of, 3390

Neck  
AS, coexisting with DISH and ossification of posterior longitudinal ligament of cervical spine, 2242  
brachio-cervical inflammatory myopathies, 1687  
Necrosis, receptors and ligands involved in cell uptake, 927  
Neonatal lupus syndrome, anti-La/SSB antiidiotypic antibodies in maternal serum and risk of, 2228  
Neonatal-onset multisystem inflammatory disease, mutational analysis in, 2703, 2704  
Neoplasms, solid malignancies, in etanercept-treated WG, 1608  
Nephritis. *See* Lupus nephritis  
Neuropsychiatric systemic lupus erythematosus (neuropsychiatric SLE)  
anti-NR2 antibodies and, 2349, 2505, 2515  
anti-P antibody testing for diagnosis of, 312  
IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid in, 675

Neutrophils  
gelatinase-associated lipocalin, as biomarker of nephritis in childhood-onset SLE, 2577  
SLE, impaired CD91 apoptotic pathways in, 1543  
systemic vasculitis, mediation of endothelial cell damage by serine proteases released from ANCA-stimulated neutrophils, 1619  
transglutaminase 2 to limit murine peritoneal acute gout-like inflammation, 3363  
NF- $\kappa$ B activation  
anti-human thrombomodulin mouse monoclonal antibodies and activation of endothelial cells, 1629  
Rel proteins and, molecular mechanisms of aPL-induced tissue factor expression through activation of, 301  
statin effects on TNF $\alpha$ -induced, RhoA-mediated activation, in RA synoviocytes, 3441  
Nidogens, and remodeling of basal lamina of labial salivary glands in SS, 3465  
Nitric oxide (NO), RA shared epitope activation of, 3423  
Nitric oxide synthase (NOS)  
endothelial dysfunction in rat adjuvant-induced arthritis, 1847  
variation in SSc skin, 202  
NK026680, crescentic glomerulonephritis prevention by, mouse study, 3707  
Noggin, haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736  
Nonsteroidal antiinflammatory drugs (NSAIDs)  
antibiotic-refractory Lyme arthritis, strategies for treatment of, 3079  
cardiovascular outcomes in new users of, 1378  
COX-2 inhibition and cardiovascular side effects of diclofenac vs. celecoxib and rofecoxib, 282  
gastrointestinal and cardiovascular safety of, 3390

North American population, *FCRL3* SNP not associated with RA in, 1022

*NOS3* gene  
RA, SNP in promoter of gene for endothelial NOS in, 3144  
SSc, hemorheologic profile and *NOS3* polymorphisms in, 2263

Notice of retraction of 2002 article by Curtis et al, 2933

Notochord cells  
connective tissue growth factor secretion and up-regulation of proteoglycan expression by, 3859  
in mammalian adult, 3728

NR2A antibodies, and cognitive dysfunction in SLE, 2515

NR2 glutamate receptors, association of IgG antibodies in cerebrospinal fluid in neuropsychiatric SLE, 675  
N-telopeptide crosslinks, serum cartilage oligomeric matrix protein and in radiographic hip OA, 236

Nucleolar staining, in SSc, by anti-RNA polymerase I/III antibodies, 3051

## O

Obesity  
arthritis prevalence in US and activity limitations associated with, 226

SLE, functional capacity and inflammation in, 1705, 1706

Obituary, Jarvis Edwin Seegmiller, MD, 3067

Occupational exposure to silica and solvent, and risk of SLE, 3648  
Odorant receptor gene, RA, HLA-linked odorant receptor gene polymorphisms and, 2705

OFELY Study, disc space narrowing and risk of vertebral fracture, 1262

Older adults

DISH and chondrocalcinosis in Azores families, clinical and radiographic manifestations, 1340

FM, heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women with FM, 1334

OA, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236  
projections of US arthritis prevalence and associated activity limitations, 226

Oncostatin M

induces angiogenesis and cartilage degradation in RA synovial tissue and human cartilage cocultures, 3152  
multiple gene up-regulation by IL-1, 540

Orphan nuclear receptor, Rev-ErbA $\alpha$  in OA chondrocytes, 3513

Ossification, IL-6 and impaired skeletal development, mouse study, 3551

Osteoarthritis (OA)

AG-rich element binding protein identification in human chondrocytes, 2471

AS, immunohistochemical analysis of hip arthritis in, 1805

AUSCAN Osteoarthritis Hand Index, validity, factor structure, and clinical relevance of, 551

BMI, effects of on later total hip arthroplasty for primary OA, 802

cartilage destruction, molecular mechanisms of, 1357

cartilage oligomeric matrix protein, heritable determinants of, 2147  
catabolic pathway mediated by Toll-like receptors, 2152  
caveolin 1-induced down-regulation of articular chondrocytes in pathogenesis of, 818

CD44, internalization of aggrecan G1 by, 443, 1028

chondrocalcinosis in Chinese vs. white subjects, 3508

diclofenac and accelerated progression of hip and knee radiographic OA, 1027

DIP joint, MRI of joint arthropathy in, 1328

disease-modifying role of caspase inhibitors in, 1814  
effects of connective tissue growth factor and CCN2 overexpression on fibrosis and cartilage damage, 1653

expression of platelet-derived growth factor C and D in synovial membrane, 788

- Osteoarthritis (OA) (*cont'd*)**
- fentanyl (transdermal) for pain and improvement in functioning, 1829
  - fibronectin neoepitopes in OA cartilage, 2912
  - gene expression profiles in intact and damaged cartilage, 808
  - gene expression profiling for pathogenetic pathways of cartilage degeneration in, 3533
  - gene therapy for, 1714
  - growth hormone and insulin-like growth factor 1 deficiencies and knee OA severity, rat study, 3850
  - hand, validity, factor structure, and clinical relevance of AUSCAN Osteoarthritis Hand Index, 551
  - hand, vitamin K status and, 1255
  - hip, acupuncture for treating, 3375, 3485
  - hip, diclofenac and accelerated progression of radiographic disease, 1027
  - hip, Frizzled-related protein variants as risk factors for, 1246
  - hip, *IL1B* associated with, 3722
  - hip, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236
  - hip, susceptibility locus on chromosome 6, 1026
  - hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194
  - 4-hydroxynonenal and cartilage degradation in, 271
  - IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267
  - IL-1-induced calcium signaling in chondrocytes, 2164
  - induction of IL-1 $\beta$  expression and TMJ changes in adult mice, 1184
  - joint space width change, hyaline articular cartilage loss or alteration in meniscus, 2488
  - knee, acupuncture for treating, 3375, 3485
  - knee, association between a variation in *LRCH1* and, 524
  - knee, association between pain, function, and radiographic features of, 230
  - knee, bone marrow lesions and cartilage loss in, 1529
  - knee, chondrocalcinosis and increased risk of cartilage loss in, 1822
  - knee, diclofenac and accelerated progression of radiographic disease, 1027
  - knee, diurnal variation of biomarkers in, 2496
  - knee, doxycycline use in, 684
  - knee, estradiol and metabolites and, 2481
  - knee, genetic associations with clinical knee OA in women and men, 533
  - knee, glucosamine sulfate long-term symptom-modifying effect, 2338, 2340
  - knee, joint loading differs in mild compared with moderate medial knee OA, 3842
  - knee, joint space width change, hyaline articular cartilage loss or alteration in meniscus, 2488
  - knee, meniscus changes and cartilage loss in symptomatic disease, 795
  - knee, oral salmon calcitonin and, 3205
  - knee, pros and cons of muscle co-contraction in, 1354
  - knee, risedronate in, 3494
  - knee, therapeutic effects of basic growth fibroblast growth factor on experimental OA in rabbit knee, 264
  - knee, vitamin K status and, 1255
  - knee, walking barefoot decreases loading on lower extremity joints in, 2923
  - orphan nuclear receptor Rev-ErbA $\alpha$  in OA chondrocytes, 3513
  - phosphocitrate treatment of calcification-induced joint degeneration in guinea pig model, 2452
  - RAGE activation leads to increased stimulation of chondrocytes and synoviocytes, 253
  - RAGE and, 14
  - runt-related transcription factor 2 in mechanical instability-induced OA in mice, 2462
  - S100A4 stimulates MMP-13 via RAGE, 2901
- Osteoarthritis (OA) (*cont'd*)**
- spine, disc space narrowing as risk factor for vertebral fracture, 1262
  - tetraspanin CD151 in OA cartilage, 3233
  - total joint arthroplasty, predictors of, 3212
  - Osteocalcin, OA, diurnal variation of biomarkers in knee OA, 2496
  - Osteoclastogenesis
  - CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747
  - fibroblasts and fibroblast-derived factors in periprosthetic osteolysis, 3221
  - IL-6 and impaired skeletal development, mouse study, 3551
  - IL-6 in antigen-induced arthritis, 158
  - RA T cells induce osteoclastogenesis in monocytes, 1151
  - Osteoclasts
  - IL-6 and impaired skeletal development, mouse study, 3551
  - RA, TNFSF14 as mediator of bone resorption, 1451
  - Osteolysis, fibroblasts and fibroblast-derived factors in periprosthetic osteolysis, 3221
  - Osteonecrosis, intravenous bisphosphonates in osteoporosis and jaw osteonecrosis, 3720, 3721
  - Osteophytes
  - dysphagia due to, 507
  - vitamin K status and hand and knee OA, 1255
  - Osteoporosis
  - aromatase inhibitors and, 1355, 1356
  - intravenous bisphosphonates in osteoporosis and jaw osteonecrosis, 3720, 3721
  - intravenous ibandronate injections in postmenopausal women, 1838
  - RA, long-term fracture risk in, 3104
  - Osteoprotegerin
  - anti-TNF therapy increases synovial osteoprotegerin expression in RA, 76
  - intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463
  - ratio of osteoprotegerin to RANKL in early RA predicts later joint destruction, 1772
  - Osteoprotegerin/RANKL system, modulation by anti-TNF therapy for RA, 76
  - Osteosclerosis, in Erdheim-Chester disease, 4018
  - Outcomes. *See also* Mortality
  - back pain, fear avoidance and prognosis in, 3999
  - enthesitis-related arthritis, 3573
  - NSAIDs and cardiovascular events, 1378
  - RA, classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 593
  - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
  - SLE, features, course, and outcome of late-onset SLE, 1580
  - SLE, in lupus pregnancy, 3640
  - SLE, mannose-binding lectin exon 1 polymorphisms and disease course and outcome, 1703
  - SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940
  - SLE renal outcome, association between serum cholesterol level and, 2211
  - SLE and RA, obstetric hospitalization in US for pregnancy, 899
  - SSc, allogeneic hematopoietic cell transplantation with severe SSc, 1982
  - SSc, lung transplantation in, 3954
  - total knee replacement, preliminary index that predicts adverse events after, 1536
  - Oxidative stress in RA, CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135
  - Oxygen tension, hypoxia and pH regulation in articular chondrocytes, 3523

P

p38 MAPK

- isoform tissue expression and activation in RA, 2745
- TNF-mediated arthritis and p38 MAPK inhibition, 463
- p53 up-regulated modulator of apoptosis (PUMA) protein regulation and proapoptotic effects in fibroblast-like synoviocytes, 587
- PA28, anti-20S proteasome autoantibodies inhibit proteasome stimulation by, 2175
- PADI4* gene, associated with RA susceptibility in Korean population, 90
- Pain**
  - AS, inflammatory back pain in, 569
  - AUSCAN Osteoarthritis Hand Index, validity, factor structure, and clinical relevance of, 551
  - back pain, fear avoidance and prognosis in, 3999
  - cytokines in chronic widespread pain, 2656
  - FM, genetic influences on chronic widespread pain, 1682
  - FM, heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women, 1334
  - induction of IL-1 $\beta$  expression and TMJ changes in adult mice, 1184
  - OA, association between pain, function, and radiographic features of knee OS, 230
  - OA, fentanyl (transdermal) for pain and improvement in functioning, 1829
  - SLE, iliopsoas bursitis of the hip with, 1686
  - transcranial direct current stimulation for, 3725, 3988
- Paraoxonase, PON1 activity and PON1 genotype and risk of SLE, 1928
- Pulmonary and activation-regulated chemokine (PARC), CCL18/  
PARC-mediated lung injury in SSc, mouse study, 2643
- Parsonage-Turner syndrome, scapular winging, 4027
- Pattern recognition receptors, for SLE, 3068
- Pediatric granulomatous arthritis, international registry, 3337
- Pediatric systemic lupus erythematosus (pediatric SLE)
  - anti-Epstein-Barr nuclear antigen 1 antibodies in, 360
  - effects of disease activity and therapy on lipid profile in, 1283
- PEG-interferon alfa-2b, for hepatitis C virus-associated mixed cryoglobulinemia vasculitis, 3696
- Pentraxin, long pentraxin PTX3 in leukocytoclastic lesions of small-vessel vasculitis, 986
- Peptidylarginine deiminase 4 (PADI4), associated with RA susceptibility in Korean population, 90
- Perinuclear antineutrophil cytoplasmic antibody (pANCA), dendritic cell inhibitor NK026680 prevents crescentic glomerulonephritis, mouse study, 3707
- Perosteal cells, mesenchymal multipotency of single cells, 1209
- Peripheral blood synoviocytes, synoviolin, overexpression of in RA and continued elevation in nonresponders to infliximab, 2109
- Periprosthetic osteolysis, fibroblasts and fibroblast-derived factors in, 3221
- Peroxisome proliferator-activated receptor  $\alpha$  pathway, to potentiate IL-1Ra production in cytokine-treated chondrocytes, 1233
- Peyer's patches, collagen-induced arthritis, suppression of by CD11c+, CD11b+ dendritic cells, 887
- Phagocytosis, receptors and ligands involved in uptake of necrotic cells, 927
- pH homeostasis, hypoxia and pH regulation in articular chondrocytes, 3523
- Phosphatidylserine, receptors and ligands involved in uptake of necrotic cells, 927
- Phosphocitrate, for calcification-induced joint degeneration in guinea pig model, 2452
- Physical activity. *See* Exercise
- Pigmented villonodular synovitis
  - gene expression pattern in, 1009
  - knee, 3422
- Platelet activation, by anti- $\beta_2$ -glycoprotein I antibody- $\beta_2$ -glycoprotein I complex, 2558

Platelet-derived growth factors C and D, in RA and OA synovial membrane, 788

Platelet function, in development of crescentic glomerulonephritis, mouse study, 2934

Pneumonia

B cells in RA-associated and idiopathic interstitial pneumonia, 635

RA treatment and risk of, 628

Pneumonitis, RA, leflunomide use and risk of interstitial lung disease, 1435

Polymorphism. *See also* Genetics; Mutations; Single-nucleotide polymorphisms

AS, B27 subtypes and tapasin dependence, 138

GCA, IL-10 promoter gene polymorphisms in, 4011

hURAT1 gene, reduced renal uric acid excretion and hyperuricemia and, 292

idiopathic inflammatory myopathy, HLA polymorphism in African Americans with, 3670

Kawasaki disease, polymorphism in mannose-binding lectin gene and risk of coronary artery lesions of, 369

Kawasaki disease, VEGF gene haplotypes in, 1588

OA, association between a variation in *LRCH1* and knee OA, 524

OA, genetic associations with clinical knee OA in women and men, 533

PsA, lack of association of IL-4 receptor SNPs with erosive disease in, 4023

RA association in Swedish and UK cohort, 3417

RA and *FCRL3* polymorphism in Canadian population, 3820

RA, HLA-linked odorant receptor gene polymorphisms and, 2705

RA, *IRF5* gene functional polymorphisms in, 3815

RA, joint damage and dendritic cell function in RA associated with *FCCR2B* variant, 3820

RA, MTX treatment outcome and genetic variants in adenosine pathway in recent-onset RA, 2830

RA, *PADI4* gene associated with RA susceptibility in Korean population, 90

RA, *PTPN22\*620W* and humoral immunity to type II collagen in early RA, 82

RA, *TNFA* polymorphism association with increased progression in seropositive RA, 1105

RA and SLE, *FCRL3* polymorphism and susceptibility to in Korean population, 3838

SLE, associated with Fc $\gamma$  receptor II transmembrane polymorphism in Taiwanese patients, 3908

SLE, mannose-binding lectin exon 1 polymorphisms and disease course and outcome, 1703

SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940

SLE, *PTPN22 R620W* polymorphism in familial and sporadic SLE, 2533

SLE, type I IFN system in, 408

SSc, endothelin axis polymorphisms in, 3034

SSc, hemorheologic profile and *NOS3* polymorphisms in, 2263

SSc, macrophage migration inhibitory factor promoter polymorphisms and clinical expression of, 3661

SSc, *PTPN22* polymorphism association with anti-topoisomerase I- and ACA-positive SSc, 3945

Polymyositis, HLA associations in African Americans with idiopathic inflammatory myopathy, 3670

Polymyositis/dermatomyositis (PM/DM), anti-PL-7 in milder muscle disease in Japanese patients, 2004

Polyreactive pathogenic autoantibodies, in BXD2 mice cause glomerulonephritis and erosive arthritis, 343

*PON1* gene, paraoxonase 1 activity and PON1 genotype and risk of SLE, 1928

Positron emission tomography (PET), GCA image, 1710

Pravastatin, statin-induced apoptosis in RA synovial cells, 579

- Pre-B cell colony-enhancing factor, regulation of by STAT-3-dependent IL-6 *trans*-signaling, 2084
- Predictors**
- catastrophic APS, mortality in, 2568
  - enthesitis-related arthritis, outcome and prognostic factors, 3573
  - hip OA, Frizzled-related protein variants as risk factors for, 1246
  - JIA, predictors of disease course and remission in systemic JIA, 1595
  - lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633
  - RA, joint damage with early RA treated with high-dose MTX with or without concomitant infliximab, 702
  - SLE, blood concentrations of hydroxychloroquine and SLE exacerbation, 3284
  - of total joint arthroplasty, 3212
  - total knee replacement, preliminary index that predicts adverse events after, 1536
- Prednisolone, RA, efficacy of combination therapy**, 2032, 2034
- Prednisone**
- pediatric SLE, effects of disease activity and therapy on lipid profile in, 1283
  - RA, radiographic followup after prednisone therapy, 1422
  - RA treatment and risk of pneumonia, 628
  - SLE, moderate-dose steroids and disease flare, 3623
- Pregnancy**
- anti-TNF therapy and, 2701
  - RA, serum fetal DNA and disease activity during pregnancy, 2069
  - SLE and hydroxychloroquine in, 3640
  - SLE and RA, obstetric hospitalization in US, 899
  - TNF inhibition in, 2353
- PREMIER Study, adalimumab plus MTX treatment of RA**, 26
- Primary angiitis of the central nervous system, in children**, 1291
- Procollagenase, MMP-10 promotion of collagenolysis via procollagenase activation**, 3244
- Progressive multifocal leukoencephalopathy**
- anti-TNF and risk of JC virus infection resulting in, 381
  - in SLE patients, 1020
- Proinflammatory high-density lipoprotein, as biomarkers for atherosclerosis in patients with SLE and RA**, 2541
- Pro-matrix metalloproteinase 7, tetraspanin CD151 in human OA cartilage**, 3233
- Proteasome**
- antiproteasome antibodies inhibit activation by proteasome activator PA28, 2175
  - SS, tissue-specific up-regulation of the proteasome subunit b5i (LMP7) in, 1501
- Protein geranylgeranylation, apoptosis of rheumatoid synoviocytes by statins through blocking of**, 579
- Protein tyrosine phosphatase 22 variant R620W, and HLA-DRB1 shared epitope and humoral autoimmunity to type II collagen in early RA**, 82
- Proteoglycan**
- activation of cultured chondrocytes by vibration and hyaluronic acid, 1897
  - arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice, 2423
  - collagen and proteoglycan turnover in focally damaged ankle cartilage, 244
  - shear stimulation of proteoglycan 4 metabolism in bovine cartilage, 1888
  - up-regulation of expression of by notochord cells, 3859
- Proximal interphalangeal (PIP) joints, joint space width in fingers of RA patients**, 1440
- Psoriasis, anti-CCP antibodies in psoriasis patients without arthritis**, 1701
- Psoriatic arthritis (PsA)**
- alefacept in combination with MTX to treat, 1638
  - classification criteria for, 2665
- Psoriatic arthritis (PsA) (*cont'd*)**
- DIP joint, MRI of joint arthropathy in, 1328
  - IL-1 family gene cluster and, 2321
  - lack of association of IL-4 receptor SNPs with erosive disease in, 4023
  - two populations of children with juvenile PsA, 3564
- Psychological factors, fear avoidance and prognosis in back pain**, 3999
- PTPN22 gene**
- RA, 620W polymorphism and humoral immunity to type II collagen in early RA, 82
  - RA and FCRL3 polymorphism in Canadian population homozygous for PTPN22 1858T variant, 3820
  - SLE, R620W polymorphism in familial and sporadic SLE, 2533
  - SSc, R620W polymorphism association with anti-topoisomerase I- and ACA-positive SSc, 3945
- PTX3, long pentraxin PTX3 in leukocytoclastic lesions of small-vessel vasculitis**, 986
- Pulmonary arterial hypertension**
- echocardiography for diagnosis of in SSc, 380
  - in diffuse SSc survival, 184
  - SSc-related, 3043
- Pulmonary fibrosis, SSc, corticosteroids and cyclophosphamide followed by azathioprine treatment**, 3962
- Pyomyositis, of lower limbs**, 2030
- PYPAF1 nonsense mutation, and unusual autoinflammatory syndrome**, 508

## R

- Rabbit studies**
- basic fibroblast growth factor, therapeutic effects on experimental OA in rabbit knee, 264
  - OA, disease-modifying role of caspase inhibitors in, 1814
  - synovial molecular sieving of hyaluronan, 1673
- Race**
- chondrocalcinosis in Chinese vs. white subjects, 3508
  - paraoxonase 1 activity and PON1 genotype and risk of SLE, 1928
- Radiography**
- DISH and chondrocalcinosis in Azores families, 1340
  - OA, association between pain, function, and radiographic features of knee OA, 230
  - OA, bone marrow lesions and cartilage loss in knee OA, 1529
  - OA, diurnal variation of biomarkers in knee OA, 2496
  - OA, joint space width change, hyaline articular cartilage loss or alteration in meniscus, 2488
  - OA, risedronate in medial compartment knee OA, 3494
  - OA, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236
  - RA, anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage, 54
  - RA, automated computer-based scoring method for joint space narrowing, 1444
  - RA, diclofenac and accelerated progression of hip and knee radiographic OA, 1027
  - RA, disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119
  - RA, implications of radiographic joint damage, 2035
  - RA, joint damage and dendritic cell function associated with CD32B (Fc $\gamma$  receptor IIb variant), 3828
  - RA, joint space width of fingers, 1440
  - RA, radiographic damage associated with impaired physical function, 68
  - RA, radiographic followup after prednisone therapy, 1422
  - RA, synovial cytokine expression and joint damage progression, 1122
  - RA, TNFA polymorphism association with increased progression in seropositive RA, 1105

### Radiography (cont'd)

- RA, variation in joint destruction in twins and pairs of unrelated patients, 2028  
WG, hidden chest lesions in, 3059  
RANTES, as markers of disease activity in JRA, 2585  
Rap1, RA, CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135  
Rapamycin, for SLE treatment, 2983  
Rapid induction of TREM-1 in murine macrophages by monosodium urate monohydrate crystals, 455  
Rapidly progressive glomerulonephritis, dendritic cell inhibitor NK026680 prevents crescentic glomerulonephritis in mice, 3707  
Rat studies  
adjuvant-induced arthritis, angiostatic effects of IL-4 gene therapy in, 2402  
adjuvant-induced arthritis, endothelial dysfunction in, 1847  
 $\beta_2$ -microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in rats, 1317  
bone morphogenetic protein 4 and muscle-derived stem cells for cartilage repair, 433  
*Chlamydia*-induced arthritis, host-microbe interactions in, 499  
collagen-induced arthritis, CTX-II as an early marker of, mouse study, 2886  
endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198  
estrogen and type II collagen degradation, 2441  
OA, growth hormone and insulin-like growth factor 1 deficiencies and knee OA severity, 3850  
RA, IKK $\beta$  inhibition protects against bone and cartilage destruction in RA rat model, 3163  
reduction of proinflammatory cytokine expression by targeting IKK $\beta$  in synovium in rats, 3716  
Raynaud's phenomenon, transition from primary to secondary disease, 1974  
Reactive arthritis, *Yersinia*-induced, antigen-specific T cells in, 3583  
Reactive oxygen species, RA, CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135  
Receptor activator of NK  $\kappa$ B ligand (RANKL)  
CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747  
intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463  
modulation of osteoprotegerin/RANKL system by anti-TNF therapy for RA, 76  
RA, ratio of osteoprotegerin to RANKL in early RA predicts later joint destruction, 1772  
T lymphocytes from early RA patients express RANKL and IL-15 and promote osteoclastogenesis in monocytes, 1151  
Receptor for advanced glycation end products (RAGE)  
expression in RA synovial tissue macrophages, 97  
immunomodulatory properties of soluble RAGE, 3898  
initiators or amplifiers of joint inflammation, 14  
OA, activation of leads to increased stimulation of chondrocytes and synoviocytes, 253  
OA, S100A4 stimulates MMP-13 production via RAGE, 2901  
soluble RAGE triggers proinflammatory cytokine cascade via  $\beta$  integrin Mac-1, 3898  
Recombinant immunotoxin, RA, efficacy of anti-folate receptor  $\beta$  immunotoxin on RA synovial cells, 3126  
Recurrent fever syndromes, autoinflammatory disease, PYPAF1 non-sense mutation in, 508  
Regenerative medicine  
human synovial mesenchymal stem cell properties, 843  
multipotent mesenchymal cells from human periosteum, 1209  
Relapse, RA, B lymphocyte stimulator levels following rituximab treatment, 723

### Remission

- JIA, predictors of disease course and remission in systemic JIA, 1595  
RA, synovitis in RA patients with DMARD-induced remission, 3761  
Renal disease. See also Kidneys  
ACR criteria for SLE clinical trials, 421  
Research, how to spot a good genetic association study, 1051, 3063, 3064  
Response to treatment  
JIA, ACR, and DAS criteria comparison, 1602  
lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633  
RA, anti-infliximab antibodies and clinical response to RA, 711  
RA, relationship between genetic variants in adenosine pathway and treatment outcome in recent-onset RA, 2830  
Retraction of 2002 article by Curtis et al, notice of, 2933  
Rev-ErbA $\alpha$ , OA, orphan nuclear receptor Rev-ErbA $\alpha$  in OA chondrocytes, 3513  
RGD-peptide liposomes, endothelial cell-targeted treatment of arthritis with dexamethasone phosphate-containing RGD peptide liposomes, 1198  
Rheumatoid arthritis (RA). See also Juvenile rheumatoid arthritis  
abatacept, safety of in RA patients receiving DMARDs, 2807  
ACCP antibodies and RF isotopes in African Americans with early RA, 3057  
aCL in patients with early RA treated with infliximab plus MTX, 2840  
ACPs and, 3381  
activation of NO signaling by RA shared epitope, 3423  
activity of serum amyloid A via NF- $\kappa$ B-dependent signal transduction, 105  
adalimumab plus MTX treatment of in the PREMIER Study, 26  
adhesion molecules in, 2707  
anti-CCL2 monoclonal antibody ABN912 treatment for, 2387  
anti-IL-6 receptor antibody therapy for, 1778  
anti-infliximab antibodies and clinical response to RA, 711  
anti-TNF therapy and combination therapy to prevent progressive radiographic joint damage in, 54  
anti-TNF use and cancer, 2757  
AS, immunohistochemical analysis of hip arthritis in, 1805  
atherosclerosis in, relation to disease severity and extraarticular manifestations, 1353  
B cell reconstitution after depletion by rituximab in RA patients, 613, 3062, 3063  
B cells in RA-associated and idiopathic interstitial pneumonia, 635  
Be and TICORA studies on translating best strategy and tight control into clinical practice, 2338, 2339  
Bim deficiency and exacerbation and prolongation of joint inflammation in, 3182  
B lymphocyte stimulator levels following rituximab treatment, 723  
CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis, 1747  
chloroquine, mechanism of acquired resistance to, 557  
citrullinated proteins associated with synovial exosomes, 3809  
classical complement pathway activation in, 1143  
classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for RA structural severity, 593  
combination therapy, efficacy of, 2032, 2034  
comet cells in, 243  
comparison of infliximab or etanercept monotherapy vs. cotherapy with another DMARD, 1786  
congestive heart failure and ischemic heart disease contributions to excess mortality in, 60  
CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135  
CXCL16, expression and function of CXCL16 in human RA synovial tissue-SCID mouse chimera, 765  
cyclic-dependent kinase 4/6 modulation of mediators of inflammation, 2074

- Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)  
 death receptor 3 gene hypermethylated promoter region, 779  
 delaying addition of anti-TNF treatment to ongoing MTX therapy in patients with early disease, 47, 1028  
 diffuse large B cell lymphomas in, 3774  
 disease activity and radiographic progression after treatment with etanercept alone or combined with MTX, 3119  
 disease phenotype in familial RA, influence of male sex on, 3087  
 Duffy antigen expression, up-regulation in early disease, 2022  
 epigallocatechin-3-gallate, role in chemokine production and MMP-2 activation synovial fibroblasts, 2393  
 Epstein-Barr infection and ACPAs, 733  
 erosive arthritis, polyreactive pathogenic autoantibodies in BXD2 mice cause glomerulonephritis and erosive arthritis, 343  
 erosive RA, association of the *IL4R* SNP 150V with rapidly erosive RA, 1491  
 erosive RA, thrombospondin 1 modulates erosive arthritis by regulating connective tissue growth factor, 2415  
 expression of platelet-derived growth factor C and D in synovial membrane, 788  
 extremity MRI in, ACR task force report, 1034, 1048  
 Fas signaling in fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473  
 fatality rates following first acute cardiovascular event in, 2061  
*FCRL3* polymorphism and in Canadian population, 3820  
*FCRL3* polymorphism and RA and SLE polymorphism in Korean population, 3838  
*FCRL3* SNP not associated with RA in white North American population, 1022  
 fibroblast-like synoviocytes, regulation of JNK by MKK-7 in, 2127  
 folate-dependent risk genotypes and MTX effects in, 607  
 folic acid supplementation and MTX efficacy, 1708, 1709  
 fractalkine serum level correlates with disease activity in rheumatoid vasculitis, 3408  
 gene identification in disease-discordant monozygotic twins, 2047  
 gene therapy for, 1714  
 glucocorticoids and adrenal response in, 1415  
 glucocorticoids treatment, benefit of low-dose treatment in early disease may outweigh the risk, 2031, 2032  
 gp130 isoform, functional properties of soluble isoform in inflammatory arthritis, 1662  
 Guillain-Barré and Miller Fisher syndromes with infliximab therapy, 1429  
 HAQ score changes over 5 years, 3113  
 with hepatitis C, concomitant IFN $\alpha$  treatment and TNF $\alpha$  inhibition for, 2335  
 high-resolution multipinhole SPECT in experimental and human arthritis, 1096  
 HLA-linked odorant receptor gene polymorphisms and, 2705  
 homeostatic proliferation-provoked arthritis, 492  
 IKK $\beta$  inhibition protects against bone and cartilage destruction in RA rat model, 3163  
 IL-10-dependent gene expression in synovial macrophages, 2711  
 IL-20 as proinflammatory molecule in, 2722  
 immunosuppressive medications and hospitalization for cardiovascular events in, 3790  
 inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with adeno-associated virus, 2119  
 infliximab safety in RA with comorbidities alone and with MTX, 1075  
 insulin resistance and impaired  $\beta$  cell function in, 2765  
 intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis, 1463  
*IRF5* gene functional polymorphisms in, 3815  
 isotype distribution of anti-CCP antibodies, 3799  
 Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)  
 joint damage and dendritic cell function associated with CD32B (Fc $\gamma$  receptor IIb variant), 3828  
 joint space narrowing, automated computer-based scoring method for, 1444  
 joint space width in fingers of patients, 1440  
 leflunomide use and risk of interstitial lung disease, 1435  
 leukocyte migration to rheumatoid joints, 2707  
 linkage analysis of RA families in US and UK, 1482  
 long-term fracture risk in, 3104  
 LUNDEX, index of drug efficacy in clinical practice, 600  
 lymphoma in, 685  
 lymphoma risk and chronic inflammation in, 692  
 Mcl-1 expression in RA synovial macrophages, 3174  
 measuring function in, identifying reversible and irreversible, 2784  
*MHC2TA* gene association with in Swedish and UK cohort, 3417  
 modulation of osteoprotegerin/RANKL system by anti-TNF therapy, 76  
 monitoring of anti-TNF $\alpha$  bioavailability and immunogenicity in, 3782  
 MTX drug monitoring, 3095  
 MTX efficacy and toxicity in early disease associated with SNPs in genes coding for folate pathway enzymes, 1087, 3372  
 MTX pharmacogenetics, 1366  
 MTX plus cyclosporine plus intraarticular betamethasone compared with MTX and intraarticular betamethasone in early disease, 1401  
 MTX treatment outcome and genetic variants in adenosine pathway in recent-onset RA, 2830  
 mutilans-type, 1352  
 new model for etiology of, 38  
 noncardiac vascular disease in, 642  
 obstetric hospitalization in US for women with SLE and RA, 899  
 oncostatin M induces angiogenesis and cartilage degradation in RA synovial tissue and human cartilage cocultures, 3152  
*PADI4* gene associated with RA susceptibility in Korean population, 90  
 predictors of joint damage with early RA treated with high-dose MTX with or without concomitant infliximab, 702  
 prednisone and radiographic followup after therapy, 1422  
 pregnancy, serum fetal DNA and disease activity during, 2069  
 proinflammatory high-density lipoprotein as biomarkers for atherosclerosis in patients with SLE and RA, 2541  
 psychological stress exacerbates RA via hormones and nerve fibers, 682  
 PTPN22\*620W and humoral immunity to type II collagen in early RA, 82  
 PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes, 587  
 radiographic damage associated with disability in, 68  
 radiographic joint damage, implications of, 2035  
 radiologic joint destruction in twins and pairs of unrelated patients, 2028  
 RAGE and, 14  
 RAGE expression in synovial tissue macrophages, 97  
 RA, HLA-C3 and smoking associated with vasculitis in, 2276  
 rates of infection in anti-TNF-treated RA patients, 2368  
 ratio of osteoprotegerin to RANKL in early RA predicts later joint destruction, 1772  
 regulatory role of heme oxygenase 1 in RA inflammation, 1132  
 rituximab efficacy and safety despite MTX treatment, 1390  
 rituximab for anti-TNF refractory RA, 2793  
 seropositive RA, doxycycline plus MTX vs. MTX alone in early disease, 621  
 seropositive RA, *TNFA* polymorphism association with increased radiographic progression in, 1105  
 smoking and, 10, 2776

Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)  
SNP in promoter of gene for endothelial NOS, 3144  
sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in synovium, 742  
sphingosine kinase 1-mediated inhibition of Fas death signaling in RA B lymphoblastoid cells, 754  
STAT-3-dependent IL-6 *trans*-signaling, regulation of pre-B cell colony-enhancing factor by, 2084  
statin antiinflammatory and immunomodulatory effects, 390, 393  
statin effects on TNF $\alpha$ -induced, RhoA-mediated activation in RA synoviocytes, 3441  
statin-induced apoptosis in RA synovial cells, 579  
synovial cytokine expression and joint damage progression, 1122  
synovial molecular sieving of hyaluronan in rabbits, 1673  
synoviolin overexpression in, 2109  
synovitis in patients with DMARD-induced remission, 3761  
T cells induce osteoclastogenesis in monocytes, 1151  
TEMPO Study results of comparison of etanercept and MTX alone and combined, 1063, 3061  
TGF $\beta$ -inducible gene h3 in, 2734  
therapeutic B cell depletion and regeneration, 2356, 2377  
tissue expression and activation of p38 MAPK isoforms in, 2745  
TNF inhibitors, effectiveness in, 3399  
TNFSF14 as mediator of bone resorption in, 1451  
tocilizumab in RA patients with incomplete MTX response, CHARISMA study, 2817  
treatment and risk of pneumonia, 628  
turmeric treatment of experimental arthritis, 3452  
vascular amino oxidases and, 2707  
vasculitis associated with HLA-C3 and smoking in, 2776  
vitamin D deficiency and, 3719  
zoledronic acid in early RA, 1410  
Rheumatoid factor (RF), ACCP antibodies and RF isotopes in African Americans with early RA, 3057  
RhoA/RhoA kinase pathway, apoptosis of rheumatoid synoviocytes by statins through blocking of, 579  
Ribosomal P proteins, anti-P antibodies in lupus glomerulonephritis, 1568, 4025, 4026  
Risedronate, in medial compartment knee OA, 3494  
Risk factors  
acute myocardial infarction, gout and risk of, 2688  
cardiovascular outcomes in new users of coxibs and NSAIDs, 1378  
HLA-DRB1 shared epitope as risk factor for predisposition to anti-CCP and not RA, 1117  
hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194  
juvenile DM, immunogenetic risk and protective factors for in Caucasians, 3979  
Kawasaki disease, polymorphism in mannose-binding lectin gene and risk of coronary artery lesions, 369  
neonatal lupus risk, anti-La/SSB antiidiotypic antibodies in maternal serum, 2228  
OA, chondrocalcinosis and increased risk of cartilage loss in, 1822  
OA, Frizzled-related protein variants as risk factors for hip OA, 1246  
progressive multifocal leukoencephalopathy, risk of JC virus infection resulting in, 381  
RA, chronic inflammation and lymphoma risk, 692  
RA, disease phenotype in familial RA and gender, 3087  
RA, folate-dependent risk genotypes and MTX effects in, 607  
RA, immunosuppressive medications and hospitalization for cardiovascular events, 3790  
RA, leflunomide use and risk of interstitial lung disease, 1435  
RA, long-term fracture risk in, 3104  
RA, treatment of and risk of pneumonia, 628  
RA, vitamin D deficiency and, 3719

#### Risk factors (*cont'd*)

SLE, occupational exposure to silica and solvent and risk in urban women, 3648  
SLE, paraoxonase 1 activity and genotype and risk of, 1928  
vertebral fracture, disc space narrowing and risk of, 1262  
Rituximab  
RA, B lymphocyte stimulator levels following rituximab treatment, 723  
RA, efficacy and safety despite MTX treatment, 1390  
RA, for anti-TNF refractory RA, 2793  
RA, reconstitution of B cells after depletion by rituximab in RA patients, 613, 3062, 3063  
RA, therapeutic B cell depletion and regeneration, 2356, 2377  
SLE, B cell depletion in the appendix following treatment, 2151  
SLE, B cell depletion therapy and autoantibody and antimicrobial antibody profiles, 3612  
for SLE and ANCA-associated vasculitis, 2970  
RNA  
cationic liposome formulation for delivery of small interfering RNA silencing TNF $\alpha$  in experimental arthritis, 1867  
IFN $\alpha$  induction by immune complexes or liposomes containing SS- or SLE-autoantigen-associated RNA, 1917  
mediation of double-stranded RNA-mediated arthritis by type I IFN, 148  
SLE, RNA components of autoantigens as endogenous adjuvants, 1557  
RNA binding protein, association of IFN $\alpha$  with anti-RNA binding protein autoantibodies in SLE, 1906  
Ro 60, SLE, RNA components of autoantigens as endogenous adjuvants, 1557  
Rofecoxib  
cardiovascular outcomes in new users of, 1378  
COX-2 inhibition by diclofenac vs. celecoxib and rofecoxib, 282  
gastrointestinal and cardiovascular safety of, 3390  
Runt-related transcription factor 2, in mechanical instability-induced OA in mice, 2462  
  
**S**  
S100A4, stimulates MMP-13 via RAGE in OA, 2901  
S100A12, RA, RAGE expression in macrophages, 97  
Sacroiliitis, enthesitis-related arthritis, outcome and prognostic factors in, 3573  
Salivary glands  
cytokine profile in mice and SS-like disease progression, 2300  
epithelial cells as source of adiponectin, 2295  
SS, antimuscarinic antibodies and salivary fluid secretion in primary SS, 1165  
SS, high mobility group box chromosomal protein 1 in salivary glands, 2289  
SS, remodeling of basal lamina of labial salivary glands, 3465  
SS, role of STAT-1 $\alpha$  in labial salivary glands, 3476  
SS, transitional type II B cells in salivary glands of SS patients, 2280  
Sarcoidosis, pediatric granulomatous arthritis, international registry, 3337  
Scapular winging, Parsonage-Turner syndrome, 4027  
Scleroderma. *See* Systemic sclerosis  
Scoring, RA, automated computer-based scoring method for joint space narrowing, 1444  
Screening tests, SSc, nucleolar staining by anti-RNA polymerase I/III antibodies, 3051  
Secreted protein, acidic and rich in cysteine (SPARC) silencing in SSc, 2626  
Seegmiller, Jarvis Edwin, MD, in memoriam, 3067  
Selective costimulation modulator, abatacept safety in RA patients receiving DMARDs, 2807  
Semicarbazide-sensitive amine oxidase inhibitors, adjuvant-induced arthritis in, 2707

- Senescence, OA, catabolic stress-induced chondrocyte senescence through overexpression of caveolin 1, 818
- Serine protease, mediation of endothelial cell damage by, 1619
- Seropositive RA  
doxycycline plus MTX vs. MTX alone for early seropositive RA, 621  
*TNFA* polymorphism association with increased radiographic progression in, 1105
- Serotonin receptor 1A-1019 G allele, self-perceived stress and increased risk of flare in lupus nephritis patients carrying the serotonin receptor 1A-1019 G allele, 3291
- Sex. See Gender
- Shared epitope  
anti-CCP, HLA-DRB1 shared epitope as risk factor for predisposition to anti-CCP and not RA, 1117
- RA, activation of NO signaling by RA shared epitope, 3423
- RA, PTPN22\*620W and humoral immunity to type II collagen in early RA, 82
- RA, *TNFA* polymorphism association with increased progression in seropositive RA, 1105
- RA, triggering of HLA-DR shared epitope genes by smoking and RA etiology, 38
- Shoes, OA, walking barefoot decreases loading on lower extremity joints in knee OA, 2923
- Sialadenitis, inducible protein 10/CXCL10 antagonist and autoimmune sialadenitis in mice, 1174
- Sicca syndrome, SSc-associated SS and relationship to limited cutaneous subtype, 2243
- Signal transducer and activator of transcription 3 (STAT-3)-dependent IL-6 *trans*-signaling, regulation of pre-B cell colony-enhancing factor by, 2084
- Signal transduction  
RA, activity of serum amyloid A via NF- $\kappa$ B-dependent signal transduction, 105
- SSc, enhanced type I collagen expression and epigenetic repression of *FLII* gene in, 2271
- Signaling  
Jab1 binds Smad5 and inhibits bone morphogenetic protein signaling, 3878
- noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis, 1736
- OA, IL-1-induced calcium signaling in chondrocytes, 2164
- OA, S100A4 stimulates MMP-13 via RAGE, 2901
- RA, activation of NO signaling by RA shared epitope, 3423
- RA, Fas signaling in fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473
- RA, sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in synovium, 742
- RA, sphingosine kinase 1-mediated inhibition of Fas death signaling in RA B lymphoblastoid cells, 754
- SSc, activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309
- STAT-3-dependent IL-6 *trans*-signaling, regulation of pre-B cell colony-enhancing factor by, 2084
- suppressor of cytokine signaling 3-induced insulin-like growth factor desensitization in chondrocytes, 1518
- Simvastatin  
RA, effects on TNF $\alpha$ -induced, RhoA-mediated activation of in RA synoviocytes, 3441
- SSc, inhibition of type I collagen production and gene expression in SSc by, 1298
- up-regulation of mevalonate kinase by manipulation of isoprenoid biosynthesis, 2306
- Single-nucleotide polymorphisms (SNPs)  
AS, association of *IL1* gene cluster with susceptibility, 974
- OA, association between a variation in *LRCH1* and knee OA, 524
- Psa, lack of association of IL-4 receptor SNPs with erosive disease in, 4023
- Single-nucleotide polymorphisms (SNPs) (*cont'd*)  
RA association in Swedish and UK cohort, 3417
- RA, association of the *IL4R* SNP 150V with rapidly erosive RA, 1491
- radiologic joint destruction in twins and pairs of unrelated patients, 2028
- RA, *FCRL3* SNP not associated with RA in white North American population, 1022
- RA, MTX efficacy and toxicity in early disease associated with SNPs in genes coding for folate pathway enzymes, 1087, 3372
- RA, *PADI4* gene associated with susceptibility in Korean population, 90
- RA, SNP in promoter of gene for endothelial NOS, 3144
- Single-photon-emission computed tomography (SPECT), high-resolution multipinhole SPECT in experimental and human arthritis, 1096
- Sjögren's syndrome (SS)  
antimuscarinic antibodies and salivary fluid secretion in primary SS, 1165
- BAFF-induced changes in B cell antigen receptor-containing lipid rafts in, 115
- chemokine blockade and, 1061
- chemokine receptor expression in B lymphocytes, 1707, 1708
- CTLA4* haplotypes and susceptibility and extraglandular manifestations in primary SS, 2434
- cytokine profile in mice and SS-like disease progression, 2300
- dissemination of an SS-associated extranodal marginal-zone B cell lymphoma, 127
- failure to confirm coxsackievirus infection in primary SS, 2026
- high mobility group box chromosomal protein 1 in salivary glands, 2289
- IFN $\alpha$  induction by immune complexes or liposomes containing SS autoantigen-associated RNA, 1917
- inducible protein 10/CXCL10 antagonist and autoimmune sialadenitis in mice, 1174
- remodeling of basal lamina of labial salivary glands, 3465
- salivary gland epithelial cells as source of adiponectin, 2295
- SSc-associated SS and relationship to limited cutaneous subtype, 2243
- tissue-specific up-regulation of the proteasome subunit b5i (LMP7) in, 1501
- transitional type II B cells in salivary glands of SS patients, 2280
- Skeletal growth. IL-6 and, mouse study, 3551
- Skin  
adenosine A<sub>2A</sub> receptors in diffuse dermal fibrosis, 2632
- cutaneous lupus erythematosus, UV-induced apoptotic cell accumulation in, 939, 3375
- DCB-3503, effect of on skin disease in murine SLE, 3277
- inflammatory arthritis, skin hyperpigmentation over inflamed joints, 2604
- juvenile DM, chronic cutaneous inflammation and calcifications in children, 3345
- neuronal NOS in SSc skin, 202
- SSc, insulin-like growth factor binding protein 5-induced skin fibrosis, mouse study, 3001
- SSc, myofibroblasts and hyalinized collagen as markers of skin disease in, 3655
- SSc, stromal cell-derived factor 1 and its receptor CXCR4, differential expression in skin and endothelial cells, 3022
- Smad5, Jab1 binds Smad5 and inhibits bone morphogenetic protein signaling, 3878
- Small interfering RNA, cationic liposome formulation for delivery of small interfering RNA silencing TNF $\alpha$  in experimental arthritis, 1867
- Small-vessel vasculitis, long pentraxin PTX3 in leukocytoclastic lesions of small-vessel vasculitis, 986

- Smoking**  
 RA and, 10, 2776  
 RA, HLA-C3 and smoking associated with vasculitis in, 2776  
 RA, new model for etiology of, 38  
**Sm/RNP, SLE**, RNA components of autoantigens as endogenous adjuvants, 1557  
**Soluble gp130**, functional properties of in inflammatory arthritis, 1662  
**Somatosensory stimulation, FM**, reduced brain habituation to somatosensory stimulation in, 1995  
**Song, "I Am the Very Model of a Modern Rheumatologist,"** 1704  
**SPARC**  
 regulatory effects of in response to TGF $\alpha$  stimulation, 3885  
 silencing in SSc, 2626  
**Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling**, in RA synovium, 742  
**Sphingosine kinase 1**, inhibition of Fas death signaling in RA B lymphoblastoid cells, 754  
**Spine**  
 AS, diffuse idiopathic skeletal hyperostosis coexisting with ossification of posterior longitudinal ligament of cervical spine, 2242  
 AS, spinal inflammation reduction in AS patients taking infliximab, 1646  
 disc space narrowing and risk of vertebral fracture, 1262  
 dysphagia due to osteophytes, 507  
 notochord cell in, 3728  
 notochord cells, connective tissue growth factor secretion and up-regulation of proteoglycan expression by, 3859  
 zygapophyseal joints in AS, immunohistologic analysis of, 2845  
**Spondylarthritis,  $\beta_2$ -microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in rats**, 1317  
**Spondylarthritis (SpA)**  
 biomarkers in, 1733, 1795  
 juvenile-onset, synovial immunopathologic characteristics of, 2594  
**Spondylarthropathy**, B27 subtypes and tapasin dependence, 138  
**Spontaneous arthritis**  
 prevention of inhibiting homeostatic expansion of autoreactive CD4+ T cells in mice, 492  
 soluble p55 and p75 TNF receptors reverse spontaneous arthritis in mice expressing transmembrane TNF $\alpha$ , mouse study, 2872  
**STAT-1 gene, SS**, role of STAT-1 $\alpha$  in labial salivary glands, 3476  
**Statins**  
 RA, antiinflammatory and immunomodulatory effects in, 390, 393, 2347  
 RA, effects on TNF $\alpha$ -induced, RhoA-mediated NF- $\kappa$ B activation in synoviocytes, 3441  
 RA, statin-induced apoptosis in RA synovial cells, 579  
 SSc, increase in circulating endothelial precursors by atorvastatin, 1946  
 SSc, inhibition of type I collagen production and gene expression in by simvastatin, 1298  
**Statistical methods**, in *A&R*, 3741  
**Stem cells**. *See also* Hematopoietic stem cell transplantation  
 bone morphogenetic protein 4 and muscle-derived stem cells for cartilage repair in rats, 433  
 bone morphogenetic proteins as inducers of cartilage repair, ex vivo transduction of muscle-derived stem cells, 387  
 human synovial mesenchymal stem cell properties, 843  
 induction of chondrocytic differentiation of stem cells by bone morphogenetic protein 6, 1222  
 multipotent mesenchymal cells from human periosteum, 1209  
**Steroid hormones**, bovine articular cartilage integration and, 3890  
**Steroidogenesis**  
 RA, anti-IL-6 receptor antibodies, 1778  
 TNF-neutralizing therapies improve altered hormone axes, 2039  
**Strength training, FM**, heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women, 1334  
**Stress**  
 RA, psychological stress exacerbates RA via hormones and nerve fibers, 682  
 self-perceived stress and increased risk of flare in lupus nephritis patients carrying the serotonin receptor 1A-1019 G allele, 3291  
**Stress protein, murine collagen-induced arthritis**, BiP treatment via IL-4+ regulatory T cells, 854  
**Stroke**  
 catastrophic APS, mortality in, 2568  
 GCA, antiplatelet and anticoagulant therapy in, 3306  
 RA, increased case fatality rates following first acute cardiovascular event in, 2061  
 SLE, occlusive large vessel disease leading to fatal stroke, 908  
**Stromal cell-derived factor 1**, differential expression in skin and endothelial cells in SSc, 3022  
**Subchondral bone marrow, AS**, immunohistochemical analysis of hip arthritis in, 1805  
**Subcutaneous fat tissue aspiration**, diagnostic accuracy of for detection of systemic amyloidosis, 2015  
**Sulfasalazine, RA**, efficacy of combination therapy, 2032, 2034  
**Superoxide**, endothelial dysfunction in rat adjuvant-induced arthritis, 1847  
**Susceptibility**  
 arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice, 2423  
 AS, association of *IL1* gene cluster with susceptibility, 974  
 GCA, IL-10 promoter gene polymorphisms in, 4011  
 hip OA susceptibility locus on chromosome 6, 1026  
*PADI4* gene associated with RA susceptibility in Korean population, 90  
 RA and SLE susceptibility and *FCRL3* polymorphism in Korean population, 3838  
 SLE, Toll-like receptor 9 genetic variation and susceptibility to, 1279  
 SS, *CTLA4* haplotypes and susceptibility and extraglandular manifestations in primary SS, 2434  
**Swedish population, RA, *MHC2TA* gene association with in Swedish and UK cohort**, 3417  
**Synovial biomarkers**. *See* Biomarkers  
**Synovial cells, RA**, efficacy of anti-folate receptor  $\beta$  immunotoxin on RA synovial cells, 3126  
**Synovial exosomes**, citrullinated proteins associated with, 3809  
**Synovial fibroblasts**. *See* Fibroblasts  
**Synovial macrophages, RA**, regulation of Mcl-1 expression in RA synovial macrophages, 3174  
**Synovial membrane**  
 expression of platelet-derived growth factors C and D in RA and OA, 788  
 RA, synovial cytokine expression and joint damage progression, 1122  
**Synovial tissue**  
 OA, effects of CCN2 overexpression on fibrosis and cartilage damage, 1653  
 RA, expression and activation of p38 MAPK isoforms in, 2756  
 RA, expression and function of CXCL16 in human RA tissue-SCID mouse chimera, 765  
 RA, oncostatin M induces angiogenesis and cartilage degradation in RA synovial tissue and human cartilage cocultures, 3152  
 RA, RAGE in macrophages, 97  
 RA, regulatory role of heme oxygenase 1 in RA inflammation, 1132  
 RA, TGF $\beta$ -inducible gene h3 in, 2734  
**Synoviocytes**  
 fibroblast-like synoviocytes, regulation of JNK by MKK-7 in, 2127  
 inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with, 2119  
 OA, RAGE activation leads to increased stimulation of, 253  
 PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes, 587

- Synoviocytes (*cont'd*)  
 RA, effect of statins on TNF $\alpha$ -induced, RhoA-mediated NF- $\kappa$ B activation in, 3441  
 RA, Fas signaling in fibroblast-like synoviocytes and regulation by FLIP and caspase 8, 1473  
 RA, hypermethylated *DR3* promoter in, 779  
 RA, statin-induced apoptosis in RA synovial cells, 579  
 RA, TGF $\beta$ -inducible gene h3 in, 2734  
 Synoviolin, overexpression of in RA and continued elevation in nonresponders to infliximab, 2109  
 Synovitis  
     gene expression pattern in pigmented villonodular synovitis, 1009  
     juvenile-onset SpA, synovial immunopathologic characteristics of, 2594  
     pigmented villonodular of the knee, 3422  
     in RA patients with DMARD-induced remission, 3761  
 Synovium  
     drug therapy targeting on inflamed synovium, 1055  
     human synovial mesenchymal stem cell properties, 843  
     molecular sieving of hyaluronan in rabbits, 1673  
     RA, CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135  
     RA, sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in synovium, 742  
     reduction of proinflammatory cytokine expression by targeting IKK $\beta$  in synovium in rat model, 3716  
     synovial mast cell phenotype, mouse study, 2863  
 Systemic amyloidosis, diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detection, 2015  
 Systemic JIA, predictors of disease course and remission in, 1595  
 Systemic lupus erythematosus (SLE)  
     ACR renal disease criteria for SLE clinical trials, 421  
     analysis of studies of, 3378  
     antimalarial agents for, 3068  
     anti-NR2 antibodies and mood and cognition in, 2505  
     antioxidized low-density lipoprotein antibodies and vascular arterial events and renal manifestations in, 2035  
     anti-P antibodies in lupus glomerulonephritis, 1568, 4025, 4026  
     aPL and cardiovascular manifestations of, 3918  
     association of IFN $\alpha$  with anti-RNA binding protein autoantibodies in, 1906  
     B cell depletion in the appendix following rituximab treatment, 2151  
     B cell depletion therapy, autoantibody and antimicrobial antibody profiles, 3612  
     blood concentrations of hydroxychloroquine and SLE disease activity, 3284  
     childhood-onset, neutrophil gelatinase-associated lipocalin as biomarker of nephritis, 2577  
     coronary artery calcification markers in, 2220  
     DCB-3503, effect of on skin disease in murine SLE, 3277  
     epratuzumab use for, 2344  
     *FCRL3* polymorphism and RA and SLE susceptibility in Korean population, 3838  
     *IFI16* in, 3939  
     IFN $\alpha$  induction by immune complexes or liposomes containing SLE autoantigen-associated RNA, 1917  
     IFN-inducible gene expression in, 2951  
     iliopsoas bursitis of the hip with, 1686  
     impaired CD91 apoptotic pathways in, 1543  
     juvenile SLE, SDI for, 2989  
     late-onset SLE, features, course, and outcome of, 1580  
     low bone density and vertebral fractures in, 378, 379  
     lupus-like disease and high IFN levels corresponding to trisomy of type I IFN cluster on chromosome 9p, 1573  
     lupus nephritis,  $\alpha$ -actinin-binding anti-dsDNA antibodies and lupus nephritis, 2523  
     lupus nephritis, chimerism in, 2944  
     Systemic lupus erythematosus (SLE) (*cont'd*)  
         lupus nephritis, C-reactive protein single injection treatment of murine disease, 325  
         lupus nephritis, glomerular structures recognized by nephritogenic antibodies, 914  
         lupus nephritis, IFN-inducible gene expression in, 2951  
         lupus nephritis, IK cytokine in treatment of in mice, 3591  
         lupus nephritis, prevalence and incidence of biopsy-proven lupus nephritis in the UK, 2963  
         lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633  
         lupus nephritis, self-perceived stress and increased risk of flare in lupus nephritis patients carrying the serotonin receptor 1A-1019 G allele, 3291  
         lupus nephritis, SLE, neutrophil gelatinase-associated lipocalin as biomarker of nephritis in childhood-onset SLE, 2577  
         Ly deficiency in B cells, 2036, 2037  
         mannose-binding lectin exon 1 polymorphisms and disease course and outcome, 1703  
         mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940  
         memory T cells, abnormal differentiation of, 2184  
         moderate-dose steroids and disease flare, 3623  
         mortality in, 2550  
         murine lupus, Toll-like receptor 9 signaling protects against, 336  
         neonatal lupus risk, anti-La/SSB antiidiotype antibodies in maternal serum, 2228  
         neuropsychiatric, anti-NR2 antibodies, 2349, 2505, 2515  
         neuropsychiatric, anti-P antibody testing for diagnosis of, 312  
         neuropsychiatric, association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid, 675  
         obesity and functional capacity and inflammation, 1705, 1706  
         occlusive large vessel disease leading to fatal stroke, 908  
         occupational exposure to silica and solvent and risk of SLE in urban women, 3648  
         paraoxonase 1 activity and genotype and risk of SLE, 1928  
         partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270  
         pattern recognition receptors for, 3068  
         pediatric SLE, anti-Epstein-Barr nuclear antigen 1 antibodies in, 360  
         pediatric SLE, BILAG, 2343, 3723  
         pediatric SLE, effects of disease activity and therapy on lipid profile in, 1283  
         platelet C4D specificity for, 670  
         pregnancy, hydroxychloroquine in lupus pregnancy, 3640  
         pregnancy, obstetric hospitalization in US for women with SLE and RA, 899  
         progressive multifocal leukoencephalopathy and, 1020  
         proinflammatory high-density lipoprotein as biomarker for atherosclerosis in SLE and RA, 2541  
         *PTPN22* R620W polymorphism in familial and sporadic SLE, 2533  
         rapamycin treatment of, 2983  
         receptors and ligands involved in uptake of necrotic cells, 927  
         renal outcome, association between serum cholesterol level and, 2211  
         revised BILAG-2004 index, 3300  
         rituximab treatment for, 2970  
         RNA components of autoantigens as endogenous adjuvants, 1557  
         SLE, Fc $\gamma$  receptor II transmembrane polymorphism associated with, in Taiwanese patients, 3908  
         Toll-like receptor 9-expressing B cells in active SLE, 3601  
         Toll-like receptor 9 genetic variation and susceptibility to, 1279  
         Toll-like receptors and, 3068  
         type I IFN system in, 408  
 Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), for juvenile SLE, 2989

- Systemic sclerosis (SSc)**
- abnormal microvascular response localized to digits in, 1952
  - activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309
  - adenosine A<sub>2A</sub> receptors in diffuse dermal fibrosis, 2632
  - allogeneic hematopoietic cell transplantation with severe SSc, 1982
  - allograft inflammatory factor 1 expression in, 2616
  - B cells and, 1
  - brain abnormalities revealed by MRI and magnetization transfer imaging, 1350
  - CCL18/PARC-mediated lung injury, mouse study, 2643
  - in childhood, 3971
  - corticosteroids and cyclophosphamide followed by azathioprine treatment for pulmonary fibrosis in SSc, 3962
  - cutaneous SSc differentiated from limited cutaneous SSc, 3939
  - defective bone marrow endothelial progenitors in, 2605
  - diffuse SSc, pulmonary arterial hypertension independent of interstitial lung disease in survival, 184
  - DNA topoisomerase I binding to fibroblasts, 963
  - echocardiography to diagnose pulmonary arterial hypertension in, 380
  - endothelin axis polymorphisms in, 3034
  - epigenetic repression of *FLII* gene in, 2271
  - failed urokinase-type plasminogen activator receptor-integrin association in with SSc human microvascular endothelial cells, 3926
  - gene profiling shows robust signatures of disease imperfectly reflected in transcript profiles of explanted fibroblasts, 1961
  - hemorheologic profile and *NOS3* polymorphisms in, 2263
  - IFI16* in, 3939
  - increase in circulating endothelial precursors by atorvastatin in, 1946
  - insulin-like growth factor binding protein 5-induced skin fibrosis, mouse model, 3001
  - localized SSc in childhood, treatment of, 3065, 3066
  - lung transplantation in, 3954
  - macrophage migration inhibitory factor promoter polymorphisms and clinical expression of, 3661
  - myofibroblasts and hyalinized collagen as markers of skin disease in, 3655
  - neuronal NOS in SSc skin, 202
  - nucleolar staining by anti-RNA polymerase I/III antibodies, 3051
  - profibrotic effects of monocyte chemoattractant protein 1 in, 214
  - PTPN22* polymorphism association with anti-topoisomerase I- and anticentromere antibody-positive SSc, 3945
  - serum induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells, 2250
  - signaling pathways regulating ICAM-1 expression by endothelin 1, 649
  - simvastatin inhibition of type I collagen in, 1298
  - SPARC silencing in, 2626
  - SSc-associated SS and relationship to limited cutaneous subtype, 2243
  - SSc-related pulmonary hypertension, 3043
  - stromal cell-derived factor 1 and its receptor CXCR4, differential expression in skin and endothelial cells in, 3022
  - TGF $\beta$  receptor and up-regulation of matrix gene program, 3011
  - vascular damage, prevention and repair, 1730
  - Systemic vasculitis, serine-mediated endothelial cell damage, 1619
- T**
- T cells (cont'd)**
- RA, CTLA-4Ig suppression of RA synovial T cell oxidative stress, 3135
  - RA T cells induce osteoclastogenesis in monocytes, 1151
  - SLE, abnormal differentiation of memory T cells, 2184
  - SSc, profibrotic effects of monocyte chemoattractant protein 1 mediated via IL-4 release from T cells in, 214
  - T cell-depleted, nonmyeloablative bone marrow transplantation in IL-1Ra-deficient mice, 1878
  - T cell epitope-specific immune therapy for rheumatic diseases, 19
  - Treg with therapeutic effect in collagen-induced arthritis induced by vasoactive intestinal peptide, 864
  - Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583
  - T lymphocytes, SSc, CCL18/PARC-mediated lung injury, mouse study, 2643
  - T regulatory cells (Treg), 864
  - Taiwanese population, *FCGR2B* transmembrane polymorphism associated with SLE in, 3908
  - Takayasu arteritis
    - presenting with subclavian aneurysm, 382
    - role of anti-aortic endothelial cell antibodies in, 2326
  - Tapasin, AS, B27 subtypes and tapasin dependence, 138
  - Temporal expression pattern, Duffy antigen in RA, 2022
  - Temporomandibular joint (TMJ)
    - induction of IL-1 $\beta$  expression and TMJ changes of adult mice, 1184
    - OA-like changes in type IX collagen-deficient mice, 2891
  - Tendons, gene expression profiling of MMPs and TIMPs in human Achilles tendon, 832
  - Tensile weakening, IL-1 $\alpha$ -induced tensile weakening of bovine articular cartilage, 3267
  - Testosterone, steroid hormones support bovine articular cartilage integration in absence of IL-1 $\beta$ , 3890
  - Tetraspanin, in human OA cartilage, 3233
  - TGF $\beta$  receptor type I
    - activator receptor-like kinase-5 signaling and scleroderma phenotype, 1309
    - up-regulation of matrix gene program in SSc and, 3011
  - Thrombomodulin, mouse monoclonal anti-human thrombomodulin antibodies activate endothelial cells, 1629
  - Thrombospondin 1, modulates erosive arthritis by regulating connective tissue growth factor, 2415
  - Thrombotic events, SLE, mannose-binding lectin exon 1 polymorphisms and vascular events in, 1940
  - Tick-borne infection
    - antibiotic-refractory Lyme arthritis, strategies for treatment of, 3079 in "cat-scratch disease," 2347
  - Tight Control for Rheumatoid Arthritis (TICORA), 2338, 2339
  - Tissue engineering
    - chondrogenesis of mesenchymal stem cells in vitro and in vivo, mouse study, 3254
    - human synovial mesenchymal stem cell properties, 843
    - mesenchymal stem cells as cell source for cartilage tissue engineering, 3075
  - Tissue factor, molecular mechanisms of aPL-induced tissue factor expression, 301
  - Tissue inhibitors of metalloproteinases (TIMPs), gene expression profiling in human Achilles tendon, 832
  - TNF inhibitors. See Anti-tumor necrosis factor
  - TNF receptors (TNFRs), soluble p55 and p75 TNFRs reverse spontaneous arthritis in mice expressing transmembrane TNF $\alpha$ , 2872
  - TNF superfamily 14 (TNFSF14), as mediator of bone resorption in RA, 1451
  - TNFA* gene, seropositive RA, *TNFA* polymorphism association with increased progression in, 1105
  - TNFR superfamily 1A (TNFRSF1A), in TRAPS, 998, 2674

- TNFR-associated periodic syndrome (TRAPS)**  
 neutrophils from *TNFRSF1A* mutations display resistance to TNF-induced apoptosis, 998  
 structural abnormalities of mutated *TNFRSF1A* in, 2674
- TNFRSF1A genes**  
 TRAPS, neutrophils from *TNFRSF1A* mutations display resistance to TNF-induced apoptosis, 998  
 TRAPS, structural abnormalities of mutated *TNFRSF1A* in, 2674
- TNFSF14, RA, TNFSF14 as mediator of bone resorption in**, 1451
- Tocilizumab**  
 AA amyloidosis complicating JIA, 2997  
 clinical trial of in RA patients with incomplete MTX response, CHARISMA study, 2817
- Toll-like receptor 9**  
 genetic variation and susceptibility to SLE, 1279  
 mammalian DNA induction of type I IFN-associated dendritic cell maturation, 951  
 Toll-like receptor 9-expressing B cells in active SLE, 3601  
 Toll-like receptor 9 signaling protects against murine lupus, 336
- Toll-like receptors**  
 OA, catabolic pathway mediated by Toll-like receptors, 2152  
 SLE and, 3068
- Tophi, gouty tophus of ankle**, 2706
- Topoisomerase, SSc, DNA topoisomerase I binding to fibroblasts**, 963
- Total hip arthroplasty**  
 BMI, effects of on later total hip arthroplasty for primary OA, 802  
 collagen degradation around loosened total hip replacement implants, 2928  
 hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194  
 predictors of undergoing, 3212
- Total joint arthroplasty**  
 fibroblasts and fibroblast-derived factors in periprosthetic osteolysis, 3221  
 predictors of, 3212
- Total knee replacement**  
 hormone therapy, effect of on risk of hip and knee joint replacement in women, 3194  
 predictors of undergoing, 3212  
 preliminary index that predicts adverse events after, 1536
- Transcranial direct current stimulation, for FM pain**, 3725, 3988
- Transcript profile studies, SSc, gene profiling shows robust signatures of disease imperfectly reflected in transcript profiles of explanted fibroblasts**, 1961
- Transdermal fentanyl, for pain and improvement in functioning in OA patients**, 1829
- Transforming growth factor (TGF)**  
 lupus nephritis, ratio of human growth factor to TGF $\beta$ 1 as predictor of cyclophosphamide response in, 3633  
 OA, diurnal variation of biomarkers in knee OA, 2496  
 RA, TGF $\beta$ -inducible gene h3 in, 2734  
 SPARC and connective tissue growth factor and, 3885  
 SSc, allograft inflammatory factor 1 expression in response to TGF $\beta$ , 2616  
 TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block, 356
- Transgene expression, inflammatory cytokines and transgene expression in fibroblast-like synoviocytes infected with adeno-associated virus**, 2119
- Transglutaminase 2, expression of in monosodium urate crystals**, 3363
- Transitional type II B cells, in salivary glands of SS patients**, 2280
- Translocation, SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with**, 1270
- Transplantation. See Bone marrow transplantation**
- TRAPS, *TNFRSF1A* mutations in, in vitro studies**, 998, 2674
- Traumatic injury, cellular events leading to chondrocyte death after cartilage impact injury**, 1509
- Treatment strategies, RA, BeSt and TICORA studies, translating best strategy and tight control into clinical practice**, 2338, 2339
- Treg, in collagen-induced arthritis, induced by vasoactive intestinal peptide**, 864
- Trial of Etanercept and Methotrexate with Radiographic and Patient Outcomes (TEMPO) study, RA, comparison of etanercept and MTX alone and combined, two-year results**, 1063, 3061
- Triggering receptor expressed on myeloid cells 1 (TREM-1)**  
 monosodium urate crystals and acute gouty arthritis, 383  
 rapid induction of TREM-1 in murine macrophages by monosodium urate monohydrate crystals, 455
- Triglycerides, pediatric SLE, effects of disease activity and therapy on lipid profile in**, 1283
- Triplet studies, TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block**, 356
- Trisomy**  
 lupus-like disease and high IFN levels corresponding to trisomy of type I IFN cluster on chromosome 9p, 1573  
 SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270
- Tumor necrosis factor (TNF)**  
 cationic liposome formulation for delivery of small interfering RNA silencing TNF $\alpha$  in experimental arthritis, 1867  
 neutrophils from *TNFRSF1A* mutations display resistance to TNF-induced apoptosis, 998  
 p38 MAPK inhibition and TNF-mediated arthritis, 463  
 seropositive RA, TNF $\alpha$  polymorphism association with increased progression in, 1105  
 soluble p55 and p75 TNF receptors reverse spontaneous arthritis in mice expressing transmembrane TNF $\alpha$ , 2872  
 statins, effects on TNF $\alpha$ -induced, RhoA-mediated NF- $\kappa$ B activation in RA synoviocytes, 3441  
 surface-bound anti-type II collagen-containing immune complexes induce production of via Fc $\gamma$  receptor IIa, 1759  
 synoviolin, overexpression of in RA and continued elevation in nonresponders to infliximab, 2109
- Turneric, experimental arthritis treatment with**, 3452
- Twin studies**  
 FM, genetic influences on chronic widespread pain, 1682  
 OA, Frizzled-related protein variants as risk factors for hip OA, 1246  
 RA, gene identification in disease-discordant monozygotic twins, 2047  
 RA, radiologic joint destruction in twins and pairs of unrelated patients, 2028  
 TGF $\beta$ 1 in pathogenesis of autoimmune congenital complete heart block, 356
- Tylophorine analog**  
 DCB-3503, effect of on skin disease in murine SLE, 3277  
 murine collagen-induced arthritis, effects of novel tylophorine analog on, 877
- Type I IFNs, myeloid dendritic cells stimulated by intracellular mammalian DNA to produce, predominantly through a Toll-like receptor 9-independent pathway**, 951

## U

- U1 small nuclear RNP, murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen**, 661
- Ubiquitin ligase, synoviolin, overexpression of in RA and continued elevation in nonresponders to infliximab**, 2109
- Ultraviolet (UV) irradiation, cutaneous lupus erythematosus, UV-induced apoptotic cell accumulation in**, 939, 3375
- Undifferentiated arthritis, HLA-DRB1 shared epitope as risk factor for predisposition to anti-CCP and not RA**, 1117
- United Kingdom (UK)**  
 impact of FM diagnosis on health care resource use by UK patients, 177

**United Kingdom (UK) (cont'd)**

- lupus nephritis, prevalence and incidence of biopsy-proven lupus nephritis in the UK, 2963
- RA, linkage analysis of RA families in US and UK, 1483
- RA, *MHC2TA* gene association with in Swedish and UK cohort, 3417
- United States (US), new regulatory rules for clinical trials in, 3735
- Upper extremities, MRI of in RA, 1034, 1048
- Urate crystals. *See* Monosodium urate
- Urokinase-type plasminogen activator, SSc, failed urokinase-type plasminogen activator receptor-integrin association in with SSc human microvascular endothelial cells, 3926
- Uveitis, pediatric granulomatous arthritis, international registry, 3337

**V**

- Valdecoxib, cardiovascular outcomes in new users of, 1378
- Vascular adhesion protein 1, RA and, 2707
- Vascular amine oxidases, RA and, 2707
- Vascular damage, SSc, prevention and repair of, 1730
- Vascular disease
  - catastrophic APS, mortality in, 2568
  - RA, noncardiac vascular disease in, 642
  - SLE, occlusive large vessel disease leading to fatal stroke, 908
- Vascular dysfunction, endothelial dysfunction in rat adjuvant-induced arthritis, 1847
- Vascular Ehlers-Danlos syndrome, clinical study of, 515
- Vascular endothelial growth factor, in Kawasaki disease, 1361, 1588
- Vascular events, SLE, antioxidantized low-density lipoprotein antibodies and vascular arterial events and renal manifestations in, 2035
- Vascular function, SSc, abnormal microvascular response localized to digits in, 1952
- Vascular structure, SSc, defective bone marrow endothelial progenitors in, 2605
- Vasculitis
  - hepatitis C virus-associated mixed cryoglobulinemia vasculitis, anti-viral therapy for, 3696
  - primary angiitis of the central nervous system in children, 1291
  - PTX3 in leukocytoclastic lesions of small-vessel vasculitis, 986
  - RA, fractalkine serum level correlates with disease activity in, 3408
  - RA, HLA-C3 and smoking associated with vasculitis in, 2776
  - rituximab treatment for, 2970
  - systemic vasculitis, serine-mediated endothelial cell damage, 1619
- Vasculogenesis, SSc, defective bone marrow endothelial progenitors in, 2605
- Vasoactive intestinal peptide, Treg with therapeutic effect in collagen-induced arthritis induced by, 864
- VEGF gene, Kawasaki disease and, 1361, 1588
- Vertebrae, dysphagia due to osteophytes, 507
- Vertebral fracture
  - disc space narrowing and risk of, 1262
  - SLE, low bone density and vertebral fractures in, 378, 379
- VHH proteins, collagen-induced arthritis treated with camelid anti-TNF VHH proteins, mouse study, 1856
- Vibration, activation of cultured chondrocytes by vibration and hyaluronic acid, 1897

**Viral infection, mediation of double-stranded RNA-mediated arthritis**

- by type I IFN, 148
- Vitamin D deficiency, RA risk and, 3719
- Vitamin K, and hand and knee OA, 1255

**W**

- Walking, barefoot walking decreases loading on lower extremity joints in knee OA, 2923
- Wegener's granulomatosis (WG)
  - hidden chest lesions in, 3059
  - solid malignancies among etanercept-treated WG patients, 1608
  - "strawberry gums," winner of annual slide competition, 690
- Weight. *See* Obesity

**Women**

- anti-TNF in pregnancy, 2353
- FM, genetic influences on chronic widespread pain, 1682
- FM, heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly FM patients, 1334
- hormone therapy, effect on risk of hip and knee joint replacement in women, 3194
- intravenous ibandronate injections in postmenopausal women with osteoporosis, 1838
- OA, genetic associations with clinical knee OA in women and men, 533
- OA, serum cartilage oligomeric matrix protein and N-telopeptide crosslinks in radiographic hip OA, 236
- obstetric hospitalization in US for women with SLE and RA, 899
- pregnancy outcome following anti-TNF therapy, 2701
- RA, serum fetal DNA and disease activity during pregnancy, 2069
- SLE, hydroxychloroquine in pregnancy, 3640
- SLE, occupational exposure to silica and solvent and risk of SLE in urban women, 3648
- SLE and RA, obstetric hospitalization in US for women with, 899
- Work. *See also* Disability
  - occupational exposure to silica and solvent and risk of SLE in urban women, 3648
  - RA, infliximab improves employability in early RA, 716
- Wrist, chondrocalcinosis in Chinese vs. white subjects, 3508

**X**

- X chromosome, SLE, partial trisomy of pseudoautosomal region 1 in an XX male patient with, 1270

**Y**

- Yeast 2-hybrid technology, Jab1 binds Smad5 and inhibits bone morphogenetic protein signaling, 3878
- Yersinia*, *Yersinia*-induced reactive arthritis, antigen-specific T cells in, 3583

**Z**

- Zaragozic acid, up-regulation of mevalonate kinase by manipulation of isoprenoid biosynthesis, 2306
- Zoledronic acid, structural benefit of in early RA, 1410
- Zygopophyseal joints, AS, immunohistologic analysis of, 2845